Environmental Health Perspectives
Vol. 74, pp. 237-329, 1987

Second Chronological Supplement to the Carcinogenic Potency Database: Standardized Results of Animal Bioassays Published through December 1984 and by the National Toxicology Program through May 1986*

by Lois Swirsky Gold,† Thomas H. Slone,† Georganne M. Backman,† Renae Magaw,† Maria Da Costa,† Peggy Lopipero,† Mark Blumenthal† and Bruce N. Ames‡

This paper is the second chronological supplement to the Carcinogenic Potency Database, published earlier in this journal (*1,2,4*). We report here results of carcinogenesis bioassays published in the general literature between January 1983 and December 1984, and in Technical Reports of the National Cancer Institute/National Toxicology Program between January 1983 and May 1986. This supplement includes results of 525 long-term, chronic experiments of 199 test compounds, and reports the same information about each experiment in the same plot format as the earlier papers: e.g., the species and strain of test animal, the route and duration of compound administration, dose level and other aspects of experimental protocol, histopathology and tumor incidence, TD_{50} (carcinogenic potency) and its statistical significance, dose response, author's opinion about carcinogenicity, and literature citation. We refer the reader to the 1984 publications for a description of the numerical index of carcinogenic potency (TD_{50}), a guide to the plot of the database, and a discussion of the sources of data, the rationale for the inclusion of particular experiments and particular target sites, and the conventions adopted in summarizing the literature. The three plots of the database are to be used together, since results of experiments published in earlier plots are not repeated. Taken together, the three plots include results for more than 3500 experiments on 975 chemicals. Appendix 14 is an index to all chemicals in the database and indicates which plot(s) each chemical appears in.

Background

This is the third paper in which a portion of the Carcinogenic Potency Database (CPDB) is published in plot format. We have developed the CPDB in an effort to improve the use of animal bioassay data in the study of chemical carcinogenesis, and in the assessment of potential health hazards to humans. Together the three plots quantify and standardize the very diverse literature of long-term, chronic carcinogenesis bioassays published through 1984. The CPDB organizes the published literature systematically and applies an index of carcinogenic potency, the TD_{50}, to the results of experiments on 975 test compounds. We first presented the database in two papers in 1984, Peto et al. (*1*) and Gold et al. (*2*). Peto et al. (*1*) described our numerical index of carcinogenic potency, the TD_{50}, and the statistical procedures adopted for estimating it from experimental data. Briefly, TD_{50} may be defined as follows: for a given target site(s), if there are no tumors in control animals, then TD_{50} is that chronic dose rate in mg/kg body weight/day which would induce tumors in half the test animals at the end of a standard lifespan for the species. Since the tumor(s) of interest often does occur in control animals, TD_{50} is more precisely defined as that chronic dose rate which will halve the probability of remaining

*A computer tape of the plot of the database and appendices can be obtained from the first author.

†Biology and Medicine Division, Lawrence Berkeley Laboratory, Berkeley, CA 94720.

‡Department of Biochemistry, University of California, Berkeley, CA 94720.

tumor-free throughout the standard lifespan of the species (*1,3*). The range of TD_{50} values for carcinogens in the CPDB is more than 10 million-fold.

Gold et al. (*2*) presented a guide to the plot of the database describing the contents, field by field, as well as a discussion of the sources of data, the criteria for the inclusion of particular experiments and particular target sites, and the conventions adopted in summarizing the literature. The second plot (*4*) covered the literature published in 1981 and 1982. The present paper is a chronological supplement for 1983 and 1984. It is our intention that the three plots be used together, and that readers who are not familiar with the database will read the earlier papers when using the plot. We have not duplicated earlier results, and thus for complete data on chemicals in more than one plot, all of the publications are necessary.

Each plot of the database provides the same set of information about each experiment in the same format, including the species, strain, and sex of test animal; features of the experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; histopathology and tumor incidence; carcinogenic potency and its statistical significance; shape of the dose-response curve; author's opinion as to carcinogenicity; and literature citation. A word of caution is necessary about the limitations of the database. We have included only long-term tests of individual compounds which fit a set of criteria compatible with calculating potency; many animal cancer tests are excluded. Moreover, we have not attempted to evaluate whether or not a compound is a carcinogen; rather, we report the published opinions of the investigators whose data we present, as well as the statistical significance of the TD_{50} calculated from their results. Further discussion of the criteria for the database and the limitations can be found in Gold et al. (*2*).

The TD_{50} values in the CPDB for the NCI/NTP bioassays have been estimated using full lifetable information. For the TD_{50} values from the general literature, the estimates use the final proportions of animals with tumors, since only this summary information is consistently published (*1,3*). In a few cases, no TD_{50} could be calculated because all dosed animals had the tumor of interest, and only summary incidence data were available (*5*). The TD_{50} values for the compounds in this supplementary plot fall within the range of values reported earlier (*2*).

In 1983 the NTP adopted a new set of categories for their interpretive conclusions. In the "author's opinion" column on our plot, we report these evaluations using the same codes as in our earlier plots with the addition of "e" to denote "equivocal evidence of carcinogenicity." The "author's opinion" column for the general literature is the same as in earlier plots. Appendix 11 in this publication lists the codes and definitions used for the author's opinion, and full details are given in Gold et al. (*2*).

The appendices to each of the three plots provide the same types of information for the data in that publication, and are given the same appendix numbers. Appendix 1 lists alphabetically the compounds included in the plot and their common synonyms; Appendix 2 provides a list of the compounds sorted by Chemical Abstracts Service (CAS) Registry number. The next several appendices provide codes and definitions required for using the plot: strains of test animal (Appendix 3); routes of administration (Appendix 4); sites of tumor induction (Appendix 5); histopathology (Appendix 6); notecodes (Appendix 7); dose-response curve symbols (Appendix 8); reference codes (Appendix 9); NCI/NTP bioassays evaluated as inadequate (Appendix 10); and author's opinion codes (Appendix 11). Appendices 12 and 13 give full bibliographic information for all experiments reported in this plot: the bibliography for the general literature (Appendix 12); and a list of the NCI/NTP Technical Reports (Appendix 13). We have added a new Appendix in this publication, Appendix 14, that indicates which plot contains results of experiments on each of the 975 chemicals in the database; it is sorted alphabetically by chemical name or common synonym.

We are continuing to update the Carcinogenic Potency Database with papers published after 1984, and are also attempting to add earlier papers which we overlooked in our literature search. Therefore, we would appreciate information about any tests which the reader notices are missing.

Plot in This Supplement

The plot of the database includes results of 525 long-term, chronic experiments with 199 chemicals. It presents results for 35 compounds from Technical Reports of the National Cancer Institute/National Toxicology Program (NCI/NTP) published between January 1983 and May 1986, as well as results for 167 compounds published in the general literature between January 1983 and December 1984. Several experiments which have been identified from earlier years are also included.

Experiments in rats, mice, and hamsters are reported here for 199 compounds representing a variety of chemical classes, (e.g., nitroso compounds and halogenated hydrocarbons) with a variety of uses. Some are naturally occurring substances which are constituents of foods (e.g., safrole, quercetin, and estragole); food additives (e.g., D,L-monosodium glutamate and butylated hydroxyanisole); industrial compounds (e.g., ethylene oxide and 1,2-propylene oxide); and drugs (e.g., phenobarbital and primodolol). Of the 199 chemicals, 66 were also included in the first or second plot, and we have flagged these with a triple asterisk (***) after the chemical name in the plot. For some substances, only a few experiments are reported here, but large numbers of experiments were previously reported (*2,3*), e.g., 2-acetylaminofluorene and DDT.

Analyses of the Database

The three plots of the CPDB include more than 3500 experiments on 975 chemicals which meet the inclusion

Table 1. Correct CAS numbers for eleven chemicals in earlier CPDB plots.

CAS number	Chemical name
520-45-6	3-Acetyl-6-methyl-2,4-pyrandione
1308-38-9	Chromic oxide pigment
75-47-8	Iodoform
592-62-1	Methylazoxymethanol acetate and cycasin mixture
53757-28-1	4-(5-Nitro-2-furyl)thiazole
69658-91-9	3-Nitrosomethylaminopyridine
3546-10-9	Phenesterin
59536-65-1	Polybrominated biphenyls
6151-25-3	Quercetin dihydrate
6379-46-0	1,2,3-Trichloro-4,6-dinitrobenzene
1694-09-3	FD&C Violet No. 1

rules of the database and are therefore suitable for estimating TD_{50}. There is great diversity in the database. Most of the chemicals have been tested in rats or mice; however, some have been tested in hamsters, dogs, or monkeys. Experiments with 95 different mouse strains and 72 rat strains are included. For a given chemical, the database may contain only a single experiment, or a great many experiments. For example, among the 706 chemicals tested in rats, 33% have only one rat test and 52% have two tests; however, 11 chemicals have more than 10 tests. Overall, about half of the 975 chemicals in the database are positive in at least one experiment according to the opinion of the published author. This proportion is similar for rats and mice and for each of the three plots of the database. There is generally good concordance between authors' opinions as to carcinogenicity and the statistical significance of the experimental results.

Of the 975 chemicals in the CPDB, 392 have been tested in both rats and mice. Among these, 130 (33%) are positive in both species, 166 (43%) are negative in both, 56 (14%) are positive only in mice, and 40 (10%) are positive only in rats. We are currently examining these results and some possible explanations for differences between the species.

Our group has used the CPDB to address several issues relevant to interspecies extrapolation and chemical carcinogenesis. The good correlation of carcinogenic potency found between rats and mice has been described using the chemicals tested by the NCI/NTP Bioassay Program and some tautologous aspects of this comparison have been examined (*5*). Two methods for estimating carcinogenic potency (TD_{50}) from animal bioassays have been compared, one based on lifetable data and one based on summary incidence data (*6*). We have described the potencies of compounds which induce tumors at particular target sites in rats and mice and have examined other indicators of a chemical's hazard, including whether tumors were induced at more than one site in a single sex-species group of test animal, whether tumors may have caused the death of the animal or were found at sacrifice, and whether metastases of induced tumors occurred (*7*). Reproducibility of results has been investigated in 70 "near-replicate" comparisons consisting of two or more tests of the same chemical administered by the same route and using the same sex and strain of rodent. Overall, there was good reproducibility of positivity, target site, and TD_{50} in rats, mice, and hamsters (*8*).

We have proposed a rough index of possible carcinogenic hazards to humans from exposures to chemicals that are carcinogenic in rodents, the HERP (human exposure dose/rodent potency dose). The HERP expresses each human exposure (mg/kg/day) as a percentage of the rodent TD_{50}. We have computed HERP values for a variety of man-made and naturally occurring substances to which people may be exposed and have constructed a scale to rank possible hazards, although not to estimate absolute risks directly (*9*). In a separate analysis using a similar index, we rank the potential carcinogenic hazards permitted to U.S. workers from exposures to 41 rodent carcinogens that are regulated with Permissible Exposure Levels (PELs) by the U.S. Occupational, Safety, and Health Administration. For some substances, exposures at the PEL would be close to the dose rate that produces tumors in 50% of test animals (*10–12*).

Errata in the Earlier Publication

A few omissions and errors in earlier plots of the CPDB (*2,4*) have come to our attention.

Definitions for two codes were omitted from the appendices: the site code "sbg" stands for sebaceous gland, and the strain code "ssa" stands for S strain, albino.

The strain code "sds" should have been "sss."

The chemical listed as mercury (II) acetate is actually phenylmercuric acetate. The CAS number is correct.

For eleven chemicals in the earlier plots, the CAS numbers were reported incorrectly. The correct numbers for these substances, sorted alphabetically, are listed in Table 1.

We would appreciate hearing about any additional errors that the reader may discover.

We thank Jerrold Ward and Leslie Bernstein for their valuable and consistent expertise in pathology and statistics during the course of our work.

This work was completed with the excellent assistance of Susan Eisenberg, Veronica Cabras, and Paul Chous.

This work was supported by NIEHS/DOE Interagency Agreement 222-Y01-AS-10066 through the Lawrence Berkeley Laboratory.

REFERENCES

1. Peto, R., Pike, M. C., Bernstein, L., Gold, L. S., and Ames, B. N. The TD_{50}: a proposed general convention for the numerical description of the carcinogenic potency of chemicals in chronic-exposure animal experiments. Environ. Health Perspect. 58: 1–8 (1984).
2. Gold, L. S., Sawyer, C. B., Magaw, R., Backman, G. M., de Veciana, M., Levinson, R., Hooper, N. K., Havender, W. R., Bernstein, L., Peto, R., Pike, M. C., and Ames, B. N. A carcinogenic potency database of the standardized results of animal bioassays. Environ. Health Perspect. 58: 9–319 (1984).
3. Sawyer, C., Peto, R., Bernstein, L., and Pike, M. C. Calculation of carcinogenic potency from long-term animal carcinogenesis experiments. Biometrics 40: 27–40 (1984).
4. Gold, L. S., de Veciana, M., Backman, G. M., Magaw, R., Lo-

pipero, P., Smith, M., Blumenthal, M., Levinson, R., Bernstein, L., and Ames, B. N. Chronological supplement to the carcinogenic potency database: standardized results of animal bioassays published through December 1982. Environ. Health Perspect. 67: 161–200 (1986).
5. Bernstein, L., Gold, L. S., Ames, B. N., Pike, M. C., and Hoel, D. G. Some tautologous aspects of the comparison of carcinogenic potency in rats and mice. Fundam. Appl. Toxicol. 5: 79–86 (1985).
6. Gold, L. S., Bernstein, L., Kaldor, J., Backman, G., and Hoel, D. An empirical comparison of methods used to estimate carcinogenic potency in long-term animal bioassays: lifetable vs. summary incidence data. Fundam. Appl. Toxicol. 6: 263–269 (1986).
7. Gold, L. S., Ward, J. M., Bernstein, L., and Stern, B. Association between carcinogenic potency and tumor pathology in rodent carcinogenesis bioassays. Fundam. Appl. Toxicol. 6: 677–690 (1986).
8. Gold, L. S., Wright, C., Bernstein, L., and de Veciana, M. Reproducibility of results in "near-replicate" carcinogenesis bioassays. JNCI 78:1149–1158 (1987).
9. Ames, B. N., Magaw, R., and Gold, L. S. Ranking possible carcinogenic hazards. Science 236: 271–280 (1987).
10. Hooper, K., and Gold, L. S. The exposure-potency index (EPI): ranking the carcinogenic hazards of volatile industrial chemicals. In: Cancer Prevention: Strategies in the Workplace (C. Becker, Ed.), Hemisphere Publishing, Washington, DC, 1985, pp. 1–11.
11. Hooper, K., and Gold, L. S. Ranking the carcinogenic hazards of occupational exposures: exposure-potency index (EPI) values for nine volatile industrial chemicals. In: Monitoring of Occupational Genotoxicants: Proceedings of a Satellite Symposium to the Fourth International Conference on Environmental Mutagens. (M. Sorsa and H. Norppa, Eds.), Alan R. Liss, Inc., New York, 1986, pp. 217–228.
12. Gold, L. S., Backman, G., Hooper, K., and Peto, R. Ranking the potential carcinogenic hazards to workers from exposures to chemicals that are tumorigenic in rodents. Environ. Health Perspect. 76: in press.

Plot of the Carcinogenic Potency Database

```
    Spe Strain  Site    Xpo+Xpt                                                                                     TD50      2Tailpvl
      Sex   Route   Hist       Notes                                                                                     DR      AuOp

ACETAMINOPHEN***                      100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
1    M f ifm eat liv mix 78w78 e                                                                        .   +    4.14gm / P<.0005+
 a   M f ifm eat lun tum 78w78 e                                                                                 no dre   P=1.
2    M m ifm eat liv mix 78w78 e                                                                    . + .        1.01gm / P<.0005+
 a   M m ifm eat liv hpc 78w78 e                                                                                 4.90gm / P<.003
 b   M m ifm eat lun tum 78w78 e                                                                                 no dre   P=1.

2-ACETYLAMINOFLUORENE***              100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
3    M f bal eat liv tum 52w52 ek                                  .>                                            no dre   P=1.

 a   M f bal eat ubl car 52w52 ek                                                                                no dre   P=1.   -
4    M m bal eat ubl car 52w52 ek                                            . +    .                            9.09mg Z P<.0005+
5    M f cd1 eat liv hpc 53w92 e                                              .+ .                               7.65mg   P<.0005+
6    M m cd1 eat liv hpc 53w92 e                                                . + .                            13.5mg   P<.0005+
 a   M m cd1 eat ubl pam 53w92 e                                                                                 34.5mg   P<.0005+
 b   M m cd1 eat ubl tcc 53w92 e                                                                                 34.5mg   P<.0005
 c   M m cd1 eat kid mix 53w92 e                                                                                 86.5mg   P<.003
 d   M m cd1 eat liv hpa 53w92 e                                                                                 639.mg   P<.8   +
7    R f lev eat liv mix 56w56                                      . + .                                        1.53mg   P<.0005+
 a   R f lev eat ski mix 56w56                                                                                   12.3mg   P<.0005+
 b   R f lev eat mgl mix 56w56                                                                                   no dre   P=1.   +
8    R m lev eat liv mix 56w56 s                                   .+   .                                        1.17mg   P<.0005+
 a   R m lev eat ski mix 56w56 s                                                                                 20.1mg   P<.09  +
 b   R m lev eat mgl tum 56w56 s                                                                                 54.4mg   P<.06  +

AFLATOXIN B1***                       100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
9    M f c5v ipj lmr tum 52w92                  .  +        .                                                    4.02ug   P<.007 -
 a   M f c5v ipj lun ben 52w92                                                                                   75.3ug   P<.3   -
 b   M f c5v ipj liv tum 52w92                                                                                   no dre   P=1.   -
 c   M f c5v ipj tba tum 52w92                                                                                   4.49ug   P<.03  -
10   M m c5v ipj lun ben 52w92                           .>                                                      .245mg   P<.9   -
 a   M m c5v ipj liv mal 52w92                                                                                   no dre   P=1.   -
 b   M m c5v ipj liv ben 52w92                                                                                   no dre   P=1.   -
 c   M m c5v ipj tba tum 52w92                                                                                   no dre   P=1.   -
11   R m buf eat liv hpc 26w52 ekr                 .  +    .                                                     5.73ug   P<.002 +
 a   R m buf eat liv nnd 26w52 ekr                                                                               7.95ug   P<.004 +

ALLANTOIN                             100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
12   R f f34 eat liv nnd 25m30 e                                                                 .>              no dre   P=1.   -
13   R m f34 eat liv nnd 25m30 e                                                                 .>              no dre   P=1.   -

ALLYL ISOVALERATE                     100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
14   M f b6c gav --- MXA 24m25                                                      :  ±                         62.8mg * P<.03  c
 a   M f b6c gav --- mlm 24m25                                                                                   102.mg * P<.08  c
 b   M f b6c gav --- mlh 24m25                                                                                   238.mg * P<.02  c
 c   M f b6c gav TBA MXB 24m25                                                                                   65.5mg * P<.3
 d   M f b6c gav liv MXB 24m25                                                                                   no dre   P=1.
 e   M f b6c gav lun MXB 24m25                                                                                   4.45gm * P<1.
15   M m b6c gav gam sqp 24m25                                                          :    ±                  #295.mg * P<.04  -
 a   M m b6c gav TBA MXB 24m25                                                                                   206.mg * P<.8
 b   M m b6c gav liv MXB 24m25                                                                                   no dre   P=1.
 c   M m b6c gav lun MXB 24m25                                                                                   no dre   P=1.
16   R f f34 gav TBA MXB 24m25                                                    :   ±                          43.5mg * P<.08  -
 a   R f f34 gav liv MXB 24m25                                                                                   no dre   P=1.
17   R m f34 gav --- MXA 24m25                                                        :  +        :              123.mg * P<.004 c
 a   R m f34 gav pre MXA 24m25                                                                                   136.mg * P<.03
 b   R m f34 gav --- mle 24m25                                                                                   149.mg * P<.02  c
 c   R m f34 gav TBA MXB 24m25                                                                                   50.5mg * P<.2
 d   R m f34 gav liv MXB 24m25                                                                                   264.mg * P<.2

2-AMINO-3-METHYL-9H-PYRIDO-|2,3-b|-INDOLE ..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
18   M f cdf eat blv hms 84w84                                                     . + .                         38.6mg   P<.0005+
 a   M f cdf eat liv mix 84w84                                                                                   38.6mg   P<.0005+
 b   M f cdf eat liv hpc 84w84                                                                                   98.9mg   P<.0005
 c   M f cdf eat liv hpa 84w84                                                                                   118.mg   P<.0005
 d   M f cdf eat lun ade 84w84                                                                                   1.84gm   P<.3
 e   M f cdf eat lun mix 84w84                                                                                   no dre   P=1.
19   M m cdf eat blv hms 73w73                                                 . + .                             15.6mg   P<.0005+
 a   M m cdf eat liv mix 73w73                                                                                   43.5mg   P<.0005+
 b   M m cdf eat liv hpa 73w73                                                                                   90.9mg   P<.0005
 c   M m cdf eat liv hpc 73w73                                                                                   127.mg   P<.0005
 d   M m cdf eat lun ade 73w73                                                                                   1.18gm   P<.7
 e   M m cdf eat lun mix 73w73                                                                                   no dre   P=1.
```

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc						Citation or Pathology Brkly Code
ACETAMINOPHEN*** (Tylenol, paracetamol) 103-90-2													
1	1579	1.95gm	12.4gm	0/51	650.mg	0/58	1.30gm	9/50					Flaks;carc,4,363-368;1983
a	1579	2.77gm	n.s.s.	0/51	650.mg	0/58	1.30gm	0/50					
2	1579	591.mg	1.97gm	1/52	600.mg	1/57	1.20gm	20/27					
a	1579	1.86gm	28.7gm	0/52	600.mg	0/57	1.20gm	5/27					
b	1579	1.93gm	n.s.s.	0/52	600.mg	0/57	1.20gm	0/27					
2-ACETYLAMINOFLUORENE*** (N-2-fluorenylacetamide) 53-96-3													
3	1665	.969mg	n.s.s.	0/24	1.04mg	0/48	3.12mg	0/48	5.85mg	0/24	7.67mg	0/16	11.2mg 0/8 Haley; pseb,152,156-159;1976
a	1665	.969mg	n.s.s.	0/24	1.04mg	0/48	3.12mg	0/48	5.85mg	0/24	7.67mg	0/16	11.2mg 0/8
4	1665	4.11mg	26.7mg	0/23	.960mg	0/41	2.88mg	0/44	5.40mg	1/22	7.08mg	3/13	10.3mg 4/8
5	1635m	5.10mg	11.9mg	0/60	22.5mg	46/58							Weikel;jcph,19,591-604;1979/pers.comm.
6	1635m	8.67mg	22.7mg	1/57	20.7mg	33/58							
a	1635m	19.2mg	71.1mg	0/57	20.7mg	16/58							
b	1635m	19.2mg	71.1mg	0/57	20.7mg	16/58							
c	1635m	37.3mg	375.mg	0/57	20.7mg	7/58							
d	1635m	53.1mg	n.s.s.	6/57	20.7mg	7/58							
7	1635m	1.05mg	2.28mg	0/60	15.0mg	60/70							
a	1635m	6.60mg	33.3mg	1/60	15.0mg	16/70							
b	1635m	16.4mg	n.s.s.	16/60	15.0mg	14/70							
8	1635m	.796mg	1.76mg	1/60	12.0mg	61/70							
a	1635m	7.46mg	n.s.s.	5/60	12.0mg	13/70							
b	1635m	16.5mg	n.s.s.	0/60	12.0mg	3/70							
AFLATOXIN B1*** 1162-65-8													
9	1636	1.62ug	67.6ug	3/11	9.69ug	12/15							Griciute;iarc,813-822;1980
a	1636	12.3ug	n.s.s.	0/11	9.69ug	1/15							
b	1636	23.4ug	n.s.s.	0/11	9.69ug	0/15							
c	1636	1.68ug	n.s.s.	4/11	9.69ug	12/15							
10	1636	11.3ug	n.s.s.	1/20	8.07ug	1/15							
a	1636	19.5ug	n.s.s.	2/20	8.07ug	0/15							
b	1636	19.5ug	n.s.s.	2/20	8.07ug	0/15							
c	1636	8.52ug	n.s.s.	11/20	8.07ug	4/14							
11	1664	2.66ug	18.7ug	0/14	20.0ug	9/20							Angsubhakorn;ijcn,28,621-626;1981
a	1664	3.40ug	47.3ug	0/14	20.0ug	7/20							
ALLANTOIN 97-59-6													
12	1654	217.mg	n.s.s.	4/24	82.5mg	3/20							Lijinsky;fctx,22,715-720;1984
13	1654	241.mg	n.s.s.	5/24	66.0mg	2/20							
ALLYL ISOVALERATE 2835-39-4													
14	c54717	26.6mg	n.s.s.	11/50	21.5mg	11/50	43.2mg	18/50					---:mlh,mlm,mlp.
a	c54717	37.7mg	n.s.s.	6/50	21.5mg	5/50	43.2mg	10/50					
b	c54717	88.9mg	n.s.s.	0/50	21.5mg	1/50	43.2mg	4/50					
c	c54717	19.8mg	n.s.s.	31/50	21.5mg	20/50	43.2mg	30/50					
d	c54717	197.mg	n.s.s.	3/50	21.5mg	0/50	43.2mg	1/50					liv:hpa,hpc,nnd.
e	c54717	90.6mg	n.s.s.	4/50	21.5mg	4/50	43.2mg	3/50					lun:a/a,a/c.
15	c54717	100.mg	n.s.s.	0/50	21.5mg	1/50	43.2mg	3/50					S
a	c54717	25.0mg	n.s.s.	36/50	21.5mg	33/50	43.2mg	34/50					
b	c54717	67.8mg	n.s.s.	23/50	21.5mg	14/50	43.2mg	15/50					liv:hpa,hpc,nnd.
c	c54717	134.mg	n.s.s.	13/50	21.5mg	6/50	43.2mg	5/50					lun:a/a,a/c.
16	c54717	17.3mg	n.s.s.	38/50	21.5mg	43/50	43.2mg	43/50					
a	c54717	276.mg	n.s.s.	1/50	21.5mg	1/50	43.2mg	0/50					liv:hpa,hpc,nnd.
17	c54717	59.7mg	934.mg	1/50	21.5mg	4/50	43.2mg	9/50					---:mle,mlh.
a	c54717	58.6mg	n.s.s.	0/50	21.5mg	5/50	43.2mg	2/50					pre:adn,can,sqc. S
b	c54717	66.7mg	n.s.s.	1/50	21.5mg	4/50	43.2mg	7/50					
c	c54717	17.3mg	n.s.s.	38/50	21.5mg	37/50	43.2mg	37/50					
d	c54717	79.8mg	n.s.s.	1/50	21.5mg	2/50	43.2mg	3/50					liv:hpa,hpc,nnd.
2-AMINO-3-METHYL-9H-PYRIDO-[2,3-b]-INDOLE (MeA-alpha-C) 68006-83-7													
18	1616	23.7mg	67.3mg	0/40	104.mg	28/40							Ohgaki;carc,5,815-819;1984
a	1616	23.7mg	67.3mg	0/40	104.mg	28/40							
b	1616	53.9mg	210.mg	0/40	104.mg	15/40							
c	1616	62.1mg	267.mg	0/40	104.mg	13/40							
d	1616	299.mg	n.s.s.	0/40	104.mg	1/40							
e	1616	273.mg	n.s.s.	2/40	104.mg	2/40							
19	1616	9.38mg	26.7mg	0/40	96.0mg	35/40							
a	1616	25.6mg	81.9mg	0/40	96.0mg	21/40							
b	1616	46.6mg	214.mg	0/40	96.0mg	12/40							
c	1616	59.7mg	372.mg	0/40	96.0mg	9/40							
d	1616	132.mg	n.s.s.	3/40	96.0mg	4/40							
e	1616	192.mg	n.s.s.	11/40	96.0mg	5/40							

	Spe Strain Sex	Site Route	Xpo+Xpt Hist	Notes	TD50 DR	2Tailpvl AuOp
2-AMINO-6-METHYLDIPYRIDO[1,2-a:3',2'-d]IMIDAZOLE				...:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
20	M f cdf	eat liv	mix 67w67	e . + .	5.08mg	P<.0005+
a	M f cdf	eat blv	mix 67w67	e	10.9mg	P<.0005+
b	M f cdf	eat blv	hms 67w67	e	13.8mg	P<.0005
c	M f cdf	eat liv	hpc 67w67	e	18.5mg	P<.0005
d	M f cdf	eat liv	hpa 67w67	e	44.1mg	P<.0005
e	M f cdf	eat lun	ade 67w67	e	166.mg	P<.02
f	M f cdf	eat lun	mix 67w67	e	308.mg	P<.4
21	M m cdf	eat blv	mix 57w57	e . + .	5.77mg	P<.0005+
a	M m cdf	eat blv	hms 57w57	e	7.81mg	P<.0005
b	M m cdf	eat blv	hae 57w57	e	98.7mg	P<.02
c	M m cdf	eat liv	hpa 57w57	e	98.7mg	P<.02 +
d	M m cdf	eat lun	ade 57w57	e	1.00gm	P<.9
e	M m cdf	eat lun	mix 57w57	e	no dre	P=1.
22	R f f34	eat liv	mix 67w67	e . + .	8.39mg	P<.0005+
a	R f f34	eat zym	sqc 67w67	e	12.7mg	P<.0005+
b	R f f34	eat smi	mix 67w67	e	26.1mg	P<.0005+
c	R f f34	eat col	mix 67w67	e	39.0mg	P<.002 +
d	R f f34	eat smi	adc 67w67	e	56.1mg	P<.005 +
e	R f f34	eat cli	tum 67w67	e	56.1mg	P<.005 +
f	R f f34	eat col	ade 67w67	e	71.0mg	P<.02 +
g	R f f34	eat smi	mcc 67w67	e	71.0mg	P<.02 +
h	R f f34	eat col	adc 67w67	e	95.9mg	P<.03 +
i	R f f34	eat bra	ast 67w67	e	95.9mg	P<.03 +
j	R f f34	eat smi	ade 67w67	e	146.mg	P<.08 +
23	R m f34	eat liv	mix 67w67	e . + .	3.25mg	P<.0005+
a	R m f34	eat smi	mix 67w67	e	5.89mg	P<.0005+
b	R m f34	eat smi	adc 67w67	e	6.71mg	P<.0005+
c	R m f34	eat smi	ade 67w67	e	8.21mg	P<.0005+
d	R m f34	eat col	mix 67w67	e	9.45mg	P<.0005+
e	R m f34	eat zym	sqc 67w67	e	10.2mg	P<.0005+
f	R m f34	eat col	ade 67w67	e	15.4mg	P<.0005+
g	R m f34	eat col	adc 67w67	e	16.9mg	P<.0005+
h	R m f34	eat smi	mcc 67w67	e	236.mg	P<.3 +
2-AMINO-3-METHYLIMIDAZO[4,5-f]QUINOLINE				..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
24	M f cdf	eat liv	mix 96w96	e . + .	17.5mg	P<.0005+
a	M f cdf	eat liv	hpc 96w96	e	24.1mg	P<.0005
b	M f cdf	eat for	mix 96w96	e	62.4mg	P<.0005+
c	M f cdf	eat lun	mix 96w96	e	67.9mg	P<.03 +
25	M m cdf	eat lun	mix 96w96	e . + .	22.4mg	P<.0005+
a	M m cdf	eat for	mix 96w96	e	42.3mg	P<.0005+
b	M m cdf	eat liv	mix 96w96	e	48.6mg	P<.002 +
c	M m cdf	eat lun	adc 96w96	e	60.2mg	P<.007
d	M m cdf	eat liv	hpc 96w96	e	91.6mg	P<.002
e	M m cdf	eat for	sqc 96w96	e	153.mg	P<.02
trans-5-AMINO-3[2-(5-NITRO-2-FURYL)VINYL-1,2,4-OXADIAZOLE				....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
26	M f cd1	eat for	sqc 31w75	es . + .	105.mg	P<.0005+
a	M f cd1	eat thm	lym 31w75	es	262.mg	P<.005 +
b	M f cd1	eat for	sqp 31w75	es	1.15gm	P<.1 +
c	M f cd1	eat lun	ade 31w75	es	1.01gm	P<.5
d	M f cd1	eat liv	hem 31w75	es	no dre	P=1.
e	M f cd1	eat rel	mix 31w75	es	no dre	P=1. +
f	M f cd1	eat tba	mix 31w75	es	no dre	P=1.
27	M m cd1	eat thm	lym 38w75	es . + .	121.mg	P<.0005+
a	M m cd1	eat for	sqc 38w75	es	130.mg	P<.0005+
b	M m cd1	eat for	sqp 38w75	es	514.mg	P<.008 +
c	M m cd1	eat rel	mix 38w75	es	492.mg	P<.08 +
d	M m cd1	eat liv	hem 38w75	es	no dre	P=1.
e	M m cd1	eat lun	ade 38w75	es	no dre	P=1.
f	M m cd1	eat tba	mix 38w75	es	29.2mg	P<.0005
2-AMINO-9H-PYRIDO(2,3-b)INDOLE				100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
28	M f cdf	eat liv	mix 97w97	. + .	35.6mg	P<.0005+
a	M f cdf	eat liv	hpc 97w97		44.7mg	P<.0005
b	M f cdf	eat blv	hms 97w97		381.mg	P<.004 +
c	M f cdf	eat lun	ade 97w97		795.mg	P<.04
d	M f cdf	eat lun	mix 97w97		1.15gm	P<.4
29	M m cdf	eat blv	mix 97w97	. + .	82.6mg	P<.0005+
a	M m cdf	eat blv	hms 97w97		103.mg	P<.0005
b	M m cdf	eat liv	mix 97w97		122.mg	P<.0005+
c	M m cdf	eat liv	hpc 97w97		225.mg	P<.0005
d	M m cdf	eat liv	hpa 97w97		352.mg	P<.004
e	M m cdf	eat lun	ade 97w97		no dre	P=1.
f	M m cdf	eat lun	mix 97w97		no dre	P=1.

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology / Brkly Code
2-AMINO-6-METHYLDIPYRIDO[1,2-a:3',2'-d]IMIDAZOLE (Glu-P-1) 67730-11-4									
20	1616	2.33mg	9.78mg	0/40	65.0mg	37/38			Ohgaki;carc,5,815-819;1984
a	1616	6.63mg	18.9mg	0/40	65.0mg	31/38			
b	1616	8.44mg	24.3mg	0/40	65.0mg	28/38			
c	1616	11.1mg	33.6mg	0/40	65.0mg	24/38			
d	1616	23.1mg	99.8mg	0/40	65.0mg	13/38			
e	1616	57.4mg	n.s.s.	0/40	65.0mg	4/38			
f	1616	65.6mg	n.s.s.	2/40	65.0mg	4/38			
21	1616	3.31mg	10.4mg	0/39	60.0mg	30/34			
a	1616	4.63mg	14.0mg	0/39	60.0mg	27/34			
b	1616	34.1mg	n.s.s.	0/39	60.0mg	4/34			
c	1616	34.1mg	n.s.s.	0/39	60.0mg	4/34			
d	1616	50.9mg	n.s.s.	3/39	60.0mg	3/34			
e	1616	50.5mg	n.s.s.	11/39	60.0mg	6/34			
22	1619m	5.07mg	15.1mg	0/50	25.0mg	24/42			Takayama;gann,75,207-213;1984/Masuda 1984
a	1619m	7.24mg	25.1mg	0/50	25.0mg	18/42			
b	1619m	12.7mg	67.7mg	0/50	25.0mg	10/42			
c	1619m	16.8mg	142.mg	0/50	25.0mg	7/42			
d	1619m	21.3mg	463.mg	0/50	25.0mg	5/42			
e	1619m	21.3mg	463.mg	0/50	25.0mg	5/42			
f	1619m	24.5mg	n.s.s.	0/50	25.0mg	4/42			
g	1619m	24.5mg	n.s.s.	0/50	25.0mg	4/42			
h	1619m	29.0mg	n.s.s.	0/50	25.0mg	3/42			
i	1619m	29.0mg	n.s.s.	0/50	25.0mg	3/42			
j	1619m	35.8mg	n.s.s.	0/50	25.0mg	2/42			
23	1619m	1.99mg	5.58mg	2/50	20.0mg	35/42			
a	1619m	3.61mg	10.4mg	0/50	20.0mg	26/42			
b	1619m	4.06mg	12.1mg	0/50	20.0mg	24/42			
c	1619m	4.84mg	15.4mg	0/50	20.0mg	21/42			
d	1619m	5.45mg	18.3mg	0/50	20.0mg	19/42			
e	1619m	5.80mg	20.1mg	0/50	20.0mg	18/42			
f	1619m	8.06mg	34.7mg	0/50	20.0mg	13/42			
g	1619m	8.68mg	39.6mg	0/50	20.0mg	12/42			
h	1619m	38.4mg	n.s.s.	0/50	20.0mg	1/42			
2-AMINO-3-METHYLIMIDAZO[4,5-f]QUINOLINE (IQ) 76180-96-6									
24	1617	10.2mg	33.6mg	3/38	39.0mg	27/36			Ohgaki;carc,5,921-924;1984
a	1617	14.2mg	44.9mg	0/38	39.0mg	22/36			
b	1617	31.2mg	154.mg	0/38	39.0mg	11/36			
c	1617	27.9mg	n.s.s.	7/38	39.0mg	15/36			
25	1617	12.2mg	60.4mg	7/33	36.0mg	27/39			
a	1617	22.6mg	109.mg	1/33	36.0mg	16/39			
b	1617	24.0mg	241.mg	3/33	36.0mg	16/39			
c	1617	27.9mg	811.mg	3/33	36.0mg	14/39			
d	1617	41.4mg	347.mg	0/33	36.0mg	8/39			
e	1617	58.1mg	n.s.s.	0/33	36.0mg	5/39			
trans-5-AMINO-3[2-(5-NITRO-2-FURYL)VINYL-1,2,4-OXADIAZOLE (SQ 18506) 28754-68-9									
26	1601	59.8mg	206.mg	0/50	134.mg	18/49			Dunsford;jnci,73,151-160;1984
a	1601	115.mg	2.33gm	1/50	134.mg	9/49			
b	1601	283.mg	n.s.s.	0/50	134.mg	2/49			
c	1601	188.mg	n.s.s.	4/50	134.mg	6/49			
d	1601	705.mg	n.s.s.	3/50	134.mg	0/49			
e	1601	234.mg	n.s.s.	9/50	134.mg	7/49			
f	1601	138.mg	n.s.s.	32/50	134.mg	24/49			
27	1601	69.5mg	240.mg	0/50	152.mg	18/50			
a	1601	73.6mg	263.mg	0/50	152.mg	17/50			
b	1601	195.mg	9.94gm	0/50	152.mg	5/50			
c	1601	171.mg	n.s.s.	2/50	152.mg	7/50			
d	1601	586.mg	n.s.s.	3/50	152.mg	1/50			
e	1601	652.mg	n.s.s.	6/50	152.mg	1/50			
f	1601	16.6mg	59.4mg	18/50	152.mg	45/50			
2-AMINO-9H-PYRIDO(2,3-b)INDOLE (A-alpha-C) 26148-68-5									
28	1616	21.8mg	60.7mg	0/40	104.mg	33/40			Ohgaki;carc,5,815-819;1984
a	1616	27.6mg	77.0mg	0/40	104.mg	30/40			
b	1616	155.mg	2.30gm	0/40	104.mg	6/40			
c	1616	241.mg	n.s.s.	0/40	104.mg	3/40			
d	1616	234.mg	n.s.s.	2/40	104.mg	4/40			
29	1616	48.1mg	158.mg	0/40	96.0mg	20/40			
a	1616	58.1mg	209.mg	0/40	96.0mg	17/40			
b	1616	66.3mg	259.mg	0/40	96.0mg	15/40			
c	1616	105.mg	657.mg	0/40	96.0mg	9/40			
d	1616	143.mg	2.12gm	0/40	96.0mg	6/40			
e	1616	288.mg	n.s.s.	3/40	96.0mg	3/40			
f	1616	390.mg	n.s.s.	11/40	96.0mg	4/40			

	Spe Strain Site Xpo+Xpt Sex Route Hist Notes		TD50 DR	2Tailpvl AuOp
2-AMINODIPYRIDO[1,2-a:3',2'-d]IMIDAZOLE		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
30	M f cdf eat liv mix 82w82	. + .	12.0mg	P<.0005+
a	M f cdf eat liv hpc 82w82		20.0mg	P<.0005
b	M f cdf eat blv mix 82w82		39.9mg	P<.0005+
c	M f cdf eat blv hms 82w82		43.0mg	P<.0005
d	M f cdf eat liv hpa 82w82		170.mg	P<.004
e	M f cdf eat lun ade 82w82		1.09gm	P<.3
f	M f cdf eat lun mix 82w82		no dre	P=1.
31	M m cdf eat blv mix 84w84	. + .	23.9mg	P<.0005+
a	M m cdf eat blv hms 84w84		27.3mg	P<.0005
b	M m cdf eat liv mix 84w84		93.2mg	P<.0005+
c	M m cdf eat liv hpa 84w84		201.mg	P<.008
d	M m cdf eat liv hpc 84w84		255.mg	P<.02
e	M m cdf eat lun ade 84w84		483.mg	P<.5
f	M m cdf eat lun mix 84w84		no dre	P=1.
32	R f f34 eat cli tum 24m24	. + .	56.4mg	P<.0005+
a	R f f34 eat smi mix 24m24		81.1mg	P<.0005+
b	R f f34 eat col mix 24m24		81.1mg	P<.0005+
c	R f f34 eat zym sqc 24m24		94.0mg	P<.002 +
d	R f f34 eat col ade 24m24		111.mg	P<.003 +
e	R f f34 eat smi adc 24m24		135.mg	P<.005 +
f	R f f34 eat smi ade 24m24		171.mg	P<.02 +
g	R f f34 eat liv mix 24m24		351.mg	P<.08 +
h	R f f34 eat col adc 24m24		351.mg	P<.08 +
i	R f f34 eat smi mcc 24m24		711.mg	P<.3 +
33	R m f34 eat smi mix 24m24	. + .	33.8mg	P<.0005+
a	R m f34 eat smi adc 24m24		45.1mg	P<.0005+
b	R m f34 eat liv mix 24m24		52.1mg	P<.003 +
c	R m f34 eat col mix 24m24		88.9mg	P<.003 +
d	R m f34 eat smi ade 24m24		137.mg	P<.02 +
e	R m f34 eat col ade 24m24		185.mg	P<.03 +
f	R m f34 eat col adc 24m24		185.mg	P<.03 +
g	R m f34 eat smi mcc 24m24		281.mg	P<.08 +
h	R m f34 eat bra ast 24m24		281.mg	P<.08 +
i	R m f34 eat zym sqc 24m24		569.mg	P<.3 +
3-AMINOTRIAZOLE***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
34	H f syg eat lun tum 28m28 ae	.>	no dre	P=1.
a	H f syg eat liv ben 28m28 ae		no dre	P=1. -
b	H f syg eat tba mix 28m28 ae		no dre	P=1. -
c	H f syg eat tba mal 28m28 ae		570.mg *	P<.6 -
35	H m syg eat liv ben 31m32 ae	.>	no dre	P=1. -
a	H m syg eat lun tum 31m32 ae		no dre	P=1.
b	H m syg eat tba mix 31m32 ae		no dre	P=1. -
c	H m syg eat tba mal 31m32 ae		no dre	P=1. -
36	M f nmr eat liv tum 33m33 ae	.>	no dre	P=1. -
a	M f nmr eat lun tum 33m33 ae		no dre	P=1.
b	M f nmr eat tba mal 33m33 ae		6.92mg Z	P<.2 -
c	M f nmr eat tba mix 33m33 ae		no dre	P=1. -
37	M m nmr eat liv mal 34m34 ae	.>	2.76gm *	P<.8 -
a	M m nmr eat lun tum 34m34 ae		no dre	P=1.
b	M m nmr eat tba mal 34m34 ae		347.mg *	P<.7 -
c	M m nmr eat tba mix 34m34 ae		no dre	P=1. -
38	R f wis eat thy ben 38m38 ae	. + .	11.5mg *	P<.0005+
a	R f wis eat thy mal 38m38 ae		17.7mg *	P<.0005+
b	R f wis eat pit ben 38m38 ae		20.8mg *	P<.0005+
c	R f wis eat liv tum 38m38 ae		no dre	P=1.
d	R f wis eat tba mix 38m38 ae		7.55mg *	P<.01
e	R f wis eat tba mal 38m38 ae		17.7mg *	P<.0005
39	R m wis eat thy ben 38m38 ae	. + .	8.75mg Z	P<.0005+
a	R m wis eat thy mal 38m38 ae		27.0mg *	P<.0005+
b	R m wis eat liv hpc 38m38 ae		no dre	P=1.
c	R m wis eat tba mix 38m38 ae		13.8mg *	P<.009
d	R m wis eat tba mal 38m38 ae		135.mg *	P<.6
ANETHOLE		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
40	M f cd1 eat liv tum 50w78 v	.>	no dre	P=1. -
a	M f cd1 eat lun ade 50w78 v		no dre	P=1. -
ARECOLINE.HCl		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
41	M f swi gav liv tum 25m25	.>	no dre	P=1. -
a	M f swi gav lun tum 25m25		no dre	P=1. -
b	M f swi gav tba tum 25m25		no dre	P=1. -
42	M f swi gav lun adc 25m25 b	. ±	61.9mg	P<.07 +
a	M f swi gav liv hem 25m25 b		116.mg	P<.06 +
b	M f swi gav tba mix 25m25 b		33.6mg	P<.008 +

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
2-AMINODIPYRIDO[1,2-a:3',2'-d]IMIDAZOLE (Glu-P-2) 67730-10-3									
30	1616	7.10mg	20.7mg	0/40	65.0mg	36/40		Ohgaki;carc,5,815-819;1984	
a	1616	12.3mg	34.4mg	0/40	65.0mg	30/40			
b	1616	23.3mg	76.3mg	0/40	65.0mg	20/40			
c	1616	24.8mg	83.5mg	0/40	65.0mg	19/40			
d	1616	69.4mg	1.03gm	0/40	65.0mg	6/40			
e	1616	178.mg	n.s.s.	0/40	65.0mg	1/40			
f	1616	224.mg	n.s.s.	2/40	65.0mg	1/40			
31	1616	14.6mg	41.9mg	0/40	60.0mg	27/40			
a	1616	16.6mg	48.9mg	0/40	60.0mg	25/40			
b	1616	45.3mg	248.mg	0/40	60.0mg	10/40			
c	1616	76.2mg	3.49gm	0/40	60.0mg	5/40			
d	1616	87.9mg	n.s.s.	0/40	60.0mg	4/40			
e	1616	92.2mg	n.s.s.	3/40	60.0mg	5/40			
f	1616	105.mg	n.s.s.	11/40	60.0mg	8/40			
32	1619	28.2mg	138.mg	0/50	25.0mg	11/42		Takayama;gann,75,207-213;1984	
a	1619	36.6mg	252.mg	0/50	25.0mg	8/42			
b	1619	36.6mg	252.mg	0/50	25.0mg	8/42			
c	1619	40.5mg	341.mg	0/50	25.0mg	7/42			
d	1619	45.3mg	525.mg	0/50	25.0mg	6/42			
e	1619	51.3mg	1.12gm	0/50	25.0mg	5/42			
f	1619	59.1mg	n.s.s.	0/50	25.0mg	4/42			
g	1619	86.3mg	n.s.s.	0/50	25.0mg	2/42			
h	1619	86.3mg	n.s.s.	0/50	25.0mg	2/42			
i	1619	116.mg	n.s.s.	0/50	25.0mg	1/42			
33	1619	18.1mg	73.9mg	0/50	20.0mg	14/42			
a	1619	22.6mg	111.mg	0/50	20.0mg	11/42			
b	1619	24.0mg	290.mg	2/50	20.0mg	11/42			
c	1619	36.2mg	420.mg	0/50	20.0mg	6/42			
d	1619	47.3mg	n.s.s.	0/50	20.0mg	4/42			
e	1619	56.0mg	n.s.s.	0/50	20.0mg	3/42			
f	1619	56.0mg	n.s.s.	0/50	20.0mg	3/42			
g	1619	69.1mg	n.s.s.	0/50	20.0mg	2/42			
h	1619	69.1mg	n.s.s.	0/50	20.0mg	2/42			
i	1619	92.6mg	n.s.s.	0/50	20.0mg	1/42			
3-AMINOTRIAZOLE*** (amitrol) 61-82-5									
34	1557o	2.00mg	n.s.s.	0/76	.105mg	0/76	1.05mg	0/76	10.5mg	0/76	Steinhoff;txap,69,161-169;1983	
a	1557o	242.mg	n.s.s.	1/76	.105mg	1/76	1.05mg	0/76	10.5mg	0/76		
b	1557o	59.5mg	n.s.s.	13/76	.105mg	10/76	1.05mg	12/76	10.5mg	11/76		
c	1557o	81.3mg	n.s.s.	1/76	.105mg	2/76	1.05mg	3/76	10.5mg	3/76		
35	1557o	2.29mg	n.s.s.	0/76	92.0ug	0/76	.920mg	0/76	9.20mg	0/75		
a	1557o	2.29mg	n.s.s.	0/76	92.0ug	0/76	.920mg	0/76	9.20mg	0/75		
b	1557o	85.6mg	n.s.s.	20/76	92.0ug	11/76	.920mg	13/76	9.20mg	11/75		
c	1557o	160.mg	n.s.s.	7/76	92.0ug	2/76	.920mg	5/76	9.20mg	2/75		
36	1557n	3.29mg	n.s.s.	0/73	.130mg	0/73	1.30mg	0/74	13.0mg	0/74		
a	1557n	3.29mg	n.s.s.	0/73	.130mg	0/73	1.30mg	0/74	13.0mg	0/74		
b	1557n	2.32mg	n.s.s.	46/73	.130mg	26/73	1.30mg	46/74	(13.0mg	38/74)		
c	1557n	26.3mg	n.s.s.	60/73	.130mg	48/73	1.30mg	59/74	13.0mg	55/74		
37	1557n	200.mg	n.s.s.	1/75	.120mg	0/73	1.20mg	1/73	12.0mg	1/72		
a	1557n	3.20mg	n.s.s.	0/75	.120mg	0/73	1.20mg	0/73	12.0mg	0/72		
b	1557n	41.1mg	n.s.s.	27/75	.120mg	38/73	1.20mg	26/73	12.0mg	32/72		
c	1557n	43.7mg	n.s.s.	52/75	.120mg	56/73	1.20mg	47/73	12.0mg	46/72		
38	1557m	7.53mg	19.8mg	7/74	50.0ug	12/75	.500mg	8/75	5.00mg	44/75		
a	1557m	11.4mg	30.1mg	0/74	50.0ug	1/75	.500mg	4/75	5.00mg	28/75		
b	1557m	11.3mg	61.3mg	14/74	50.0ug	20/75	.500mg	15/75	5.00mg	36/75		
c	1557m	1.71mg	n.s.s.	0/74	50.0ug	0/75	.500mg	0/75	5.00mg	0/75		
d	1557m	3.11mg	626.mg	59/74	50.0ug	67/75	.500mg	60/75	5.00mg	71/75		
e	1557m	9.13mg	73.9mg	20/74	50.0ug	34/75	.500mg	29/75	5.00mg	45/75		
39	1557m	5.85mg	14.2mg	5/75	40.0ug	9/74	.400mg	4/75	4.00mg	45/75		
a	1557m	15.2mg	60.5mg	3/75	40.0ug	0/74	.400mg	3/75	4.00mg	18/75		
b	1557m	115.mg	n.s.s.	0/75	40.0ug	0/74	.400mg	1/75	4.00mg	0/75		
c	1557m	6.31mg	441.mg	36/75	40.0ug	41/74	.400mg	44/75	4.00mg	53/75		
d	1557m	21.4mg	n.s.s.	19/75	40.0ug	20/74	.400mg	23/75	4.00mg	23/75		
ANETHOLE (p-propenylanisole) 104-46-1									
40	1582	563.mg	n.s.s.	0/30	162.mg	0/30		Miller;canr,43,1124-1134;1983	
a	1582	563.mg	n.s.s.	1/30	162.mg	0/30			
ARECOLINE.HCl 61-94-9									
41	1659m	114.mg	n.s.s.	0/20	28.6mg	0/18		Shide;zkko,107,169-171;1984/pers.comm.	
a	1659m	114.mg	n.s.s.	0/20	28.6mg	0/18			
b	1659m	114.mg	n.s.s.	0/20	28.6mg	0/18			
42	1659n	18.6mg	n.s.s.	1/16	28.6mg	4/12			
a	1659n	28.4mg	n.s.s.	0/16	28.6mg	2/12			
b	1659n	12.5mg	690.mg	1/16	28.6mg	6/12			


Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
43 M m swi gav liv hem 25m25 67.8mg P<.006 +
a M m swi gav sto sqc 25m25 196.mg P<.1 +
b M m swi gav lun adc 25m25 251.mg P<.5 +
c M m swi gav tba mix 25m25 r 34.6mg P<.002 +
44 M m swi gav liv hem 25m25 b 114.mg P<.04 +
a M m swi gav lun adc 25m25 b 325.mg P<.7 +
b M m swi gav tba mix 25m25 b 57.6mg P<.06 +
AROCLOR 1260***
45 R m wis eat liv hpc 27m27 er 5.39mg P<.0005+
L-ASCORBIC ACID
46 M f b6c eat TBA MXB 24m24 :no dre P=1. -
a M f b6c eat liv MXB 24m24 no dre P=1.
b M f b6c eat lun MXB 24m24 no dre P=1.
47 M m b6c eat TBA MXB 24m24 no dre P=1. -
a M m b6c eat liv MXB 24m24 no dre P=1.
b M m b6c eat lun MXB 24m24 115.gm * P<.7
48 R f f34 eat TBA MXB 24m24 no dre P=1. -
a R f f34 eat liv MXB 24m24 no dre P=1.
49 R m f34 eat TBA MXB 24m24 no dre P=1. -
a R m f34 eat liv MXB 24m24 no dre P=1.
ASPIRIN***
50 R b alb gav for tum 78w78 r no dre P=1. -
a R b alb gav stg tum 78w78 r no dre P=1. -
AZASERINE***
51 R m wis ipj pan tum 24m24 r no dre P=1. -
AZATHIOPRINE
52 R f f34 eat edu sqc 52w52 ekr 10.1mg P<.2
a R f f34 eat liv tum 52w52 ekr no dre P=1. -
AZOXYMETHANE
53 R m f34 wat liv mix 7m23 e 30.2ug \ P<.0005+
a R m f34 wat liv hpc 7m23 e 67.7ug \ P<.0005+
b R m f34 wat kid mix 7m23 e .388mg * P<.0005+
c R m f34 wat col a/2 7m23 e .585mg * P<.0005+
d R m f34 wat liv hes 7m23 e .982mg * P<.2
e R m f34 wat liv nnd 7m23 e 28.6mg * P<1.
f R m f34 wat tba mix 7m23 e noTD50 P=1.
BENZENE***
54 M f b6c gav MXB MXB 24m24 23.7mg * P<.0005
a M f b6c gav MXB MXB 24m24 24.6mg * P<.0005
b M f b6c gav liv hpa 24m24 38.1mg Z P<.008
c M f b6c gav liv MXA 24m24 53.6mg Z P<.009
d M f b6c gav ova mtb 24m24 66.5mg Z P<.0005c
e M f b6c gav lun MXA 24m24 83.6mg * P<.002 c
f M f b6c gav lun a/c 24m24 117.mg * P<.0005c
g M f b6c gav ova MXB 24m24 119.mg * P<.0005
h M f b6c gav mgl MXA 24m24 132.mg * P<.0005c
i M f b6c gav ova MXA 24m24 146.mg * P<.002
j M f b6c gav ova gct 24m24 157.mg * P<.002 c
k M f b6c gav ova tue 24m24 +historical * P<.006 a
l M f b6c gav mgl cas 24m24 382.mg * P<.005 c
m M f b6c gav hag can 24m24 509.mg * P<.006
n M f b6c gav MXA MXA 24m24 79.1mg * P<.04
o M f b6c gav MXA MXA 24m24 94.2mg * P<.07 c
p M f b6c gav hag MXA 24m24 128.mg * P<.02
q M f b6c gav lun a/a 24m24 169.mg * P<.02 c
r M f b6c gav MXA MXA 24m24 173.mg * P<.02
s M f b6c gav ova lut 24m24 +historical * P<.05 a
t M f b6c gav zym sqc 24m24 421.mg * P<.02 c
u M f b6c gav ova pcy 24m24 +historical * P<.08 a
v M f b6c gav TBA MXB 24m24 30.4mg * P<.002
w M f b6c gav liv MXB 24m24 53.6mg Z P<.009
x M f b6c gav lun MXB 24m24 83.6mg * P<.002
55 M m b6c gav MXB MXB 24m24 15.1mg * P<.0005
a M m b6c gav pre MXA 24m24 21.8mg Z P<.0005
b M m b6c gav pre sqc 24m24 25.5mg Z P<.0005c

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
43	1659m	30.6mg	524.mg	0/20	23.8mg	8/35				
a	1659m	59.4mg	n.s.s.	0/20	23.8mg	3/35				
b	1659m	55.5mg	n.s.s.	1/20	23.8mg	4/35				
c	1659m	17.8mg	143.mg	1/20	23.8mg	15/35				
44	1659n	34.5mg	n.s.s.	0/21	23.8mg	3/21				
a	1659n	40.6mg	n.s.s.	2/21	23.8mg	3/21				
b	1659n	20.3mg	n.s.s.	2/21	23.8mg	7/21				
AROCLOR 1260*** (PCB, clophen A 60) 11096-82-5										
45	1605	3.90mg	7.75mg	1/131	4.00mg	61/129			Schaeffer;txap,75,278-288;1984	
L-ASCORBIC ACID (vitamin C) 50-81-7										
46	c54808	8.40gm	n.s.s.	30/50	3.19gm	28/50	6.38gm	27/50		
a	c54808	30.6gm	n.s.s.	3/50	3.19gm	1/50	6.38gm	3/50	liv:hpa,hpc,nnd.	
b	c54808	24.1gm	n.s.s.	1/50	3.19gm	4/50	6.38gm	1/50	lun:a/a,a/c.	
47	c54808	11.9gm	n.s.s.	29/50	2.94gm	31/50	5.89gm	24/50		
a	c54808	16.4gm	n.s.s.	16/50	2.94gm	16/50	5.89gm	13/50	liv:hpa,hpc,nnd.	
b	c54808	16.5gm	n.s.s.	5/50	2.94gm	4/50	5.89gm	8/50	lun:a/a,a/c.	
48	c54808	1.86gm	n.s.s.	41/50	1.23gm	45/50	2.45gm	40/50		
a	c54808	28.7gm	n.s.s.	2/50	1.23gm	0/50	2.45gm	0/50	liv:hpa,hpc,nnd.	
49	c54808	2.05gm	n.s.s.	37/50	981.mg	41/50	1.96gm	39/50		
a	c54808	16.7gm	n.s.s.	2/50	981.mg	0/50	1.96gm	1/50	liv:hpa,hpc,nnd.	
ASPIRIN*** 50-78-2										
50	1571	125.mg	n.s.s.	0/23	26.9mg	0/40			Tsung-Hsien;jnci,70,1067-1069;1983	
a	1571	125.mg	n.s.s.	0/23	26.9mg	0/40				
AZASERINE*** 115-02-6										
51	1746	.736mg	n.s.s.	0/9	.714mg	0/5			McGuinness;sjge,18,189-192;1983	
AZATHIOPRINE 446-86-6										
52	1695	3.04mg	n.s.s.	0/12	7.50mg	3/25			Frankel;txap,17,462-480;1970	
a	1695	9.66mg	n.s.s.	0/12	7.50mg	0/25				
AZOXYMETHANE 25843-45-2										
53	1641	14.6ug	73.4ug	2/20	85.3ug	17/20	(.361mg	16/20)	Lijinsky;clet,24,273-280;1984/1985a	
a	1641	33.1ug	.168mg	0/20	85.3ug	11/20	(.361mg	13/20)		
b	1641	.192mg	.957mg	0/20	85.3ug	0/20	.361mg	11/20		
c	1641	.263mg	1.73mg	0/20	85.3ug	0/20	.361mg	8/20		
d	1641	.354mg	n.s.s.	0/20	85.3ug	3/20	.361mg	3/20		
e	1641	.465mg	n.s.s.	2/20	85.3ug	5/20	.361mg	3/20		
f	1641	n.s.s.	n.s.s.	20/20	85.3ug	20/20	.361mg	20/20		
BENZENE*** 71-43-2										
54	c55276	14.9mg	50.7mg	17/50	17.7mg	28/50	35.4mg	41/50	70.7mg 42/50 lun:a/a,a/c; mgl:can,cas,sqc; mul:mlh,mlm,mlp,mlu,mno; ova:gct,lut,mtb,pcy,tua; spl:mlm.	T
a	c55276	15.3mg	54.6mg	17/50	17.7mg	28/50	35.4mg	40/50	70.7mg 41/50 lun:a/a,a/c; mgl:can,cas,sqc; mul:mlh,mlm,mlp,mlu,mno; ova:gct,mtb; spl:mlm,mlu,mno; ute:mlh.	C
b	c55276	15.9mg	880.mg	1/50	17.7mg	8/50	(35.4mg	5/50	70.7mg 4/50)	S
c	c55276	26.3mg	2.27gm	4/50	17.7mg	12/50	35.4mg	13/50	(70.7mg 7/50) liv:hpa,hpc.	S
d	c55276	34.6mg	156.mg	0/50	17.7mg	1/50	35.4mg	12/50	(70.7mg 7/50)	
e	c55276	44.0mg	354.mg	4/50	17.7mg	5/50	35.4mg	10/50	70.7mg 13/50 lun:a/a,a/c.	
f	c55276	63.4mg	390.mg	0/50	17.7mg	3/50	35.4mg	6/50	70.7mg 6/50	
g	c55276	63.8mg	374.mg	0/50	17.7mg	2/50	35.4mg	7/50	70.7mg 5/50 ova:lut,pcy,tua.	A
h	c55276	73.1mg	294.mg	0/50	17.7mg	2/50	35.4mg	5/50	70.7mg 10/50 mgl:can,sqc.	
i	c55276	74.0mg	571.mg	1/50	17.7mg	1/50	35.4mg	6/50	70.7mg 8/50 ova:gcc,gct.	S
j	c55276	77.1mg	793.mg	1/50	17.7mg	1/50	35.4mg	6/50	70.7mg 7/50	
k	c55276	120.mg	3.25gm	0/50	17.7mg	0/50	35.4mg	3/50	70.7mg 3/50	
l	c55276	143.mg	3.12gm	0/50	17.7mg	0/50	35.4mg	1/50	70.7mg 4/50	
m	c55276	174.mg	5.94gm	0/50	17.7mg	0/50	35.4mg	0/50	70.7mg 4/50	S
n	c55276	34.3mg	n.s.s.	15/50	17.7mg	25/50	35.4mg	26/50	70.7mg 22/50 mul:lkn,mlh,mlm,mlp,mlu,mno,ule; spl:mlm,mlu,mno; ute:mlh.	S
o	c55276	37.2mg	n.s.s.	15/50	17.7mg	24/50	35.4mg	24/50	70.7mg 20/50 mul:mlh,mlm,mlp,mlu,mno; spl:mlm,mlu,mno; ute:mlh.	
p	c55276	57.4mg	n.s.s.	5/50	17.7mg	6/50	35.4mg	10/50	70.7mg 10/50 hag:adn,can.	S
q	c55276	72.8mg	n.s.s.	4/50	17.7mg	2/50	35.4mg	5/50	70.7mg 9/50	
r	c55276	77.4mg	n.s.s.	1/50	17.7mg	3/50	35.4mg	6/50	70.7mg 5/50 cat:sqp; sto:sqp.	S
s	c55276	106.mg	n.s.s.	0/50	17.7mg	2/50	35.4mg	3/50	70.7mg 2/50	
t	c55276	146.mg	n.s.s.	0/50	17.7mg	0/50	35.4mg	1/50	70.7mg 3/50	
u	c55276	174.mg	n.s.s.	0/50	17.7mg	0/50	35.4mg	2/50	70.7mg 1/50	
v	c55276	16.1mg	158.mg	36/50	17.7mg	40/50	35.4mg	48/50	70.7mg 48/50	
w	c55276	26.3mg	2.27gm	4/50	17.7mg	12/50	35.4mg	13/50	(70.7mg 7/50) liv:hpa,hpc,nnd.	
x	c55276	44.0mg	354.mg	4/50	17.7mg	5/50	35.4mg	10/50	70.7mg 13/50 lun:a/a,a/c.	
55	c55276	10.1mg	26.0mg	13/50	17.7mg	28/50	35.4mg	35/50	71.4mg 42/50 hag:adn; lun:a/a,a/c; mul:mlh,mlm,mlp,mlu,mno; pre:sqc; spl:mlh,mno; zym:sqc.	C
a	c55276	15.1mg	32.6mg	0/50	17.7mg	5/50	35.4mg	19/50	71.4mg 31/50 pre:can,sqc.	S
b	c55276	17.3mg	38.9mg	0/50	17.7mg	3/50	35.4mg	18/50	71.4mg 28/50	

	Spe Strain Site Xpo+Xpt Sex Route Hist Notes	TD50 2Tailpvl DR AuOp
c	M m b6c gav hag MXA 24m24	39.5mg * P<.0005
d	M m b6c gav hag adn 24m24	40.7mg * P<.0005c
e	M m b6c gav lun MXA 24m24	42.5mg * P<.0005c
f	M m b6c gav MXA MXA 24m24	50.9mg * P<.0005
g	M m b6c gav MXA MXA 24m24	51.8mg * P<.0005c
h	M m b6c gav zym sqc 24m24	56.3mg Z P<.0005c
i	M m b6c gav lun a/c 24m24	59.5mg * P<.0005c
j	M m b6c gav lun a/a 24m24	103.mg * P<.004
k	M m b6c gav adr phe 24m24	116.mg Z P<.01
l	M m b6c gav ski MXA 24m24	262.mg * P<.004
m	M m b6c gav MXA MXA 24m24	269.mg * P<.005 c
n	M m b6c gav MXA MXA 24m24	169.mg * P<.02
o	M m b6c gav cst sqp 24m24	222.mg * P<.03
p	M m b6c gav TBA MXB 24m24	17.1mg * P<.0005
q	M m b6c gav liv MXB 24m24	102.mg * P<.2
r	M m b6c gav lun MXB 24m24	42.5mg * P<.0005
56	R f f34 gav MXB MXB 24m24 : + :	55.1mg * P<.0005
a	R f f34 gav zym MXA 24m24	97.9mg * P<.0005
b	R f f34 gav zym can 24m24	109.mg * P<.0005c
c	R f f34 gav MXA MXA 24m24	113.mg * P<.0005c
d	R f f34 gav ute esp 24m24	158.mg * P<.008
e	R f f34 gav MXA MXA 24m24	186.mg * P<.01 c
f	R f f34 gav MXA MXA 24m24	290.mg * P<.002 c
g	R f f34 gav ton MXA 24m24	295.mg * P<.003 c
h	R f f34 gav ton sqc 24m24	368.mg * P<.003 c
i	R f f34 gav pal MXA 24m24	288.mg * P<.06 c
j	R f f34 gav MXA MXA 24m24	364.mg * P<.04
k	R f f34 gav TBA MXB 24m24	46.7mg * P<.006
l	R f f34 gav liv MXB 24m24	no dre P=1.
57	R m f34 gav MXB MXB 24m24 : + :	51.1mg * P<.0005
a	R m f34 gav MXA MXA 24m24	91.5mg * P<.0005c
b	R m f34 gav MXA MXA 24m24	140.mg * P<.0005c
c	R m f34 gav zym MXA 24m24	155.mg * P<.0005
d	R m f34 gav zym can 24m24	166.mg * P<.0005c
e	R m f34 gav ski MXA 24m24	181.mg * P<.0005
f	R m f34 gav ski MXA 24m24	191.mg * P<.0005
g	R m f34 gav lpp MXA 24m24	220.mg * P<.0005c
h	R m f34 gav pal MXA 24m24	243.mg * P<.0005c
i	R m f34 gav pal sqp 24m24	250.mg * P<.0005c
j	R m f34 gav ski sqc 24m24	260.mg * P<.0005c
k	R m f34 gav lpp sqp 24m24	284.mg * P<.002 c
l	R m f34 gav MXA MXA 24m24	295.mg * P<.0005c
m	R m f34 gav ski sqp 24m24	427.mg * P<.003 c
n	R m f34 gav ton MXA 24m24	382.mg * P<.02 c
o	R m f34 gav ton sqc 24m24	430.mg * P<.02 c
p	R m f34 gav lpp sqc 24m24	1.15gm * P<.02 c
q	R m f34 gav TBA MXB 24m24	68.1mg * P<.006
r	R m f34 gav liv MXB 24m24	1.91gm * P<.7
BENZIDINE.2HCl***	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10	
58	M f cbn wat liv hpc 33m33 e .+.	18.9mg * P<.0005+
a	M f cbn wat hag ade 33m33 e	41.1mg Z P<.0005+
b	M f cbn wat ute agm 33m33 e	402.mg * P<.005 +
59	M m cbn wat liv hpc 33m33 e .+ .	60.5mg * P<.0005+
a	M m cbn wat hag ade 33m33 e	208.mg * P<.02 +
60	M f cff wat liv hpc 33m33 e .+.	10.9mg * P<.0005+
a	M f cff wat hag ade 33m33 e	51.7mg Z P<.0005+
b	M f cff wat ute agm 33m33 e	335.mg * P<.006 +
61	M m cff wat liv hpc 33m33 e .+ .	31.2mg * P<.0005+
a	M m cff wat hag ade 33m33 e	129.mg * P<.0005+
BENZO(a)PYRENE***	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10	
62	M f c5v gav lun ben 52w92 .>	12.1ug P<.2 -
a	M f c5v gav liv tum 52w92	no dre P=1. -
b	M f c5v gav tba mix 52w92	2.68ug P<.2 -

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc			Citation or Pathology	Brkly Code
c	c55276	24.5mg	79.0mg	1/50	17.7mg	10/50	35.4mg	13/50	71.4mg	14/50	hag:adn,can.	S
d	c55276	25.7mg	73.0mg	0/50	17.7mg	9/50	35.4mg	13/50	71.4mg	11/50		
e	c55276	24.1mg	121.mg	10/50	17.7mg	16/50	35.4mg	19/50	71.4mg	21/50	lun:a/a,a/c.	
f	c55276	28.4mg	141.mg	4/50	17.7mg	10/50	35.4mg	10/50	71.4mg	15/50	mul:lkn,mlh,mlm,mlp,mlu,mno; spl:mlh,mno.	S
g	c55276	28.8mg	141.mg	4/50	17.7mg	9/50	35.4mg	9/50	71.4mg	15/50	mul:mlh,mlm,mlp,mlu,mno; spl:mlh,mno.	
h	c55276	33.8mg	101.mg	0/50	17.7mg	1/50	35.4mg	4/50	71.4mg	21/50		
i	c55276	31.8mg	214.mg	5/50	17.7mg	11/50	35.4mg	12/50	71.4mg	14/50		
j	c55276	48.7mg	900.mg	6/50	17.7mg	6/50	35.4mg	8/50	71.4mg	12/50		S
k	c55276	47.9mg	14.1gm	1/50	17.7mg	1/50	35.4mg	7/50	(71.4mg	1/50)		S
l	c55276	94.4mg	1.96gm	0/50	17.7mg	0/50	35.4mg	2/50	71.4mg	3/50	ski:sqc,squ.	S
m	c55276	98.0mg	2.24gm	0/50	17.7mg	0/50	35.4mg	3/50	71.4mg	3/50	mul:mlh; spl:mlh.	
n	c55276	66.5mg	n.s.s.	2/50	17.7mg	2/50	35.4mg	3/50	71.4mg	5/50	cst:sqc,sqp; sto:sqc.	S
o	c55276	80.3mg	n.s.s.	2/50	17.7mg	1/50	35.4mg	2/50	71.4mg	5/50		S
p	c55276	10.4mg	38.6mg	33/50	17.7mg	40/50	35.4mg	48/50	71.4mg	46/50		
q	c55276	35.1mg	n.s.s.	15/50	17.7mg	17/50	35.4mg	22/50	71.4mg	11/50	liv:hpa,hpc,nnd.	
r	c55276	24.1mg	121.mg	10/50	17.7mg	16/50	35.4mg	19/50	71.4mg	21/50	lun:a/a,a/c.	
56	c55276	37.2mg	96.2mg	1/50	17.7mg	10/50	35.4mg	16/50	70.7mg	21/50	cst:sqp; lpp:sqp; pal:sqc,sqp; ton:sqc,sqp; zym:can.	C
a	c55276	60.8mg	179.mg	0/50	17.7mg	5/50	35.4mg	6/50	70.7mg	15/50	zym:adn,can.	S
b	c55276	66.3mg	207.mg	0/50	17.7mg	5/50	35.4mg	5/50	70.7mg	14/50		
c	c55276	65.7mg	333.mg	1/50	17.7mg	5/50	35.4mg	12/50	70.7mg	9/50	cst:sqp; lpp:sqp; pal:sqc,sqp; ton:sqc,sqp.	
d	c55276	73.3mg	4.18gm	7/50	17.7mg	7/50	35.4mg	7/50	70.7mg	14/50		S
e	c55276	90.9mg	13.1gm	1/50	17.7mg	4/50	35.4mg	8/50	70.7mg	5/50	cst:sqp; lpp:sqp; pal:sqp; ton:sqp.	
f	c55276	141.mg	1.14gm	0/50	17.7mg	1/50	35.4mg	4/50	70.7mg	5/50	pal:sqc; ton:sqc.	
g	c55276	143.mg	1.56gm	0/50	17.7mg	1/50	35.4mg	5/50	70.7mg	4/50	ton:sqc,sqp.	
h	c55276	166.mg	1.76gm	0/50	17.7mg	0/50	35.4mg	4/50	70.7mg	4/50		
i	c55276	118.mg	n.s.s.	1/50	17.7mg	4/50	35.4mg	5/50	70.7mg	4/50	pal:sqc,sqp.	
j	c55276	157.mg	n.s.s.	0/50	17.7mg	2/50	35.4mg	3/50	70.7mg	2/50	cvu:adq; utm:acn,can.	S
k	c55276	23.3mg	567.mg	38/50	17.7mg	39/50	35.4mg	41/50	70.7mg	42/50		
l	c55276	238.mg	n.s.s.	0/50	17.7mg	3/50	35.4mg	1/50	70.7mg	0/50	liv:hpa,hpc,nnd.	
57	c55276	35.9mg	83.8mg	3/50	35.4mg	21/50	70.7mg	27/50	142.mg	37/50	lpp:sqc,sqp; pal:sqc,sqp; ski:sqc,sqp; ton:sqc,sqp; zym:can.	C
a	c55276	59.4mg	174.mg	1/50	35.4mg	9/50	70.7mg	16/50	142.mg	19/50	lpp:sqc,sqp; pal:sqc,sqp; ton:sqc,sqp.	
b	c55276	84.2mg	334.mg	1/50	35.4mg	6/50	70.7mg	11/50	142.mg	13/50	lpp:sqp; pal:sqp; ton:sqp.	
c	c55276	92.8mg	363.mg	2/50	35.4mg	7/50	70.7mg	10/50	142.mg	18/50	zym:adn,can.	S
d	c55276	98.3mg	401.mg	2/50	35.4mg	6/50	70.7mg	10/50	142.mg	17/50		
e	c55276	102.mg	544.mg	1/50	35.4mg	7/50	70.7mg	5/50	142.mg	12/50	ski:adq,sqc,sqp,ulc.	S
f	c55276	105.mg	656.mg	1/50	35.4mg	7/50	70.7mg	5/50	142.mg	11/50	ski:adq,sqc,sqp.	S
g	c55276	120.mg	519.mg	0/50	35.4mg	2/50	70.7mg	5/50	142.mg	8/50	lpp:sqc,sqp.	
h	c55276	135.mg	635.mg	0/50	35.4mg	4/50	70.7mg	5/50	142.mg	9/50	pal:sqc,sqp.	
i	c55276	138.mg	668.mg	0/50	35.4mg	4/50	70.7mg	4/50	142.mg	9/50		
j	c55276	143.mg	859.mg	0/50	35.4mg	5/50	70.7mg	3/50	142.mg	8/50		
k	c55276	145.mg	986.mg	0/50	35.4mg	2/50	70.7mg	5/50	142.mg	5/50		
l	c55276	156.mg	977.mg	0/50	35.4mg	3/50	70.7mg	5/50	142.mg	7/50	lpp:sqc; pal:sqc; ton:sqc.	
m	c55276	192.mg	2.56gm	0/50	35.4mg	2/50	70.7mg	1/50	142.mg	5/50		
n	c55276	173.mg	n.s.s.	1/50	35.4mg	3/50	70.7mg	6/50	142.mg	6/50	ton:sqc,sqp.	
o	c55276	206.mg	n.s.s.	0/50	35.4mg	3/50	70.7mg	4/50	142.mg	4/50		
p	c55276	349.mg	n.s.s.	0/50	35.4mg	0/50	70.7mg	0/50	142.mg	3/50		
q	c55276	33.7mg	799.mg	39/50	35.4mg	44/50	70.7mg	45/50	142.mg	47/50		
r	c55276	261.mg	n.s.s.	2/50	35.4mg	2/50	70.7mg	5/50	142.mg	1/50	liv:hpa,hpc,nnd.	

BENZIDINE.2HCl* 531-85-1**

58	1563n	15.2mg	25.0mg	10/125	4.00mg	54/119	6.00mg	43/95	8.00mg	31/71	12.0mg	37/72	16.0mg	51/69	
					24.0mg	56/72					Littlefield;jtxe,12,671-685;1983/1984/Nelson pers.comm.				
a	1563n	25.9mg	104.mg	6/121	4.00mg	28/117	6.00mg	16/94	8.00mg	17/71	(12.0mg	10/70	16.0mg	9/67	
					24.0mg	8/68)									
b	1563n	201.mg	3.98gm	3/124	4.00mg	1/114	6.00mg	3/94	8.00mg	2/71	12.0mg	5/70	16.0mg	7/68	
					24.0mg	5/71									
59	1563n	43.3mg	97.6mg	17/123	5.00mg	20/118	6.67mg	20/95	10.0mg	23/72	13.3mg	24/71	20.0mg	37/71	
					26.7mg	32/71									
a	1563n	99.0mg	n.s.s.	10/122	5.00mg	19/113	6.67mg	17/92	10.0mg	13/72	13.3mg	13/68	20.0mg	16/69	
					26.7mg	13/66									
60	1563m	9.29mg	13.0mg	3/124	4.00mg	51/120	6.00mg	52/95	8.00mg	45/72	12.0mg	55/71	16.0mg	60/69	
					24.0mg	64/72									
a	1563m	33.3mg	130.mg	5/123	4.00mg	21/118	6.00mg	22/95	8.00mg	20/70	12.0mg	11/68	(16.0mg	12/68	
					24.0mg	8/71)									
b	1563m	163.mg	4.82gm	4/122	4.00mg	5/117	6.00mg	5/95	8.00mg	5/68	12.0mg	4/72	16.0mg	5/71	
					24.0mg	10/71									
61	1563m	24.9mg	41.2mg	14/125	5.00mg	24/119	6.67mg	30/96	10.0mg	23/71	13.3mg	35/71	20.0mg	51/71	
					26.7mg	49/71									
a	1563m	73.0mg	462.mg	6/124	5.00mg	21/117	6.67mg	19/93	10.0mg	18/70	13.3mg	16/70	20.0mg	13/67	
					26.7mg	17/68									

BENZO(a)PYRENE* 50-32-8**

62	1636	2.97ug	n.s.s.	0/11	3.23ug	2/15		Griciute;iarc,813-822;1980
a	1636	7.81ug	n.s.s.	0/11	3.23ug	0/15		
b	1636	863.ng	n.s.s.	4/11	3.23ug	10/15		

	Spe Strain Site Xpo+Xpt Sex Route Hist Notes		TD50 DR	ZTailpvl AuOp
63	M m c5v gav lun ben 52w92	.>	15.7ug	P<.4 -
a	M m c5v gav liv mal 52w92		no dre	P=1. -
b	M m c5v gav liv ben 52w92		no dre	P=1. -
c	M m c5v gav tba mix 52w92		no dre	P=1. -
C.I.	DISPERSE BLUE 1	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
64	M f b6c eat liv hpa 24m25	: +	#150.mg Z	P<.01 -
a	M f b6c eat TBA MXB 24m25		no dre	P=1.
b	M f b6c eat liv MXB 24m25		no dre	P=1.
c	M f b6c eat lun MXB 24m25		9.31gm *	P<.8
65	M m b6c eat lun a/a 24m24	: ±	925.mg *	P<.05
a	M m b6c eat liv MXA 24m24		534.mg *	P<.2 e
b	M m b6c eat TBA MXB 24m24		1.29gm Z	P<.7
c	M m b6c eat liv MXB 24m24		534.mg *	P<.2
d	M m b6c eat lun MXB 24m24		701.mg *	P<.06
66	R f f34 eat ubl MXB 24m24	: +:	131.mg Z	P<.0005
a	R f f34 eat ubl MXA 24m24		198.mg Z	P<.0005c
b	R f f34 eat ubl MXA 24m24		250.mg Z	P<.0005c
c	R f f34 eat ubl lei 24m24		294.mg Z	P<.0005c
d	R f f34 eat ubl tcc 24m24		307.mg Z	P<.0005c
e	R f f34 eat ubl tpp 24m24		317.mg Z	P<.0005c
f	R f f34 eat ubl MXA 24m24		664.mg Z	P<.0005c
g	R f f34 eat ubl sqp 24m24		1.02gm Z	P<.0005c
h	R f f34 eat ubl ley 24m24		1.54gm *	P<.004 c
i	R f f34 eat ubl sqc 24m24		1.58gm *	P<.004 c
j	R f f34 eat pni isc 24m24		291.mg *	P<.02
k	R f f34 eat MXA MXA 24m24		323.mg *	P<.03
l	R f f34 eat TBA MXB 24m24		130.mg *	P<.005
m	R f f34 eat liv MXB 24m24		no dre	P=1.
67	R m f34 eat ubl MXB 24m24	: + :	89.3mg Z	P<.0005
a	R m f34 eat ubl MXA 24m24		129.mg Z	P<.0005c
b	R m f34 eat ubl lei 24m24		131.mg Z	P<.0005c
c	R m f34 eat ubl MXA 24m24		245.mg Z	P<.0005c
d	R m f34 eat ubl tpp 24m24		370.mg *	P<.0005c
e	R m f34 eat pni MXA 24m24		414.mg *	P<.005
f	R m f34 eat ubl tcc 24m24		506.mg Z	P<.0005c
g	R m f34 eat ubl MXA 24m24		803.mg *	P<.002 c
h	R m f34 eat ubl sqp 24m24		1.26gm *	P<.006 c
i	R m f34 eat sub srn 24m24		1.83gm Z	P<.01
j	R m f34 eat tes ict 24m24		100.mg *	P<.05
k	R m f34 eat thy MXA 24m24		474.mg *	P<.03
l	R m f34 eat thy cca 24m24		529.mg *	P<.02
m	R m f34 eat pni isa 24m24		810.mg *	P<.03
n	R m f34 eat TBA MXB 24m24		39.3mg Z	P<.0005
o	R m f34 eat liv MXB 24m24		no dre	P=1.
HC	BLUE NO. 1	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
68	M f b6c eat liv MXA 24m24	:+ :	179.mg *	P<.0005
a	M f b6c eat liv hpc 24m24		208.mg *	P<.0005c
b	M f b6c eat liv hpa 24m24		697.mg \	P<.004
c	M f b6c eat TBA MXB 24m24		373.mg *	P<.002
d	M f b6c eat liv MXB 24m24		179.mg *	P<.0005
e	M f b6c eat lun MXB 24m24		no dre	P=1.
69	M m b6c eat liv MXA 24m24	: + :	259.mg *	P<.002
a	M m b6c eat liv hpa 24m24		286.mg \	P<.008
b	M m b6c eat MXB MXB 24m24		369.mg *	P<.002
c	M m b6c eat liv hpc 24m24		389.mg *	P<.002 c
d	M m b6c eat thy fca 24m24		2.23gm *	P<.008 c
e	M m b6c eat TBA MXB 24m24		561.mg *	P<.3
f	M m b6c eat liv MXB 24m24		259.mg *	P<.002
g	M m b6c eat lun MXB 24m24		no dre	P=1.
70	R f f34 eat ute esp 24m24	: ±	429.mg *	P<.05
a	R f f34 eat lun MXA 24m24		702.mg *	P<.03 a
b	R f f34 eat lun a/c 24m24		1.19gm *	P<.02 a
c	R f f34 eat TBA MXB 24m24		no dre	P=1.
d	R f f34 eat liv MXB 24m24		3.31gm *	P<.3
71	R m f34 eat liv MXA 24m24	: ±	938.mg *	P<.06 e
a	R m f34 eat liv nnd 24m24		1.66gm *	P<.05
b	R m f34 eat TBA MXB 24m24		no dre	P=1.
c	R m f34 eat liv MXB 24m24		938.mg *	P<.06
HC	BLUE NO. 2	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
72	M f b6c eat TBA MXB 24m24 s	:>	42.0gm *	P<.9 -
a	M f b6c eat liv MXB 24m24 s		19.0gm /	P<.4
b	M f b6c eat lun MXB 24m24 s		no dre	P=1.
73	M m b6c eat MXA MXA 24m24	: ±	#970.mg \	P<.02 -
a	M m b6c eat --- MXA 24m24		4.04gm *	P<.05

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
63	1636	2.66ug	n.s.s.	1/20	2.69ug	2/15				
a	1636	6.51ug	n.s.s.	2/20	2.69ug	0/15				
b	1636	6.51ug	n.s.s.	2/20	2.69ug	0/15				
c	1636	3.15ug	n.s.s.	11/20	2.69ug	4/15				
C.I. DISPERSE BLUE 1 2475-45-8										
64	c54900	67.2mg	19.8gm	2/50	76.5mg	12/50	(153.mg	3/50 319.mg 2/50)		S
a	c54900	275.mg	n.s.s.	29/50	76.5mg	33/50	153.mg	33/50 319.mg 30/50		
b	c54900	904.mg	n.s.s.	3/50	76.5mg	13/50	153.mg	3/50 319.mg 4/50	liv:hpa,hpc,nnd.	
c	c54900	791.mg	n.s.s.	1/50	76.5mg	5/50	153.mg	2/50 319.mg 3/50	lun:a/a,a/c.	
65	c54900	386.mg	n.s.s.	1/50	71.3mg	3/50	143.mg	5/50 297.mg 5/50		S
a	c54900	187.mg	n.s.s.	9/50	71.3mg	21/50	143.mg	20/50 297.mg 16/50	liv:hpa,hpc.	
b	c54900	164.mg	n.s.s.	35/50	71.3mg	44/50	143.mg	34/50 297.mg 34/50		
c	c54900	187.mg	n.s.s.	9/50	71.3mg	21/50	143.mg	20/50 297.mg 16/50	liv:hpa,hpc,nnd.	
d	c54900	275.mg	n.s.s.	4/50	71.3mg	9/50	143.mg	5/50 297.mg 11/50	lun:a/a,a/c.	
66	c54900	92.4mg	192.mg	0/50	61.3mg	0/50	124.mg	17/50 248.mg 37/50	ubl:lei,ley,sqc,sqp,tcc,tpp.	C
a	c54900	131.mg	318.mg	0/50	61.3mg	0/50	124.mg	15/50 248.mg 21/50	ubl:tcc,tpp.	
b	c54900	158.mg	424.mg	0/50	61.3mg	0/50	124.mg	3/50 248.mg 26/50	ubl:lei,ley.	
c	c54900	181.mg	520.mg	0/50	61.3mg	0/50	124.mg	2/50 248.mg 23/50		
d	c54900	186.mg	559.mg	0/50	61.3mg	0/50	124.mg	10/50 248.mg 13/50		
e	c54900	192.mg	571.mg	0/50	61.3mg	0/50	124.mg	9/50 248.mg 15/50		
f	c54900	338.mg	1.55gm	0/50	61.3mg	0/50	124.mg	1/50 248.mg 11/50	ubl:sqc,sqp.	
g	c54900	454.mg	3.15gm	0/50	61.3mg	0/50	124.mg	1/50 248.mg 7/50		
h	c54900	579.mg	10.3gm	0/50	61.3mg	0/50	124.mg	1/50 248.mg 4/50		
i	c54900	599.mg	10.9gm	0/50	61.3mg	0/50	124.mg	1/50 248.mg 4/50		
j	c54900	135.mg	n.s.s.	10/50	61.3mg	21/50	124.mg	20/50 248.mg 15/50		S
k	c54900	139.mg	n.s.s.	12/50	61.3mg	24/50	124.mg	20/50 248.mg 16/50	pit:can; pni:isc.	S
l	c54900	65.7mg	1.28gm	44/50	61.3mg	41/50	124.mg	45/50 248.mg 43/50		
m	c54900	1.04gm	n.s.s.	1/50	61.3mg	0/50	124.mg	2/50 248.mg 0/50	liv:hpa,hpc,nnd.	
67	c54900	63.0mg	130.mg	0/50	49.3mg	0/50	99.0mg	17/50 198.mg 45/50	ubl:lei,ley,sqc,sqp,tcc,tpp.	C
a	c54900	86.9mg	196.mg	0/50	49.3mg	0/50	99.0mg	7/50 198.mg 41/50	ubl:lei,ley.	
b	c54900	88.0mg	200.mg	0/50	49.3mg	0/50	99.0mg	6/50 198.mg 41/50		
c	c54900	141.mg	463.mg	0/50	49.3mg	0/50	99.0mg	10/50 198.mg 11/50	ubl:tcc,tpp.	
d	c54900	183.mg	910.mg	0/50	49.3mg	0/50	99.0mg	8/50 198.mg 4/50		
e	c54900	178.mg	4.62gm	1/50	49.3mg	2/50	99.0mg	5/50 198.mg 3/50	pni:isa,isc.	S
f	c54900	249.mg	1.18gm	0/50	49.3mg	0/50	99.0mg	4/50 198.mg 8/50		
g	c54900	311.mg	3.41gm	0/50	49.3mg	0/50	99.0mg	2/50 198.mg 4/50	ubl:sqc,sqp.	
h	c54900	401.mg	15.0gm	0/50	49.3mg	0/50	99.0mg	1/50 198.mg 3/50		
i	c54900	548.mg	99.7gm	0/50	49.3mg	0/50	99.0mg	0/50 198.mg 3/50		S
j	c54900	41.2mg	n.s.s.	44/50	49.3mg	44/50	99.0mg	38/50 198.mg 16/50		S
k	c54900	187.mg	n.s.s.	2/50	49.3mg	4/50	99.0mg	5/50 198.mg 3/50	thy:cca,ccr.	S
l	c54900	213.mg	n.s.s.	1/50	49.3mg	2/50	99.0mg	4/50 198.mg 3/50		S
m	c54900	278.mg	n.s.s.	1/50	49.3mg	0/50	99.0mg	4/50 198.mg 2/50		S
n	c54900	24.9mg	79.8mg	49/50	49.3mg	49/50	99.0mg	47/50 198.mg 46/50		
o	c54900	540.mg	n.s.s.	4/50	49.3mg	2/50	99.0mg	2/50 198.mg 0/50	liv:hpa,hpc,nnd.	
HC BLUE NO. 1 2784-94-3										
68	c04159	129.mg	274.mg	3/50	379.mg	33/50	765.mg	47/50	liv:hpa,hpc.	S
a	c04159	150.mg	304.mg	1/50	379.mg	24/50	765.mg	47/50		
b	c04159	314.mg	4.97gm	2/50	379.mg	11/50	(765.mg	4/50)		S
c	c04159	199.mg	1.72gm	29/50	379.mg	35/50	765.mg	47/50		
d	c04159	129.mg	274.mg	3/50	379.mg	33/50	765.mg	47/50	liv:hpa,hpc,nnd.	
e	c04159	2.59gm	n.s.s.	4/50	379.mg	2/50	765.mg	2/50	lun:a/a,a/c.	
69	c04159	142.mg	1.13gm	15/50	176.mg	31/50	355.mg	37/50	liv:hpa,hpc.	S
a	c04159	133.mg	6.59gm	4/50	176.mg	17/50	(355.mg	10/50)		S
b	c04159	202.mg	1.61gm	11/50	176.mg	20/50	355.mg	31/50	liv:hpc; thy:fca.	C
c	c04159	210.mg	1.95gm	11/50	176.mg	20/50	355.mg	30/50		
d	c04159	846.mg	39.1gm	0/50	176.mg	0/50	355.mg	5/50		
e	c04159	165.mg	n.s.s.	36/50	176.mg	44/50	355.mg	43/50		
f	c04159	142.mg	1.13gm	15/50	176.mg	31/50	355.mg	37/50	liv:hpa,hpc,nnd.	
g	c04159	1.12gm	n.s.s.	5/50	176.mg	6/50	355.mg	3/50	lun:a/a,a/c.	
70	c04159	185.mg	n.s.s.	5/50	72.9mg	9/50	148.mg	14/50		S
a	c04159	299.mg	n.s.s.	1/50	72.9mg	3/50	148.mg	7/50	lun:a/a,a/c.	
b	c04159	453.mg	n.s.s.	0/50	72.9mg	1/50	148.mg	4/50		
c	c04159	108.mg	n.s.s.	45/50	72.9mg	43/50	148.mg	45/50		
d	c04159	809.mg	n.s.s.	0/50	72.9mg	1/50	148.mg	1/50	liv:hpa,hpc,nnd.	
71	c04159	334.mg	n.s.s.	1/50	58.3mg	0/50	118.mg	6/50	liv:hpc,nnd.	
a	c04159	499.mg	n.s.s.	0/50	58.3mg	0/50	118.mg	3/50		S
b	c04159	117.mg	n.s.s.	41/50	58.3mg	41/50	118.mg	37/50		
c	c04159	334.mg	n.s.s.	1/50	58.3mg	0/50	118.mg	6/50	liv:hpa,hpc,nnd.	
HC BLUE NO. 2 33229-34-4										
72	c54897	2.24gm	n.s.s.	31/50	1.29gm	19/50	2.58gm	22/50		
a	c54897	4.32gm	n.s.s.	7/50	1.29gm	1/50	2.58gm	8/50	liv:hpa,hpc,nnd.	
b	c54897	8.92gm	n.s.s.	1/50	1.29gm	3/50	2.58gm	0/50	lun:a/a,a/c.	
73	c54897	416.mg	n.s.s.	4/50	594.mg	14/50	(1.19gm	9/50)	ski:fbs,fib; sub:fbs,fib.	S
a	c54897	1.77gm	n.s.s.	1/50	594.mg	5/50	1.19gm	8/50	---:mlh,mlm,mlp.	S

	Spe Strain Site Xpo+Xpt Sex Route Hist Notes	TD50 DR	2Tailpvl AuOp
b	M m b6c eat --- mlp 24m24	5.45gm *	P<.03
c	M m b6c eat TBA MXB 24m24	5.02gm *	P<.7
d	M m b6c eat liv MXB 24m24	6.55gm *	P<.6
e	M m b6c eat lun MXB 24m24	no dre	P=1.
74	R f f34 eat liv MXA 24m24	#8.15gm *	P<.04 -
a	R f f34 eat TBA MXB 24m24	3130.gm	P<1.
b	R f f34 eat liv MXB 24m24	8.15gm *	P<.04
75	R m f34 eat thy ccr 24m24	#1.99gm *	P<.02 -
a	R m f34 eat TBA MXB 24m24	no dre	P=1.
b	R m f34 eat liv MXB 24m24	20.3gm *	P<.7
	BROMATE, POTASSIUM*** 100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
76	R f f34 wat kid mix 26m26 e	13.7mg *	P<.0005+
a	R f f34 wat kid adc 26m26 e	16.4mg *	P<.0005
b	R f f34 wat kid ade 26m26 e	87.5mg *	P<.0005
c	R f f34 wat thy mix 26m26 e	97.6mg *	P<.01
d	R f f34 wat liv mix 26m26 e	no dre	P=1.
e	R f f34 wat tba mix 26m26 e	9.05mg *	P<.003
77	R m f34 wat kid mix 26m26 ev	9.62mg *	P<.0005+
a	R m f34 wat kid adc 26m26 ev	12.6mg *	P<.0005
b	R m f34 wat per mso 26m26 ev	25.3mg *	P<.0005+
c	R m f34 wat kid ade 26m26 ev	46.2mg \	P<.0005
d	R m f34 wat liv mix 26m26 ev	164.mg *	P<.2
e	R m f34 wat tba mix 26m26 ev	noTD50	P=1.
	1,3-BUTADIENE 100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
78	M f b6c inh MXB MXB 61w61	53.0mg \	P<.0005
a	M f b6c inh MXA MXA 61w61	147.mg \	P<.0005
b	M f b6c inh lun MXA 61w61	203.mg *	P<.0005c
c	M f b6c inh lun a/c 61w61	227.mg \	P<.0005c
d	M f b6c inh lun a/a 61w61	259.mg *	P<.0005c
e	M f b6c inh --- mno 61w61	270.mg \	P<.0005c
f	M f b6c inh hea hes 61w61	283.mg *	P<.0005c
g	M f b6c inh ova MXA 61w61	370.mg *	P<.0005c
h	M f b6c inh for MXA 61w61	396.mg \	P<.002
i	M f b6c inh for sqp 61w61	461.mg \	P<.005 c
j	M f b6c inh for MXA 61w61	462.mg *	P<.0005
k	M f b6c inh for MXA 61w61	483.mg *	P<.0005
l	M f b6c inh mgl acc 61w61	1.03gm *	P<.002 c
m	M f b6c inh liv MXA 61w61	1.17gm *	P<.004 c
n	M f b6c inh liv hpa 61w61	1.59gm *	P<.009 c
o	M f b6c inh ova gcc 61w61	7.58gm *	P<.2 c
p	M f b6c inh TBA MXB 61w61	41.5mg \	P<.0005
q	M f b6c inh liv MXB 61w61	1.17gm *	P<.004
r	M f b6c inh lun MXB 61w61	203.mg *	P<.0005
79	M m b6c inh MXB MXB 60w60	28.8mg \	P<.0005
a	M m b6c inh lun MXA 60w60	65.9mg *	P<.0005c
b	M m b6c inh MXA MXA 60w60	96.7mg \	P<.0005
c	M m b6c inh hea hes 60w60	96.7mg \	P<.0005c
d	M m b6c inh lun a/a 60w60	96.9mg *	P<.0005c
e	M m b6c inh --- mno 60w60	105.mg *	P<.0005c
f	M m b6c inh for MXA 60w60	120.mg \	P<.0005
g	M m b6c inh for MXA 60w60	140.mg \	P<.0005c
h	M m b6c inh lun a/c 60w60	312.mg *	P<.0005c
i	M m b6c inh pre MXA 60w60	403.mg *	P<.002
j	M m b6c inh pre sqc 60w60	538.mg *	P<.004
k	M m b6c inh for MXA 60w60	557.mg *	P<.004
l	M m b6c inh TBA MXB 60w60	28.8mg \	P<.0005
m	M m b6c inh liv MXB 60w60	541.mg *	P<.2
n	M m b6c inh lun MXB 60w60	65.9mg *	P<.0005
	N-BUTYL CHLORIDE 100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
80	M f b6c gav lun a/c 24m24	#1.71gm	P<.03 -
a	M f b6c gav TBA MXB 24m24	no dre	P=1.
b	M f b6c gav liv MXB 24m24	1.38gm	P<.2
c	M f b6c gav lun MXB 24m24	1.16gm	P<.08
81	M f b6c gav TBA MXB 24m24	no dre	P=1. -
a	M f b6c gav liv MXB 24m24	no dre	P=1.
b	M f b6c gav lun MXB 24m24	13.1gm	P<1.
82	M m b6c gav liv MXA 24m24	#808.mg *	P<.02 -
a	M m b6c gav MXA MXA 24m24	2.83gm *	P<.04
b	M m b6c gav TBA MXB 24m24	423.mg *	P<.01
c	M m b6c gav liv MXB 24m24	808.mg *	P<.02
d	M m b6c gav lun MXB 24m24	3.19gm *	P<.4
83	M m b6c gav TBA MXB 24m24	no dre	P=1. -
a	M m b6c gav liv MXB 24m24	623.mg	P<.3

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
b	c54897	2.35gm	n.s.s.	0/50	594.mg	2/50	1.19gm	5/50		S
c	c54897	777.mg	n.s.s.	23/50	594.mg	33/50	1.19gm	37/50		
d	c54897	1.18gm	n.s.s.	10/50	594.mg	16/50	1.19gm	18/50	liv:hpa,hpc,nnd.	
e	c54897	2.44gm	n.s.s.	5/50	594.mg	9/50	1.19gm	6/50	lun:a/a,a/c.	
74	c54897	3.08gm	n.s.s.	0/50	495.mg	2/50	990.mg	3/50	liv:hpc,nnd.	S
a	c54897	800.mg	n.s.s.	43/50	495.mg	36/50	990.mg	41/50		
b	c54897	3.08gm	n.s.s.	0/50	495.mg	2/50	990.mg	3/50	liv:hpa,hpc,nnd.	
75	c54897	902.mg	n.s.s.	0/50	198.mg	3/50	396.mg	5/50		S
a	c54897	302.mg	n.s.s.	43/50	198.mg	33/50	(396.mg	32/50)		
b	c54897	2.26gm	n.s.s.	1/50	198.mg	0/50	396.mg	2/50	liv:hpa,hpc,nnd.	
BROMATE, POTASSIUM*** 7758-01-2										
76	1550	9.90mg	19.5mg	0/47	14.2mg	28/50	28.3mg	39/49	Kurokawa;jnci,71,965-972;1983	
a	1550	11.7mg	23.7mg	0/47	14.2mg	21/50	28.3mg	39/49		
b	1550	49.6mg	234.mg	0/47	14.2mg	8/50	28.3mg	9/49		
c	1550	48.2mg	7.87gm	3/52	14.2mg	10/52	28.3mg	12/52		
d	1550	220.mg	n.s.s.	2/52	14.2mg	1/52	28.3mg	2/52		
e	1550	3.96mg	62.6mg	44/52	14.2mg	48/52	28.3mg	52/52		
77	1550	6.93mg	13.9mg	3/53	12.4mg	32/53	22.5mg	46/52		
a	1550	9.00mg	18.6mg	3/53	12.4mg	24/53	22.5mg	44/52		
b	1550	16.1mg	49.8mg	6/53	12.4mg	17/52	22.5mg	28/46		
c	1550	22.5mg	124.mg	0/53	12.4mg	10/53	(22.5mg	5/52)		
d	1550	62.8mg	n.s.s.	2/53	12.4mg	7/53	22.5mg	6/52		
e	1550	n.s.s.	n.s.s.	53/53	12.4mg	53/53	22.5mg	52/52		
1,3-BUTADIENE 106-99-0										
78	c50602	30.6mg	106.mg	4/50	435.mg	30/50	(869.mg	44/50)	---:mno; for:sqp; hea:hes; liv:hpa,hpc; lun:a/a,a/c; mgl:acc;	
									ova:gcc,gct.	C
a	c50602	73.4mg	333.mg	0/50	435.mg	13/50	(869.mg	19/50)	hea:hes; liv:hes; sub:hes.	S
b	c50602	126.mg	411.mg	3/50	435.mg	12/50	869.mg	23/50	lun:a/a,a/c.	
c	c50602	91.8mg	825.mg	0/50	435.mg	6/50	(869.mg	8/50)		
d	c50602	153.mg	585.mg	3/50	435.mg	9/50	869.mg	20/50		
e	c50602	114.mg	1.03gm	1/50	435.mg	10/50	(869.mg	10/50)		
f	c50602	179.mg	483.mg	0/50	435.mg	11/50	869.mg	18/50		
g	c50602	214.mg	728.mg	0/50	435.mg	6/50	869.mg	13/50	ova:gcc,gct.	
h	c50602	133.mg	2.44gm	0/50	435.mg	4/50	(869.mg	1/50)	for:sqc,sqp.	S
i	c50602	140.mg	5.15gm	0/50	435.mg	3/50	(869.mg	1/50)		
j	c50602	252.mg	1.03gm	0/50	435.mg	5/50	869.mg	10/50	for:ppn,sqc,sqp.	S
k	c50602	259.mg	1.10gm	0/50	435.mg	4/50	869.mg	10/50	for:ppn,sqp.	S
l	c50602	462.mg	4.19gm	0/50	435.mg	2/50	869.mg	6/50		
m	c50602	496.mg	6.82gm	0/50	435.mg	2/50	869.mg	5/50	liv:hpa,hpc.	
n	c50602	596.mg	36.9gm	0/50	435.mg	1/50	869.mg	4/50		
o	c50602	1.23gm	n.s.s.	0/50	435.mg	0/50	869.mg	1/50		
p	c50602	25.1mg	75.8mg	6/50	435.mg	40/50	(869.mg	46/50)		
q	c50602	496.mg	6.82gm	0/50	435.mg	2/50	869.mg	5/50	liv:hpa,hpc,nnd.	
r	c50602	126.mg	411.mg	3/50	435.mg	12/50	869.mg	23/50	lun:a/a,a/c.	
79	c50602	17.5mg	50.0mg	2/50	362.mg	43/50	(724.mg	39/50)	---:mno; for:ppn,sqp; hea:hes; lun:a/a,a/c.	C
a	c50602	38.7mg	128.mg	2/50	362.mg	14/50	724.mg	15/50	lun:a/a,a/c.	
b	c50602	51.1mg	198.mg	0/50	362.mg	16/50	(724.mg	8/50)	hea:hes; pac:hes.	S
c	c50602	51.1mg	198.mg	0/50	362.mg	16/50	(724.mg	7/50)		
d	c50602	54.4mg	203.mg	2/50	362.mg	12/50	724.mg	11/50		
e	c50602	70.1mg	158.mg	0/50	362.mg	23/50	724.mg	29/50		
f	c50602	49.6mg	391.mg	0/50	362.mg	7/50	(724.mg	1/50)	for:ppn,sqc,sqp.	S
g	c50602	53.3mg	600.mg	0/50	362.mg	5/50	(724.mg	0/50)	for:ppn,sqp.	
h	c50602	126.mg	1.08gm	0/50	362.mg	2/50	724.mg	5/50		
i	c50602	150.mg	1.92gm	0/50	362.mg	3/50	724.mg	2/50	pre:can,sqc.	S
j	c50602	181.mg	4.83gm	0/50	362.mg	3/50	724.mg	1/50		S
k	c50602	197.mg	4.31gm	0/50	362.mg	4/50	724.mg	1/50	for:sqc,sqp.	S
l	c50602	17.3mg	52.5mg	10/50	362.mg	44/50	(724.mg	40/50)		
m	c50602	149.mg	n.s.s.	8/50	362.mg	6/50	724.mg	2/50	liv:hpa,hpc,nnd.	
n	c50602	38.7mg	128.mg	2/50	362.mg	14/50	724.mg	15/50	lun:a/a,a/c.	
N-BUTYL CHLORIDE 109-69-3										
80	c06155	592.mg	n.s.s.	0/50	350.mg	4/50				S
a	c06155	295.mg	n.s.s.	31/50	350.mg	29/50				
b	c06155	442.mg	n.s.s.	3/50	350.mg	8/50			liv:hpa,hpc,nnd.	
c	c06155	411.mg	n.s.s.	3/50	350.mg	9/50			lun:a/a,a/c.	
81	c06156	198.mg	n.s.s.	35/50	176.mg	35/50				
a	c06156	521.mg	n.s.s.	9/50	176.mg	7/50			liv:hpa,hpc,nnd.	
b	c06156	366.mg	n.s.s.	6/50	176.mg	8/50			lun:a/a,a/c.	
82	c06155	359.mg	n.s.s.	12/50	354.mg	13/50	707.mg	15/50	liv:hpa,hpc.	S
a	c06155	1.03gm	n.s.s.	1/50	354.mg	3/50	707.mg	4/50	bom:hes; k/p:hes; liv:hes; mul:hes; omt:hes; spl:hes; thx:hes.	S
b	c06155	199.mg	49.9gm	32/50	354.mg	38/50	707.mg	29/50		
c	c06155	359.mg	n.s.s.	12/50	354.mg	13/50	707.mg	15/50	liv:hpa,hpc,nnd.	
d	c06155	742.mg	n.s.s.	6/50	354.mg	10/50	707.mg	4/50	lun:a/a,a/c.	
83	c06156	135.mg	n.s.s.	41/50	177.mg	39/50				
a	c06156	177.mg	n.s.s.	15/50	177.mg	21/50			liv:hpa,hpc,nnd.	

	Spe Strain Site Sex Route Hist	Xpo+Xpt Notes	TD50 DR	2Tailpvl AuOp
b	M m b6c gav lun MXB 24m24		no dre	P=1.
84	R f f34 gav TBA MXB 24m24	:>	100.mg *	P<.3 -
a	R f f34 gav liv MXB 24m24		1.51gm *	P<.8
85	R m f34 gav tes ict 24m24	: ±	#45.1mg *	P<.02 -
a	R m f34 gav TBA MXB 24m24		40.5mg *	P<.009
b	R m f34 gav liv MXB 24m24		no dre	P=1.
N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE***		.:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
86	R m f34 wat ubl mix 25m26 ae	. + .	.432mg *	P<.0005+
a	R m f34 wat ubl pam 25m26 ae		.447mg *	P<.0005
87	R m sda gav ubl mix 39w74	.+ .	1.17mg	P<.0005+
a	R m sda gav lun car 39w74		166.mg	P<.3
b	R m sda gav liv tum 39w74		no dre	P=1.
N-N-BUTYL-N-NITROSOUREA		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
88	R f f3d wat dgt mix 50w50 ev	. (+).	1.30mg	P<.0005+
a	R f f3d wat for mix 50w50 ev		2.43mg	P<.0005+
b	R f f3d wat eso mix 50w50 ev		3.21mg	P<.0005+
c	R f f3d wat for pam 50w50 ev		4.00mg	P<.0005
d	R f f3d wat vag mix 50w50 ev		5.05mg	P<.0005+
e	R f f3d wat vag pam 50w50 ev		6.00mg	P<.0005
f	R f f3d wat eso pam 50w50 ev		6.58mg	P<.0005
g	R f f3d wat eso sqc 50w50 ev		8.05mg	P<.0005
h	R f f3d wat phr mix 50w50 ev		8.05mg	P<.0005
i	R f f3d wat for sqc 50w50 ev		10.2mg	P<.0005
j	R f f3d wat phr sqc 50w50 ev		10.2mg	P<.0005
k	R f f3d wat ton mix 50w50 ev		10.2mg	P<.0005
l	R f f3d wat edu mix 50w50 ev		11.6mg	P<.0005+
m	R f f3d wat ton pam 50w50 ev		13.5mg	P<.002
n	R f f3d wat edu ssc 50w50 ev		19.4mg	P<.008
o	R f f3d wat --- mix 50w50 ev		24.7mg	P<.02 +
p	R f f3d wat tba mix 50w50 ev		noTD50	P<.0005
89	R m f3d wat dgt mix 50w50 ev	.(+) .	.910mg	P<.0005+
a	R m f3d wat for mix 50w50 ev		2.62mg	P<.0005+
b	R m f3d wat eso mix 50w50 ev		3.02mg	P<.0005+
c	R m f3d wat for pam 50w50 ev		3.25mg	P<.0005
d	R m f3d wat eso pam 50w50 ev		4.08mg	P<.0005
e	R m f3d wat --- mix 50w50 ev		10.2mg	P<.002 +
f	R m f3d wat duo mix 50w50 ev		11.8mg	P<.002
g	R m f3d wat edu mix 50w50 ev		11.8mg	P<.002 +
h	R m f3d wat pls mix 50w50 ev		11.8mg	P<.002
i	R m f3d wat eso sqc 50w50 ev		17.0mg	P<.009
j	R m f3d wat pls sqc 50w50 ev		17.0mg	P<.009
k	R m f3d wat tba mix 50w50 ev		noTD50	P<.0005
BUTYLATED HYDROXYANISOLE***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
90	R f f34 eat for pam 24m26 e	.+ .	490.mg /	P<.0005+
a	R f f34 eat for sqc 24m26 e		2.75gm /	P<.0005+
b	R f f34 eat liv hnd 24m26 e		162.gm *	P<.9
91	R m f34 eat for pam 24m26 e	. + .	349.mg /	P<.0005+
a	R m f34 eat for sqc 24m26 e		1.80gm /	P<.0005+
b	R m f34 eat liv hnd 24m26 e		no dre	P=1.
92	R m f34 eat liv tum 60w60 er	.>	no dre	P=1.
CAFFEINE***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
93	R f sda wat liv cad 24m24 e	.>	15.6gm *	P<.9 -
a	R f sda wat liv clc 24m24 e		no dre	P=1. -
b	R f sda wat liv hpa 24m24 e		no dre	P=1. -
c	R f sda wat tba mix 24m24 e		no dre	P=1. -
94	R m sda wat liv clc 24m24 e	.>	no dre	P=1. -
a	R m sda wat liv hpa 24m24 e		no dre	P=1. -
b	R m sda wat tba mix 24m24 e		no dre	P=1. -
CAPTAFOL		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
95	M f b6c eat liv mix 22m24 ae	. + .	89.4mg Z	P<.0005+
a	M f b6c eat smi mix 22m24 ae		359.mg Z	P<.0005+
b	M f b6c eat liv hpc 22m24 ae		398.mg Z	P<.003 +
c	M f b6c eat smi adc 22m24 ae		512.mg Z	P<.0005+
d	M f b6c eat hea hae 22m24 ae		1.40gm *	P<.0005+
e	M f b6c eat spl hem 22m24 ae		1.47gm Z	P<.02 +
f	M f b6c eat for mix 22m24 ae		2.19gm *	P<.03 +
g	M f b6c eat for sqc 22m24 ae		22.6gm *	P<.2 +
h	M f b6c eat lun adc 22m24 ae		134.gm *	P<1.
i	M f b6c eat lun mix 22m24 ae		no dre	P=1.
96	M m b6c eat smi mix 22m24 e	. + .	137.mg Z	P<.0005+
a	M m b6c eat liv hpc 22m24 e		138.mg Z	P<.003 +
b	M m b6c eat smi adc 22m24 e		151.mg Z	P<.0005+
c	M m b6c eat hea hae 22m24 e		647.mg Z	P<.0005+

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology Brkly Code
b	c06156	354.mg	n.s.s.	14/50	177.mg	11/50			lun:a/a,a/c.
84	c06155	28.6mg	n.s.s.	47/50	42.0mg	46/50	84.1mg	25/50	
a	c06155	187.mg	n.s.s.	1/50	42.0mg	4/50	84.1mg	0/50	liv:hpa,hpc,nnd.
85	c06155	21.3mg	n.s.s.	46/50	42.0mg	45/50	84.5mg	39/50	S
a	c06155	19.8mg	1.01gm	48/50	42.0mg	48/50	84.5mg	42/50	
b	c06155	265.mg	n.s.s.	3/50	42.0mg	3/50	84.5mg	1/50	liv:hpa,hpc,nnd.
N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE*** (butyl-butanol-nitrosamine) 3817-11-6									
86	1606	.281mg	.680mg	0/50	50.0ug	0/29	.250mg	6/30	.500mg 23/30 2.50mg 30/30 Ito;zkko,108,169-173;1984
a	1606	.298mg	.691mg	0/50	50.0ug	2/29	.250mg	7/30	.500mg 23/30 2.50mg 29/30
87	1637	.641mg	2.03mg	0/40	10.5mg	44/46			Tacchi;ctet,22,89-94;1984
a	1637	27.1mg	n.s.s.	0/40	10.5mg	1/46			
b	1637	50.6mg	n.s.s.	0/40	10.5mg	0/46			
N-N-BUTYL-N-NITROSOUREA 869-01-2									
88	1620m	.779mg	2.24mg	0/40	16.8mg	34/39			Takeuchi;zkko,107,32-37;1984
a	1620m	1.48mg	4.31mg	0/40	16.8mg	26/39			
b	1620m	1.91mg	5.96mg	0/40	16.8mg	22/39			
c	1620m	2.30mg	7.77mg	0/40	16.8mg	19/39			
d	1620m	2.80mg	10.5mg	0/40	16.8mg	16/39			
e	1620m	3.21mg	13.1mg	0/40	16.8mg	14/39			
f	1620m	3.45mg	14.9mg	0/40	16.8mg	13/39			
g	1620m	4.03mg	19.9mg	0/40	16.8mg	11/39			
h	1620m	4.03mg	19.9mg	0/40	16.8mg	11/39			
i	1620m	4.78mg	29.5mg	0/40	16.8mg	9/39			
j	1620m	4.78mg	29.5mg	0/40	16.8mg	9/39			
k	1620m	4.78mg	29.5mg	0/40	16.8mg	9/39			
l	1620m	5.25mg	38.3mg	0/40	16.8mg	8/39			
m	1620m	5.82mg	54.3mg	0/40	16.8mg	7/39			
n	1620m	7.38mg	282.mg	0/40	16.8mg	5/39			
o	1620m	8.51mg	n.s.s.	0/40	16.8mg	4/39			
p	1620m	n.s.s.	1.08mg	1/40	16.8mg	39/39			
89	1620n	.519mg	1.60mg	0/38	14.7mg	36/39			
a	1620n	1.57mg	4.80mg	0/38	14.7mg	23/39			
b	1620n	1.77mg	5.68mg	0/38	14.7mg	21/39			
c	1620n	1.89mg	6.21mg	0/38	14.7mg	20/39			
d	1620n	2.29mg	8.25mg	0/38	14.7mg	17/39			
e	1620n	4.60mg	34.5mg	0/38	14.7mg	8/39			
f	1620n	5.09mg	49.9mg	0/38	14.7mg	7/39			
g	1620n	5.09mg	49.9mg	0/38	14.7mg	7/39			
h	1620n	5.09mg	49.9mg	0/38	14.7mg	7/39			
i	1620n	6.45mg	362.mg	0/38	14.7mg	5/39			
j	1620n	6.45mg	362.mg	0/38	14.7mg	5/39			
k	1620n	n.s.s.	.991mg	5/38	14.7mg	39/39			
BUTYLATED HYDROXYANISOLE*** (BHA, 2(3)-tert-butyl-4-hydroxyanisole) 25013-16-5									
90	1568	334.mg	744.mg	0/51	232.mg	1/51	929.mg	49/51	Ito;jnci,70,343-352;1983
a	1568	1.51gm	5.82gm	0/51	232.mg	0/51	929.mg	15/51	
b	1568	8.36gm	n.s.s.	1/51	232.mg	0/51	929.mg	1/51	
91	1568	238.mg	528.mg	0/51	186.mg	1/50	743.mg	52/52	
a	1568	1.04gm	3.56gm	0/51	186.mg	0/50	743.mg	18/52	
b	1568	4.38gm	n.s.s.	4/51	186.mg	3/50	743.mg	3/52	
92	1640	343.mg	n.s.s.	0/25	200.mg	0/25			Rao;canr,44,1072-1076;1984
CAFFEINE*** 58-08-2									
93	1615	849.mg	n.s.s.	1/100	11.4mg	2/50	24.6mg	0/50	53.1mg 1/50 114.mg 1/50 Mohr;fctx,22,377-382;1984
a	1615	1.32gm	n.s.s.	1/100	11.4mg	0/50	24.6mg	2/50	53.1mg 0/50 114.mg 0/50
b	1615	1.21gm	n.s.s.	0/100	11.4mg	0/50	24.6mg	1/50	53.1mg 0/50 114.mg 0/50
c	1615	281.mg	n.s.s.	84/100	11.4mg	40/50	24.6mg	40/50	53.1mg 36/50 114.mg 31/50
94	1615	1.18gm	n.s.s.	1/100	10.0mg	0/50	21.5mg	0/50	46.5mg 1/50 100.mg 0/50
a	1615	1.65gm	n.s.s.	2/100	10.0mg	1/50	21.5mg	0/50	46.5mg 0/50 100.mg 0/50
b	1615	366.mg	n.s.s.	69/100	10.0mg	35/50	21.5mg	29/50	46.5mg 27/50 100.mg 22/50
CAPTAFOL 2425-06-1									
95	1625	52.7mg	188.mg	4/48	90.0mg	27/50	(180.mg	22/49	390.mg 0/51) Ito;gann,75,853-865;1984
a	1625	216.mg	666.mg	0/48	90.0mg	6/50	180.mg	16/49	(390.mg 12/51)
b	1625	216.mg	2.43gm	2/48	90.0mg	13/50	180.mg	12/49	(390.mg 0/51)
c	1625	286.mg	1.09gm	0/48	90.0mg	3/50	180.mg	13/49	(390.mg 7/51)
d	1625	770.mg	3.35gm	0/48	90.0mg	2/50	180.mg	2/49	390.mg 11/51
e	1625	599.mg	n.s.s.	0/48	90.0mg	2/50	180.mg	4/49	(390.mg 0/51)
f	1625	1.07gm	n.s.s.	0/48	90.0mg	2/50	180.mg	4/49	390.mg 4/51
g	1625	3.68gm	n.s.s.	0/48	90.0mg	0/50	180.mg	0/49	390.mg 1/51
h	1625	n.s.s.	n.s.s.	1/48	90.0mg	1/50	180.mg	3/49	390.mg 1/51
i	1625	2.61gm	n.s.s.	2/48	90.0mg	1/50	180.mg	3/49	390.mg 1/51
96	1625	93.5mg	212.mg	0/47	83.1mg	10/51	166.mg	32/46	(332.mg 26/47)
a	1625	68.5mg	901.mg	8/47	83.1mg	23/51	(166.mg	15/46	332.mg 1/47)
b	1625	101.mg	237.mg	0/47	83.1mg	7/51	166.mg	32/46	(332.mg 22/47)
c	1625	401.mg	1.14gm	0/47	83.1mg	1/51	166.mg	4/46	332.mg 20/47

Spe Strain Site Xpo+Xpt TD50 2Tailpvl
Sex Route Hist Notes DR AuOp

d M m b6c eat spl hem 22m24 e 1.57gm Z P<.008 +
e M m b6c eat liv mix 22m24 e 166.mg Z P<.03
f M m b6c eat for mix 22m24 e 1.81gm * P<.02 +
g M m b6c eat for sqc 22m24 e 6.19gm * P<.06 +
h M m b6c eat spl mix 22m24 e 2.56gm Z P<.3
i M m b6c eat spl hae 22m24 e 79.1gm * P<.9 +
j M m b6c eat lun adc 22m24 e no dre P=1.
k M m b6c eat lun mix 22m24 e no dre P=1.

CARBON TETRACHLORIDE*** 100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
97 M f b6c gav liv hpc 78w90 ej . + . 184.mg * P<.0005+
a M f b6c gav adr mix 78w90 ej 899.mg \ P<.0005+
b M f b6c gav tba mix 78w90 ej 195.mg * P<.0005
98 M m b6c gav liv hpc 78w90 ej . + . 127.mg * P<.0005+
a M m b6c gav adr mix 78w90 ej 683.mg * P<.0005+
b M m b6c gav tba mix 78w90 ej 130.mg * P<.0005
99 R f osm gav liv nnd 18m26 ej .> 390.mg * P<.3 +
a R f osm gav liv hpc 18m26 ej no dre P=1.
b R f osm gav tba mix 18m26 ej no dre P=1.
100 R m osm gav liv nnd 18m26 ej .> 529.mg * P<.2 +
a R m osm gav liv hpc 18m26 ej 666.mg * P<.4
b R m osm gav tba mix 18m26 ej 166.mg * P<.4

CARBOXYMETHYLNITROSOUREA*** 100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
101 R f don wat mgl mix 68w68 e . + . 2.30mg Z P<.0005+
a R f don wat mgl fba 68w68 e 2.92mg Z P<.0005
b R f don wat itn mix 68w68 e 5.37mg * P<.0005+
c R f don wat smi ade 68w68 e 8.09mg * P<.0005
d R f don wat smi adc 68w68 e 11.6mg * P<.0005
e R f don wat tba mix 68w68 e 1.38mg * P<.0005

CHLORINATED PARAFFINS (C23, 43% CHLORINE) ..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
102 M f b6c gav liv MXA 24m24 s : 10.5gm * P<.1 e
a M f b6c gav liv hpc 24m24 s 14.0gm * P<.05 e
b M f b6c gav liv hpa 24m24 s 16.2gm * P<.2 e
c M f b6c gav TBA MXB 24m24 s 5.83gm * P<.5
d M f b6c gav liv MXB 24m24 s 10.5gm * P<.1
e M f b6c gav lun MXB 24m24 s 1220.gm P<1.
103 M m b6c gav MXA MXA 24m24 : ± 6.54gm * P<.03 c
a M m b6c gav MXA MXA 24m24 22.9gm * P<.04 c
b M m b6c gav mul mlh 24m24 43.2gm * P<.05 c
c M m b6c gav thy fcc 24m24 44.0gm * P<.05
d M m b6c gav MXA MXA 24m24 12.1gm * P<.2 c
e M m b6c gav TBA MXB 24m24 36.4gm * P<.9
f M m b6c gav liv MXB 24m24 12.3gm * P<.4
g M m b6c gav lun MXB 24m24 31.1gm * P<.7
104 R f f34 gav amd MXA 24m24 : ± 2.35gm * P<.06 e
a R f f34 gav TBA MXB 24m24 no dre P=1.
b R f f34 gav liv MXB 24m24 24.8gm * P<.7
105 R m f34 gav liv nnd 24m24 : #14.5gm * P<.04 -
a R m f34 gav pni isa 24m24 17.6gm * P<.02
b R m f34 gav TBA MXB 24m24 no dre P=1.
c R m f34 gav liv MXB 24m24 14.5gm * P<.04

CHLORINATED PARAFFINS (C12, 60% CHLORINE) ..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
106 M f b6c gav MXB MXB 24m24 : + : 86.8mg * P<.0005
a M f b6c gav liv MXA 24m24 93.8mg * P<.0005c
b M f b6c gav liv hpa 24m24 105.mg * P<.0005c
c M f b6c gav mul mlp 24m24 599.mg * P<.002
d M f b6c gav thy MXA 24m24 307.mg * P<.03 c
e M f b6c gav hag adn 24m24 347.mg \ P<.04
f M f b6c gav thy fca 24m24 372.mg * P<.06 c
g M f b6c gav liv hpc 24m24 596.mg * P<.03
h M f b6c gav TBA MXB 24m24 170.mg * P<.2
i M f b6c gav liv MXB 24m24 93.8mg * P<.0005
j M f b6c gav lun MXB 24m24 no dre P=1.
107 M m b6c gav liv MXA 24m24 : + : 143.mg * P<.006 c
a M m b6c gav liv hpa 24m24 157.mg * P<.002 c
b M m b6c gav lun a/c 24m24 606.mg * P<.004
c M m b6c gav TBA MXB 24m24 211.mg * P<.2
d M m b6c gav liv MXB 24m24 143.mg * P<.006
e M m b6c gav lun MXB 24m24 851.mg * P<.3
108 R f f34 gav mul mnl 24m24 s : + 345.mg \ P<.009
a R f f34 gav MXB MXB 24m24 s 583.mg * P<.0005
b R f f34 gav thy fca 24m24 s 736.mg \ P<.003
c R f f34 gav liv MXA 24m24 s 1.14gm * P<.002 c
d R f f34 gav thy MXA 24m24 s 1.16gm * P<.003 c

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc		Citation or Pathology	Brkly Code
d	1625	596.mg	30.9gm	0/47	83.1mg	0/51	166.mg	5/46	(332.mg 0/47)		
e	1625	75.7mg	n.s.s.	22/47	83.1mg	41/51	166.mg	31/46	(332.mg 8/47)		
f	1625	882.mg	n.s.s.	0/47	83.1mg	2/51	166.mg	4/46	332.mg 4/47		
g	1625	1.87gm	n.s.s.	0/47	83.1mg	0/51	166.mg	1/46	332.mg 2/47		
h	1625	674.mg	n.s.s.	2/47	83.1mg	0/51	166.mg	5/46	(332.mg 1/47)		
i	1625	3.37gm	n.s.s.	1/47	83.1mg	0/51	166.mg	0/46	332.mg 1/47		
j	1625	1.68gm	n.s.s.	1/47	83.1mg	2/51	166.mg	3/46	332.mg 1/47		
k	1625	2.22gm	n.s.s.	4/47	83.1mg	5/51	166.mg	4/46	332.mg 1/47		
CARBON TETRACHLORIDE*** 56-23-5											
97	1469m	119.mg	287.mg	1/18	774.mg	40/42	1.55gm	43/45		Weisburger;enhp,21,7-16;1977/National Cancer Institute 1976	
a	1469m	490.mg	2.35gm	0/18	774.mg	15/42	(1.55gm	10/45)			
b	1469m	123.mg	324.mg	3/18	774.mg	40/42	1.55gm	43/45			
98	1469m	70.1mg	220.mg	3/18	774.mg	49/49	1.55gm	47/48			
a	1469m	487.mg	1.21gm	0/18	774.mg	28/49	1.55gm	28/48			
b	1469m	70.9mg	230.mg	4/18	774.mg	49/49	1.55gm	47/48			
99	1469n	140.mg	n.s.s.	1/20	40.5mg	11/50	81.0mg	9/49			
a	1469n	415.mg	n.s.s.	1/20	40.5mg	4/50	81.0mg	2/49			
b	1469n	144.mg	n.s.s.	10/20	40.5mg	34/50	81.0mg	20/49			
100	1469n	201.mg	n.s.s.	0/20	23.8mg	2/49	47.6mg	3/50			
a	1469n	230.mg	n.s.s.	0/20	23.8mg	2/49	47.6mg	2/50			
b	1469n	48.7mg	n.s.s.	7/20	23.8mg	21/49	47.6mg	24/50			
CARBOXYMETHYLNITROSOUREA*** (CMNU) 60391-92-6											
101	1547	1.44mg	4.77mg	9/36	5.71mg	28/40	11.4mg	30/38	(22.9mg 11/34)	Maekawa;zkko,106,12-16;1983	
a	1547	1.75mg	7.34mg	9/36	5.71mg	27/40	11.4mg	27/38	(22.9mg 10/34)		
b	1547	3.75mg	7.98mg	0/36	5.71mg	5/40	11.4mg	19/38	22.9mg 27/34		
c	1547	5.45mg	12.7mg	0/36	5.71mg	4/40	11.4mg	15/38	22.9mg 20/34		
d	1547	7.38mg	19.5mg	0/36	5.71mg	1/40	11.4mg	9/38	22.9mg 19/34		
e	1547	.854mg	2.48mg	14/36	5.71mg	34/40	11.4mg	35/38	22.9mg 34/34		
CHLORINATED PARAFFINS (C23, 43% CHLORINE) (Chlorowax 40, Avg. Mol. Wt. = 560) 63449-39-8											
102	c53543	3.84gm	n.s.s.	4/50	1.75gm	3/50	3.54gm	10/50		liv:hpa,hpc.	
a	c53543	5.22gm	n.s.s.	1/50	1.75gm	1/50	3.54gm	6/50			
b	c53543	4.96gm	n.s.s.	3/50	1.75gm	2/50	3.54gm	7/50			
c	c53543	1.34gm	n.s.s.	32/50	1.75gm	29/50	3.54gm	38/50			
d	c53543	3.84gm	n.s.s.	4/50	1.75gm	3/50	3.54gm	10/50		liv:hpa,hpc,nnd.	
e	c53543	8.55gm	n.s.s.	3/50	1.75gm	3/50	3.54gm	3/50		lun:a/a,a/c.	
103	c53543	2.96gm	n.s.s.	6/50	1.77gm	12/50	3.54gm	16/50	liv:mno; mln:mlm,mlp; mul:mlh,mlm,mlp; smi:mlm; spl:mlm.		
a	c53543	8.63gm	n.s.s.	0/50	1.77gm	2/50	3.54gm	3/50		mln:mlp; mul:mlp.	
b	c53543	13.0gm	n.s.s.	0/50	1.77gm	0/50	3.54gm	3/50			
c	c53543	13.2gm	n.s.s.	0/50	1.77gm	0/50	3.54gm	3/50			S
d	c53543	4.09gm	n.s.s.	5/50	1.77gm	10/50	3.54gm	10/50	mln:mlm; mul:mlm; smi:mlm; spl:mlm.		
e	c53543	2.12gm	n.s.s.	43/50	1.77gm	41/50	3.54gm	43/50			
f	c53543	3.06gm	n.s.s.	18/50	1.77gm	21/50	3.54gm	23/50		liv:hpa,hpc,nnd.	
g	c53543	4.75gm	n.s.s.	11/50	1.77gm	10/50	3.54gm	13/50		lun:a/a,a/c.	
104	c53543	868.mg	n.s.s.	1/50	70.1mg	4/50	210.mg	6/50	631.mg 7/50	and:phe,phm.	
a	c53543	511.mg	n.s.s.	46/50	70.1mg	45/50	210.mg	40/50	631.mg 41/50		
b	c53543	2.49gm	n.s.s.	1/50	70.1mg	2/50	210.mg	1/50	631.mg 2/50	liv:hpa,hpc,nnd.	
105	c53543	5.89gm	n.s.s.	0/50	1.31gm	3/50	2.63gm	3/50			S
a	c53543	6.56gm	n.s.s.	0/50	1.31gm	1/50	2.63gm	4/50			S
b	c53543	1.78gm	n.s.s.	46/50	1.31gm	42/50	2.63gm	41/50			
c	c53543	5.89gm	n.s.s.	0/50	1.31gm	3/50	2.63gm	3/50		liv:hpa,hpc,nnd.	
CHLORINATED PARAFFINS (C12, 60% CHLORINE) (Chlorowax 500c, Avg. Mol. Wt. = 411) 63449-39-8											
106	c53587	53.3mg	200.mg	11/50	87.6mg	29/50	176.mg	34/50		liv:hpa,hpc; thy:fca,fcc.	C
a	c53587	62.2mg	169.mg	3/50	87.6mg	22/50	176.mg	28/50		liv:hpa,hpc.	
b	c53587	70.9mg	164.mg	0/50	87.6mg	18/50	176.mg	22/50			
c	c53587	278.mg	2.56gm	0/50	87.6mg	3/50	176.mg	6/50			S
d	c53587	136.mg	n.s.s.	8/50	87.6mg	12/50	176.mg	15/50		thy:fca,fcc.	
e	c53587	126.mg	n.s.s.	1/50	87.6mg	6/50	(176.mg	2/50)			S
f	c53587	150.mg	n.s.s.	8/50	87.6mg	12/50	176.mg	13/50			
g	c53587	247.mg	n.s.s.	3/50	87.6mg	4/50	176.mg	9/50			S
h	c53587	64.1mg	n.s.s.	40/50	87.6mg	42/50	176.mg	42/50			
i	c53587	62.2mg	169.mg	3/50	87.6mg	22/50	176.mg	28/50		liv:hpa,hpc,nnd.	
j	c53587	581.mg	n.s.s.	3/50	87.6mg	4/50	176.mg	1/50		lun:a/a,a/c.	
107	c53587	71.9mg	1.83gm	20/50	87.6mg	34/50	177.mg	38/50		liv:hpa,hpc.	
a	c53587	83.9mg	811.mg	11/50	87.6mg	20/50	177.mg	29/50			
b	c53587	284.mg	1.65gm	0/50	87.6mg	3/50	177.mg	6/50			S
c	c53587	74.9mg	n.s.s.	37/50	87.6mg	44/50	177.mg	46/50			
d	c53587	71.9mg	1.83gm	20/50	87.6mg	34/50	177.mg	38/50		liv:hpa,hpc,nnd.	
e	c53587	263.mg	n.s.s.	5/50	87.6mg	6/50	177.mg	9/50		lun:a/a,a/c.	
108	c53587	158.mg	11.0gm	11/50	221.mg	22/50	(442.mg	16/50)			S
a	c53587	351.mg	1.17gm	0/50	221.mg	11/50	442.mg	12/50		liv:hpc,nnd; thy:fca,fcc.	C
b	c53587	290.mg	3.62gm	0/50	221.mg	6/50	(442.mg	3/50)			S
c	c53587	577.mg	4.00gm	0/50	221.mg	5/50	442.mg	7/50		liv:hpc,nnd.	
d	c53587	592.mg	5.24gm	0/50	221.mg	6/50	442.mg	6/50		thy:fca,fcc.	

```
     Spe Strain  Site    Xpo+Xpt                                                                                   TD50      2Tailpvl
       Sex   Route   Hist       Notes                                                                                  DR       AuOp

 e   R f f34 gav liv nnd 24m24 s                                                                                1.20gm * P<.002 c
 f   R f f34 gav ute MXA 24m24 s                                                                                394.mg \ P<.02
 g   R f f34 gav pan ana 24m24 s                                                                                839.mg \ P<.04
 h   R f f34 gav thy fcc 24m24 s                                                                                4.06gm * P<.04
 i   R f f34 gav TBA MXB 24m24 s                                                                                1.10gm * P<.6
 j   R f f34 gav liv MXB 24m24 s                                                                                1.14gm * P<.002
109  R m f34 gav tes ict 24m24 s                                                      : +   :                   75.2mg * P<.0005
 a   R m f34 gav MXB MXB 24m24 s                                                                                110.mg * P<.0005
 b   R m f34 gav liv MXA 24m24 s                                                                                123.mg * P<.0005c
 c   R m f34 gav pan MXA 24m24 s                                                                                144.mg * P<.0005
 d   R m f34 gav pan ana 24m24 s                                                                                150.mg * P<.0005
 e   R m f34 gav liv nnd 24m24 s                                                                                173.mg * P<.0005c
 f   R m f34 gav adr MXA 24m24 s                                                                                192.mg * P<.0005
 g   R m f34 gav kid MXA 24m24 s                                                                                196.mg \ P<.0005c
 h   R m f34 gav MXA MXA 24m24 s                                                                                406.mg * P<.003
 i   R m f34 gav kid tla 24m24 s                                                                                417.mg * P<.0005
 j   R m f34 gav liv hpc 24m24 s                                                                                551.mg * P<.002
 k   R m f34 gav MXA MXA 24m24 s                                                                                332.mg \ P<.04
 l   R m f34 gav pre MXA 24m24 s                                                                                522.mg * P<.03
 m   R m f34 gav mgl fba 24m24 s                                                                                566.mg * P<.03
 n   R m f34 gav pre adn 24m24 s                                                                                568.mg * P<.02
 o   R m f34 gav TBA MXB 24m24 s                                                                                75.7mg * P<.0005
 p   R m f34 gav liv MXB 24m24 s                                                                                123.mg * P<.0005

[4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYLTHIO]ACETIC ACID***..:..100....:..1mg....:..10.....:..100....:..1g.....:..10
110  M m csb eat liv hpc 53w63 erv                                                 <+                           noTD50    P<.0005+
111  R m f34 eat liv thc 69w69 er                                                 <+                            noTD50    P<.0005+

CHLOROBENZENE                            100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
112  M f b6c gav TBA MXB 24m24                                                           :>                     373.mg * P<.5    -
 a   M f b6c gav liv MXB 24m24                                                                                  235.mg \ P<.09
 b   M f b6c gav lun MXB 24m24                                                                                  623.mg * P<.08
113  M m b6c gav TBA MXB 24m24                                                      :>                          60.1mg * P<.2    -
 a   M m b6c gav liv MXB 24m24                                                                                  382.mg * P<.7
 b   M m b6c gav lun MXB 24m24                                                                                  190.mg * P<.2
114  R f f34 gav MXA MXA 24m24                                                           :    ±                #520.mg * P<.05   -
 a   R f f34 gav TBA MXB 24m24                                                                                  no dre    P=1.
 b   R f f34 gav liv MXB 24m24                                                                                  867.mg * P<.2
115  R m f34 gav liv nnd 24m24                                                          :  ±                    247.mg * P<.02   a
 a   R m f34 gav TBA MXB 24m24                                                                                  190.mg * P<.4
 b   R m f34 gav liv MXB 24m24                                                                                  328.mg * P<.08

CHLORODIBROMOMETHANE*                    100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
116  M f b6c gav liv MXA 24m25                                                         :  ±                     139.mg * P<.03   a
 a   M f b6c gav liv hpa 24m25                                                                                  211.mg * P<.02   a
 b   M f b6c gav TBA MXB 24m25                                                                                  no dre    P=1.
 c   M f b6c gav liv MXB 24m25                                                                                  139.mg * P<.03
 d   M f b6c gav lun MXB 24m25                                                                                  no dre    P=1.
117  M m b6c gav liv MXA 24m25 s                                                  :   +        :               #20.7mg \ P<.006
 a   M m b6c gav liv hpc 24m25 s                                                                                33.5mg \ P<.006 e
 b   M m b6c gav TBA MXB 24m25 s                                                                                11.3mg \ P<.002
 c   M m b6c gav liv MXB 24m25 s                                                                                20.7mg \ P<.006
 d   M m b6c gav lun MXB 24m25 s                                                                                115.mg \ P<.4
118  R f f34 gav TBA MXB 24m24                                                      :>                          no dre    P=1.   -
 a   R f f34 gav liv MXB 24m24                                                                                  591.mg * P<.1
119  R m f34 gav TBA MXB 24m24                                                       :>                         no dre    P=1.   -
 a   R m f34 gav liv MXB 24m24                                                                                  150.mg \ P<.2

CHLORPHENIRAMINE MALEATE                 100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
120  R f f34 eat liv nnd 25m30 ev                                                          .>                   no dre    P=1.   -
121  R m f34 eat liv nnd 25m30 ev                                                         .>                    no dre    P=1.   -

CIPROFIBRATE                             100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
122  R m f34 eat liv hpc 60w60 er                                      <+                                       noTD50    P<.0005+
 a   R m f34 eat liv mix 60w60 er                                                                               noTD50    P<.0005+
 b   R m f34 eat liv nnd 60w60 er                                                                               noTD50    P<.0005+

CITRININ                                 100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
123  R m f34 eat kid cla 60w60 kr                                                <+                             noTD50    P<.0005+
124  R m f34 eat kid cla 80w80 r                                                     <+                         noTD50    P<.0005+

CLOPHEN A 30                             100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
125  R m wis eat liv hpc 27m27 e                                        .                 .>                    157.mg    P<.2    +
```

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
e	c53587	597.mg	2.94gm	0/50	221.mg	4/50	442.mg	7/50		
f	c53587	167.mg	n.s.s.	6/50	221.mg	14/50	(442.mg	11/50)	ute:esp,ess.	S
g	c53587	286.mg	n.s.s.	1/50	221.mg	5/50	(442.mg	2/50)		S
h	c53587	1.23gm	n.s.s.	0/50	221.mg	0/50	442.mg	3/50		S
i	c53587	205.mg	n.s.s.	48/50	221.mg	45/50	442.mg	46/50		
j	c53587	577.mg	4.00gm	0/50	221.mg	5/50	442.mg	7/50	liv:hpa,hpc,nnd.	
109	c53587	41.7mg	187.mg	48/50	221.mg	49/50	442.mg	47/50		S
a	c53587	61.4mg	202.mg	0/50	221.mg	18/50	442.mg	18/50	kid:tla,uac; liv:hpc,nnd.	C
b	c53587	65.6mg	240.mg	0/50	221.mg	13/50	442.mg	16/50	liv:hpc,nnd.	
c	c53587	76.1mg	369.mg	11/50	221.mg	22/50	442.mg	17/50	pan:acc,ana.	S
d	c53587	77.5mg	409.mg	11/50	221.mg	22/50	442.mg	15/50		S
e	c53587	88.6mg	335.mg	0/50	221.mg	10/50	442.mg	16/50		
f	c53587	88.0mg	864.mg	15/50	221.mg	15/50	442.mg	15/50	adr:phe,phm.	S
g	c53587	75.8mg	591.mg	0/50	221.mg	9/50	(442.mg	3/50)	kid:tla,uac.	
h	c53587	169.mg	2.48gm	7/50	221.mg	12/50	442.mg	14/50	mul:mnl; spl:mnl.	S
i	c53587	164.mg	1.43gm	0/50	221.mg	7/50	442.mg	3/50		S
j	c53587	184.mg	3.24gm	0/50	221.mg	3/50	442.mg	2/50		S
k	c53587	90.5mg	n.s.s.	3/50	221.mg	5/50	(442.mg	1/50)	ski:fib; sub:fib.	S
l	c53587	173.mg	n.s.s.	9/50	221.mg	4/50	442.mg	9/50	pre:adn,can.	S
m	c53587	172.mg	n.s.s.	2/50	221.mg	4/50	442.mg	2/50		S
n	c53587	183.mg	n.s.s.	4/50	221.mg	3/50	442.mg	7/50		S
o	c53587	41.8mg	193.mg	50/50	221.mg	49/50	442.mg	48/50		
p	c53587	65.6mg	240.mg	0/50	221.mg	13/50	442.mg	16/50	liv:hpa,hpc,nnd.	
[4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYLTHIO]ACETIC ACID*** 50892-23-4										
110	1656	n.s.s.	10.8mg	0/10	76.3mg	18/18			Reddy;canr,29,152-161;1979	
111	1656	n.s.s.	7.47mg	0/10	40.0mg	15/15				
CHLOROBENZENE (monochlorobenzene) 108-90-7										
112	c54886	82.2mg	n.s.s.	25/50	42.0mg	26/50	84.1mg	29/50		
a	c54886	79.9mg	n.s.s.	2/50	42.0mg	7/50	(84.1mg	2/50)	liv:hpa,hpc,nnd.	
b	c54886	223.mg	n.s.s.	1/50	42.0mg	2/50	84.1mg	5/50	lun:a/a,a/c.	
113	c54886	22.3mg	n.s.s.	30/50	21.0mg	31/50	42.0mg	35/50		
a	c54886	48.4mg	n.s.s.	16/50	21.0mg	15/50	42.0mg	14/50	liv:hpa,hpc,nnd.	
b	c54886	62.2mg	n.s.s.	6/50	21.0mg	4/50	42.0mg	10/50	lun:a/a,a/c.	
114	c54886	198.mg	n.s.s.	0/50	42.4mg	2/50	84.9mg	3/50	pty:adn; thy:fcc; tyf:cyn.	S
a	c54886	64.1mg	n.s.s.	36/50	42.4mg	30/50	84.9mg	36/50		
b	c54886	263.mg	n.s.s.	0/50	42.4mg	1/50	84.9mg	2/50	liv:hpa,hpc,nnd.	
115	c54886	109.mg	n.s.s.	2/50	42.4mg	4/50	84.9mg	8/50		
a	c54886	48.4mg	n.s.s.	33/50	42.4mg	36/50	84.9mg	28/50		
b	c54886	119.mg	n.s.s.	4/50	42.4mg	4/50	84.9mg	8/50	liv:hpa,hpc,nnd.	
CHLORODIBROMOMETHANE* (dibromochloromethane) 124-48-1										
116	c55254	64.4mg	n.s.s.	6/50	35.0mg	10/50	70.4mg	19/50	liv:hpa,hpc.	
a	c55254	96.2mg	n.s.s.	2/50	35.0mg	4/50	70.4mg	11/50		
b	c55254	61.6mg	n.s.s.	33/50	35.0mg	32/50	70.4mg	37/50		
c	c55254	64.4mg	n.s.s.	6/50	35.0mg	10/50	70.4mg	19/50	liv:hpa,hpc,nnd.	
d	c55254	276.mg	n.s.s.	5/50	35.0mg	0/50	70.4mg	5/50	lun:a/a,a/c.	
117	c55254	8.25mg	294.mg	23/50	35.0mg	14/50	(70.8mg	27/50)	liv:hpa,hpc.	S
a	c55254	12.5mg	491.mg	10/50	35.0mg	9/50	(70.8mg	19/50)		
b	c55254	5.19mg	58.7mg	41/50	35.0mg	23/50	(70.8mg	31/50)		
c	c55254	8.25mg	294.mg	23/50	35.0mg	14/50	(70.8mg	27/50)	liv:hpa,hpc,nnd.	
d	c55254	22.3mg	n.s.s.	11/50	35.0mg	5/50	(70.8mg	4/50)	lun:a/a,a/c.	
118	c55254	23.7mg	n.s.s.	43/50	28.3mg	38/50	(56.6mg	32/50)		
a	c55254	204.mg	n.s.s.	0/50	28.3mg	2/50	56.6mg	2/50	liv:hpa,hpc,nnd.	
119	c55254	31.5mg	n.s.s.	43/50	28.3mg	37/50	(56.6mg	29/50)		
a	c55254	46.3mg	n.s.s.	3/50	28.3mg	8/50	(56.6mg	3/50)	liv:hpa,hpc,nnd.	
CHLORPHENIRAMINE MALEATE 113-92-8										
120	1654	141.mg	n.s.s.	4/24	42.0mg	3/24			Lijinsky;fctx,22,715-720;1984	
121	1654	122.mg	n.s.s.	5/24	33.6mg	3/24				
CIPROFIBRATE 52214-84-3										
122	1640	n.s.s.	1.09mg	0/25	10.0mg	25/25			Rao;canr,44,1072-1076;1984	
a	1640	n.s.s.	1.09mg	0/25	10.0mg	25/25				
b	1640	n.s.s.	1.09mg	0/25	10.0mg	25/25				
CITRININ (antimycin) 518-75-2										
123	1533m	n.s.s.	5.28mg	0/5	40.0mg	17/17			Arai;clet,17,281-287;1983	
124	1533n	n.s.s.	12.8mg	0/10	40.0mg	10/10				
CLOPHEN A 30 55600-34-5										
125	1605	43.0mg	n.s.s.	1/131	4.00mg	4/138			Schaeffer;txap,75,278-288;1984	

	Spe Strain Site Xpo+Xpt Sex Route Hist Notes	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10	TD50 DR	2Tailpvl AuOp
COMPOUND 50-892		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
126	M f cd1 eat lun a/c 86w86	.>	4.60gm *	P<.7 -
a	M f cd1 eat lun a/a 86w86		no dre	P=1. -
b	M f cd1 eat liv hes 86w86		no dre	P=1. -
c	M f cd1 eat lun mhb 86w86		no dre	P=1. -
127	M m cd1 eat lun a/c 86w86	.>	8.40gm *	P<.8 -
a	M m cd1 eat lun a/a 86w86		no dre	P=1. -
b	M m cd1 eat liv hes 86w86		no dre	P=1. -
128	R f sdz eat liv nnd 24m24	.>	2.22gm *	P<.7 -
a	*R f sdz eat liv hpc 24m24*		*no dre*	P=1. -
b	R f sdz eat mam fba 24m24		no dre	P=1. -
129	R m sdz eat adr mal 24m24	. + .	113.mg Z	P<.003 -
a	*R m sdz eat liv tum 24m24*		*no dre*	P=1. -
CYCLOPHOSPHAMIDE***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
130	R b sda wat ubl tcc 32m36 ae	. + .	21.4mg *	P<.0005+
a	R b sda wat --- mix 32m36 ae		34.9mg *	P<.2 +
b	R b sda wat vse hms 32m36 ae		65.6mg *	P<.3
c	R b sda wat liv tum 32m36 ae		189.mg *	P<.3
d	R b sda wat ner ngs 32m36 ae		no dre	P=1. +
e	R b sda wat tba mal 32m36 ae		12.8mg *	P<.05 +
131	R m sda ivj mix hae 12m24 e	. + .	3.38mg	P<.007
a	R m sda ivj tba mal 12m24 e		1.41mg	P<.002 +
p,p'-DDE***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
132	M f syg eat liv nnd 28m28 e	. + .	354.mg *	P<.003 +
a	M f syg eat adr mix 28m28 e		458.mg *	P<.03
b	M f syg eat lun tum 28m28 e		no dre	P=1.
c	M f syg eat tba mix 28m28 e		634.mg *	P<.4
133	M m syg eat liv nnd 28m28 e	. ±	141.mg *	P<.04 +
a	M m syg eat lun tum 28m28 e		no dre	P=1.
b	M m syg eat tba mix 28m28 e		1.30gm *	P<.8
DDT***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
134	M f syg eat adr ade 28m28 e	. + .	345.mg	P<.005 -
a	*M f syg eat liv hem 28m28 e*		3.39gm	P<.3 -
b	M f syg eat lun tum 28m28 e		no dre	P=1. -
c	M f syg eat tba mix 28m28 e		781.mg	P<.5 -
135	M m syg eat liv tum 28m28 e	.>	no dre	P=1. -
a	M m syg eat lun tum 28m28 e		no dre	P=1. -
b	M m syg eat tba mix 28m28 e		no dre	P=1. -
DECABROMODIPHENYL OXIDE		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
136	M f b6c eat TBA MXB 24m24	:>	no dre	P=1. -
a	M f b6c eat liv MXB 24m24		33.4gm *	P<.5
b	M f b6c eat lun MXB 24m24		no dre	P=1.
137	M m b6c eat thy MXA 24m24		:20.5gm *	P<.09 e
a	M m b6c eat liv MXA 24m24		11.2gm *	P<.3 e
b	M m b6c eat TBA MXB 24m24		9.06gm *	P<.4
c	M m b6c eat liv MXB 24m24		11.2gm *	P<.3
d	M m b6c eat lun MXB 24m24		no dre	P=1.
138	R f f34 eat liv MXA 24m24	: +	6.58gm *	P<.004
a	R f f34 eat liv nnd 24m24		7.74gm *	P<.005 a
b	R f f34 eat TBA MXB 24m24		4.38gm *	P<.5
c	R f f34 eat liv MXB 24m24		6.58gm *	P<.004
139	*R m f34 eat liv nnd 24m24*	: + :	*2.13gm* *	*P<.0005a*
a	R m f34 eat liv MXA 24m24		2.22gm *	P<.0005
b	R m f34 eat pan ana 24m24		13.9gm *	P<.02
c	*R m f34 eat TBA MXB 24m24*		2.23gm *	P<.3
d	R m f34 eat liv MXB 24m24		2.22gm *	P<.0005
DEXTRAN		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
140	R f aci eat ubl tum 68w68	. ±	1.64gm	P<.02 -
141	R m aci eat ubl tum 68w68	.>	3.19gm	P<.4 -
DEXTRAN SULFATE SODIUM (DS-M-1)***		..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
142	R f aci eat clr pam 68w68	. + .	219.mg	P<.0005+
a	R f aci eat clr adc 68w68		373.mg	P<.0005+
b	R f aci eat clr ade 68w68		977.mg	P<.004 +
c	R f aci eat cec ade 68w68		1.27gm	P<.009
d	R f aci eat clr sqc 68w68		1.76gm	P<.03 +
143	R m aci eat clr adc 68w68	. + .	182.mg	P<.0005+
a	R m aci eat clr pam 68w68		466.mg	P<.0005+
b	R m aci eat clr sqc 68w68		2.05gm	P<.06 +
c	R m aci eat clr ade 68w68		1.70gm	P<.2 +

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc				Citation or Pathology / Brkly Code
COMPOUND 50-892 (1-isopropyl-4-(m-methoxyphenyl)-7-methyl-2(1H)-quinazolinone) 65765-07-3											
126	1667	455.mg n.s.s.	1/50	25.0mg	2/50	150.mg	2/50				Van Ryzin;dact,3,361-379;1980
a	1667	96.6mg n.s.s.	10/50	25.0mg	4/50	(150.mg	3/50)				
b	1667	1.08gm n.s.s.	2/50	25.0mg	1/50	150.mg	0/50				
c	1667	802.mg n.s.s.	0/50	25.0mg	1/50	150.mg	0/50				
127	1667	463.mg n.s.s.	0/50	25.0mg	2/50	150.mg	1/50				
a	1667	261.mg n.s.s.	13/50	25.0mg	8/50	150.mg	11/50				
b	1667	1.08gm n.s.s.	2/50	25.0mg	1/50	150.mg	0/50				
128	1667	286.mg n.s.s.	7/50	4.30mg	4/50	20.0mg	6/50	102.mg	7/50		
a	1667	35.2mg n.s.s.	1/50	4.30mg	0/50	20.0mg	0/50	102.mg	0/50		
b	1667	156.mg n.s.s.	22/50	4.30mg	32/50	20.0mg	27/50	102.mg	25/50		
129	1667	48.7mg 566.mg	0/50	4.30mg	1/50	20.0mg	6/50	(102.mg	1/50)		
a	1667	35.2mg n.s.s.	0/50	4.30mg	0/50	20.0mg	0/50	102.mg	0/50		
CYCLOPHOSPHAMIDE*** (Endoxan) 50-18-0											
130	1705	12.1mg 70.4mg	0/74	.221mg	2/77	.450mg	2/78	.893mg	5/73	1.79mg 8/72	Schmahl;ijcn,23,706-712;1979
a	1705	12.1mg n.s.s.	0/74	.221mg	3/77	.450mg	6/78	.893mg	6/73	1.79mg 4/72	
b	1705	17.1mg n.s.s.	1/74	.221mg	4/77	.450mg	2/78	.893mg	7/73	1.79mg 3/72	
c	1705	46.4mg n.s.s.	0/74	.221mg	0/77	.450mg	1/78	.893mg	0/73	1.79mg 1/72	
d	1705	29.6mg n.s.s.	1/74	.221mg	7/77	.450mg	5/78	.893mg	6/73	1.79mg 1/72	
e	1705	5.20mg n.s.s.	9/74	.221mg	22/77	.450mg	27/78	.893mg	26/73	1.79mg 22/72	
131	1703	1.29mg 65.1mg	1/52	.929mg	6/32						Schmahl;zkko,81,211-215;1974
a	1703	.656mg 6.75mg	6/52	.929mg	14/32						
p,p'-DDE*** 72-55-9											
132	1556	166.mg 1.76gm	0/31	52.3mg	4/26	105.mg	5/24				Rossi;canr,43,776-781;1983
a	1556	205.mg n.s.s.	2/42	52.3mg	7/39	105.mg	8/39				
b	1556	1.13gm n.s.s.	2/42	52.3mg	0/39	105.mg	1/39				
c	1556	163.mg n.s.s.	13/42	52.3mg	13/39	105.mg	16/39				
133	1556	77.0mg n.s.s.	0/10	46.0mg	7/15	92.0mg	8/24				
a	1556	273.mg n.s.s.	1/31	46.0mg	0/30	92.0mg	0/39				
b	1556	136.mg n.s.s.	15/31	46.0mg	11/30	92.0mg	20/39				
DDT*** 50-29-3											
134	1556	152.mg 3.14gm	2/42	105.mg	10/36						Rossi;canr,43,776-781;1983
a	1556	551.mg n.s.s.	0/42	105.mg	1/36						
b	1556	1.03gm n.s.s.	2/42	105.mg	0/36						
c	1556	158.mg n.s.s.	13/42	105.mg	14/36						
135	1556	883.mg n.s.s.	0/31	92.0mg	0/35						
a	1556	883.mg n.s.s.	1/31	92.0mg	0/35						
b	1556	167.mg n.s.s.	15/31	92.0mg	15/35						
DECABROMODIPHENYL OXIDE 1163-19-5											
136	c55287	5.88gm n.s.s.	35/50	3.22gm	37/50	6.44gm	35/50				
a	c55287	6.93gm n.s.s.	8/50	3.22gm	13/50	6.44gm	13/50				liv:hpa,hpc,nnd.
b	c55287	22.4gm n.s.s.	6/50	3.22gm	4/50	6.44gm	4/50				lun:a/a,a/c.
137	c55287	8.82gm n.s.s.	0/50	2.97gm	4/50	6.00gm	3/50				thy:fca,fcc.
a	c55287	3.50gm n.s.s.	8/50	2.97gm	22/50	6.00gm	18/50				liv:hpa,hpc.
b	c55287	2.36gm n.s.s.	21/50	2.97gm	37/50	6.00gm	36/50				
c	c55287	3.50gm n.s.s.	8/50	2.97gm	22/50	6.00gm	18/50				liv:hpa,hpc,nnd.
d	c55287	12.7gm n.s.s.	5/50	2.97gm	4/50	6.00gm	5/50				lun:a/a,a/c.
138	c55287	3.25gm 48.3gm	1/50	1.24gm	5/50	2.48gm	9/50				liv:hpc,nnd. S
a	c55287	3.68gm 61.9gm	1/50	1.24gm	3/50	2.48gm	9/50				
b	c55287	1.06gm n.s.s.	49/50	1.24gm	49/50	2.48gm	50/50				
c	c55287	3.25gm 48.3gm	1/50	1.24gm	5/50	2.48gm	9/50				liv:hpa,hpc,nnd.
139	c55287	1.22gm 5.14gm	1/50	990.mg	7/50	1.98gm	15/50				
a	c55287	1.23gm 6.55gm	2/50	990.mg	8/50	1.98gm	15/50				liv:hpc,nnd. S
b	c55287	4.77gm n.s.s.	0/50	990.mg	0/50	1.98gm	4/50				S
c	c55287	681.mg n.s.s.	49/50	990.mg	50/50	1.98gm	49/50				
d	c55287	1.23gm 6.55gm	2/50	990.mg	8/50	1.98gm	15/50				liv:hpa,hpc,nnd.
DEXTRAN 9004-54-0											
140	1540	494.mg n.s.s.	0/20	1.25gm	3/15						Hirono;clet,18,29-34;1983
141	1540	540.mg n.s.s.	1/20	1.00gm	2/15						
DEXTRAN SULFATE SODIUM (DS-M-1)*** (Mol. Wt. = 54,000) 9011-18-1											
142	1540	103.mg 525.mg	0/20	1.25gm	13/16						Hirono;clet,18,29-34;1983
a	1540	174.mg 982.mg	0/20	1.25gm	10/16						
b	1540	368.mg 5.89gm	0/20	1.25gm	5/16						
c	1540	437.mg 31.1gm	0/20	1.25gm	4/16						
d	1540	532.mg n.s.s.	0/20	1.25gm	3/16						
143	1540	84.0mg 452.mg	0/20	1.00gm	12/15						
a	1540	197.mg 1.53gm	0/20	1.00gm	7/15						
b	1540	502.mg n.s.s.	0/20	1.00gm	2/15						
c	1540	419.mg n.s.s.	1/20	1.00gm	3/15						

	Spe Strain Site Xpo+Xpt Sex Route Hist Notes	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10	TD50 DR	2Tailpvl AuOp
DEXTRAN SULFATE SODIUM (DST-H)				
144	R f aci eat ubl tum 68w68	. ±	2.56gm	P<.06 -
145	R m aci eat cec ade 68w68	.>	4.25gm	P<.2 -
DEXTRAN SULFATE SODIUM (KMDS-H)				
146	R f aci eat ubl tum 68w68	. ±	1.64gm	P<.02 -
147	R m aci eat clr pam 68w68	.>	4.25gm	P<.2 -
DIACETYL HYDRAZINE				
148	M f swi gav lun mix 95w95 rs	,>	no dre	P=1. -
149	*M f swi gav lun mix 34w95 rs*	.>	*no dre*	P=1. -
150	M m swi gav lun mix 95w95 rs	.>	411.mg *	P<.7 -
151	M m swi gav lun mix 34w95 rs	.>	144.mg	P<.8 -
DIALLYL PHTHALATE				
152	M f b6c gav for ppn 24m25		+historical	P=1. a
a	M f b6c gav TBA MXB 24m25		10.1gm *	P<1.
b	M f b6c gav liv MXB 24m25		2.93gm *	P<.4
c	M f b6c gav lun MXB 24m25		4.18gm *	P<.4
153	M m b6c gav ··· mno 24m25	: ±	816.mg *	P<.09 e
a	M m b6c gav liv hpa 24m25		2.45gm *	P<.04
b	M m b6c gav for ppn 24m25		+historical	P=1. a
c	M m b6c gav TBA MXB 24m25		717.mg *	P<.4
d	M m b6c gav liv MXB 24m25		6.68gm *	P<.9
e	M m b6c gav lun MXB 24m25		8.52gm *	P<.9
154	R f f34 gav ··· mnl 24m24	: ±	138.mg *	P<.05 e
a	R f f34 gav TBA MXB 24m24		163.mg *	P<.5
b	R f f34 gav liv MXB 24m24		no dre	P=1.
155	R m f34 gav TBA MXB 24m24	:>	2.99gm *	P<1. -
a	R m f34 gav liv MXB 24m24		no dre	P=1.
1,1-DIALLYLHYDRAZINE				
156	M f swa wat lun mix 23m23 es	. + .	34.9mg	P<.0005+
a	M f swa wat lun ade 23m23 es		37.8mg	P<.0005
b	M f swa wat lun adc 23m23 es		112.mg	P<.0005
c	M f swa wat for sqp 23m23 es		332.mg	P<.1 +
d	M f swa wat liv ang 23m23 es		no dre	P=1. -
e	M f swa wat liv agm 23m23 es		no dre	P=1. -
157	*M m swa wat lun mix 93w93 es*	. + .	*25.7mg*	*P<.0005+*
a	M m swa wat lun ade 93w93 es		29.8mg	P<.0005
b	M m swa wat lun adc 93w93 es		38.9mg	P<.0005
c	*M m swa wat for sqp 93w93 es*		*48.1mg*	*P<.0005+*
d	M m swa wat liv ang 93w93 es		723.mg	P<.5 -
e	M m swa wat liv agm 93w93 es		no dre	P=1. -
DIBROMONEOPENTYL GLYCOL				
158	R f sss eat liv hph 24m24 e	.>	2.55gm *	P<.5 -
a	R f sss eat liv hpc 24m24 e		no dre	P=1. -
b	R f sss eat tba mix 24m24 e		1.73gm *	P<1. -
159	R m sss eat liv hph 24m24 e	.>	no dre	P=1. -
a	R m sss eat liv hpc 24m24 e		no dre	P=1. -
b	R m sss eat tba mix 24m24 e		no dre	P=1. -
DICHLOROACETYLENE				
160	M f nmr inh hag cye 18m28 es	. + .	.550mg	P<.002 +
a	M f nmr inh kid cye 18m28 es		1.08mg	P<.002 +
b	M f nmr inh lun ade 18m28 es		2.73mg	P<.04
c	M f nmr inh lun car 18m28 es		no dre	P=1.
d	M f nmr inh lun mix 18m28 es		no dre	P=1.
161	M f nmr inh kid cye 52w98 es	. + .	1.03mg	P<.0005+
a	M f nmr inh hag cye 52w98 es		3.02mg	P<.07 +
b	M f nmr inh lun ade 52w98 es		no dre	P=1.
c	M f nmr inh lun car 52w98 es		no dre	P=1.
162	M f nmr inh hag cye 18m30 es	. + .	.499mg	P<.0005+
a	M f nmr inh kid cye 18m30 es		7.80mg	P<.5 +
b	M f nmr inh lun ade 18m30 es		no dre	P=1.
c	*M f nmr inh lun car 18m30 es*		*no dre*	P=1.
163	M m nmr inh kid cye 18m29 es	. + .	.466mg	P<.003 +
a	M m nmr inh kid cyc 18m29 es		.501mg	P<.0005+
b	*M m nmr inh hag cye 18m29 es*		1.01mg	P<.2 +
c	M m nmr inh lun ade 18m29 es		no dre	P=1.
d	M m nmr inh lun car 18m29 es		no dre	P=1.
164	M m nmr inh kid cye 52w92 es	. + .	.486mg	P<.0005+
a	M m nmr inh kid cyc 52w92 es		3.89mg	P<.02 +
b	M m nmr inh hag cye 52w92 es		no dre	P=1. +
c	M m nmr inh lun ade 52w92 es		no dre	P=1.

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology / Brkly Code
DEXTRAN SULFATE SODIUM (DST-H) (Mol. Wt. = 9500) 9011-18-1									
144	1540	628.mg	n.s.s.	0/20	1.25gm	2/15			Hirono;clet,18,29-34;1983
145	1540	691.mg	n.s.s.	0/20	1.00gm	1/15			
DEXTRAN SULFATE SODIUM (KMDS-H) (Mol. Wt. = 520,000) 9011-18-1									
146	1540	494.mg	n.s.s.	0/20	1.25gm	3/15			Hirono;clet,18,29-34;1983
147	1540	691.mg	n.s.s.	0/20	1.00gm	1/15			
DIACETYL HYDRAZINE 3148-73-0									
148	1661m	59.0mg	n.s.s.	3/20	22.9mg	0/15			Bhide;clet,23,235-240;1984/pers.comm.,
149	1661n	29.5mg	n.s.s.	3/20	11.4mg	0/15			
150	1661m	43.8mg	n.s.s.	2/20	19.0mg	0/15	26.2mg	3/15	
151	1661n	10.9mg	n.s.s.	2/20	9.52mg	2/15			
DIALLYL PHTHALATE 131-17-9									
152	c50657	n.s.s.	n.s.s.	0/50	104.mg	0/50	208.mg	0/50	
a	c50657	215.mg	n.s.s.	31/50	104.mg	28/50	208.mg	32/50	
b	c50657	736.mg	n.s.s.	1/50	104.mg	2/50	208.mg	3/50	liv:hpa,hpc,nnd.
c	c50657	911.mg	n.s.s.	1/50	104.mg	0/50	208.mg	3/50	lun:a/a,a/c.
153	c50657	304.mg	n.s.s.	6/50	104.mg	5/50	208.mg	12/50	
a	c50657	740.mg	n.s.s.	0/50	104.mg	0/50	208.mg	3/50	S
b	c50657	n.s.s.	n.s.s.	0/50	104.mg	0/50	208.mg	0/50	
c	c50657	180.mg	n.s.s.	23/50	104.mg	23/50	208.mg	26/50	
d	c50657	517.mg	n.s.s.	7/50	104.mg	5/50	208.mg	7/50	liv:hpa,hpc,nnd.
e	c50657	587.mg	n.s.s.	5/50	104.mg	4/50	208.mg	5/50	lun:a/a,a/c.
154	c50657	58.3mg	n.s.s.	15/50	35.5mg	15/50	71.1mg	25/50	
a	c50657	37.9mg	n.s.s.	41/50	35.5mg	37/50	71.1mg	42/50	
b	c50657	371.mg	n.s.s.	5/50	35.5mg	0/50	71.1mg	3/50	liv:hpa,hpc,nnd.
155	c50657	61.9mg	n.s.s.	36/50	35.5mg	37/50	71.1mg	29/50	
a	c50657	542.mg	n.s.s.	2/50	35.5mg	0/50	71.1mg	1/50	liv:hpa,hpc,nnd.
1,1-DIALLYLHYDRAZINE 5164-11-4									
156	1676	20.6mg	70.2mg	25/99	62.5mg	38/50			Toth;acnr,1,259-262;1981
a	1676	22.6mg	74.3mg	20/99	62.5mg	36/50			
b	1676	58.3mg	312.mg	6/99	62.5mg	17/50			
c	1676	105.mg	n.s.s.	4/61	62.5mg	7/41			
d	1676	336.mg	n.s.s.	3/61	62.5mg	1/41			
e	1676	421.mg	n.s.s.	5/67	62.5mg	1/47			
157	1676	15.0mg	53.2mg	26/96	52.1mg	38/50			
a	1676	17.9mg	58.3mg	16/96	52.1mg	34/50			
b	1676	22.8mg	80.1mg	12/96	52.1mg	29/50			
c	1676	27.0mg	97.4mg	0/63	52.1mg	17/38			
d	1676	120.mg	n.s.s.	4/68	52.1mg	4/42			
e	1676	254.mg	n.s.s.	7/63	52.1mg	1/38			
DIBROMONEOPENTYL GLYCOL 3296-90-0									
158	1642	409.mg	n.s.s.	3/48	5.00mg	0/50	100.mg	3/50	Keyes;jctx,7,77-98;1980
a	1642	49.1mg	n.s.s.	1/48	5.00mg	0/50	100.mg	0/50	
b	1642	23.6mg	n.s.s.	47/50	5.00mg	49/50	100.mg	48/50	
159	1642	49.1mg	n.s.s.	1/50	5.00mg	0/50	100.mg	0/50	
a	1642	1.01gm	n.s.s.	1/50	5.00mg	1/50	100.mg	0/50	
b	1642	74.9mg	n.s.s.	39/50	5.00mg	40/50	100.mg	39/50	
DICHLOROACETYLENE 7572-29-4									
160	1651m	.264mg	2.65mg	3/30	.321mg	14/30			Reichert;carc,5,1411-1420;1984
a	1651m	.467mg	4.34mg	0/30	.321mg	7/30			
b	1651m	.827mg	n.s.s.	0/30	.321mg	3/30			
c	1651m	2.60mg	n.s.s.	4/30	.321mg	0/30			
d	1651m	1.18mg	n.s.s.	4/30	.321mg	3/30			
161	1651n	.554mg	2.19mg	0/30	1.17mg	15/30			
a	1651n	1.10mg	n.s.s.	2/24	1.17mg	8/29			
b	1651n	4.98mg	n.s.s.	5/30	1.17mg	1/30			
c	1651n	6.42mg	n.s.s.	1/30	1.17mg	0/30			
162	1651o	.280mg	1.01mg	1/28	.592mg	21/29			
a	1651o	1.44mg	n.s.s.	4/30	.592mg	6/30			
b	1651o	3.40mg	n.s.s.	1/30	.592mg	1/30			
c	1651o	3.40mg	n.s.s.	1/30	.592mg	1/30			
163	1651m	.221mg	2.66mg	4/30	.251mg	15/30			
a	1651m	.256mg	1.18mg	0/30	.251mg	12/30			
b	1651m	.332mg	n.s.s.	6/30	.251mg	11/29			
c	1651m	.842mg	n.s.s.	4/30	.251mg	4/30			
d	1651m	1.79mg	n.s.s.	5/30	.251mg	1/30			
164	1651n	.248mg	1.50mg	8/30	1.04mg	23/30			
a	1651n	1.34mg	n.s.s.	0/30	1.04mg	4/30			
b	1651n	1.18mg	n.s.s.	6/26	1.04mg	5/22			
c	1651n	3.08mg	n.s.s.	5/30	1.04mg	2/30			

```
     Spe Strain  Site     Xpo+Xpt                                                                                  TD50      2Tailpvl
       Sex    Route   Hist       Notes                                                                                  DR       AuOp

165  M m nmr inh hag cye 18m27 es                                      .  +    .                                 .687mg   P<.0005+
 a   M m nmr inh kid cye 18m27 es                                                                                .769mg   P<.002 +
 b   M m nmr inh kid cyc 18m27 es                                                                                4.52mg   P<.04  +
 c   M m nmr inh lun ade 18m27 es                                                                                no dre   P=1.
 d   M m nmr inh lun car 18m27 es                                                                                no dre   P=1.
166  R f wis inh --- mly 18m35 es                                            .   ±                               3.86mg   P<.04  +
 a   R f wis inh liv cho 18m35 es                                                                                3.86mg   P<.04  +
 b   R f wis inh kid cye 18m35 es                                                                                11.5mg   P<.04  +
 c   R f wis inh liv hpa 18m35 es                                                                                17.5mg   P<.1   +
167  R m wis inh kid cye 18m36 es                                            .   +     .                         3.34mg   P<.002 +
 a   R m wis inh liv cho 18m36 es                                                                                3.97mg   P<.004 +
 b   R m wis inh liv hpa 18m36 es                                                                                12.9mg   P<.1   +
 c   R m wis inh kid cyc 18m36 es                                                                                26.2mg   P<.3   +
 d   R m wis inh liv cvh 18m36 es                                                                                no dre   P=1.
 e   R m wis inh liv hpc 18m36 es                                                                                no dre   P=1.

1,2-DICHLOROBENZENE               100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
168  M f b6c gav --- mlh 24m24                                                                 :    ±           #1.11gm * P<.05  -
 a   M f b6c gav TBA MXB 24m24                                                                                   no dre   P=1.
 b   M f b6c gav liv MXB 24m24                                                                                   no dre   P=1.
 c   M f b6c gav lun MXB 24m24                                                                                   no dre   P=1.
169  M m b6c gav --- mlh 24m24                                                               :    ±             #648.mg * P<.04  -
 a   M m b6c gav TBA MXB 24m24                                                                                   no dre   P=1.
 b   M m b6c gav liv MXB 24m24                                                                                   no dre   P=1.
 c   M m b6c gav lun MXB 24m24                                                                                   767.mg * P<.6
170  R f f34 gav TBA MXB 24m24                                                           :>                      1.16gm * P<.9   -
 a   R f f34 gav liv MXB 24m24                                                                                   1.13gm * P<.4
171  R m f34 gav tes ict 24m24 s                                                      :  ±                      #48.5mg * P<.03  -
 a   R m f34 gav TBA MXB 24m24 s                                                                                 81.4mg * P<.05
 b   R m f34 gav liv MXB 24m24 s                                                                                 696.mg * P<.09

DIFTALONE                         100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
172  M f bld eat liv ang 19m28 e                                                                .   +    .       852.mg * P<.002 +
 a   M f bld eat liv hpa 19m28 e                                                                                 1.15gm * P<.009 +
 b   M f bld eat lun mix 19m28 e                                                                                 269.mg * P<.04  -
 c   M f bld eat liv hpc 19m28 e                                                                                 3.54gm * P<.08  +
 d   M f bld eat liv agm 19m28 e                                                                                 7.13gm * P<.3
173  M m bld eat liv ang 19m28 e                                                                .   +    .       879.mg Z P<.0005+
 a   M m bld eat liv agm 19m28 e                                                                                 1.37gm Z P<.03  +
 b   M m bld eat lun mix 19m28 e                                                                                 412.mg * P<.3   -
 c   M m bld eat liv hpc 19m28 e                                                                                 no dre   P=1.
 d   M m bld eat liv hpa 19m28 e                                                                                 no dre   P=1.

DIMETHYL HYDROGEN PHOSPHITE       100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
174  M f b6c gav liv hpa 24m24                                                              :   +        :      #286.mg \ P<.005 -
 a   M f b6c gav TBA MXB 24m24                                                                                   no dre   P=1.
 b   M f b6c gav liv MXB 24m24                                                                                   1.71gm * P<.6
 c   M f b6c gav lun MXB 24m24                                                                                   no dre   P=1.
175  M m b6c gav TBA MXB 24m24                                                              :>                   864.mg * P<.7   -
 a   M m b6c gav liv MXB 24m24                                                                                   no dre   P=1.
 b   M m b6c gav lun MXB 24m24                                                                                   2.43gm * P<.8
176  R f f34 gav lun a/c 24m24                                                                 :   ±             600.mg * P<.04  e
 a   R f f34 gav for MXA 24m24                                                                               +historical * P<.09  e
 b   R f f34 gav TBA MXB 24m24                                                                                   183.mg * P<.5
 c   R f f34 gav liv MXB 24m24                                                                                   2.46gm * P<.3
177  R m f34 gav MXB MXB 24m24 s                                                           : + :                 105.mg / P<.0005
 a   R m f34 gav lun MXA 24m24 s                                                                                 139.mg / P<.0005c
 b   R m f34 gav lun a/c 24m24 s                                                                                 167.mg / P<.0005c
 c   R m f34 gav for MXA 24m24 s                                                                                 577.mg * P<.002 c
 d   R m f34 gav lun a/a 24m24 s                                                                                 903.mg * P<.006 c
 e   R m f34 gav lun sqc 24m24 s                                                                                 951.mg * P<.006 c
 f   R m f34 gav for sqp 24m24 s                                                                                 990.mg * P<.03  c
 g   R m f34 gav for sqc 24m24 s                                                                                 1.42gm * P<.03  c
 h   R m f34 gav TBA MXB 24m24 s                                                                                 119.mg * P<.04
 i   R m f34 gav liv MXB 24m24 s                                                                                 no dre   P=1.

DIMETHYL MORPHOLINOPHOSPHORAMIDATE     ..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
178  M f b6c gav TBA MXB 24m24 s                                                                  :>             no dre   P=1.   -
 a   M f b6c gav liv MXB 24m24 s                                                                                 no dre   P=1.
 b   M f b6c gav lun MXB 24m24 s                                                                                 17.6gm * P<.9
179  M m b6c gav TBA MXB 24m24                                                                 :>                no dre   P=1.   -
 a   M m b6c gav liv MXB 24m24                                                                                   1.27gm * P<.4
 b   M m b6c gav lun MXB 24m24                                                                                   3.90gm * P<.8
180  R f f34 gav --- mnl 24m24 s                                                                 :  ±            788.mg * P<.02  a
 a   R f f34 gav TBA MXB 24m24 s                                                                                 774.mg * P<.3
 b   R f f34 gav liv MXB 24m24 s                                                                                 8.24gm * P<.2
```

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc			Citation or Pathology	Brkly Code
165	1651o	.345mg	2.45mg	4/30	.540mg	17/30						
a	1651o	.376mg	3.31mg	4/30	.540mg	16/30						
b	1651o	1.37mg	n.s.s.	0/30	.540mg	3/30						
c	1651o	2.49mg	n.s.s.	8/30	.540mg	3/30						
d	1651o	4.30mg	n.s.s.	3/30	.540mg	0/30						
166	1651n	1.52mg	n.s.s.	4/30	.849mg	11/30						
a	1651n	1.52mg	n.s.s.	4/30	.849mg	11/30						
b	1651n	3.47mg	n.s.s.	0/30	.849mg	3/30						
c	1651n	4.31mg	n.s.s.	0/30	.849mg	2/30						
167	1651n	1.44mg	13.4mg	0/30	.568mg	7/30						
a	1651n	1.62mg	22.8mg	0/30	.568mg	6/30						
b	1651n	3.16mg	n.s.s.	0/30	.568mg	2/30						
c	1651n	4.26mg	n.s.s.	0/30	.568mg	1/30						
d	1651n	8.00mg	n.s.s.	1/30	.568mg	0/30						
e	1651n	8.00mg	n.s.s.	1/30	.568mg	0/30						
1,2-DICHLOROBENZENE (o-dichlorobenzene) 95-50-1												
168	c54944	335.mg	n.s.s.	0/50	42.0mg	0/50	84.1mg	3/50				S
a	c54944	120.mg	n.s.s.	32/50	42.0mg	28/50	84.1mg	29/50				
b	c54944	319.mg	n.s.s.	4/50	42.0mg	5/50	84.1mg	3/50			liv:hpa,hpc,nnd.	
c	c54944	306.mg	n.s.s.	3/50	42.0mg	4/50	84.1mg	3/50			lun:a/a,a/c.	
169	c54944	245.mg	n.s.s.	0/50	42.0mg	1/50	84.1mg	4/50				S
a	c54944	109.mg	n.s.s.	38/50	42.0mg	32/50	84.1mg	36/50				
b	c54944	93.2mg	n.s.s.	19/50	42.0mg	14/50	(84.1mg	11/50)			liv:hpa,hpc,nnd.	
c	c54944	130.mg	n.s.s.	8/50	42.0mg	8/50	84.1mg	13/50			lun:a/a,a/c.	
170	c54944	57.8mg	n.s.s.	39/50	42.0mg	40/50	84.9mg	40/50				
a	c54944	269.mg	n.s.s.	1/50	42.0mg	1/50	84.9mg	3/50			liv:hpa,hpc,nnd.	
171	c54944	22.1mg	n.s.s.	47/50	42.2mg	49/50	84.9mg	41/50				S
a	c54944	34.0mg	n.s.s.	33/50	42.2mg	38/50	84.9mg	29/50				
b	c54944	211.mg	n.s.s.	0/50	42.2mg	2/50	84.9mg	1/50			liv:hpa,hpc,nnd.	
DIFTALONE 21626-89-1												
172	1638	386.mg	2.95gm	0/38	26.2mg	0/43	52.4mg	1/45	105.mg	7/43	Della Porta;zkko,108,308-311;1984	
a	1638	471.mg	39.9gm	0/38	26.2mg	1/43	52.4mg	0/45	105.mg	5/43		
b	1638	118.mg	n.s.s.	8/38	26.2mg	13/43	52.4mg	19/45	105.mg	18/43		
c	1638	871.mg	n.s.s.	0/38	26.2mg	0/43	52.4mg	0/45	105.mg	2/43		
d	1638	1.16gm	n.s.s.	0/38	26.2mg	0/43	52.4mg	0/45	105.mg	1/43		
173	1638	398.mg	2.78gm	0/40	24.2mg	0/48	48.4mg	0/50	96.8mg	8/48		
a	1638	507.mg	n.s.s.	1/40	24.2mg	0/48	48.4mg	0/50	96.8mg	6/48		
b	1638	122.mg	n.s.s.	13/40	24.2mg	19/48	48.4mg	26/50	96.8mg	21/48		
c	1638	847.mg	n.s.s.	2/40	24.2mg	1/48	48.4mg	3/50	96.8mg	1/48		
d	1638	563.mg	n.s.s.	3/40	24.2mg	5/48	48.4mg	2/50	96.8mg	4/48		
DIMETHYL HYDROGEN PHOSPHITE (DMHP) 868-85-9												
174	c54773	117.mg	2.00gm	0/50	70.1mg	6/50	(140.mg	3/50)				S
a	c54773	145.mg	n.s.s.	37/50	70.1mg	30/50	140.mg	32/50				
b	c54773	331.mg	n.s.s.	2/50	70.1mg	6/50	140.mg	3/50			liv:hpa,hpc,nnd.	
c	c54773	839.mg	n.s.s.	4/50	70.1mg	3/50	140.mg	1/50			lun:a/a,a/c.	
175	c54773	124.mg	n.s.s.	34/50	70.1mg	21/50	140.mg	31/50				
a	c54773	277.mg	n.s.s.	19/50	70.1mg	10/50	140.mg	13/50			liv:hpa,hpc,nnd.	
b	c54773	251.mg	n.s.s.	12/50	70.1mg	7/50	140.mg	11/50			lun:a/a,a/c.	
176	c54773	207.mg	n.s.s.	0/50	35.2mg	1/50	70.4mg	3/50				
a	c54773	312.mg	n.s.s.	0/50	35.2mg	0/50	70.4mg	2/50			for:sqc,sqp.	
b	c54773	42.8mg	n.s.s.	36/50	35.2mg	38/50	70.4mg	38/50				
c	c54773	401.mg	n.s.s.	0/50	35.2mg	0/50	70.4mg	1/50			liv:hpa,hpc,nnd.	
177	c54773	68.4mg	172.mg	0/50	70.4mg	2/50	141.mg	31/50			for:sqc,sqp; lun:a/a,a/c,sqc.	C
a	c54773	85.7mg	246.mg	0/50	70.4mg	1/50	141.mg	24/50			lun:a/a,a/c.	
b	c54773	98.8mg	311.mg	0/50	70.4mg	1/50	141.mg	20/50				
c	c54773	248.mg	2.58gm	0/50	70.4mg	1/50	141.mg	6/50			for:sqc,sqp.	
d	c54773	339.mg	8.99gm	0/50	70.4mg	0/50	141.mg	5/50				
e	c54773	358.mg	3.71gm	0/50	70.4mg	0/50	141.mg	5/50				
f	c54773	342.mg	n.s.s.	0/50	70.4mg	1/50	141.mg	3/50				
g	c54773	426.mg	n.s.s.	0/50	70.4mg	0/50	141.mg	3/50				
h	c54773	52.0mg	n.s.s.	38/50	70.4mg	36/50	141.mg	45/50				
i	c54773	1.34gm	n.s.s.	3/50	70.4mg	0/50	141.mg	0/50			liv:hpa,hpc,nnd.	
DIMETHYL MORPHOLINOPHOSPHORAMIDATE 597-25-1												
178	c54740	493.mg	n.s.s.	31/50	210.mg	28/50	420.mg	24/50				
a	c54740	2.18gm	n.s.s.	7/50	210.mg	4/50	420.mg	2/50			liv:hpa,hpc,nnd.	
b	c54740	1.34gm	n.s.s.	4/50	210.mg	3/50	420.mg	4/50			lun:a/a,a/c.	
179	c54740	247.mg	n.s.s.	26/50	105.mg	29/50	210.mg	25/50				
a	c54740	310.mg	n.s.s.	11/50	105.mg	13/50	210.mg	15/50			liv:hpa,hpc,nnd.	
b	c54740	458.mg	n.s.s.	6/50	105.mg	8/50	210.mg	7/50			lun:a/a,a/c.	
180	c54740	362.mg	n.s.s.	9/50	105.mg	13/50	210.mg	12/50	420.mg	18/50		
a	c54740	229.mg	n.s.s.	35/50	105.mg	37/50	210.mg	35/50	420.mg	34/50		
b	c54740	2.01gm	n.s.s.	0/50	105.mg	0/50	210.mg	1/50	420.mg	1/50	liv:hpa,hpc,nnd.	

No.	Spe	Sex	Strain	Route	Site	Hist	Xpo+Xpt	Notes	Plot	TD50	DR	2Tailpvl	AuOp
181	R	m	f34	gav	---	mnl	24m24		: + :	503.mg	*	P<.006	a
a	R	m	f34	gav	tes	ict	24m24			283.mg	*	P<.04	
b	R	m	f34	gav	TBA	MXB	24m24			283.mg	*	P<.04	
c	R	m	f34	gav	liv	MXB	24m24			2.82gm	*	P<.2	
N,N-DIMETHYLDODECYLAMINE-N-OXIDE									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
182	R	f	f34	wat	liv	nnd	22m30	e	.>	no dre		P=1.	-
183	R	m	f34	wat	liv	mix	22m30	e	.>	231.mg		P<.5	-
a	R	m	f34	wat	liv	nnd	22m30	e		496.mg		P<.7	-
b	R	m	f34	wat	liv	hpc	22m30	e		519.mg		P<.6	-
2,4-DINITROPHENOL, SODIUM									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
184	M	f	dbx	eat	mgl	car	90w90	er	.>	no dre		P=1.	-
1,4-DINITROSO-2,6-DIMETHYLPIPERAZINE									..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
185	H	m	syg	gav	for	pam	35w76		. ±	3.10mg		P<.04	+
a	H	m	syg	gav	lun	ade	35w76			6.04mg		P<.02	
b	H	m	syg	gav	liv	ang	35w76			8.30mg		P<.04	
c	H	m	syg	gav	tba	mix	35w76			.932mg		P<.0005	
DIPHENHYDRAMINE.HCl									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
186	R	f	f34	eat	liv	nnd	25m30	e	.>	no dre		P=1.	-
187	R	m	f34	eat	liv	nnd	25m30	e	.>	no dre		P=1.	-
DIPYRONE									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
188	M	f	b6c	wat	liv	mix	75w86	ae	. + .	742.mg	/	P<.0005	+
a	M	f	b6c	wat	liv	hpc	75w86	ae		7.12gm	*	P<.02	
189	M	m	b6c	wat	liv	mix	77w86	ae	. + .	547.mg	*	P<.0005	+
ENFLURANE									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
190	M	f	sic	inh	lun	ade	52w52	ek	.>	8.93gm		P<.4	-
a	M	f	sic	inh	liv	tum	52w52	ek		no dre		P=1.	-
191	M	f	sic	inh	lun	ade	78w82	e	.>	18.9gm		P<.2	-
a	M	f	sic	inh	liv	mix	78w82	e		no dre		P=1.	-
192	M	m	sic	inh	liv	mix	52w52	ek	. ±	8.12gm		P<.1	-
a	M	m	sic	inh	lun	ade	52w52	ek		no dre		P=1.	-
193	M	m	sic	inh	liv	mix	78w82	e	.	11.7gm		P<.1	-
a	M	m	sic	inh	lun	ade	78w82	e		60.9gm		P<.8	-
EPHEDRINE SULPHATE									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
194	M	f	b6c	eat	TBA	MXB	24m24		:>	259.mg	*	P<.9	-
a	M	f	b6c	eat	liv	MXB	24m24			no dre		P=1.	
b	M	f	b6c	eat	lun	MXB	24m24			789.mg	*	P<.6	
195	M	m	b6c	eat	MXA	MXA	24m24		: ±	#194.mg	*	P<.02	-
a	M	m	b6c	eat	TBA	MXB	24m24			no dre		P=1.	
b	M	m	b6c	eat	liv	MXB	24m24			264.mg	*	P<.7	
c	M	m	b6c	eat	lun	MXB	24m24			no dre		P=1.	
196	R	f	f34	eat	TBA	MXB	24m24		:>	no dre		P=1.	-
a	R	f	f34	eat	liv	MXB	24m24			no dre		P=1.	
197	R	m	f34	eat	TBA	MXB	24m24		:>	no dre		P=1.	-
a	R	m	f34	eat	liv	MXB	24m24			166.mg	*	P<.7	
ERYTHORBATE, SODIUM									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
198	R	f	f3d	wat	liv	hpa	24m26	e		no dre		P=1.	-
a	R	f	f3d	wat	tba	mix	24m26	e		no dre		P=1.	-
199	R	m	f3d	wat	liv	hpa	24m26	e		no dre		P=1.	-
a	R	m	f3d	wat	tba	mix	24m26	e		no dre		P=1.	-
ESTRAGOLE									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
200	M	f	cd1	eat	liv	hpt	51w86	v	. +.	51.8mg	*	P<.0005	+
a	M	f	cd1	eat	lun	ade	51w86	v		no dre		P=1.	
ETHOXYQUIN									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
201	R	m	f34	eat	liv	tum	60w60	er	.>	no dre		P=1.	
ETHYL ALCOHOL***									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
202	M	f	c3s	wat	mam	adc	86w86	r		no dre		P=1.	
1-ETHYL-1-NITROSOUREA									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
203	R	f	f3d	wat	---	mnl	24m26	ae	. + .	.151mg	Z	P<.0005	
a	R	f	f3d	wat	ute	esp	24m26	ae		.883mg	*	P<.003	
b	R	f	f3d	wat	bra	mix	24m26	ae		.904mg	*	P<.0005	+
c	R	f	f3d	wat	mgl	adc	24m26	ae		2.54mg	*	P<.002	
d	R	f	f3d	wat	utm	sar	24m26	ae		2.56mg	*	P<.003	
e	R	f	f3d	wat	dgt	mix	24m26	ae		2.56mg	*	P<.003	+
f	R	f	f3d	wat	duo	mix	24m26	ae		7.68mg	*	P<.006	+
g	R	f	f3d	wat	ute	ade	24m26	ae		4.08mg	*	P<.1	

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology / Brkly Code
181	c54740	247.mg	6.51gm	14/50	105.mg	21/50	210.mg	19/50	420.mg 25/50
a	c54740	124.mg	n.s.s.	45/50	105.mg	45/50	210.mg	44/50	420.mg 46/50 S
b	c54740	122.mg	n.s.s.	49/50	105.mg	47/50	210.mg	48/50	420.mg 49/50
c	c54740	880.mg	n.s.s.	1/50	105.mg	3/50	210.mg	3/50	420.mg 3/50 liv:hpa,hpc,nnd.
N,N-DIMETHYLDODECYLAMINE-N-OXIDE 1643-20-5									
182	1654	107.mg	n.s.s.	4/24	31.8mg	3/24			Lijinsky;fctx,22,715-720;1984
183	1654	45.1mg	n.s.s.	3/24	22.2mg	5/24			
a	1654	61.5mg	n.s.s.	2/24	22.2mg	3/24			
b	1654	71.6mg	n.s.s.	1/24	22.2mg	2/24			
2,4-DINITROPHENOL, SODIUM 1011-73-0									
184	1652	2.38gm	n.s.s.	37/50	325.mg	1/50			Tannenbaum;canr,9,403-410;1949
1,4-DINITROSO-2,6-DIMETHYLPIPERAZINE 55380-34-2									
185	1570	1.17mg	n.s.s.	3/20	3.68mg	9/20			Lijinsky;carc,4,1165-1167;1983
a	1570	2.08mg	n.s.s.	0/20	3.68mg	4/20			
b	1570	2.50mg	n.s.s.	0/20	3.68mg	3/20			
c	1570	.448mg	2.63mg	3/20	3.68mg	16/20			
DIPHENHYDRAMINE.HCl 147-24-0									
186	1654	277.mg	n.s.s.	4/24	82.5mg	3/24			Lijinsky;fctx,22,715-720;1984
187	1654	193.mg	n.s.s.	5/24	66.0mg	4/24			
DIPYRONE (sulpyrin) 68-89-3									
188	1545	484.mg	1.22gm	3/51	448.mg	3/47	1.71gm	36/44	Kumagai;jnci,71,1295-1297;1983
a	1545	2.77gm	n.s.s.	1/51	448.mg	1/47	1.71gm	6/44	
189	1545	300.mg	1.79gm	8/44	189.mg	16/46	746.mg	27/48	
ENFLURANE 13838-16-9									
190	1677m	1.84gm	n.s.s.	2/25	4.74gm	4/25			Baden;anes,56,9-13;1982
a	1677m	6.11gm	n.s.s.	0/25	4.74gm	0/25			
191	1677n	6.69gm	n.s.s.	13/98	4.51gm	21/97			
a	1677n	56.1gm	n.s.s.	2/98	4.51gm	0/97			
192	1677m	2.00gm	n.s.s.	0/25	3.95gm	2/25			
a	1677m	3.10gm	n.s.s.	5/25	3.95gm	2/25			
193	1677n	4.41gm	n.s.s.	18/96	3.76gm	28/96			
a	1677n	7.07gm	n.s.s.	19/96	3.76gm	21/96			
EPHEDRINE SULPHATE 134-72-5									
194	c55652	19.8mg	n.s.s.	43/50	16.1mg	45/50	32.2mg	41/50	
a	c55652	67.6mg	n.s.s.	9/50	16.1mg	3/50	(32.2mg	3/50)	liv:hpa,hpc,nnd.
b	c55652	132.mg	n.s.s.	1/50	16.1mg	1/50	32.2mg	2/50	lun:a/a,a/c.
195	c55652	79.1mg	n.s.s.	0/50	14.9mg	2/50	29.7mg	4/50	mey:mlm; mul:mlm; spl:mlm, S
a	c55652	27.8mg	n.s.s.	38/50	14.9mg	31/50	29.7mg	36/50	
b	c55652	37.9mg	n.s.s.	19/50	14.9mg	18/50	29.7mg	21/50	liv:hpa,hpc,nnd.
c	c55652	98.7mg	n.s.s.	9/50	14.9mg	11/50	29.7mg	4/50	lun:a/a,a/c.
196	c55652	13.6mg	n.s.s.	45/50	6.19mg	43/50	12.4mg	45/50	
a	c55652	98.6mg	n.s.s.	2/50	6.19mg	2/50	12.4mg	0/50	liv:hpa,hpc,nnd.
197	c55652	8.33mg	n.s.s.	43/50	4.95mg	47/50	9.90mg	45/50	
a	c55652	21.5mg	n.s.s.	3/50	4.95mg	5/50	9.90mg	5/50	liv:hpa,hpc,nnd.
ERYTHORBATE, SODIUM (isoascorbate) 6381-77-7									
198	1736	15.5gm	n.s.s.	1/48	663.mg	1/49	1.33gm	0/45	Abe;eamp,41,35-43;1984
a	1736	1.69gm	n.s.s.	45/48	663.mg	43/49	1.33gm	35/45	
199	1736	12.5gm	n.s.s.	1/49	580.mg	0/48	1.16gm	1/50	
a	1736	n.s.s.	n.s.s.	49/49	580.mg	48/48	1.16gm	50/50	
ESTRAGOLE 140-67-0									
200	1582	37.3mg	74.3mg	0/50	74.2mg	27/50	148.mg	35/50	Miller;canr,43,1124-1134;1983
a	1582	666.mg	n.s.s.	2/50	74.2mg	1/50	148.mg	2/50	
ETHOXYQUIN 91-53-2									
201	1640	343.mg	n.s.s.	0/25	200.mg	0/25			Rao;canr,44,1072-1076;1984
ETHYL ALCOHOL*** 64-17-5									
202	1632	15.3gm	n.s.s.	23/30	24.0gm	8/15			Schrauzer;jsac,40,240-246;1979
1-ETHYL-1-NITROSOUREA (ENU, N-ethyl-N-nitrosourea) 759-73-9									
203	1614	90.2ug	.351mg	5/52	12.0ug	8/51	40.2ug	18/52	.120mg 24/50 (.429mg 27/50) Maekawa;gann,75,117-125;1984
a	1614	.419mg	6.46mg	9/52	12.0ug	10/51	40.2ug	16/52	.120mg 16/50 .429mg 22/50
b	1614	.544mg	1.66mg	0/52	12.0ug	0/51	40.2ug	0/52	.120mg 2/50 .429mg 20/50
c	1614	1.12mg	12.3mg	1/52	12.0ug	1/51	40.2ug	1/52	.120mg 1/50 .429mg 8/50
d	1614	1.10mg	18.2mg	2/52	12.0ug	1/51	40.2ug	1/52	.120mg 2/50 .429mg 8/50
e	1614	1.10mg	18.2mg	2/52	12.0ug	1/51	40.2ug	1/52	.120mg 2/50 .429mg 8/50
f	1614	2.32mg	106.mg	0/52	12.0ug	0/51	40.2ug	0/52	.120mg 0/50 .429mg 3/50
g	1614	1.24mg	n.s.s.	0/52	12.0ug	5/51	40.2ug	3/52	.120mg 3/50 .429mg 6/50

	Spe Strain Site Xpo+Xpt Sex Route Hist Notes	TD50 DR	2Tailpvl AuOp
h	R f f3d wat tyf ppa 24m26 ae	8.70mg *	P<.08
i	R f f3d wat liv nnd 24m26 ae	no dre	P=1.
j	R f f3d wat tba mix 24m26 ae	68.7ug *	P<.0005
204	R m f3d wat per mso 23m26 ae . + .	.109mg Z	P<.0005
a	R m f3d wat lun ade 23m26 ae	.518mg *	P<.0005
b	R m f3d wat mgl fib 23m26 ae	.889mg *	P<.0005
c	R m f3d wat bra mix 23m26 ae	.997mg *	P<.0005+
d	R m f3d wat dgt mix 23m26 ae	1.15mg *	P<.0005+
e	R m f3d wat lun adc 23m26 ae	2.00mg *	P<.0005
f	R m f3d wat sub fib 23m26 ae	2.42mg *	P<.02
g	R m f3d wat tyf ppa 23m26 ae	3.90mg *	P<.05 +
h	R m f3d wat tyf pac 23m26 ae	8.53mg *	P<.09 +
i	R m f3d wat pns mix 23m26 ae	10.2mg *	P<.4 +
j	R m f3d wat liv nnd 23m26 ae	16.4mg *	P<.7
k	R m f3d wat duo mix 23m26 ae	31.2mg *	P<.5 +
l	R m f3d wat tba mix 23m26 ae	25.0ug *	P<.3
ETHYLENE OXIDE***	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
205	R m f3h inh per mso 23m24 eis pool .(+) .	30.8mg *	P<.0005+
a	R m f3h inh bra gli 23m24 eis	121.mg *	P<.01 +
b	R m f3h inh spl mnl 23m24 eis	47.3mg *	P<.3 +
c	R m f3h inh liv nnd 23m24 eis	no dre	P=1.
206	R f fmf inh pit ade 76w78 ikr pool . (±)	29.8mg	P<.08 -
a	R f fmf inh bra mix 76w78 ikr	237.mg *	P<.6 +
207	R f fmf inh bra mix 23m24 ir pool . (±)	143.mg *	P<.02 +
208	R m fmf inh adr phe 76w78 ikr pool . (±)	26.1mg	P<.08 -
a	R m fmf inh bra ast 76w78 ikr	102.mg *	P<.7 +
b	R m fmf inh pit ade 76w78 ikr	no dre	P=1. -
c	R m fmf inh tes ict 76w78 ikr	no dre	P=1. -
209	R m fmf inh bra mix 24m25 ir pool . (+) .	70.7mg *	P<.002 +
EUGENOL	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
210	M f b6c eat liv MXA 24m24 : ±	2.91gm *	P<.04 e
a	M f b6c eat TBA MXB 24m24	no dre	P=1.
b	M f b6c eat liv MXB 24m24	2.91gm *	P<.04
c	M f b6c eat lun MXB 24m24	25.3gm *	P<.8
211	M m b6c eat liv MXA 24m24 : ±	451.mg \	P<.02 e
a	M m b6c eat liv hpc 24m24	710.mg \	P<.03 e
b	M m b6c eat liv hpa 24m24	781.mg \	P<.02 e
c	M m b6c eat thy fca 24m24	8.52gm *	P<.04
d	M m b6c eat TBA MXB 24m24	1.55gm *	P<.3
e	M m b6c eat liv MXB 24m24	451.mg \	P<.02
f	M m b6c eat lun MXB 24m24	no dre	P=1.
212	M f cd1 eat lun ade 50w78 v .>	no dre	P=1. -
a	M f cd1 eat liv tum 50w78 v	no dre	P=1. -
213	R f f34 eat TBA MXB 24m24 :>	no dre	P=1. -
a	R f f34 eat liv MXB 24m24	no dre	P=1.
214	R m f34 eat lun MXA 24m24 : ±	#424.mg \	P<.02 -
a	R m f34 eat TBA MXB 24m24	293.mg \	P<.5
b	R m f34 eat liv MXB 24m24	no dre	P=1.
FENVALERATE	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
215	R f sda eat mgl fib 24m24 e . ±	2.55mg Z	P<.02 -
a	R f sda eat mam ben 24m24 e	43.7mg *	P<.2 -
b	R f sda eat mgl fba 24m24 e	58.0mg *	P<.3 -
c	R f sda eat mam mal 24m24 e	150.mg *	P<.5 -
216	R f sda eat mam ben 24m24 e .>	247.mg	P<.4 -
a	R f sda eat liv rcs 24m24 e	no dre	P=1. -
b	R f sda eat mam mal 24m24 e	no dre	P=1. -
217	R m sda eat sub fbs 24m24 e . + .	5.04mg Z	P<.003 -
218	R m sda eat sub scs 24m24 e . + .	266.mg	P<.009 -
FLECAINIDE ACETATE	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
219	M f cd1 eat lun ade 78w78 e .>	938.mg *	P<.7 -
a	M f cd1 eat liv ade 78w78 e	no dre	P=1. -
220	M m cd1 eat lun ade 78w78 e .>	no dre	P=1. -
a	M m cd1 eat liv ade 78w78 e	no dre	P=1. -
b	M m cd1 eat liv hpc 78w78 e	no dre	P=1. -
221	R f crw eat liv ade 24m24 e .>	no dre	P=1. -
222	R m crw eat tes ica 24m24 e . + .	79.1mg *	P<.004 -
a	R m crw eat liv ade 24m24 e	3.58gm *	P<.2 -
FLUORIDE, SODIUM***	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
223	M f dbx eat mgl car 90w90 er .>	no dre	P=1. -

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc				Citation or Pathology Brkly Code
h	1614	2.35mg	n.s.s.	0/52	12.0ug	0/51	40.2ug	1/52	.120mg	0/50	.429mg	2/50
i	1614	4.88mg	n.s.s.	0/52	12.0ug	0/51	40.2ug	1/52	.120mg	0/50	.429mg	0/50
j	1614	32.6ug	.202mg	38/52	12.0ug	39/51	40.2ug	44/52	.120mg	46/50	.429mg	50/50
204	1614	71.0ug	.200mg	1/51	11.2ug	10/52	37.5ug	13/52	.112mg	28/51	(.400mg	32/52)
a	1614	.326mg	.976mg	5/51	11.2ug	0/52	37.5ug	6/52	.112mg	11/51	.400mg	25/52
b	1614	.460mg	3.25mg	6/51	11.2ug	5/52	37.5ug	6/52	.112mg	13/51	.400mg	18/52
c	1614	.588mg	1.90mg	0/51	11.2ug	0/52	37.5ug	2/52	.112mg	2/51	.400mg	16/52
d	1614	.629mg	2.84mg	1/51	11.2ug	2/52	37.5ug	1/52	.112mg	4/51	.400mg	14/52
e	1614	.942mg	7.80mg	1/51	11.2ug	1/52	37.5ug	1/52	.112mg	2/51	.400mg	9/52
f	1614	.961mg	n.s.s.	0/51	11.2ug	1/52	37.5ug	2/52	.112mg	5/51	.400mg	5/52
g	1614	1.29mg	n.s.s.	0/51	11.2ug	1/52	37.5ug	4/52	.112mg	1/51	.400mg	5/52
h	1614	2.27mg	n.s.s.	0/51	11.2ug	0/52	37.5ug	1/52	.112mg	0/51	.400mg	2/52
i	1614	2.34mg	n.s.s.	0/51	11.2ug	2/52	37.5ug	0/52	.112mg	2/51	.400mg	2/52
j	1614	1.73mg	n.s.s.	4/51	11.2ug	0/52	37.5ug	6/52	.112mg	3/51	.400mg	4/52
k	1614	3.55mg	n.s.s.	0/51	11.2ug	1/52	37.5ug	0/52	.112mg	0/51	.400mg	1/52
l	1614	n.s.s.	n.s.s.	51/51	11.2ug	51/52	37.5ug	52/52	.112mg	51/51	.400mg	52/52
ETHYLENE OXIDE*** 75-21-8												
205	1624	18.3mg	77.8mg	3/78p	5.42mg	9/79	10.8mg	21/79				Lynch;txap,76,69-84;1984
a	1624	52.3mg	4.81gm	0/76p	5.42mg	2/77	10.8mg	5/79				
b	1624	14.3mg	n.s.s.	24/77p	5.42mg	38/79	10.8mg	30/76				
c	1624	88.2mg	n.s.s.	2/78p	5.42mg	3/78	10.8mg	2/79				
206	1666m	8.48mg	n.s.s.	2/40p	13.3mg	4/20						Snellings;txap,75,105-117;1984/Garman 1985
a	1666m	24.7mg	n.s.s.	1/40p	1.31mg	0/20	4.34mg	0/20	13.3mg	1/20		
207	1666o	61.7mg	n.s.s.	0/154p	1.31mg	1/78	4.32mg	3/79	13.2mg	3/79		
208	1666m	6.94mg	n.s.s.	1/40p	9.29mg	3/20						
a	1666m	16.5mg	n.s.s.	0/40p	.920mg	0/20	3.04mg	1/20	9.29mg	0/20		
b	1666m	9.53mg	n.s.s.	7/40p	9.29mg	3/20						
c	1666m	2.56mg	n.s.s.	35/40p	9.29mg	16/20						
209	1666o	33.5mg	313.mg	1/156p	.916mg	1/79	3.02mg	4/78	9.25mg	7/79		
EUGENOL (1-allyl-3-methoxy-4-hydroxybenzene) 97-53-0												
210	c50453	1.29gm	n.s.s.	2/50	383.mg	7/50	773.mg	9/50				liv:hpa,hpc.
a	c50453	1.12gm	n.s.s.	27/50	383.mg	22/50	773.mg	26/50				
b	c50453	1.29gm	n.s.s.	2/50	383.mg	7/50	773.mg	9/50				liv:hpa,hpc,nnd.
c	c50453	2.22gm	n.s.s.	4/50	383.mg	6/50	773.mg	5/50				lun:a/a,a/c.
211	c50453	208.mg	124.gm	14/50	353.mg	28/50	(713.mg	18/50)				liv:hpa,hpc.
a	c50453	298.mg	n.s.s.	10/50	353.mg	20/50	(713.mg	9/50)				
b	c50453	336.mg	n.s.s.	4/50	353.mg	13/50	(713.mg	10/50)				
c	c50453	2.58gm	n.s.s.	0/50	353.mg	0/50	713.mg	3/50				S
d	c50453	464.mg	n.s.s.	27/50	353.mg	36/50	713.mg	32/50				
e	c50453	208.mg	124.gm	14/50	353.mg	28/50	(713.mg	18/50)				liv:hpa,hpc,nnd.
f	c50453	1.77gm	n.s.s.	13/50	353.mg	8/50	713.mg	9/50				lun:a/a,a/c.
212	1582	370.mg	n.s.s.	1/30	176.mg	1/30						Miller;canr,43,1124-1134;1983
a	1582	612.mg	n.s.s.	0/30	176.mg	0/30						
213	c50453	723.mg	n.s.s.	33/40	294.mg	41/50	619.mg	38/50				
a	c50453	n.s.s.	n.s.s.	0/40	294.mg	0/50	619.mg	0/50				liv:hpa,hpc,nnd.
214	c50453	158.mg	n.s.s.	0/40	118.mg	5/50	(238.mg	2/50)				lun:a/a,a/c. S
a	c50453	62.8mg	n.s.s.	30/40	118.mg	40/50	(238.mg	33/50)				
b	c50453	1.75gm	n.s.s.	2/40	118.mg	0/50	238.mg	1/50				liv:hpa,hpc,nnd.
FENVALERATE (cyano-(3-phenoxyphenyl)methyl-4-chloro-alpha-(1-methylethyl)benzene acetate) 51630-58-1												
215	1650m	.882mg	n.s.s.	0/102	50.0ug	1/51	.250mg	3/51	(1.25mg	1/51	12.5mg	0/48) Parker;jtxe,13,83-97;1984
a	1650m	14.0mg	n.s.s.	25/102	50.0ug	16/51	.250mg	18/51	1.25mg	21/51	12.5mg	20/48
b	1650m	15.8mg	n.s.s.	25/102	50.0ug	18/51	.250mg	18/51	1.25mg	19/51	12.5mg	19/48
c	1650m	26.2mg	n.s.s.	18/102	50.0ug	9/51	.250mg	11/51	1.25mg	9/51	12.5mg	11/48
216	1650n	60.6mg	n.s.s.	16/50	50.0mg	20/49						
a	1650n	505.mg	n.s.s.	1/50	50.0mg	0/49						
b	1650n	179.mg	n.s.s.	10/50	50.0mg	7/49						
217	1650m	2.18mg	38.3mg	0/103	40.0ug	1/51	.200mg	3/51	1.00mg	5/51	(10.0mg	0/51)
218	1650n	101.mg	6.25gm	0/50	40.0mg	5/51						
FLECAINIDE ACETATE (2,5-bis(2,2,2-trifluorethoxyl)-N-(2-piperidylmethyl)benzamide acetate) 54143-56-5												
219	1649n	136.mg	n.s.s.	5/69	15.0mg	5/69	30.0mg	7/68	60.0mg	6/67		Case;txap,73,232-242;1984
a	1649n	68.0mg	n.s.s.	1/69	15.0mg	0/69	30.0mg	0/68	60.0mg	0/67		
220	1649n	165.mg	n.s.s.	10/67	15.0mg	7/69	30.0mg	7/69	60.0mg	7/60		
a	1649n	269.mg	n.s.s.	10/67	15.0mg	4/69	30.0mg	5/69	60.0mg	4/60		
b	1649n	584.mg	n.s.s.	2/67	15.0mg	0/69	30.0mg	1/69	60.0mg	0/60		
221	1649m	820.mg	n.s.s.	2/49	15.0mg	0/50	30.0mg	1/50	60.0mg	0/50		
222	1649m	40.8mg	561.mg	19/50	15.0mg	16/50	30.0mg	23/50	60.0mg	32/50		
a	1649m	583.mg	n.s.s.	0/50	15.0mg	0/50	30.0mg	0/50	60.0mg	1/50		
FLUORIDE, SODIUM*** 7681-49-4												
223	1652	276.mg	n.s.s.	37/50	117.mg	20/48						Tannenbaum;canr,9,403-410;1949

	Spe Strain Site Xpo+Xpt Sex Route Hist Notes	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10	TD50 DR	2Tailpvl AuOp
FLUOROCARBON 31				
224	R f aap gav sto mix 12m25 e	pool . + .	26.5mg	P<.0005+
a	R f aap gav sto sqc 12m25 e		69.4mg	P<.0005+
b	R f aap gav sto fbs 12m25 e		119.mg	P<.0005+
c	R f aap gav sto car 12m25 e		2.71gm	P<.1 +
d	R f aap gav sto sar 12m25 e		2.71gm	P<.1 +
225	R m aap gav sto mix 12m23 e	pool . + .	28.5mg	P<.0005+
a	R m aap gav sto sqc 12m23 e		46.9mg	P<.0005+
b	R m aap gav sto fbs 12m23 e		88.1mg	P<.0005+
FLUOROCARBON 133a		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
226	R f aap gav ute adc 12m29 e	pool . + .	160.mg	P<.0005+
227	R m aap gav tes ict 12m29 e	pool . + .	60.0mg	P<.0005+
*FORMALDEHYDE***		*100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10*		
228	M f b6c inh nas tum 52w52 ek	.>	no dre	P=1.
a	M f b6c inh lun tum 52w52 ek		no dre	P=1.
b	*M f b6c inh liv tum 52w52 ek*		*no dre*	P=1.
229	M f b6c inh nas tum 78w78 ek	.>	no dre	P=1.
a	M f b6c inh liv mix 78w78 ek		no dre	P=1.
b	*M f b6c inh lun tum 78w78 ek*		*no dre*	P=1.
230	M f b6c inh lun mix 24m24 ek	.>	47.3mg	P<.3
a	M f b6c inh liv mix 24m24 ek		98.7mg	P<.6
b	M f b6c inh nas tum 24m24 ek		no dre	P=1.
231	M f b6c inh nas tum 24m27 e	.>	no dre	P=1.
a	M f b6c inh lun mix 24m27 e		no dre	P=1.
b	M f b6c inh liv tum 24m27 e		no dre	P=1.
232	M m b6c inh liv hpc 52w52 ek	.>	7.85mg	P<.3
a	M m b6c inh lun tum 52w52 ek		no dre	P=1.
b	M m b6c inh nas tum 52w52 ek		no dre	P=1.
233	M m b6c inh ntu sqc 24m24 es	. ±	43.9mg *	P<.04 +
a	M m b6c inh liv mix 24m24 es		34.5mg	P<.2
b	M m b6c inh lun mix 24m24 es		no dre	P=1.
234	R f f34 inh nas tum 52w52 ek	.>	no dre	P=1.
a	R f f34 inh liv tum 52w52 ek		no dre	P=1.
235	R f f34 inh ntu sqc 78w78 ek	. + .	3.67mg *	P<.005 +
a	R f f34 inh liv nnd 78w78 ek		192.mg	P<1.
b	R f f34 inh ntu pla 78w78 ek		no dre	P=1.
236	R f f34 inh ntu sqc 25m25 s	: + :	1.37mg Z	P<.0005+
a	R f f34 inh ntu pla 25m25 s		7.95mg Z	P<.4
b	R f f34 inh liv nnd 25m25 es		no dre	P=1.
237	R m f34 inh nas tum 52w52 ek	.>	no dre	P=1.
a	R m f34 inh liv tum 52w52 ek		no dre	P=1.
238	R m f34 inh ntu sqc 78w78 ek	. + .	2.57mg *	P<.005 +
a	R m f34 inh ntu pla 78w78 ek		5.39mg *	P<.2
b	*R m f34 inh liv tum 78w78 ek*		*no dre*	P=1.
239	R m f34 inh ntu sqc 24m24 s	: +:	.798mg Z	P<.0005+
a	R m f34 inh ntu pla 24m24 s		3.01mg *	P<.03
b	*R m f34 inh liv mix 24m24 es*		*no dre*	P=1.
FUSARENON-X		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
240	R m don eat liv hnd 24m24 e	.>	no dre	P=1.
a	R m don eat tba mix 24m24 e		no dre	P=1.
241	R m don eat liv hnd 18m24 ae	.>	no dre	P=1.
a	R m don eat tba mix 18m24 ae		no dre	P=1.
L-GLUTAMIC ACID		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
242	M m cbl eat liv tum 24m24 e	.>	no dre	P=1. -
a	M m cbl eat lun tum 24m24 e		no dre	P=1. -
b	M m cbl eat tba tum 24m24 e		no dre	P=1. -
HEXACHLOROCYCLOHEXANE		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
243	M m swi eat liv hpc 52w52 kr	. ±	25.3mg	P<.05 +
HYDRAZINE SULFATE***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
244	M b swi gav lun adc 95w95 r	.+ .	9.81mg	P<.0005+
N-HYDROXY-2-ACETYLAMINOFLUORENE***		..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
245	M f ddd eat for mix 30w76 e	. + .	6.23mg	P<.0005+
a	M f ddd eat ubl mix 30w76 e		7.32mg	P<.0005+
b	*M f ddd eat liv hpt 30w76 e*		*16.0mg*	*P<.0005+*
c	M f ddd eat ubl epc 30w76 e		16.0mg	P<.0005
d	M f ddd eat eso ept 30w76 e		28.8mg	P<.009 +
e	*M f ddd eat k/p ept 30w76 e*		*164.mg*	P<.3 +
f	M f ddd eat lun ade 30w76 e		no dre	P=1. -

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc			Citation or Pathology / Brkly Code
FLUOROCARBON 31 (chlorofluoromethane) 593-70-4										
224	1623	14.0mg	48.8mg	1/104p	103.mg	34/36				Longstaff;txap,72,15-31;1984/pers.comm.
a	1623	41.4mg	126.mg	0/104p	103.mg	24/36				
b	1623	66.8mg	242.mg	0/104p	103.mg	17/36				
c	1623	441.mg	n.s.s.	0/104p	103.mg	1/36				
d	1623	441.mg	n.s.s.	0/104p	103.mg	1/36				
225	1623	16.0mg	51.3mg	1/104p	111.mg	33/36				
a	1623	28.2mg	82.9mg	0/104p	111.mg	28/36				
b	1623	50.8mg	171.mg	1/104p	111.mg	20/36				
FLUOROCARBON 133a (2-chloro-1,1,1-trifluoroethane) 75-88-7										
226	1623	86.4mg	351.mg	1/104p	89.1mg	15/35				Longstaff;txap,72,15-31;1984/pers.comm.
227	1623	34.4mg	117.mg	16/104p	89.1mg	29/36				
FORMALDEHYDE* 50-00-0**										
228	1566a	.271mg	n.s.s.	0/10	.772mg	0/10	2.32mg	0/10	5.79mg 0/10	Pavkov;ciit;1981/Kerns 1983
a	1566a	2.98mg	n.s.s.	0/10	5.79mg	0/10				
b	1566a	2.98mg	n.s.s.	0/10	5.79mg	0/10				
229	1566b	1.21mg	n.s.s.	0/20	.772mg	0/20	2.32mg	0/20	5.79mg 0/19	
a	1566b	8.42mg	n.s.s.	2/20	5.79mg	1/19				
b	1566b	12.8mg	n.s.s.	0/20	5.79mg	0/19				
230	1566c	10.9mg	n.s.s.	1/30	5.79mg	3/27				
a	1566c	14.4mg	n.s.s.	1/30	5.79mg	2/28				
b	1566c	3.10mg	n.s.s.	0/30	.772mg	0/26	2.32mg	0/41	5.79mg 0/28	
231	1566m	6.06mg	n.s.s.	0/50	.686mg	0/54	2.06mg	0/39	5.15mg 0/54	
a	1566m	44.5mg	n.s.s.	1/50	5.15mg	1/54				
b	1566m	72.5mg	n.s.s.	0/50	5.15mg	0/54				
232	1566a	1.28mg	n.s.s.	0/10	4.83mg	1/10				
a	1566a	2.49mg	n.s.s.	0/10	4.83mg	0/10				
b	1566a	.226mg	n.s.s.	0/10	.644mg	0/10	1.93mg	0/10	4.83mg 0/10	
233	1566c	10.8mg	n.s.s.	0/20	.644mg	0/22	1.93mg	0/19	4.83mg 2/17	
a	1566c	9.67mg	n.s.s.	4/62	4.83mg	6/40				
b	1566c	6.53mg	n.s.s.	6/25	4.83mg	4/18				
234	1566n	64.6ug	n.s.s.	0/10	.184mg	0/10	.552mg	0/10	1.38mg 0/10	
a	1566n	.710mg	n.s.s.	0/10	1.38mg	0/10				
235	1566o	1.27mg	33.9mg	0/20	.184mg	0/20	.552mg	0/20	1.38mg 4/19	
a	1566o	1.81mg	n.s.s.	1/20	1.38mg	1/19				
b	1566o	3.23mg	n.s.s.	0/20	.184mg	1/20	.552mg	0/20	1.38mg 0/19	
236	1566r	.952mg	2.06mg	0/78	.184mg	0/79	.552mg	1/76	1.38mg 48/73	
a	1566r	1.25mg	n.s.s.	0/78	.184mg	3/79	.552mg	0/76	1.38mg 1/73	
b	1566r	4.13mg	n.s.s.	1/67	1.38mg	0/14				
237	1566n	45.2ug	n.s.s.	0/10	.129mg	0/10	.386mg	0/10	.965mg 0/10	
a	1566n	.497mg	n.s.s.	0/10	.965mg	0/10				
238	1566o	.886mg	23.8mg	0/20	.129mg	0/20	.386mg	0/20	.965mg 4/19	
a	1566o	1.32mg	n.s.s.	0/20	.129mg	0/20	.386mg	1/20	.965mg 1/19	
b	1566o	2.24mg	n.s.s.	0/20	.965mg	0/20				
239	1566r	.510mg	1.23mg	0/79	.129mg	0/80	.386mg	1/79	.965mg 47/73	
a	1566r	1.10mg	n.s.s.	1/79	.129mg	4/80	.386mg	5/79	.965mg 3/73	
b	1566r	2.85mg	n.s.s.	4/74	.965mg	1/22				
FUSARENON-X 23255-69-8										
240	1748m	.319mg	n.s.s.	1/19	100.ug	0/22	.210mg	0/25		Saito;jjem,50,293-302;1980/Ohtsubo pers.comm.
a	1748m	.684mg	n.s.s.	4/19	100.ug	3/22	.210mg	2/25		
241	1748n	.218mg	n.s.s.	0/23	100.ug	0/24	.105mg	0/18		
a	1748n	.464mg	n.s.s.	4/23	100.ug	2/24	.105mg	1/18		
L-GLUTAMIC ACID 56-86-0										
242	1631	4.06gm	n.s.s.	0/55	1.20gm	0/20	4.80gm	0/29		Ebert;txlt,3,65-70;1979
a	1631	4.06gm	n.s.s.	0/55	1.20gm	0/20	4.80gm	0/29		
b	1631	4.06gm	n.s.s.	0/55	1.20gm	0/20	4.80gm	0/29		
HEXACHLOROCYCLOHEXANE 608-73-1										
243	1744	10.9mg	n.s.s.	0/6	60.0mg	7/21				Kandarkar;ijmr,78,155-161;1983
HYDRAZINE SULFATE* 10034-93-2**										
244	1552	6.55mg	15.7mg	1/20	27.6mg	51/63				Menon;zkko,105,258-261;1983
N-HYDROXY-2-ACETYLAMINOFLUORENE* (hydroxy-N-2-fluorenylacetamide) 53-95-2**										
245	1628	3.08mg	14.3mg	0/16	25.6mg	14/18				Enomoto;jjem,44,37-54;1974
a	1628	3.62mg	17.1mg	0/16	25.6mg	13/18				
b	1628	7.10mg	52.5mg	0/16	25.6mg	8/18				
c	1628	7.10mg	52.5mg	0/16	25.6mg	8/18				
d	1628	10.9mg	632.mg	0/16	25.6mg	5/18				
e	1628	26.7mg	n.s.s.	0/16	25.6mg	1/18				
f	1628	34.0mg	n.s.s.	2/16	25.6mg	1/18				


Spe Strain Site Xpo+Xpt
Sex Route Hist Notes
TD50 2Tailpvl
DR AuOp
1'-HYDROXYESTRAGOLE
100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
246 M f cd1 eat liv hpt 51w86 v 57.8mg P<.0005+
a M f cd1 eat lun ade 51w86 v no dre P=1.
8-HYDROXYQUINOLINE***
247 M f b6c eat --- MXA 24m24 #819.mg \ P<.02 -
a M f b6c eat TBA MXB 24m24 no dre P=1.
b M f b6c eat liv MXB 24m24 no dre P=1.
c M f b6c eat lun MXB 24m24 2.98gm * P<.5
248 M m b6c eat TBA MXB 24m24 no dre P=1. -
a M m b6c eat liv MXB 24m24 17.7gm * P<1.
b M m b6c eat lun MXB 24m24 2.77gm * P<.6
249 R f f34 eat TBA MXB 24m24 434.mg * P<.6 -
a R f f34 eat liv MXB 24m24 no dre P=1.
250 R m f34 eat lun MXA 24m24 #651.mg * P<.03 -
a R m f34 eat thy ccr 24m24 1.06gm * P<.03
b R m f34 eat TBA MXB 24m24 no dre P=1.
c R m f34 eat liv MXB 24m24 no dre P=1.
1'-HYDROXYSAFROLE***
251 M f b6b eat liv hpt 52w69 ev 1.53gm * P<.3
252 M f b6n eat liv hpt 52w69 ev 53.3mg * P<.0005+
253 M f cd1 eat liv hpt 52w69 ev 49.1mg * P<.0005+
a M f cd1 eat lun ade 52w69 ev 3.67gm * P<.9
ISONIAZID***
254 M b swi gav lun adc 95w95 r 28.8mg P<.0005+
ISONICOTINAMIDE
255 M f swa wat liv hpt 28m28 e 21.3gm P<.2 -
a M f swa wat lun mix 28m28 e no dre P=1. -
256 M m swa wat lun mix 27m27 e no dre P=1. -
a M m swa wat liv mix 27m27 e no dre P=1.
ISOPHORONE
257 M f b6c gav TBA MXB 24m24 no dre P=1. -
a M f b6c gav liv MXB 24m24 2.74gm * P<.5
b M f b6c gav lun MXB 24m24 no dre P=1.
258 M m b6c gav --- mlh 24m24 s 244.mg \ P<.002 e
a M m b6c gav --- MXA 24m24 s 203.mg \ P<.06 e
b M m b6c gav --- MXA 24m24 s 236.mg \ P<.1 e
c M m b6c gav sub MXA 24m24 s 654.mg * P<.03 e
d M m b6c gav sub MXA 24m24 s 703.mg * P<.04 e
e M m b6c gav sub fbs 24m24 s 1.17gm * P<.09 e
f M m b6c gav sub fib 24m24 s 1.21gm * P<.06 e
g M m b6c gav liv MXA 24m24 s 573.mg * P<.3 e
h M m b6c gav MXA MXA 24m24 s 840.mg * P<.2 e
i M m b6c gav MXA MXA 24m24 s 882.mg * P<.2 e
j M m b6c gav MXA MXA 24m24 s 1.21gm * P<.2 e
k M m b6c gav sub MXA 24m24 s 1.26gm * P<.2 e
l M m b6c gav TBA MXB 24m24 s no dre P=1.
m M m b6c gav liv MXB 24m24 s 573.mg * P<.3
n M m b6c gav lun MXB 24m24 s no dre P=1.
259 R f f34 gav TBA MXB 24m24 s 16.6gm * P<1. -
a R f f34 gav liv MXB 24m24 s no dre P=1.
260 R m f34 gav MXB MXB 24m24 774.mg * P<.0005
a R m f34 gav kid MXA 24m24 1.21gm * P<.008 a
b R m f34 gav pre can 24m24 2.25gm * P<.005 a
c R m f34 gav TBA MXB 24m24 237.mg * P<.05
d R m f34 gav liv MXB 24m24 9.08gm * P<.9
KAEMPFEROL
261 R f aci eat tba mix 77w77 e 55.3mg P<.4 -
262 R m aci eat adr coa 77w77 e 17.9mg P<.1 -
LOFEXIDINE.HCl
263 R f lev eat tba tum 52w52 e 2.30mg \ P<.09 -
264 R m lev eat tba tum 52w52 e 2.30mg \ P<.09 -
MELAMINE
265 M f b6c eat TBA MXB 24m24 no dre P=1. -
a M f b6c eat liv MXB 24m24 no dre P=1.
b M f b6c eat lun MXB 24m24 no dre P=1.
266 M m b6c eat TBA MXB 24m24 3.20gm * P<.7 -
a M m b6c eat liv MXB 24m24 4.37gm * P<.6
b M m b6c eat lun MXB 24m24 no dre P=1.

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
1'-HYDROXYESTRAGOLE 51410-44-7									
246 1582	35.2mg	104.mg	0/50	80.7mg	24/50			Miller;canr,43,1124-1134;1983	
a 1582	383.mg	n.s.s.	2/50	80.7mg	1/50				
8-HYDROXYQUINOLINE*** (8-quinolinol) 148-24-3									
247 c55298	305.mg	n.s.s.	0/50	193.mg	5/50	(386.mg	1/50)	---:hem,hes.	S
a c55298	172.mg	n.s.s.	33/50	193.mg	30/50	(386.mg	25/50)		
b c55298	1.36gm	n.s.s.	5/50	193.mg	2/50	386.mg	4/50	liv:hpa,hpc,nnd.	
c c55298	713.mg	n.s.s.	2/50	193.mg	5/50	386.mg	5/50	lun:a/a,a/c.	
248 c55298	373.mg	n.s.s.	35/50	178.mg	35/50	357.mg	35/50		
a c55298	478.mg	n.s.s.	14/50	178.mg	15/50	357.mg	17/50	liv:hpa,hpc,nnd.	
b c55298	550.mg	n.s.s.	6/50	178.mg	10/50	357.mg	10/50	lun:a/a,a/c.	
249 c55298	84.9mg	n.s.s.	40/50	74.3mg	44/50	149.mg	45/50		
a c55298	552.mg	n.s.s.	4/50	74.3mg	2/50	149.mg	4/50	liv:hpa,hpc,nnd.	
250 c55298	277.mg	n.s.s.	0/50	59.4mg	3/50	119.mg	4/50	lun:a/a,a/c.	S
a c55298	362.mg	n.s.s.	0/50	59.4mg	0/50	119.mg	4/50		S
b c55298	141.mg	n.s.s.	43/50	59.4mg	42/50	119.mg	36/50		
c c55298	693.mg	n.s.s.	7/50	59.4mg	1/50	119.mg	3/50	liv:hpa,hpc,nnd.	
1'-HYDROXYSAFROLE*** 5208-87-7									
251 1581n	404.mg	n.s.s.	1/44	135.mg	2/41	260.mg	3/42	Boberg;canr,43,5163-5173;1983	
252 1581n	36.6mg	81.6mg	1/49	135.mg	24/38	260.mg	27/38		
253 1581m	32.7mg	77.2mg	0/32	135.mg	17/29	260.mg	25/32		
a 1581m	597.mg	n.s.s.	0/32	135.mg	1/29	260.mg	0/32		
ISONIAZID*** (INH) 54-85-3									
254 1552	17.2mg	80.7mg	1/20	27.6mg	27/60			Menon;zkko,105,258-261;1983	
ISONICOTINAMIDE 1453-82-3									
255 1732	3.47gm	n.s.s.	0/28	2.00gm	1/12			Toth;onco,40,72-75;1983/1979	
a 1732	6.83gm	n.s.s.	15/91	2.00gm	5/33				
256 1732	5.77gm	n.s.s.	22/88	1.67gm	9/43				
a 1732	13.9gm	n.s.s.	2/62	1.67gm	0/32				
ISOPHORONE 78-59-1									
257 c55618	136.mg	n.s.s.	36/50	175.mg	41/50	(354.mg	28/50)		
a c55618	604.mg	n.s.s.	4/50	175.mg	6/50	354.mg	8/50	liv:hpa,hpc,nnd.	
b c55618	1.88gm	n.s.s.	3/50	175.mg	1/50	354.mg	2/50	lun:a/a,a/c.	
258 c55618	109.mg	928.mg	0/50	177.mg	9/50	(354.mg	4/50)		
a c55618	80.2mg	n.s.s.	7/50	177.mg	19/50	(354.mg	5/50)	---:mlh,mlm,mlp.	
b c55618	85.7mg	n.s.s.	8/50	177.mg	19/50	(354.mg	5/50)	---:lkn,mlh,mlm,mlp.	
c c55618	293.mg	n.s.s.	3/50	177.mg	6/50	354.mg	13/50	sub:fbs,fib.	
d c55618	301.mg	n.s.s.	4/50	177.mg	6/50	354.mg	14/50	sub:fbs,fib,nfs,sar.	
e c55618	444.mg	n.s.s.	3/50	177.mg	4/50	354.mg	10/50		
f c55618	460.mg	n.s.s.	0/50	177.mg	2/50	354.mg	3/50		
g c55618	162.mg	n.s.s.	18/50	177.mg	18/50	354.mg	29/50	liv:hpa,hpc.	
h c55618	308.mg	n.s.s.	5/50	177.mg	7/50	354.mg	13/50	ski:fib; sub:fbs,fib.	
i c55618	309.mg	n.s.s.	6/50	177.mg	8/50	354.mg	14/50	ski:fib,nfs; sub:fbs,fib,nfs,sar.	
j c55618	434.mg	n.s.s.	4/50	177.mg	5/50	354.mg	11/50	ski:nfs; sub:fbs,nfs,sar.	
k c55618	451.mg	n.s.s.	4/50	177.mg	4/50	354.mg	11/50	sub:fbs,nfs,sar.	
l c55618	174.mg	n.s.s.	35/50	177.mg	40/50	354.mg	40/50		
m c55618	162.mg	n.s.s.	18/50	177.mg	18/50	354.mg	29/50	liv:hpa,hpc,nnd.	
n c55618	1.39gm	n.s.s.	7/50	177.mg	1/50	354.mg	3/50	lun:a/a,a/c.	
259 c55618	192.mg	n.s.s.	43/50	175.mg	36/50	350.mg	30/50		
a c55618	1.45gm	n.s.s.	3/50	175.mg	1/50	350.mg	1/50	liv:hpa,hpc,nnd.	
260 c55618	378.mg	2.07gm	0/50	175.mg	3/50	350.mg	8/50	kid:tla,uac; pre:can.	A
a c55618	492.mg	21.4gm	0/50	175.mg	3/50	350.mg	3/50	kid:tla,uac.	
b c55618	818.mg	19.3gm	0/50	175.mg	0/50	350.mg	5/50		
c c55618	99.5mg	n.s.s.	38/50	175.mg	42/50	350.mg	33/50		
d c55618	522.mg	n.s.s.	5/50	175.mg	9/50	350.mg	2/50	liv:hpa,hpc,nnd.	
KAEMPFEROL 520-18-3									
261 1662	6.92mg	n.s.s.	1/22	20.0mg	1/6			Takanashi;jfds,5,55-60;1983	
262 1662	3.71mg	n.s.s.	2/30	16.0mg	2/6				
LOFEXIDINE.HCl (2-|1-(2,6-dichlorphenoxy)-ethyl|-2-imidazoline.HCl) 21498-08-8									
263 1668	.563mg	n.s.s.	0/10	3.00mg	2/10	(8.00mg	0/20)	Tsai;arzn,31,955-962;1982	
264 1668	.563mg	n.s.s.	0/10	3.00mg	2/10	(8.00mg	0/20)		
MELAMINE 108-78-1									
265 c50715	804.mg	n.s.s.	28/50	287.mg	33/50	574.mg	26/50		
a c50715	2.61gm	n.s.s.	4/50	287.mg	6/50	574.mg	2/50	liv:hpa,hpc,nnd.	
b c50715	3.53gm	n.s.s.	5/50	287.mg	1/50	574.mg	3/50	lun:a/a,a/c.	
266 c50715	525.mg	n.s.s.	23/50	265.mg	22/50	530.mg	20/50		
a c50715	820.mg	n.s.s.	12/50	265.mg	8/50	530.mg	12/50	liv:hpa,hpc,nnd.	
b c50715	2.37gm	n.s.s.	5/50	265.mg	4/50	530.mg	1/50	lun:a/a,a/c.	

	Spe Strain Site Xpo+Xpt Sex Route Hist Notes		TD50 DR	2Tailpvl AuOp
267	R f f34 eat thy MXA 24m24	: ±	#2.47gm *	P<.03 -
a	R f f34 eat thy ccr 24m24		4.16gm *	P<.04
b	R f f34 eat TBA MXB 24m24		3.93gm *	P<.9
c	R f f34 eat liv MXB 24m24		4.41gm *	P<.2
268	R m f34 eat ubl MXA 24m24	: + :	679.mg /	P<.0005
a	R m f34 eat ubl tcc 24m24		735.mg /	P<.002 c
b	R m f34 eat TBA MXB 24m24		149.mg *	P<.04
c	R m f34 eat liv MXB 24m24		no dre	P=1.
	2-MERCAPTOETHANESULFONATE, SODIUM 100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10			
269	R m sda wat liv tum 9m24	.>	no dre	P=1.
a	R m sda wat lun tum 9m24		no dre	P=1.
b	R m sda wat ubl tum 9m24		no dre	P=1.
	METHAPYRILENE.HCl 100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10			
270	H m syg gav liv nnd 58w61	.>	150.mg	P<.4
a	H m syg gav tba tum 58w61		no dre	P=1.
271	R f f34 eat liv mix 26m31	. + .	7.65mg *	P<.0005+
a	R f f34 eat liv nnd 26m31		11.8mg *	P<.0005
b	R f f34 eat liv hpc 26m31		61.6mg /	P<.004 +
272	R m f34 eat liv bsa 73w73 ekr	<+	noTD50	P<.009 +
a	R m f34 eat liv esa 73w73 ekr		noTD50	P<.009 +
b	R m f34 eat liv hpc 73w73 ekr		14.7mg	P<.02 +
c	R m f34 eat liv hps 73w73 ekr		26.4mg	P<.08 +
d	R m f34 eat liv thc 73w73 ekr		26.4mg	P<.08 +
273	R m f34 eat liv mix 26m31	. + .	7.70mg *	P<.0005+
a	R m f34 eat liv nnd 26m31		11.1mg *	P<.003
b	R m f34 eat liv hpc 26m31		77.0mg *	P<.04 +
c	R m f34 eat liv clc 26m31		400.mg *	P<.3
	N-METHYL-N'-NITRO-N-NITROSOGUANIDINE***..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10			
274	R b alb wat for pam 78w78 r	. ±	22.9mg	P<.02
a	R b alb wat stg adc 78w78 r		22.9mg	P<.02
275	R m f34 wat stg mix 12m29	. + .	1.42mg	P<.0005+
a	R m f34 wat stg ade 12m29		2.38mg	P<.003 +
b	R m f34 wat stg adc 12m29		5.22mg	P<.04 +
c	R m f34 wat stg sar 12m29		16.5mg	P<.3 +
d	R m f34 wat liv nnd 12m29		no dre	P=1.
276	R m f34 wat stg mix 12m24	. + .	.592mg	P<.0005+
a	R m f34 wat stg ade 12m24		1.65mg	P<.002 +
b	R m f34 wat stg sar 12m24		2.48mg	P<.007 +
c	R m f34 wat stg adc 12m24		3.19mg	P<.02 +
d	R m f34 wat liv nnd 12m24		no dre	P=1.
277	R m wis wat git adc 28w58 r	. + .	.810mg	P<.0005+
a	R m wis wat smi adc 28w58 r		1.21mg	P<.003
b	R m wis wat stg adc 28w58 r		4.31mg	P<.1
278	R m wis wat duo tum 30w54 er	. ±	3.44mg	P<.1 +
279	R m wis wat git mix 26w52 er	. ±	1.60mg	P<.04 +
a	R m wis wat duo tum 26w52 er		2.21mg	P<.07
b	R m wis wat stg a/2 26w52 er		7.06mg	P<.3 +
280	R m wis wat git mix 26w52 er	. ±	1.92mg	P<.04 +
a	R m wis wat stg a/2 26w52 er		2.28mg	P<.06 +
b	R m wis wat duo tum 26w52 er		7.28mg	P<.3
	METHYL 12-OXO-trans-10-OCTADECENOATE ..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10			
281	M b stm eat --- mly 42w84 e	.>	2.94gm	P<.7 -
	METHYLENE CHLORIDE 100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10			
282	M f b6c inh MXB MXB 24m24	: + :	817.mg *	P<.0005
a	M f b6c inh lun MXA 24m24		917.mg *	P<.0005c
b	M f b6c inh lun a/a 24m24		1.42gm *	P<.0005c
c	M f b6c inh liv MXA 24m24		1.43gm /	P<.0005c
d	M f b6c inh lun a/c 24m24		1.69gm /	P<.0005c
e	M f b6c inh liv hpc 24m24		1.85gm /	P<.0005c
f	M f b6c inh liv hpa 24m24		3.17gm /	P<.0005c
g	M f b6c inh thy fca 24m24		15.8gm *	P<.05
h	M f b6c inh TBA MXB 24m24		1.02gm *	P<.0005
i	M f b6c inh liv MXB 24m24		1.43gm /	P<.0005
j	M f b6c inh lun MXB 24m24		917.mg *	P<.0005
283	M m b6c inh lun MXA 24m24	: + :	920.mg *	P<.0005c
a	M m b6c inh MXB MXB 24m24		1.09gm *	P<.0005
b	M m b6c inh lun a/a 24m24		1.68gm *	P<.0005c
c	M m b6c inh lun a/c 24m24		1.71gm /	P<.0005c
d	M m b6c inh liv MXA 24m24		1.80gm *	P<.0005c
e	M m b6c inh liv hpc 24m24		2.69gm *	P<.0005c
f	M m b6c inh liv hpa 24m24		3.48gm *	P<.003 c
g	M m b6c inh --- hes 24m24		12.9gm *	P<.02

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
267	c50715	937.mg	n.s.s.	0/50	221.mg	2/50	441.mg	3/50	thy:cca,ccr.	S
a	c50715	1.26gm	n.s.s.	0/50	221.mg	0/50	441.mg	3/50		S
b	c50715	273.mg	n.s.s.	42/50	221.mg	43/50	441.mg	37/50		
c	c50715	1.33gm	n.s.s.	0/50	221.mg	2/50	441.mg	1/50	liv:hpa,hpc,nnd.	
268	c50715	308.mg	2.04gm	0/50	88.3mg	0/50	177.mg	9/50	ubl:tcc,tpp.	S
a	c50715	322.mg	2.51gm	0/50	88.3mg	0/50	177.mg	8/50		
b	c50715	65.3mg	n.s.s.	30/50	88.3mg	36/50	177.mg	38/50		
c	c50715	n.s.s.	n.s.s.	0/50	88.3mg	1/50	177.mg	0/50	liv:hpa,hpc,nnd.	
2-MERCAPTOETHANESULFONATE, SODIUM 19767-45-4										
269	1637	717.mg	n.s.s.	0/40	87.0mg	0/40			Tacchi;clet,22,89-94;1984	
a	1637	717.mg	n.s.s.	0/40	87.0mg	0/40				
b	1637	717.mg	n.s.s.	0/40	87.0mg	0/40				
METHAPYRILENE.HCl 135-23-9										
270	1572	24.4mg	n.s.s.	0/12	32.6mg	1/20			Lijinsky;jtxe,12,653-657;1983	
a	1572	23.8mg	n.s.s.	2/12	32.6mg	2/20				
271	1644	4.54mg	15.6mg	3/20	5.17mg	12/30	10.3mg	20/20	Lijinsky;fctx,22,27-30;1984	
a	1644	6.62mg	35.1mg	3/20	5.17mg	12/30	10.3mg	15/20		
b	1644	25.1mg	363.mg	0/20	5.17mg	0/30	10.3mg	6/20		
272	1618	n.s.s.	18.7mg	0/5	40.0mg	5/5			Ohshima;jnci,72,759-768;1984	
a	1618	n.s.s.	18.7mg	0/5	40.0mg	5/5				
b	1618	4.11mg	n.s.s.	0/5	40.0mg	3/5				
c	1618	6.29mg	n.s.s.	0/5	40.0mg	2/5				
d	1618	6.29mg	n.s.s.	0/5	40.0mg	2/5				
273	1644	4.27mg	22.2mg	5/20	4.14mg	13/30	8.27mg	18/20	Lijinsky;fctx,22,27-30;1984	
a	1644	5.69mg	68.0mg	5/20	4.14mg	12/30	8.27mg	15/20		
b	1644	26.6mg	n.s.s.	0/20	4.14mg	1/30	8.27mg	3/20		
c	1644	65.1mg	n.s.s.	0/20	5.17mg	0/30	10.3mg	1/20		
N-METHYL-N'-NITRO-N-NITROSOGUANIDINE*** (MNNG) 70-25-7										
274	1571	7.87mg	n.s.s.	0/23	13.2mg	4/20			Tsung-Hsien;jnci,70,1067-1069;1983	
a	1571	7.87mg	n.s.s.	0/23	13.2mg	4/20				
275	1611m	.658mg	4.00mg	0/20	.857mg	9/20			Lijinsky;canr,44,447-449;1984	
a	1611m	.963mg	12.4mg	0/20	.857mg	6/20				
b	1611m	1.58mg	n.s.s.	0/20	.857mg	3/20				
c	1611m	2.69mg	n.s.s.	0/20	.857mg	1/20				
d	1611m	3.94mg	n.s.s.	5/20	.857mg	1/20				
276	1611n	.302mg	1.33mg	0/20	1.02mg	14/20				
a	1611n	.708mg	6.27mg	0/20	1.02mg	7/20				
b	1611n	.936mg	28.6mg	0/20	1.02mg	5/20				
c	1611n	1.10mg	n.s.s.	0/20	1.02mg	4/20				
d	1611n	3.31mg	n.s.s.	5/20	1.02mg	1/20				
277	1678	.444mg	1.92mg	0/12	2.90mg	16/30			Domellof;ajsu,142,551-554;1981	
a	1678	.617mg	4.60mg	0/12	2.90mg	12/30				
b	1678	1.49mg	n.s.s.	0/12	2.90mg	4/30				
278	1724m	.839mg	n.s.s.	0/8	4.68mg	2/9			Morishita;clet,17,347-352;1983/pers.comm.	
279	1724n	.549mg	n.s.s.	0/12	2.50mg	4/17				
a	1724n	.665mg	n.s.s.	0/12	2.50mg	3/17				
b	1724n	1.15mg	n.s.s.	0/12	2.50mg	1/17				
280	1724o	.827mg	n.s.s.	0/12	2.50mg	7/35				
a	1724o	.927mg	n.s.s.	0/12	2.50mg	6/35				
b	1724o	1.79mg	n.s.s.	0/12	2.50mg	2/35				
METHYL 12-OXO-trans-10-OCTADECENOATE 21308-79-2										
281	1627	361.mg	n.s.s.	2/30	239.mg	3/30			Kiaer;apms,83,550-558;1975	
METHYLENE CHLORIDE (dichloromethane, Freon 30) 75-09-2										
282	c50102	568.mg	1.28gm	5/50	2.14gm	36/50	4.28gm	46/50	liv:hpa,hpc; lun:a/a,a/c.	C
a	c50102	635.mg	1.43gm	3/50	2.14gm	30/50	4.28gm	41/50	lun:a/a,a/c.	
b	c50102	938.mg	2.39gm	2/50	2.14gm	23/50	4.28gm	28/50		
c	c50102	956.mg	2.31gm	3/50	2.14gm	16/50	4.28gm	40/50	liv:hpa,hpc.	
d	c50102	1.10gm	2.81gm	1/50	2.14gm	13/50	4.28gm	29/50		
e	c50102	1.20gm	3.04gm	1/50	2.14gm	11/50	4.28gm	32/50		
f	c50102	1.85gm	6.50gm	2/50	2.14gm	6/50	4.28gm	22/50		
g	c50102	5.11gm	n.s.s.	1/50	2.14gm	1/50	4.28gm	4/50		S
h	c50102	652.mg	1.93gm	18/50	2.14gm	41/50	4.28gm	47/50		
i	c50102	956.mg	2.31gm	3/50	2.14gm	16/50	4.28gm	40/50	liv:hpa,hpc,nnd.	
j	c50102	635.mg	1.43gm	3/50	2.14gm	30/50	4.28gm	41/50	lun:a/a,a/c.	
283	c50102	630.mg	1.46gm	5/50	1.79gm	27/50	3.57gm	40/50	lun:a/a,a/c.	
a	c50102	672.mg	2.27gm	27/50	1.79gm	35/50	3.57gm	45/50	liv:hpa,hpc; lun:a/a,a/c.	C
b	c50102	1.08gm	2.98gm	3/50	1.79gm	19/50	3.57gm	24/50		
c	c50102	1.09gm	2.95gm	2/50	1.79gm	10/50	3.57gm	28/50		
d	c50102	1.01gm	4.99gm	22/50	1.79gm	24/50	3.57gm	33/50	liv:hpa,hpc.	
e	c50102	1.49gm	7.70gm	13/50	1.79gm	15/50	3.57gm	26/50		
f	c50102	1.68gm	23.5gm	10/50	1.79gm	14/50	3.57gm	14/50		
g	c50102	4.78gm	n.s.s.	1/50	1.79gm	2/50	3.57gm	5/50		S

	Spe	Sex	Strain	Route	Site	Hist	Xpo+Xpt	Notes		TD50	DR	2Tailpvl	AuOp
h	M	m	b6c	inh	---	MXA	24m24			13.2gm	*	P<.03	
i	M	m	b6c	inh	TBA	MXB	24m24			1.16gm	*	P<.0005	
j	M	m	b6c	inh	liv	MXB	24m24			1.80gm	*	P<.0005	
k	M	m	b6c	inh	lun	MXB	24m24			920.mg	*	P<.0005	
284	R	f	f34	inh	mgl	MXA	24m24		: + :	598.mg	*	P<.0005	c
a	R	f	f34	inh	mgl	MXA	24m24			630.mg	*	P<.0005	
b	R	f	f34	inh	mgl	fba	24m24			632.mg	*	P<.0005	c
c	R	f	f34	inh	mgl	MXA	24m24			670.mg	*	P<.0005	
d	R	f	f34	inh	---	mnl	24m24			1.28gm	*	P<.02	
e	R	f	f34	inh	liv	MXA	24m24			4.27gm	*	P<.05	
f	R	f	f34	inh	TBA	MXB	24m24			501.mg	*	P<.007	
g	R	f	f34	inh	liv	MXB	24m24			4.27gm	*	P<.05	
285	R	m	f34	inh	MXA	MXA	24m24		: + :	917.mg	*	P<.0005	a
a	R	m	f34	inh	MXA	MXA	24m24			1.44gm	*	P<.006	
b	R	m	f34	inh	mgl	MXA	24m24			1.64gm	*	P<.002	a
c	R	m	f34	inh	tnv	MXA	24m24			1.64gm	*	P<.005	
d	R	m	f34	inh	mgl	fba	24m24			1.77gm	*	P<.004	a
e	R	m	f34	inh	sub	MXA	24m24			1.99gm	*	P<.003	
f	R	m	f34	inh	sub	fib	24m24			2.18gm	*	P<.007	
g	R	m	f34	inh	tnv	msm	24m24			4.31gm	*	P<.04	
h	R	m	f34	inh	TBA	MXB	24m24			539.mg	*	P<.2	
i	R	m	f34	inh	liv	MXB	24m24			no dre		P=1.	
286	R	f	sss	inh	mgl	ben	24m24	e	.>	4.43gm	*	P<.7	
a	R	f	sss	inh	pit	ade	24m24	e		no dre		P=1.	
287	R	m	sss	inh	slg	mix	24m24	e	. +	4.26gm	*	P<.0005	
a	R	m	sss	inh	mgl	ben	24m24	e		5.08gm	*	P<.03	
4,4'-METHYLENEDIANILINE.2HCl									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
288	M	f	b6c	wat	MXB	MXB	24m24		: + :	32.6mg	*	P<.0005	
a	M	f	b6c	wat	liv	MXA	24m24			59.3mg	*	P<.0005	c
b	M	f	b6c	wat	---	MXA	24m24			64.7mg	*	P<.007	c
c	M	f	b6c	wat	thy	MXA	24m24			128.mg	/	P<.0005	
d	M	f	b6c	wat	liv	hpc	24m24			137.mg	*	P<.002	c
e	M	f	b6c	wat	thy	fca	24m24			150.mg	/	P<.0005	c
f	M	f	b6c	wat	liv	hpa	24m24			135.mg	*	P<.02	c
g	M	f	b6c	wat	lun	MXA	24m24			268.mg	*	P<.04	
h	M	f	b6c	wat	lun	a/a	24m24			327.mg	*	P<.04	
i	M	f	b6c	wat	TBA	MXB	24m24			52.1mg	*	P<.05	
j	M	f	b6c	wat	liv	MXB	24m24			59.3mg	*	P<.0005	
k	M	f	b6c	wat	lun	MXB	24m24			268.mg	*	P<.04	
289	M	m	b6c	wat	liv	MXA	24m24		: + :	17.0mg	\	P<.0005	
a	M	m	b6c	wat	liv	hpc	24m24			22.3mg	\	P<.0005	c
b	M	m	b6c	wat	MXB	MXB	24m24			28.7mg	*	P<.0005	
c	M	m	b6c	wat	adr	phe	24m24			70.0mg	*	P<.0005	c
d	M	m	b6c	wat	thy	fca	24m24			88.4mg	/	P<.0005	c
e	M	m	b6c	wat	TBA	MXB	24m24			47.4mg	*	P<.07	
f	M	m	b6c	wat	liv	MXB	24m24			17.0mg	\	P<.0005	
g	M	m	b6c	wat	lun	MXB	24m24			no dre		P=1.	
290	R	f	f34	wat	thy	MXB	24m24		: + :	22.0mg	*	P<.0005	
a	R	f	f34	wat	thy	MXA	24m24			27.2mg	*	P<.0005	
b	R	f	f34	wat	thy	fca	24m24			33.5mg	/	P<.0005	c
c	R	f	f34	wat	thy	cca	24m24			73.7mg	*	P<.007	c
d	R	f	f34	wat	thy	MXA	24m24			70.0mg	*	P<.04	
e	R	f	f34	wat	TBA	MXB	24m24			277.mg	*	P<1.	
f	R	f	f34	wat	liv	MXB	24m24			118.mg	*	P<.4	
291	R	m	f34	wat	MXB	MXB	24m24		:+ :	12.5mg	*	P<.0005	
a	R	m	f34	wat	liv	nnd	24m24			14.3mg	*	P<.0005	c
b	R	m	f34	wat	thy	MXA	24m24			49.5mg	*	P<.006	
c	R	m	f34	wat	thy	fcc	24m24			85.4mg	*	P<.003	c
d	R	m	f34	wat	TBA	MXB	24m24			no dre		P=1.	
e	R	m	f34	wat	liv	MXB	24m24			14.1mg	*	P<.0005	
METHYLNITROSOCYANAMIDE									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
292	R	f	sda	wat	for	mix	60w95	er	. + .	.480mg	*	P<.0005	+
a	R	f	sda	wat	for	car	60w95	er		1.17mg	*	P<.0005	+
METHYLTHIOURACIL***									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
293	M	b	cfi	eat	liv	hpt	51w78	erv	.>	1.37gm		P<.3	
a	M	b	cfi	eat	thy	tum	51w78	erv		no dre		P=1.	
MONOACETYL HYDRAZINE									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
294	M	f	swi	gav	lun	mix	95w95	rs	.>	53.8mg		P<.3	+
295	M	f	swi	gav	lun	mix	34w95	rs	. ±	18.8mg		P<.1	+
296	M	m	swi	gav	lun	mix	95w95	rs	. ±	35.6mg	*	P<.02	+
297	M	m	swi	gav	lun	mix	34w95	rs	. + .	4.48mg		P<.0005	+

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc			Citation or Pathology	Brkly Code
h	c50102	4.82gm	n.s.s.	2/50	1.79gm	2/50	3.57gm	6/50				---:hem,hes. S
i	c50102	688.mg	2.76gm	34/50	1.79gm	37/50	3.57gm	46/50				
j	c50102	1.01gm	4.99gm	22/50	1.79gm	24/50	3.57gm	33/50				liv:hpa,hpc,nnd.
k	c50102	630.mg	1.46gm	5/50	1.79gm	27/50	3.57gm	40/50				lun:a/a,a/c.
284	c50102	361.mg	1.36gm	5/50	255.mg	11/50	510.mg	13/50	1.02gm	23/50		mgl:adn,fba.
a	c50102	371.mg	1.57gm	6/50	255.mg	13/50	510.mg	14/50	1.02gm	23/50		mgl:acn,adn,fba. S
b	c50102	378.mg	1.49gm	5/50	255.mg	11/50	510.mg	13/50	1.02gm	22/50		
c	c50102	385.mg	1.80gm	7/50	255.mg	13/50	510.mg	14/50	1.02gm	23/50		mgl:acn,adn,fba,mtm. S
d	c50102	578.mg	n.s.s.	17/50	255.mg	17/50	510.mg	23/50	1.02gm	23/50		S
e	c50102	1.56gm	n.s.s.	2/50	255.mg	1/50	510.mg	4/50	1.02gm	5/50		liv:hpc,nnd. S
f	c50102	244.mg	8.34gm	41/50	255.mg	46/50	510.mg	48/50	1.02gm	48/50		
g	c50102	1.56gm	n.s.s.	2/50	255.mg	1/50	510.mg	4/50	1.02gm	5/50		liv:hpa,hpc,nnd.
285	c50102	477.mg	2.17gm	0/50	179.mg	1/50	357.mg	4/50	714.mg	9/50		mgl:adn,fba; sub:fib.
a	c50102	686.mg	16.1gm	0/50	179.mg	2/50	357.mg	5/50	714.mg	4/50		mul:men,msm; tnv:men,msm. S
b	c50102	693.mg	7.00gm	0/50	179.mg	0/50	357.mg	2/50	714.mg	5/50		mgl:adn,fba.
c	c50102	739.mg	12.2gm	0/50	179.mg	1/50	357.mg	4/50	714.mg	4/50		tnv:men,msm. S
d	c50102	716.mg	11.2gm	0/50	179.mg	0/50	357.mg	2/50	714.mg	4/50		
e	c50102	853.mg	11.1gm	0/50	179.mg	1/50	357.mg	2/50	714.mg	5/50		sub:fib,srn. S
f	c50102	892.mg	28.3gm	0/50	179.mg	1/50	357.mg	2/50	714.mg	4/50		S
g	c50102	1.34gm	n.s.s.	0/50	179.mg	1/50	357.mg	0/50	714.mg	3/50		S
h	c50102	186.mg	n.s.s.	46/50	179.mg	48/50	357.mg	49/50	714.mg	48/50		
i	c50102	1.43gm	n.s.s.	2/50	179.mg	2/50	357.mg	4/50	714.mg	1/50		liv:hpa,hpc,nnd.
286	1600	627.mg	n.s.s.	79/96	130.mg	81/95	390.mg	80/96	910.mg	83/97		Burek;faat,4,30-47;1984/pers.comm.
a	1600	1.25gm	n.s.s.	34/96	130.mg	24/95	390.mg	30/96	(910.mg	16/97)		
287	1600	2.28gm	12.1gm	1/92	91.0mg	0/95	273.mg	5/95	637.mg	11/97		
e	1600	2.17gm	n.s.s.	7/92	91.0mg	3/95	273.mg	7/95	637.mg	14/97		
4,4'-METHYLENEDIANILINE.2HCl 13552-44-8												
288	c54604	19.1mg	95.5mg	16/50	29.4mg	36/50	59.1mg	44/50				---:mlh,mlm,mlu,mno; liv:hpa,hpc; thy:fca. C
a	c54604	35.2mg	162.mg	4/50	29.4mg	15/50	59.1mg	23/50				liv:hpa,hpc.
b	c54604	32.7mg	1.16gm	13/50	29.4mg	28/50	59.1mg	29/50				---:mlh,mlm,mlu,mno.
c	c54604	71.6mg	265.mg	0/50	29.4mg	1/50	59.1mg	15/50				thy:fca,fcc. S
d	c54604	72.0mg	611.mg	1/50	29.4mg	6/50	59.1mg	11/50				
e	c54604	80.7mg	338.mg	0/50	29.4mg	1/50	59.1mg	13/50				
f	c54604	65.1mg	n.s.s.	3/50	29.4mg	9/50	59.1mg	12/50				
g	c54604	109.mg	n.s.s.	2/50	29.4mg	3/50	59.1mg	8/50				lun:a/a,a/c. S
h	c54604	129.mg	n.s.s.	1/50	29.4mg	2/50	59.1mg	6/50				S
i	c54604	22.1mg	n.s.s.	32/50	29.4mg	47/50	59.1mg	47/50				
j	c54604	35.2mg	162.mg	4/50	29.4mg	15/50	59.1mg	23/50				liv:hpa,hpc,nnd.
k	c54604	109.mg	n.s.s.	2/50	29.4mg	3/50	59.1mg	8/50				lun:a/a,a/c.
289	c54604	9.07mg	65.8mg	17/50	24.5mg	43/50	(49.5mg	37/50)				liv:hpa,hpc. S
a	c54604	12.1mg	75.5mg	10/50	24.5mg	33/50	(49.5mg	29/50)				
b	c54604	17.1mg	78.7mg	12/50	24.5mg	36/50	49.5mg	34/50				adr:phe; liv:hpc; thy:fca. C
c	c54604	39.7mg	231.mg	2/50	24.5mg	12/50	49.5mg	14/50				
d	c54604	51.4mg	172.mg	0/50	24.5mg	3/50	49.5mg	16/50				
e	c54604	19.1mg	n.s.s.	37/50	24.5mg	47/50	49.5mg	45/50				
f	c54604	9.07mg	65.8mg	17/50	24.5mg	43/50	(49.5mg	37/50)				liv:hpa,hpc,nnd.
g	c54604	168.mg	n.s.s.	13/50	24.5mg	12/50	49.5mg	4/50				lun:a/a,a/c.
290	c54604	13.9mg	38.4mg	0/50	8.41mg	5/50	16.7mg	22/50				thy:cca,fca. C
a	c54604	16.6mg	50.3mg	0/50	8.41mg	4/50	16.7mg	19/50				thy:fca,fcc. S
b	c54604	19.5mg	66.1mg	0/50	8.41mg	2/50	16.7mg	17/50				
c	c54604	34.7mg	873.mg	0/50	8.41mg	3/50	16.7mg	6/50				
d	c54604	30.6mg	n.s.s.	1/50	8.41mg	5/50	16.7mg	7/50				thy:cca,ccr. S
e	c54604	10.6mg	n.s.s.	43/50	8.41mg	48/50	16.7mg	49/50				
f	c54604	31.5mg	n.s.s.	4/50	8.41mg	8/50	16.7mg	8/50				liv:hpa,hpc,nnd.
291	c54604	8.33mg	22.0mg	1/50	7.36mg	12/50	14.7mg	29/50				liv:nnd; thy:fcc. C
a	c54604	9.35mg	27.1mg	1/50	7.36mg	12/50	14.7mg	25/50				
b	c54604	24.4mg	535.mg	1/50	7.36mg	4/50	14.7mg	10/50				thy:fca,fcc. S
c	c54604	36.9mg	422.mg	0/50	7.36mg	0/50	14.7mg	7/50				
d	c54604	15.3mg	n.s.s.	45/50	7.36mg	42/50	14.7mg	40/50				
e	c54604	9.22mg	26.6mg	1/50	7.36mg	13/50	14.7mg	25/50				liv:hpa,hpc,nnd.
METHYLNITROSOCYANAMIDE 33868-17-6												
292	1733	.283mg	.828mg	0/9	.573mg	2/12	1.08mg	12/15	2.23mg	15/15	4.39mg	14/14 Endo;pipa,50,497-502;1974/pers.comm.
a	1733	.713mg	2.02mg	0/9	.573mg	0/12	1.08mg	5/15	2.23mg	12/15	4.39mg	13/14
METHYLTHIOURACIL*** 56-04-2												
293	1630	337.mg	n.s.s.	0/9	375.mg	2/20						Jemec;canc,40,2188-2202;1977
a	1630	869.mg	n.s.s.	0/9	375.mg	0/20						
MONOACETYL HYDRAZINE 1068-57-1												
294	1661m	13.9mg	n.s.s.	3/20	22.9mg	5/15						Bhide;clet,23,235-240;1984/pers.comm.
295	1661n	5.77mg	n.s.s.	3/20	11.4mg	6/15						
296	1661m	15.2mg	n.s.s.	2/20	19.0mg	4/15	26.2mg	7/15				
297	1661n	1.98mg	15.0mg	2/20	9.52mg	11/15						

	Spe Strain Site Xpo+Xpt Sex Route Hist Notes	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10	TD50 DR	2Tailpvl AuOp
MONOCROTALINE				
298	R m cdr gav liv hpc 42w71 erv	. ±	1.16mg	P<.02 +
299	R m cdr gav liv hpc 42w71 cerv	. + .	.790mg	P<.005 +
DL-MONOSODIUM GLUTAMATE				
300	M m cbl eat liv tum 24m24 e	.>	no dre	P=1. -
a	M m cbl eat lun ade 24m24 e		no dre	P=1. -
b	M m cbl eat tba mix 24m24 e		no dre	P=1. -
L-MONOSODIUM GLUTAMATE				
301	M m cbl eat liv tum 24m24 e	.>	no dre	P=1. -
a	M m cbl eat lun tum 24m24 e		no dre	P=1. -
b	M m cbl eat tba tum 24m24 e		no dre	P=1. -
NICOTINAMIDE				
302	M f swa wat lun mix 26m26 e	.>	no dre	P=1. -
a	M f swa wat liv tum 26m26 e		no dre	P=1.
303	M m swa wat lun mix 25m25 e		no dre	P=1. -
a	M m swa wat liv mix 25m25 e		no dre	P=1.
NITRITE, SODIUM***				
304	R f f34 eat liv mix 24m30 e	. + .	124.mg	P<.003 +
a	R f f34 eat liv nnd 24m30 e		199.mg	P<.03
b	R f f34 eat liv car 24m30 e		470.mg	P<.02
305	R f f34 eat liv mix 24m30 e	. + .	141.mg	P<.007 +
a	R f f34 eat liv nnd 24m30 e		164.mg	P<.02
b	R f f34 eat liv hpc 24m30 e		629.mg	P<.04
306	R f f34 wat adr mdt 24m30 e	. + .	163.mg	P<.0005
a	R f f34 wat thy car 24m30 e		163.mg	P<.0005
b	R f f34 wat mam tum 24m30 e		115.mg	P<.05
c	R f f34 wat liv mix 24m30 e		153.mg	P<.03 +
d	R f f34 wat liv nnd 24m30 e		185.mg	P<.06
e	R f f34 wat ute pol 24m30 e		218.mg	P<.02
f	R f f34 wat liv hpc 24m30 e		1.55gm	P<.3
307	R m f34 eat liv mix 24m30 e	.>	445.mg	P<.3
a	R m f34 eat liv nnd 24m30 e		467.mg	P<.3
b	R m f34 eat liv car 24m30 e		no dre	P=1.
308	R m f34 eat liv nnd 24m30 e	.>	no dre	P=1.
309	R m f34 wat liv mix 24m30 e	.>	946.mg	P<.7
a	R m f34 wat liv hpc 24m30 e		1.04gm	P<.6
b	R m f34 wat liv nnd 24m30 e		no dre	P=1.
N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]FORMAMIDE***		....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
310	M f cd1 eat ubl tcc 36w68 e	. + .	33.3mg	P<.0005+
a	M f cd1 eat ubl spt 36w68 e		128.mg	P<.002 +
b	M f cd1 eat ubl sqc 36w68 e		128.mg	P<.002 +
c	M f cd1 eat lun ade 36w68 e		1.12gm	P<.6
d	M f cd1 eat liv tum 36w68 e		no dre	P=1.
e	M f cd1 eat tba mix 36w68 e		18.7mg	P<.0005
311	M m cd1 eat ubl tcc 40w77 e	. + .	30.5mg	P<.0005+
a	M m cd1 eat ubl spt 40w77 e		97.1mg	P<.0005+
b	M m cd1 eat ubl sqc 40w77 e		250.mg	P<.009 +
c	M m cd1 eat lun ade 40w77 e		no dre	P=1.
d	M m cd1 eat liv hpc 40w77 e		no dre	P=1.
e	M m cd1 eat tba mix 40w77 e		21.5mg	P<.0005
312	R m f34 eat ubl car 7m24	. +.	3.18mg Z	P<.0005+
313	R m fis eat liv tum 24m24	.>	no dre	P=1.
a	R m fis eat ubl tum 24m24		no dre	P=1.
314	R m fis eat ubl car 36w74	. + .	4.51mg	P<.0005+
a	R m fis eat ubl ivc 36w74		9.74mg	P<.0005
b	R m fis eat ubl nvc 36w74		60.5mg	P<.003
c	R m fis eat liv hnd 36w74		263.mg	P<.2
315	R m fis eat ubl car 77w77	. + .	9.87mg	P<.0005+
a	R m fis eat ubl ivc 77w77		18.1mg	P<.0005
b	R m fis eat ubl nvc 77w77		195.mg	P<.004
c	R m fis eat liv tum 77w77		no dre	P=1.
1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN***		.1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
316	M f bd1 eat lun adc 24m24	.>	no dre	P=1. -
a	M f bd1 eat liv hem 24m24		no dre	P=1. -
b	M f bd1 eat tba mix 24m24		no dre	P=1. -
317	M m bd1 eat lun ade 24m24	.>	53.9gm *	P<.9 -
a	M m bd1 eat liv hem 24m24		no dre	P=1. -
b	M m bd1 eat liv ade 24m24		no dre	P=1. -
c	M m bd1 eat liv mix 24m24		no dre	P=1.
d	M m bd1 eat tba mix 24m24		no dre	P=1. -
318	R f sda eat mgl fba 24m24	. + .	54.3mg	P<.006
a	R f sda eat tba mix 24m24		64.2mg	P<.2

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology / Brkly Code
MONOCROTALINE 315-22-0								
298	1719m	.566mg	n.s.s.	0/15	.813mg	10/50		Newberne;pffm,1,23-31;1973
299	1719n	.424mg	4.36mg	0/15	.813mg	14/50		
DL-MONOSODIUM GLUTAMATE 32221-81-1								
300	1631	4.51gm	n.s.s.	0/55	1.20gm	0/23	4.80gm 0/27	Ebert;txlt,3,65-70;1979
a	1631	17.6gm	n.s.s.	0/55	1.20gm	1/23	4.80gm 0/27	
b	1631	17.6gm	n.s.s.	0/55	1.20gm	1/23	4.80gm 0/27	
L-MONOSODIUM GLUTAMATE 142-47-2								
301	1631	4.68gm	n.s.s.	0/55	1.20gm	0/25	4.80gm 0/23	Ebert;txlt,3,65-70;1979
a	1631	4.68gm	n.s.s.	0/55	1.20gm	0/25	4.80gm 0/23	
b	1631	4.68gm	n.s.s.	0/55	1.20gm	0/25	4.80gm 0/23	
NICOTINAMIDE 98-92-0								
302	1732	7.03gm	n.s.s.	15/89	2.00gm	7/45		Toth;onco,40,72-75;1983/1979
a	1732	23.8gm	n.s.s.	0/98	2.00gm	0/49		
303	1732	9.34gm	n.s.s.	21/87	1.67gm	6/50		
a	1732	15.8gm	n.s.s.	2/61	1.67gm	0/42		
NITRITE, SODIUM* 7632-00-0**								
304	1645m	56.7mg	817.mg	4/24	80.0mg	14/24		Lijinsky;jtxe,13,609-614;1984/1983a
a	1645m	78.9mg	n.s.s.	4/24	80.0mg	11/24		
b	1645m	162.mg	n.s.s.	0/24	80.0mg	4/24		
305	1654m	62.0mg	2.04gm	4/24	80.9mg	13/24		Lijinsky;fctx,22,715-720;1984/1983a
a	1654m	69.2mg	n.s.s.	4/24	80.9mg	12/24		
b	1654m	190.mg	n.s.s.	0/24	80.9mg	3/24		
306	1654n	73.1mg	523.mg	0/24	63.5mg	8/24		
a	1654n	73.1mg	523.mg	0/24	63.5mg	8/24		
b	1654n	44.1mg	n.s.s.	8/24	63.5mg	15/24		
c	1654n	60.7mg	n.s.s.	4/24	63.5mg	11/24		
d	1654n	68.2mg	n.s.s.	4/24	63.5mg	10/24		
e	1654n	85.8mg	n.s.s.	1/24	63.5mg	7/24		
f	1654n	252.mg	n.s.s.	0/24	63.5mg	1/24		
307	1645m	114.mg	n.s.s.	3/24	64.0mg	6/24		Lijinsky;jtxe,13,609-614;1984/1983a
a	1645m	125.mg	n.s.s.	2/24	64.0mg	5/24		
b	1645m	297.mg	n.s.s.	1/24	64.0mg	1/24		
308	1654m	235.mg	n.s.s.	5/24	64.7mg	3/24		Lijinsky;fctx,22,715-720;1984/1983a
309	1654n	109.mg	n.s.s.	3/24	44.5mg	4/24		
a	1654n	143.mg	n.s.s.	1/24	44.5mg	2/24		
b	1654n	160.mg	n.s.s.	2/24	44.5mg	2/24		
N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]FORMAMIDE* (FANFT) 24554-26-5**								
310	1601	20.5mg	58.9mg	0/53	68.8mg	25/55		Dunsford;jnci,73,151-160;1984
a	1601	58.0mg	449.mg	0/53	68.8mg	8/55		
b	1601	58.0mg	449.mg	0/53	68.8mg	8/55		
c	1601	148.mg	n.s.s.	1/53	68.8mg	2/55		
d	1601	333.mg	n.s.s.	0/53	68.8mg	0/55		
e	1601	10.6mg	45.9mg	19/53	68.8mg	43/55		
311	1601	19.5mg	51.4mg	0/55	62.3mg	30/56		
a	1601	49.9mg	230.mg	0/55	62.3mg	12/56		
b	1601	95.0mg	6.08gm	0/55	62.3mg	5/56		
c	1601	298.mg	n.s.s.	4/55	62.3mg	1/56		
d	1601	298.mg	n.s.s.	4/55	62.3mg	1/56		
e	1601	12.6mg	47.6mg	17/55	62.3mg	43/56		
312	1575	2.25mg	4.56mg	0/40	.115mg	0/40	.577mg 0/40 1.15mg 0/40 5.77mg 34/40 11.5mg 39/40 (23.1mg 36/40)	Arai;clet,18,261-269;1983
313	1574	8.24mg	n.s.s.	0/30	2.00mg	0/20		Murasaki;carc,4,97-99;1983
a	1574	8.24mg	n.s.s.	0/30	2.00mg	0/20		
314	1657m	1.85mg	10.3mg	0/42	38.9mg	19/20		Cohen;canr,39,1207-1217;1979
a	1657m	4.99mg	21.5mg	0/42	38.9mg	15/20		
b	1657m	20.8mg	378.mg	0/42	38.9mg	4/20		
c	1657m	42.8mg	n.s.s.	0/42	38.9mg	1/20		
315	1657n	5.36mg	17.5mg	0/42	80.0mg	40/42		
a	1657n	11.3mg	30.5mg	0/42	80.0mg	34/42		
b	1657n	79.4mg	1.19gm	0/42	80.0mg	6/42		
c	1657n	380.mg	n.s.s.	0/42	80.0mg	0/42		
1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN* (macrodantin, nitrofurantoin) 67-20-9**								
316	1747	3.26gm	n.s.s.	0/54	97.5mg	1/54	390.mg 0/54	Ito;hijm,32,99-102;1983
a	1747	3.65gm	n.s.s.	1/54	97.5mg	2/54	390.mg 0/54	
b	1747	956.mg	n.s.s.	16/54	97.5mg	9/54	390.mg 14/54	
317	1747	2.85gm	n.s.s.	1/53	90.0mg	0/52	360.mg 1/52	
a	1747	2.45gm	n.s.s.	3/53	90.0mg	0/52	360.mg 2/52	
b	1747	771.mg	n.s.s.	6/53	90.0mg	1/52	(360.mg 0/52)	
c	1747	3.17gm	n.s.s.	9/53	90.0mg	1/52	360.mg 2/52	
d	1747	2.54gm	n.s.s.	12/53	90.0mg	1/52	360.mg 4/52	
318	1622	21.1mg	675.mg	2/11	94.0mg	9/12		Wang;clet,21,303-308;1984
a	1622	17.9mg	n.s.s.	6/11	94.0mg	10/12		

	Spe Strain Site Xpo+Xpt Sex Route Hist Notes	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10	TD50 DR	2Tailpvl AuOp
1-NITROPROPANE				
319	R f leb inh liv hpc 52w52 ekr	.>	no dre	P=1. -
320	R f leb inh liv hpc 78w78 ekr	.>	no dre	P=1. -
321	R f leb inh liv hpc 93w93 ekr	.>	no dre	P=1. -
322	R f leb inh liv hpc 52w93 ekr	.>	no dre	P=1. -
323	R m leb inh liv hpc 52w52 ekr	.>	no dre	P=1. -
324	R m leb inh liv hpc 78w78 ekr	.>	no dre	P=1. -
325	R m leb inh liv hpc 93w93 ekr	.>	no dre	P=1. -
326	R m leb inh liv hpc 52w93 ekr	.>	no dre	P=1. -
1-NITROSO-5,6-DIHYDROTHYMINE		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
327	R f mrw wat liv mix 12m29 e	. ±	31.2mg	P<.1
a	R f mrw wat tba mix 12m29 e		no dre	P=1. -
328	R m mrw wat liv tum 12m29 e	.>	no dre	P=1. -
a	*R m mrw wat tba mix 12m29 e*		*no dre*	P=1. -
N-NITROSO-2,3-DIHYDROXYPROPYL-2-HYDROXYPROPYLAMINE		.:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
329	H f syg gav for mix 41w75 e	. + .	1.59mg	P<.0005+
a	H f syg gav for sqp 41w75 e		1.59mg	P<.0005+
b	H f syg gav liv cad 41w75 e		32.6mg	P<.3
c	H f syg gav lun tum 41w75 e		no dre	P=1.
330	R f f34 wat eso mix 37w85	. + .	53.5ug	P<.0005+
a	R f f34 wat ton mix 37w85		88.8ug	P<.0005+
b	R f f34 wat eso car 37w85		.117mg	P<.0005
c	R f f34 wat for mix 37w85		.178mg	P<.0005+
d	R f f34 wat ton sqc 37w85		.241mg	P<.0005
e	R f f34 wat liv hpc 37w85		2.40mg	P<.3
f	R f f34 wat liv mix 37w85		no dre	P=1.
NITROSO-2,3-DIHYDROXYPROPYL-2-OXOPROPYLAMINE		....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
331	H f syg gav for mix 35w55 e	. + .	.754mg	P<.0005+
a	H f syg gav for sqp 35w55 e		.868mg	P<.0005+
b	H f syg gav pdu c/a 35w55 e		3.63mg	P<.007 +
c	H f syg gav liv hpa 35w55 e		9.92mg	P<.1
d	H f syg gav liv mix 35w55 e		9.92mg	P<.1
e	H f syg gav lun car 35w55 e		20.4mg	P<.3
f	H f syg gav liv hpc 35w55 e		20.4mg	P<.3
332	R f f34 wat eso mix 31w55	. + .	35.2ug	P<.0005+
a	R f f34 wat for mix 31w55		48.2ug	P<.0005+
b	R f f34 wat ton mix 31w55		55.5ug	P<.0005+
c	R f f34 wat eso car 31w55		63.7ug	P<.0005+
d	R f f34 wat ton car 31w55		96.4ug	P<.0005+
e	R f f34 wat for car 31w55		.155mg	P<.002 +
f	R f f34 wat liv hpc 31w55		1.30mg	P<.3 -
N-NITROSO-2,3-DIHYDROXYPROPYLETHANOLAMINE		..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
333	H f syg gav trh ade 12m24 e	. ±	52.7mg	P<.04
a	H f syg gav lun tum 12m24 e		no dre	P=1.
b	H f syg gav liv tum 12m24 e		no dre	P=1.
334	R f f34 wat liv mix 17m28	. ±	5.98mg *	P<.02 +
a	R f f34 wat liv nnd 17m28		8.69mg *	P<.04 +
b	R f f34 wat liv hpc 17m28		11.5mg *	P<.02 +
N-NITROSO-(2-HYDROXYPROPYL)-(2-HYDROXYETHYL)AMINE		..:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
335	R f f34 wat liv hpc 50w75	. + .	1.02mg	P<.0005+
a	R f f34 wat liv mix 50w75		1.12mg	P<.0005+
b	R f f34 wat liv ang 50w75		4.50mg	P<.002 +
c	R f f34 wat nas olc 50w75		5.44mg	P<.003
d	R f f34 wat eso mix 50w75		6.74mg	P<.007 +
e	R f f34 wat liv nnd 50w75		no dre	P=1.
N-NITROSO-3-HYDROXYPYRROLIDINE		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
336	R b sda wat liv hpc 26m26	. + .	8.11mg	P<.006
a	R b sda wat tba mal 26m26		7.65mg	P<.03 +
N-NITROSO-N-ISOBUTYLUREA		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
337	R f don wat dgt mix 76w76 e	.+ .	4.73mg *	P<.0005+
a	*R f don wat duo mix 76w76 e*		*7.22mg* *	*P<.0005+*
b	R f don wat stg mix 76w76 e		23.1mg *	P<.05
c	R f don wat liv mix 76w76 e		1.22gm *	P<1.
d	*R f don wat tba mix 76w76 e*		*4.70mg* *	*P<.02*
N-NITROSO-N-METHYL-N-DODECYLAMINE***		..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
338	R f f34 gav ubl tum 30w65	. + .	.656mg	P<.0005+
a	R f f34 gav lun tum 30w65		1.32mg	P<.0005
b	R f f34 gav liv tum 30w65		no dre	P=1.
c	R f f34 gav tba tum 30w65		noTD50	P=1.

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology / Brkly Code
1-NITROPROPANE 108-03-2								
319	1670m	16.4mg n.s.s.	0/10	31.8mg	0/10			Griffin;eaes,6,268-282;1982
320	1670n	36.9mg n.s.s.	0/10	31.8mg	0/10			
321	1670o	147.mg n.s.s.	0/59	31.8mg	0/28			
322	1670r	23.4mg n.s.s.	0/59	17.8mg	0/8			
323	1670m	11.5mg n.s.s.	0/10	22.3mg	0/10			
324	1670n	25.8mg n.s.s.	0/10	22.3mg	0/10			
325	1670o	99.1mg n.s.s.	0/60	22.3mg	0/27			
326	1670r	12.3mg n.s.s.	0/60	12.4mg	0/6			
1-NITROSO-5,6-DIHYDROTHYMINE 62641-67-2								
327	1607	7.66mg n.s.s.	0/20	3.21mg	2/20			Lawson;jnci,73,515-519;1984
a	1607	2.67mg n.s.s.	15/20	3.21mg	14/20			
328	1607	13.1mg n.s.s.	0/23	2.25mg	0/19			
a	1607	7.43mg n.s.s.	9/23	2.25mg	3/19			
N-NITROSO-2,3-DIHYDROXYPROPYL-2-HYDROXYPROPYLAMINE 89911-79-5								
329	1682	.804mg 3.67mg	0/20	4.69mg	13/20			Lijinsky;jnci,74,923-926;1985
a	1682	.804mg 3.67mg	0/20	4.69mg	13/20			
b	1682	5.30mg n.s.s.	0/20	4.69mg	1/20			
c	1682	10.0mg n.s.s.	0/20	4.69mg	0/20			
330	1612	25.4ug .117mg	0/20	.269mg	18/20			Lijinsky;carc,5,167-170;1984
a	1612	45.5ug .196mg	0/20	.269mg	15/20			
b	1612	59.3ug .271mg	0/20	.269mg	13/20			
c	1612	84.8ug .464mg	0/20	.269mg	10/20			
d	1612	.108mg .762mg	0/20	.269mg	8/20			
e	1612	.391mg n.s.s.	0/20	.269mg	1/20			
f	1612	.526mg n.s.s.	3/20	.269mg	1/20			
NITROSO-2,3-DIHYDROXYPROPYL-2-OXOPROPYLAMINE 92177-50-9								
331	1682	.386mg 1.66mg	0/20	5.45mg	15/20			Lijinsky;jnci,74,923-926;1985
a	1682	.443mg 1.95mg	0/20	5.45mg	14/20			
b	1682	1.37mg 41.9mg	0/20	5.45mg	5/20			
c	1682	2.44mg n.s.s.	0/20	5.45mg	2/20			
d	1682	2.44mg n.s.s.	0/20	5.45mg	2/20			
e	1682	3.32mg n.s.s.	0/20	5.45mg	1/20			
f	1682	3.32mg n.s.s.	0/20	5.45mg	1/20			
332	1639	17.6ug 76.3ug	0/20	.349mg	17/20			Lijinsky;zkko,107,178-182;1984
a	1639	24.7ug .106mg	0/20	.349mg	15/20			
b	1639	28.3ug .125mg	0/20	.349mg	14/20			
c	1639	32.2ug .147mg	0/20	.349mg	13/20			
d	1639	46.0ug .252mg	0/20	.349mg	10/20			
e	1639	66.4ug .588mg	0/20	.349mg	7/20			
f	1639	.212mg n.s.s.	0/20	.349mg	1/20			
N-NITROSO-2,3-DIHYDROXYPROPYLETHANOLAMINE 89911-78-4								
333	1682	15.9mg n.s.s.	0/20	12.5mg	3/20			Lijinsky;jnci,74,923-926;1985
a	1682	51.5mg n.s.s.	0/20	12.5mg	0/20			
b	1682	51.5mg n.s.s.	0/20	12.5mg	0/20			
334	1612	2.75mg n.s.s.	3/20	1.87mg	8/20	3.74mg	10/20	Lijinsky;carc,5,167-170;1984
a	1612	3.59mg n.s.s.	3/20	1.87mg	5/20	3.74mg	9/20	
b	1612	5.18mg n.s.s.	0/20	1.87mg	4/20	3.74mg	4/20	
N-NITROSO-(2-HYDROXYPROPYL)-(2-HYDROXYETHYL)AMINE 75896-33-2								
335	1612	.511mg 2.21mg	0/20	5.44mg	17/20			Lijinsky;carc,5,167-170;1984
a	1612	.532mg 2.94mg	3/20	5.44mg	17/20			
b	1612	1.93mg 17.0mg	0/20	5.44mg	7/20			
c	1612	2.20mg 28.4mg	0/20	5.44mg	6/20			
d	1612	2.55mg 77.7mg	0/20	5.44mg	5/20			
e	1612	11.7mg n.s.s.	3/20	5.44mg	0/20			
N-NITROSO-3-HYDROXYPYRROLIDINE 56222-35-6								
336	1634	3.07mg 85.1mg	0/24	2.50mg	5/23			Eisenbrand;iarc,657-663;1980
a	1634	2.80mg n.s.s.	1/24	2.50mg	6/23			
N-NITROSO-N-ISOBUTYLUREA (N-isobutyl-N-nitrosourea) 760-60-1								
337	1549	3.18mg 7.32mg	0/17	5.71mg	6/25	11.4mg	14/24	22.9mg 25/28 Ogiu;gann,74,342-350;1983
a	1549	4.72mg 11.7mg	0/17	5.71mg	2/25	11.4mg	12/24	22.9mg 21/28
b	1549	12.7mg n.s.s.	0/17	5.71mg	3/25	11.4mg	7/24	22.9mg 5/28
c	1549	30.4mg n.s.s.	1/17	5.71mg	2/25	11.4mg	3/24	22.9mg 2/28
d	1549	2.04mg n.s.s.	12/17	5.71mg	20/25	11.4mg	20/24	22.9mg 27/28
N-NITROSO-N-METHYL-N-DODECYLAMINE* 55090-44-3**								
338	1561	.323mg 1.50mg	1/20	4.52mg	17/20			Lijinsky;fctx,21,601-605;1983
a	1561	.658mg 3.15mg	0/20	4.52mg	12/20			
b	1561	7.28mg n.s.s.	0/20	4.52mg	0/20			
c	1561	n.s.s. n.s.s.	20/20	4.52mg	20/20			

```
    Spe Strain  Site    Xpo+Xpt                                                                          TD50      2Tailpvl
      Sex   Route  Hist      Notes                                                                             DR      AuOp

N-NITROSO-N-METHYL-4-FLUOROANILINE      ..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
339  R m f34 wat eso mix 12m26                                  .  +  .                                   .255mg    P<.0005+
 a   R m f34 wat liv hnd 12m26                                                                            10.3mg    P<.7
 b   R m f34 wat tba mix 12m26                                                                            no dre    P=1.

N-NITROSO-N-METHYL-4-NITROANILINE 100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
340  R m f34 wat liv hnd 12m26                                             .>                             5.87mg    P<.4    -
 a   R m f34 wat tba mix 12m26                                                                            no dre    P=1.    -

N-NITROSO-1,3-OXAZOLIDINE         100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
341  H m syg gav liv clc 35w65                                    .  +  .                                 .471mg    P<.0005+
 a   H m syg gav liv hpa 35w65                                                                            .949mg    P<.0005+
 b   H m syg gav liv hpc 35w65                                                                            2.63mg    P<.007 +
 c   H m syg gav lun car 35w65                                                                            14.8mg    P<.3
 d   H m syg gav tba mix 35w65                                                                            .267mg    P<.0005

NITROSO-2-OXOPROPYLETHANOLAMINE   100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
342  H f syg gav liv mix 50w65 e                                     . +   .                              .997mg    P<.0005+
 a   H f syg gav pdu c/a 50w65 e                                                                          2.31mg    P<.0005+
 b   H f syg gav liv caa 50w65 e                                                                          2.68mg    P<.0005+
 c   H f syg gav pdu car 50w65 e                                                                          3.72mg    P<.002
 d   H f syg gav liv hca 50w65 e                                                                          3.72mg    P<.002 +
 e   H f syg gav liv hpa 50w65 e                                                                          5.58mg    P<.007
 f   H f syg gav liv clc 50w65 e                                                                          5.58mg    P<.007
 g   H f syg gav lun ade 50w65 e                                                                          31.3mg    P<.3
343  R f f34 wat liv mix 12m28                                        .   +    .                          1.80mg    P<.002 +
 a   R f f34 wat liv hpc 12m28                                                                            2.70mg    P<.007 +
 b   R f f34 wat liv nnd 12m28                                                                            2.70mg    P<.007 +

DI(N-NITROSO)-PERHYDROPYRIMIDINE  100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
344  R m sda ipj pnl sqc 24m24 rs                              .   +    .                                 .166mg *  P<.003 +

N-NITROSO(2,2,2-TRIFLUOROETHYL)ETHYLAMINE ..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
345  R m sda gav eso pmc 88w88                                              . + .                          2.52mg *  P<.0005+
 a   R m sda gav nas mix 88w88                                                                            7.34mg Z  P<.007 +
 b   R m sda gav liv hes 88w88                                                                            no dre    P=1.

1-NITROSO-3,4,5-TRIMETHYLPIPERAZINE     ..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
346  H m syg gav for pam 46w69                                       .   +    .                           1.32mg    P<.0005+
 a   H m syg gav lun ade 46w69                                                                            1.73mg    P<.0005+
 b   H m syg gav lun car 46w69                                                                            3.20mg    P<.002 +
 c   H m syg gav liv ang 46w69                                                                            6.18mg    P<.02
 d   H m syg gav tba mix 46w69                                                                            noTD50    P<.0005
347  R f f34 wat nas olc 30w85                                 . +  .                                     .151mg *  P<.0005+
 a   R f f34 wat liv nnd 30w85                                                                            no dre    P=1.
 b   R f f34 wat tba mix 30w85                                                                            no dre    P=1.

N-NITROSOALLYL-2,3-DIHYDROXYPROPYLAMINE..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
348  R f f34 wat eso mix 50w55                                         .  +  .                            .825mg    P<.0005+
 a   R f f34 wat nas mix 50w55                                                                            .972mg    P<.0005+
 b   R f f34 wat eso car 50w55                                                                            1.13mg    P<.0005+
 c   R f f34 wat liv nnd 50w55                                                                            no dre    P=1.    -

N-NITROSOALLYL-2-HYDROXYPROPYLAMINE     ..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
349  R f f34 wat nas mix 50w65                                         .  +  .                            .877mg    P<.0005+
 a   R f f34 wat liv hpc 50w65                                                                            1.38mg    P<.0005+
 b   R f f34 wat eso mix 50w65                                                                            4.67mg    P<.003 +

N-NITROSOALLYL-2-OXOPROPYLAMINE   100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
350  H f syg gav nac mix 40w55 e                                       . +    .                           1.19mg    P<.0005+
 a   H f syg gav nac car 40w55 e                                                                          1.36mg    P<.0005
 b   H f syg gav liv mix 40w55 e                                                                          3.78mg    P<.007
 c   H f syg gav liv hpa 40w55 e                                                                          4.87mg    P<.02  +
 d   H f syg gav liv clc 40w55 e                                                                          21.2mg    P<.3
 e   H f syg gav lun tum 40w55 e                                                                          no dre    P=1.
351  R f f34 wat liv hpc 50w85                                   .  +  .                                  .335mg    P<.0005+
 a   R f f34 wat eso mix 50w85                                                                            1.25mg    P<.002 +

N-NITROSOALLYLETHANOLAMINE        100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
352  R f f34 wat nas mix 50w65                                     .  +  .                                .491mg    P<.0005+
 a   R f f34 wat liv hpc 50w65                                                                            4.12mg    P<.003 +

N-NITROSOAZETIDINE                100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
353  H m syg gav liv mix 50w85                                                .   +    .                   7.14mg    P<.002 +
 a   H m syg gav liv hpa 50w85                                                                            10.7mg    P<.007
 b   H m syg gav lun tum 50w85                                                                            no dre    P=1.
 c   H m syg gav tba mix 50w85                                                                            8.83mg    P<.08
```

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc				Citation or Pathology / Brkly Code
N-NITROSO-N-METHYL-4-FLUOROANILINE 937-25-7											
339	1544	.121mg .558mg	0/20	.714mg	18/20						Kroeger-Koepke;carc,4,157-160;1983
a	1544	1.29mg n.s.s.	2/20	.714mg	3/20						
b	1544	.234mg n.s.s.	19/20	.714mg	18/20						
N-NITROSO-N-METHYL-4-NITROANILINE 943-41-9											
340	1544	1.22mg n.s.s.	2/20	.840mg	4/20						Kroeger-Koepke;carc,4,157-160;1983
a	1544	.149mg n.s.s.	19/20	.840mg	19/20						
N-NITROSO-1,3-OXAZOLIDINE 39884-52-1											
341	1608	.240mg 1.02mg	0/20	2.83mg	16/20						Lijinsky;carc,5,875-878;1984
a	1608	.464mg 2.35mg	0/20	2.83mg	11/20						
b	1608	.995mg 30.4mg	0/20	2.83mg	5/20						
c	1608	2.40mg n.s.s.	0/20	2.83mg	1/20						
d	1608	.106mg .681mg	3/20	2.83mg	19/20						
NITROSO-2-OXOPROPYLETHANOLAMINE 92177-49-6											
342	1682	.508mg 2.17mg	0/20	5.99mg	16/20						Lijinsky;jnci,74,923-926;1985
a	1682	1.10mg 6.05mg	0/20	5.99mg	10/20						
b	1682	1.24mg 7.57mg	0/20	5.99mg	9/20						
c	1682	1.59mg 14.1mg	0/20	5.99mg	7/20						
d	1682	1.59mg 14.1mg	0/20	5.99mg	7/20						
e	1682	2.11mg 64.3mg	0/20	5.99mg	5/20						
f	1682	2.11mg 64.3mg	0/20	5.99mg	5/20						
g	1682	5.09mg n.s.s.	0/20	5.99mg	1/20						
343	1639	.770mg 6.82mg	0/20	.850mg	7/20						Lijinsky;zkko,107,178-182;1984
a	1639	1.02mg 31.1mg	0/20	.850mg	5/20						
b	1639	1.02mg 31.1mg	0/20	.850mg	5/20						
DI(N-NITROSO)-PERHYDROPYRIMIDINE 15973-99-6											
344	1538	67.8ug .778mg	0/40	10.0ug	0/40	28.6ug	6/40				Habs;zkko,105,191-193;1983
N-NITROSO(2,2,2-TRIFLUOROETHYL)ETHYLAMINE 82018-90-4											
345	1554	1.73mg 4.45mg	0/20	2.14mg	9/20	4.29mg	18/20	8.57mg	14/20	17.1mg 17/20	Preussmann;carc,4,755-757;1983
a	1554	4.14mg 120.mg	0/20	2.14mg	4/20	4.29mg	8/20	8.57mg	5/20	(17.1mg 3/20)	
b	1554	65.7mg n.s.s.	0/20	2.14mg	1/20	4.29mg	0/20	8.57mg	0/20	17.1mg 0/20	
1-NITROSO-3,4,5-TRIMETHYLPIPERAZINE 75881-18-4											
346	1570	.623mg 4.85mg	3/20	4.57mg	14/20						Lijinsky;carc,4,1165-1167;1983
a	1570	.844mg 4.28mg	0/20	4.57mg	11/20						
b	1570	1.37mg 12.1mg	0/20	4.57mg	7/20						
c	1570	2.13mg n.s.s.	0/20	4.57mg	4/20						
d	1570	n.s.s. .813mg	3/20	4.57mg	20/20						
347	1570	88.2ug .270mg	0/20	.259mg	13/20	.980mg	18/20				
a	1570	.564mg n.s.s.	2/20	.259mg	0/20	.980mg	0/20				
b	1570	.184mg n.s.s.	19/20	.259mg	17/20	.980mg	18/20				
N-NITROSOALLYL-2,3-DIHYDROXYPROPYLAMINE 88208-16-6											
348	1613	.412mg 1.78mg	0/20	8.16mg	17/20						Lijinsky;clet,22,281-288;1984
a	1613	.495mg 2.11mg	0/20	8.16mg	16/20						
b	1613	.578mg 2.49mg	0/20	8.16mg	15/20						
c	1613	9.41mg n.s.s.	2/20	8.16mg	0/20						
N-NITROSOALLYL-2-HYDROXYPROPYLAMINE 91308-70-2											
349	1613	.438mg 1.90mg	0/20	6.22mg	17/20						Lijinsky;clet,22,281-288;1984
a	1613	.705mg 3.11mg	0/20	6.22mg	14/20						
b	1613	1.89mg 24.4mg	0/20	6.22mg	6/20						
N-NITROSOALLYL-2-OXOPROPYLAMINE 91308-71-3											
350	1682	.591mg 2.83mg	0/20	5.67mg	12/20						Lijinsky;jnci,74,923-926;1985
a	1682	.665mg 3.37mg	0/20	5.67mg	11/20						
b	1682	1.43mg 43.5mg	0/20	5.67mg	5/20						
c	1682	1.68mg n.s.s.	0/20	5.67mg	4/20						
d	1682	3.45mg n.s.s.	0/20	5.67mg	1/20						
e	1682	6.53mg n.s.s.	0/20	5.67mg	0/20						
351	1613	.170mg .728mg	0/20	1.18mg	16/20						Lijinsky;clet,22,281-288;1984
a	1613	.535mg 4.73mg	0/20	1.18mg	7/20						
N-NITROSOALLYLETHANOLAMINE 91308-69-9											
352	1613	.202mg 1.12mg	0/20	5.49mg	19/20						Lijinsky;clet,22,281-288;1984
a	1613	1.67mg 21.5mg	0/20	5.49mg	6/20						
N-NITROSOAZETIDINE 15216-10-1											
353	1608	3.06mg 27.1mg	0/20	6.72mg	7/20						Lijinsky;carc,5,875-878;1984
a	1608	4.04mg 123.mg	0/20	6.72mg	5/20						
b	1608	18.5mg n.s.s.	0/20	6.72mg	0/20						
c	1608	3.05mg n.s.s.	3/20	6.72mg	8/20						

No.	Spe	Sex	Strain	Route	Site	Hist	Xpo+Xpt	Notes	Plot	TD50	DR	2Tailpvl	AuOp
N-NITROSOBIS(2-HYDROXYPROPYL)AMINE* **									..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
354	R	f	f34	wat	eso	mix	42w55		. + .	.813mg		P<.0005	+
a	R	f	f34	wat	eso	car	42w55			1.25mg		P<.0005	
b	R	f	f34	wat	nas	olc	42w55			3.04mg		P<.002	+
c	R	f	f34	wat	liv	nnd	42w55			no dre		P=1.	
355	R	m	mrw	gav	pro	car	74w74	er	.>	437.mg	*	P<.7	+
N-NITROSOBIS(2-OXOPROPYL)AMINE* **									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
356	R	f	f34	gav	liv	hpc	30w95		. + .	.684mg		P<.002	+
a	R	f	f34	gav	tba	mix	30w95			noTD50		P<.6	
357	R	f	f34	wat	liv	mix	50w75		. + .	.232mg		P<.0005	+
a	R	f	f34	wat	lun	mix	50w75			.399mg		P<.0005	+
b	R	f	f34	wat	liv	hpc	50w75			.582mg		P<.0005	+
c	R	f	f34	wat	liv	hes	50w75			.892mg		P<.0005	+
358	R	m	mrw	gav	pro	car	74w74	er	. + .	1.53mg	*	P<.003	+
N-NITROSOCIMETIDINE									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
359	R	f	f34	wat	thy	tum	25m30		. + .	18.8mg		P<.007	-
a	R	f	f34	wat	pit	tum	25m30			3.60mg		P<.02	-
b	R	f	f34	wat	liv	nnd	25m30			43.3mg		P<.5	-
360	R	m	f34	wat	liv	nnd	25m30		.>	no dre		P=1.	-
361	R	f	sda	gav	tba	mix	12m24		.>	no dre		P=1.	-
a	R	f	sda	gav	tba	mal	12m24			no dre		P=1.	-
362	R	m	sda	gav	tba	mix	12m24		.>	no dre		P=1.	-
a	R	m	sda	gav	tba	mal	12m24			4.82gm	*	P<.9	-
NITROSODIBUTYLAMINE* **									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
363	R	m	f34	gav	liv	hpc	7m25		. + .	.691mg		P<.0005	+
a	R	m	f34	gav	for	car	7m25			.914mg		P<.0005	+
b	R	m	f34	gav	lun	car	7m25			1.16mg		P<.003	+
c	R	m	f34	gav	ubl	tcc	7m25			1.47mg		P<.002	+
d	R	m	f34	gav	tba	mix	7m25			no dre		P=1.	
N-NITROSODIETHANOLAMINE* **									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
364	R	f	f34	wat	liv	hpc	13m24	a	. + .	3.27mg	*	P<.0005	+
a	R	f	f34	wat	nas	adc	13m24	a		44.1mg	Z	P<.0005	+
b	R	f	f34	wat	nas	olc	13m24	a		128.mg	Z	P<.005	+
c	R	f	f34	wat	liv	clc	13m24	a		197.mg	*	P<.007	+
d	R	f	f34	wat	kid	tum	13m24	a		327.mg	*	P<.009	+
e	R	f	f34	wat	eso	pam	13m24	a		2.05gm	*	P<.2	+
f	R	f	f34	wat	nas	sqc	13m24	a		4.32gm	*	P<.9	+
365	R	f	f34	wat	liv	mix	17m30	a	.+ .	1.90mg	*	P<.0005	+
a	R	f	f34	wat	liv	nnd	17m30	a		2.93mg	*	P<.0005	+
b	R	f	f34	wat	liv	hpc	17m30	a		4.05mg	*	P<.0005	+
c	R	f	f34	wat	kid	mix	17m30	a		42.2mg	*	P<.03	+
d	R	f	f34	wat	liv	caa	17m30	a		56.8mg	*	P<.08	
366	R	m	f34	wat	liv	hpc	48w95	a	. + .	2.77mg	*	P<.0005	+
a	R	m	f34	wat	nas	adc	48w95	a		15.5mg	*	P<.0005	+
b	R	m	f34	wat	liv	clc	48w95	a		23.9mg	Z	P<.002	+
c	R	m	f34	wat	nas	olc	48w95	a		50.4mg	Z	P<.003	+
d	R	m	f34	wat	kid	tum	48w95	a		99.7mg	*	P<.002	+
e	R	m	f34	wat	eso	pam	48w95	a		207.mg	*	P<.003	+
f	R	m	f34	wat	nas	sqc	48w95	a		280.mg	*	P<.009	+
g	R	m	f34	wat	eso	car	48w95	a		432.mg	*	P<.2	+
367	R	m	f34	wat	liv	mix	17m29	a	. + .	2.84mg	Z	P<.0005	+
a	R	m	f34	wat	liv	nnd	17m29	a		3.93mg	*	P<.002	+
b	R	m	f34	wat	liv	hpc	17m29	a		9.03mg	*	P<.0005	+
c	R	m	f34	wat	kid	mix	17m29	a		19.0mg	*	P<.07	+
d	R	m	f34	wat	liv	caa	17m29	a		38.6mg	*	P<.06	
N-NITROSODIETHYLAMINE* **									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
368	R	f	f34	wat	eso	tum	30w65		. + .	21.9ug		P<.0005	+
a	R	f	f34	wat	liv	tum	30w65			no dre		P=1.	
b	R	f	f34	wat	tba	tum	30w65			no dre		P=1.	
N-NITROSODIMETHYLAMINE* **									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
369	R	m	buf	eat	liv	hpc	26w52	ekr	.>	1.76mg		P<.4	+
370	R	f	f34	wat	liv	mix	7m26		. + .	58.7ug	*	P<.0005	+
a	R	f	f34	wat	liv	hpc	7m26			.135mg	*	P<.0005	+
b	R	f	f34	wat	liv	hes	7m26			.438mg	*	P<.002	+
c	R	f	f34	wat	liv	nnd	7m26			no dre		P=1.	
N-NITROSODIPROPYLAMINE									100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10				
371	R	f	f34	gav	liv	hpc	30w60		. + .	.186mg		P<.0005	+
a	R	f	f34	gav	nas	car	30w60			.186mg		P<.0005	+
b	R	f	f34	gav	eso	mix	30w60			.505mg		P<.004	+
c	R	f	f34	gav	tba	mix	30w60			noTD50		P<.6	

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc			Citation or Pathology Brkly Code
N-NITROSOBIS(2-HYDROXYPROPYL)AMINE* (N-bis(2-hydroxypropyl)nitrosamine) 53609-64-6**										
354	1612	.414mg 1.77mg	0/20	6.83mg	16/20					Lijinsky;carc,5,167-170;1984
a	1612	.630mg 2.88mg	0/20	6.83mg	13/20					
b	1612	1.30mg 11.5mg	0/20	6.83mg	7/20					
c	1612	7.87mg n.s.s.	3/20	6.83mg	0/20					
355	1553	55.4mg n.s.s.	0/15	17.9mg	2/14	35.7mg	1/15	71.4mg	1/15	Pour;carc,4,49-55;1983
N-NITROSOBIS(2-OXOPROPYL)AMINE* 60599-38-4**										
356	1551	.254mg 3.08mg	0/20	.644mg	5/12					Lijinsky;clet,19,207-213;1983
a	1551	n.s.s. n.s.s.	18/20	.644mg	12/12					
357	1639	.110mg .506mg	0/20	1.50mg	18/20					Lijinsky;zkko,107,178-182;1984
a	1639	.200mg .967mg	1/20	1.50mg	15/20					
b	1639	.290mg 1.39mg	0/20	1.50mg	12/20					
c	1639	.413mg 2.52mg	0/20	1.50mg	9/20					
358	1553	.658mg 7.19mg	0/15	.357mg	0/15	.714mg	2/12	1.43mg	5/15	Pour;carc,4,49-55;1983
N-NITROSOCIMETIDINE 73785-40-7										
359	1611	7.11mg 217.mg	0/20	4.99mg	5/20					Lijinsky;canr,44,447-449;1984
a	1611	1.32mg n.s.s.	11/20	4.99mg	18/20					
b	1611	8.56mg n.s.s.	3/20	4.99mg	5/20					
360	1611	7.07mg n.s.s.	5/20	3.49mg	5/20					
361	1699	142.mg n.s.s.	10/50	7.17mg	1/20	71.7mg	3/20			Habs;hepg,29,265-266;1982
a	1699	232.mg n.s.s.	7/50	7.17mg	0/20	71.7mg	1/20			
362	1699	136.mg n.s.s.	9/50	7.17mg	1/20	71.7mg	3/20			
a	1699	149.mg n.s.s.	5/50	7.17mg	1/20	71.7mg	2/20			
NITROSODIBUTYLAMINE* 924-16-3**										
363	1551	.345mg 1.65mg	0/20	.857mg	12/20					Lijinsky;clet,19,207-213;1983
a	1551	.436mg 2.39mg	0/20	.857mg	10/20					
b	1551	.508mg 6.79mg	1/20	.857mg	9/20					
c	1551	.629mg 5.57mg	0/20	.857mg	7/20					
d	1551	.136mg n.s.s.	19/20	.857mg	19/20					
N-NITROSODIETHANOLAMINE* 1116-54-7**										
364	1610	1.86mg 5.75mg	0/40	7.77mg	15/16	14.4mg	16/16	31.4mg	19/20	99.8mg 20/20 Lijinsky;fctx,22,23-26; 1984/pers.comm.
a	1610	23.1mg 106.mg	0/40	7.77mg	3/16	14.4mg	2/16	31.4mg	8/20	(99.8mg 1/20)
b	1610	48.4mg 1.12gm	0/40	7.77mg	1/16	14.4mg	0/16	31.4mg	4/20	(99.8mg 1/20)
c	1610	81.3mg 3.82gm	0/40	7.77mg	3/16	14.4mg	1/16	31.4mg	3/20	99.8mg 5/20
d	1610	133.mg 13.1gm	0/40	7.77mg	0/16	14.4mg	0/16	31.4mg	4/20	99.8mg 2/20
e	1610	333.mg n.s.s.	0/40	7.77mg	0/16	14.4mg	0/16	31.4mg	0/20	99.8mg 1/20
f	1610	190.mg n.s.s.	0/40	7.77mg	3/16	14.4mg	1/16	31.4mg	2/20	99.8mg 1/20
365	1707	1.32mg 2.92mg	1/20	.879mg	10/39	1.00mg	5/20	2.01mg	14/20	2.51mg 27/27 Lijinsky;carc,6,1697-1681;1985
a	1707	1.96mg 5.05mg	1/20	.879mg	8/39	1.00mg	4/20	2.01mg	13/20	2.51mg 19/27
b	1707	2.65mg 6.65mg	0/20	.879mg	5/39	1.00mg	2/20	2.01mg	7/20	2.51mg 19/27
c	1707	14.6mg n.s.s.	0/20	.879mg	0/39	1.00mg	0/20	2.01mg	1/20	2.51mg 3/27
d	1707	17.2mg n.s.s.	0/20	.879mg	0/39	1.00mg	0/20	2.01mg	2/20	2.51mg 1/27
366	1610	1.72mg 4.60mg	1/28	6.02mg	14/16	9.02mg	14/16	16.8mg	18/20	48.4mg 20/20 Lijinsky;fctx,22,23-26; 1984/pers.comm.
a	1610	10.1mg 32.1mg	0/28	6.02mg	5/16	9.02mg	9/16	16.8mg	8/20	48.4mg 14/20
b	1610	12.3mg 89.9mg	0/28	6.02mg	4/16	9.02mg	2/16	16.8mg	6/20	(48.4mg 4/20)
c	1610	20.5mg 265.mg	0/28	6.02mg	0/16	9.02mg	1/16	16.8mg	5/20	(48.4mg 2/20)
d	1610	45.1mg 409.mg	0/28	6.02mg	0/16	9.02mg	1/16	16.8mg	2/20	48.4mg 5/20
e	1610	71.3mg 1.32gm	0/28	6.02mg	0/16	9.02mg	0/16	16.8mg	0/20	48.4mg 4/20
f	1610	84.7mg 9.40gm	0/28	6.02mg	0/16	9.02mg	0/16	16.8mg	0/20	48.4mg 3/20
g	1610	106.mg n.s.s.	0/28	6.02mg	0/16	9.02mg	0/16	16.8mg	1/20	48.4mg 1/20
367	1707	1.72mg 6.81mg	4/20	.640mg	6/39	.795mg	2/20	1.46mg	11/20	1.83mg 19/27 Lijinsky;carc,6,1697-1681;1985
a	1707	2.19mg 15.1mg	4/20	.640mg	6/39	.795mg	2/20	1.46mg	7/20	1.83mg 17/27
b	1707	4.65mg 24.9mg	0/20	.640mg	0/39	.795mg	1/20	1.46mg	4/20	1.83mg 7/27
c	1707	7.77mg n.s.s.	0/20	.640mg	1/39	.795mg	1/20	1.46mg	2/20	1.83mg 2/27
d	1707	11.7mg n.s.s.	0/20	.640mg	0/39	.795mg	0/20	1.46mg	1/20	1.83mg 2/27
N-NITROSODIETHYLAMINE* (DEN) 55-18-5**										
368	1561	11.2ug 47.7ug	0/20	.132mg	16/20					Lijinsky;fctx,21,601-605;1983
a	1561	.127mg n.s.s.	1/20	.132mg	1/20					
b	1561	16.1ug n.s.s.	20/20	.132mg	18/20					
N-NITROSODIMETHYLAMINE* (DMN) 62-75-9**										
369	1664	.286mg n.s.s.	0/14	.500mg	1/21					Angsubhakorn;ijcn,28,621-626;1981
370	1609	33.8ug .123mg	2/20	63.1ug	14/20	.168mg	17/20			Lijinsky;clet,22,83-88;1984
a	1609	77.5ug .316mg	0/20	63.1ug	9/20	.168mg	10/20			
b	1609	.188mg 1.56mg	0/20	63.1ug	0/20	.168mg	7/20			
c	1609	.309mg n.s.s.	2/20	63.1ug	5/20	.168mg	2/20			
N-NITROSODIPROPYLAMINE 621-64-7										
371	1551	79.3ug .564mg	0/20	.898mg	8/12					Lijinsky;clet,19,207-213;1983
a	1551	79.3ug .564mg	0/20	.898mg	8/12					
b	1551	.172mg 3.75mg	0/20	.898mg	4/12					
c	1551	n.s.s. n.s.s.	18/20	.898mg	12/12					

	Spe Strain Site Xpo+Xpt Sex Route Hist Notes	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10	TD50 DR	2Tailpvl AuOp
NITROSODODECAMETHYLENEIMINE				
372	R f nzd gav liv hct 12m40 e	. + .	10.9mg	P<.007 +
a	R f nzd gav lun mix 12m40 e		7.96mg	P<.03
373	R m nzd gav hea tum 12m35 e	. ±	2.15mg	P<.03
a	R m nzd gav lun mix 12m35 e		14.6mg	P<.5
b	*R m nzd gav liv hct 12m35 e*		*16.8mg*	*P<.3 +*
NITROSOETHYLMETHYLAMINE**		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
374	R f f34 wat --- tum 7m27	. ±	38.6ug	P<.03
a	R f f34 wat liv tum 7m27		no dre	P=1.
b	R f f34 wat tba tum 7m27		no dre	P=1.
N-NITROSOHEXAMETHYLENEIMINE		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
375	M f nzb wat ssq mix 32w74	. + .	.415mg	P<.0005+
a	M f nzb wat eso mix 32w74		.725mg	P<.0005+
b	M f nzb wat liv hpc 32w74		3.21mg	P<.004 +
c	M f nzb wat stg mix 32w74		4.05mg	P<.0005+
d	M f nzb wat opx mix 32w74		6.37mg	P<.003 +
e	M f nzb wat lun mix 32w74		no dre	P=1.
376	M m nzb wat eso mix 32w60	. + .	.313mg	P<.0005+
a	M m nzb wat ssq mix 32w60		.448mg	P<.0005+
b	M m nzb wat opx mix 32w60		1.41mg	P<.0005+
c	M m nzb wat stg mix 32w60		3.23mg	P<.0005+
d	M m nzb wat lun mix 32w60		1.93mg	P<.2
e	M m nzb wat liv hpc 32w60		8.03mg	P<.2 +
N-NITROSOMETHYL-2,3-DIHYDROXYPROPYLAMINE		.:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
377	H f syg gav nac mix 41w81	. + .	.940mg	P<.0005+
a	H f syg gav nac car 41w81		1.51mg	P<.002
b	H f syg gav liv h/2 41w81		12.7mg	P<.3 -
c	H f syg gav tba mix 41w81		.509mg	P<.0005
378	*R f f34 wat lun mix 9m26*	. + .	*.646mg*	*P<.0005+*
a	R f f34 wat liv mix 9m26		.670mg	P<.02
b	R f f34 wat liv nnd 9m26		1.01mg	P<.06 +
c	R f f34 wat eso mix 9m26		1.48mg	P<.02 +
d	R f f34 wat nas mix 9m26		1.48mg	P<.02 +
e	R f f34 wat liv hpc 9m26		3.13mg	P<.1
N-NITROSOMETHYL-2-HYDROXYPROPYLAMINE		..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
379	R f f34 wat nas mix 30w75	. + .	48.6ug	P<.0005+
a	R f f34 wat eso mix 30w75		.105mg	P<.0005+
b	R f f34 wat eso car 30w75		.408mg	P<.003
c	R f f34 wat lun mix 30w75		.408mg	P<.003
d	R f f34 wat liv hpc 30w75		.895mg	P<.04
e	R f f34 wat liv mix 30w75		.798mg	P<.3
f	R f f34 wat liv nnd 30w75		2.54mg	P<.7
380	*R m f34 wat nas mix 30w75*	. + .	*44.2ug*	*P<.0005+*
a	R m f34 wat eso mix 30w75		.170mg	P<.0005+
b	R m f34 wat liv mix 30w75		no dre	P=1.
c	R m f34 wat liv nnd 30w75		no dre	P=1.
NITROSOMETHYLANILINE***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
381	R f f34 wat eso car 12m26	. + .	.458mg	P<.0005+
a	R f f34 wat liv car 12m26		no dre	P=1.
b	R f f34 wat tba mix 12m26		no dre	P=1.
382	R m f34 wat eso mix 12m26	. + .	.272mg	P<.0005+
a	R m f34 wat liv car 12m26		no dre	P=1.
b	*R m f34 wat tba mix 12m26*		*no dre*	*P=1.*
N-NITROSOMORPHOLINE		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
383	H f syg wat res mix 24m24 e	. + .	1.35mg Z	P<.0005+
a	*H f syg wat liv mix 24m24 e*		*51.6mg **	*P<.0005+*
b	H f syg wat tba mix 24m24 e		1.48mg Z	P<.0005
384	H m syg wat res mix 24m24 e	.+ .	5.98mg *	P<.0005+
a	H m syg wat liv mix 24m24 e		9.14mg *	P<.0005+
b	H m syg wat tba mix 24m24 e		5.56mg *	P<.0005
N'-NITROSONORNICOTINE		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
385	H f syg wat res pam 31w96	. ±	11.5mg	P<.04 +
a	H f syg wat liv tum 31w96		no dre	P=1.
386	H m syg wat res pam 31w96	. ±	10.1mg	P<.04 +
a	H m syg wat liv ang 31w96		34.4mg	P<.3
N'-NITROSONORNICOTINE-1-N-OXIDE		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
387	H f syg wat liv ang 31w96	.>	39.0mg	P<.3 -
388	H m syg wat liv tum 31w96	.>	no dre	P=1.
389	R f f34 wat nas mix 8m24	. + .	1.86mg	P<.0005+
a	R f f34 wat eso mix 8m24		5.65mg	P<.04 +

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology / Brkly Code
NITROSODODECAMETHYLENEIMINE 40580-89-0								
372	1603	2.67mg	255.mg	0/109	.619mg	2/20		Goodall;carc,5,537-540;1984
a	1603	2.20mg	n.s.s.	2/109	.619mg	3/20		
373	1603	.730mg	n.s.s.	18/108	.495mg	8/20		
a	1603	1.88mg	n.s.s.	6/108	.495mg	2/20		
b	1603	2.30mg	n.s.s.	1/108	.495mg	1/20		
NITROSOETHYLMETHYLAMINE ** 10595-95-6**								
374	1561	13.4ug	n.s.s.	12/20	63.9ug	18/20		Lijinsky;fctx,21,601-605;1983
a	1561	.322mg	n.s.s.	1/20	63.9ug	0/20		
b	1561	13.5ug	n.s.s.	20/20	63.9ug	19/20		
N-NITROSOHEXAMETHYLENEIMINE 932-83-2								
375	1738	.156mg	1.13mg	0/113	3.07mg	12/13		Goodall;txcy,33,251-259;1984
a	1738	.320mg	1.96mg	0/113	3.07mg	10/13		
b	1738	1.02mg	40.6mg	4/113	3.07mg	4/13		
c	1738	1.22mg	29.1mg	0/113	3.07mg	3/13		
d	1738	1.56mg	88.1mg	0/113	3.07mg	2/13		
e	1738	1.58mg	n.s.s.	39/113	3.07mg	4/13		
376	1738	.110mg	.974mg	0/194	3.16mg	9/10		
a	1738	.176mg	1.40mg	0/194	3.16mg	8/10		
b	1738	.477mg	7.31mg	0/194	3.16mg	4/10		
c	1738	.789mg	43.0mg	0/194	3.16mg	2/10		
d	1738	.458mg	n.s.s.	53/194	3.16mg	5/10		
e	1738	1.14mg	n.s.s.	3/194	3.16mg	1/10		
N-NITROSOMETHYL-2,3-DIHYDROXYPROPYLAMINE 86451-37-8								
377	1715	.449mg	2.46mg	0/20	1.57mg	10/20		Lijinsky;zkko,109,1-4;1985
a	1715	.647mg	5.73mg	0/20	1.57mg	7/20		
b	1715	2.07mg	n.s.s.	0/20	1.57mg	1/20		
c	1715	.250mg	1.38mg	2/20	1.57mg	15/20		
378	1609	.289mg	2.04mg	0/20	.430mg	8/20		Lijinsky;clet,22,83-88;1984
a	1609	.275mg	n.s.s.	2/20	.430mg	9/20		
b	1609	.358mg	n.s.s.	2/20	.430mg	7/20		
c	1609	.509mg	n.s.s.	0/20	.430mg	4/20		
d	1609	.509mg	n.s.s.	0/20	.430mg	4/20		
e	1609	.769mg	n.s.s.	0/20	.430mg	2/20		
N-NITROSOMETHYL-2-HYDROXYPROPYLAMINE 75411-83-5								
379	1609	20.0ug	.111mg	0/20	.408mg	19/20		Lijinsky;clet,22,83-88;1984
a	1609	53.7ug	.231mg	0/20	.408mg	15/20		
b	1609	.165mg	2.13mg	0/20	.408mg	6/20		
c	1609	.165mg	2.13mg	0/20	.408mg	6/20		
d	1609	.270mg	n.s.s.	0/20	.408mg	3/20		
e	1609	.215mg	n.s.s.	2/20	.408mg	5/20		
f	1609	.318mg	n.s.s.	2/20	.408mg	3/20		
380	1609	21.0ug	96.7ug	0/20	.286mg	18/20		
a	1609	78.9ug	.480mg	0/20	.286mg	9/20		
b	1609	.291mg	n.s.s.	2/20	.286mg	2/20		
c	1609	.407mg	n.s.s.	2/20	.286mg	1/20		
NITROSOMETHYLANILINE* 614-00-6**								
381	1544	.233mg	.996mg	0/20	.895mg	16/20		Kroeger-Koepke;carc,4,157-160;1983
a	1544	3.30mg	n.s.s.	4/20	.895mg	1/20		
b	1544	.258mg	n.s.s.	18/20	.895mg	18/20		
382	1544	.136mg	.588mg	0/20	.627mg	17/20		
a	1544	2.20mg	n.s.s.	3/20	.627mg	1/20		
b	1544	.205mg	n.s.s.	19/20	.627mg	18/20		
N-NITROSOMORPHOLINE 59-89-2								
383	1543	.714mg	2.97mg	0/50	1.36mg	14/28	(6.82mg 16/30 13.6mg 22/30)	Ketkar;clet,17,333-338;1983/pers.comm.
a	1543	23.4mg	156.mg	0/50	1.36mg	0/28	6.82mg 2/30 13.6mg 6/30	
b	1543	.746mg	4.02mg	3/50	1.36mg	14/28	(6.82mg 17/30 13.6mg 23/30)	
384	1543	4.03mg	9.71mg	0/50	1.20mg	8/29	6.00mg 13/29 12.0mg 21/30	
a	1543	5.87mg	15.4mg	0/50	1.20mg	4/29	6.00mg 9/29 12.0mg 18/30	
b	1543	3.40mg	10.8mg	8/50	1.20mg	12/29	6.00mg 14/29 12.0mg 26/30	
N'-NITROSONORNICOTINE 16543-55-8								
385	1539	3.45mg	n.s.s.	0/10	7.05mg	3/10		Hecht;clet,20,333-340;1983
a	1539	12.4mg	n.s.s.	0/10	7.05mg	0/10		
386	1539	3.03mg	n.s.s.	0/10	6.20mg	3/10		
a	1539	5.58mg	n.s.s.	0/10	6.20mg	1/10		
N'-NITROSONORNICOTINE-1-N-OXIDE 78246-24-9								
387	1539n	6.34mg	n.s.s.	0/10	7.05mg	1/10		Hecht;clet,20,333-340;1983
388	1539n	10.9mg	n.s.s.	0/10	6.20mg	0/10		
389	1539m	.769mg	6.48mg	0/12	2.37mg	7/12		
a	1539m	1.70mg	n.s.s.	0/12	2.37mg	3/12		

	Spe Strain Site Xpo+Xpt Sex Route Hist Notes		TD50 DR	2Tailpvl AuOp
390	R m f34 wat nas mix 8m24	. + .	.573mg	P<.0005+
a	R m f34 wat eso mix 8m24		1.63mg	P<.0005+
b	R m f34 wat nas mal 8m24		1.63mg	P<.0005
c	R m f34 wat eso pam 8m24		2.64mg	P<.005
d	R m f34 wat nas pam 8m24		2.64mg	P<.005
N-NITROSOPIPERIDINE***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
391	H f syg wat res mix 24m24	. + .	96.7mg *	P<.0005+
a	H f syg wat dgt mix 24m24		132.mg *	P<.002 +
b	H f syg wat liv mix 24m24		307.mg *	P<.005 +
c	H f syg wat tba mix 24m24		9.89mg Z	P<.0005
392	H m syg wat res mix 24m24	. + .	50.9mg *	P<.0005+
a	H m syg wat dgt mix 24m24		98.2mg *	P<.0005+
b	H m syg wat liv mix 24m24		135.mg *	P<.0005+
c	H m syg wat tba mix 24m24		52.9mg *	P<.0005
393	R b sda wat liv mix 27m33 a	. + .	.963mg Z	P<.0005
a	R b sda wat mix mix 27m33 a		2.32mg *	P<.0005
b	R b sda wat tba mal 27m33 a		1.57mg *	P<.0005+
PENTACHLOROETHANE		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
394	M f b6c gav liv MXA 24m24 as	: + :	39.8mg /	P<.0005c
a	M f b6c gav liv hpc 24m24 as		66.6mg *	P<.0005c
b	M f b6c gav liv hpa 24m24 as		153.mg /	P<.0005c
c	M f b6c gav TBA MXB 24m24 as		39.5mg /	P<.0005
d	M f b6c gav liv MXB 24m24 as		39.8mg /	P<.0005
e	M f b6c gav lun MXB 24m24 as		1.03gm /	P<.2
395	M m b6c gav liv hpc 24m24 as	: + :	102.mg /	P<.0005c
a	M m b6c gav liv MXA 24m24 as		107.mg /	P<.0005
b	M m b6c gav TBA MXB 24m24 as		85.6mg /	P<.0005
c	M m b6c gav liv MXB 24m24 as		107.mg /	P<.0005
d	M m b6c gav lun MXB 24m24 as		no dre	P=1.
396	R f f34 gav TBA MXB 24m24 s	:>	1.66gm *	P<.9 -
a	R f f34 gav liv MXB 24m24 s		no dre	P=1.
397	R m f34 gav kid tla 24m24 s	: +	+historical *	P<.009 a
a	R m f34 gav kid MXA 24m24 s		+historical *	P<.07 a
b	R m f34 gav TBA MXB 24m24 s		no dre	P=1.
c	R m f34 gav liv MXB 24m24 s		no dre	P=1.
2,3,4,5,6-PENTACHLOROPHENOL***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
398	M f cd1 eat lun ade 52w69 e	.>	448.mg	P<.3
a	M f cd1 eat liv tum 52w69 e		no dre	P=1.
PHENACETIN***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
399	R f wis eat unt tum 69w69 er	.>	no dre	P=1. -
PHENOBARBITAL***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
400	M f cd1 wat liv hpt 78w78	. ±	559.mg	P<.1
a	M f cd1 wat lun ade 78w78		no dre	P=1.
401	R m fis eat liv tum 39w78 e	.>	no dre	P=1. -
a	R m fis eat tba tum 39w78 e		no dre	P=1. -
p-PHENYLENEDIAMINE		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
402	R f f34 eat adr phe 80w80 e	.>	4.28gm *	P<1. -
a	R f f34 eat liv tum 80w80 e		no dre	P=1.
403	R m f34 eat adr phe 80w80 e	.>	no dre	P=1. -
a	R m f34 eat liv tum 80w80 e		no dre	P=1.
PHENYLGLYCIDYL ETHER		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
404	R f cdr inh nas epc 24m24 r	. + .	90.2mg *	P<.005 +
405	R m cdr inh nas mix 24m24 r	. + .	29.1mg *	P<.0005+
beta-PHENYLISOPROPYLHYDRAZINE.HCl		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
406	M f swa wat liv hpt 28m29 aes	.>	no dre	P=1. -
a	M f swa wat lun tum 28m29 aes		no dre	P=1. -
407	M m swa wat liv hpt 23m26 aes	.>	no dre	P=1. -
a	M m swa wat lun tum 23m26 aes		no dre	P=1. -
o-PHENYLPHENATE, SODIUM***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
408	M f b6c eat liv hpc 22m24 e	.>	13.0gm Z	P<.4 -
a	M f b6c eat lun ade 22m24 e		143.gm *	P<.3 -
b	M f b6c eat liv hnd 22m24 e		no dre	P=1. -
409	M m b6c eat liv hpc 22m24 e	. +	5.42gm *	P<.009 -
a	M m b6c eat liv hes 22m24 e		11.6gm *	P<.09 -
b	M m b6c eat liv fbs 22m24 e		132.gm *	P<.7 -
c	M m b6c eat liv hem 22m24 e		no dre	P=1. -
d	M m b6c eat liv hnd 22m24 e		no dre	P=1. -
e	M m b6c eat lun adc 22m24 e		no dre	P=1. -
f	M m b6c eat lun ade 22m24 e		no dre	P=1. -

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc				Citation or Pathology / Brkly Code
390	1539m	.211mg	1.62mg	0/12	2.08mg	11/12						
a	1539m	.673mg	5.67mg	0/12	2.08mg	7/12						
b	1539m	.673mg	5.67mg	0/12	2.08mg	7/12						
c	1539m	.983mg	21.2mg	0/12	2.08mg	5/12						
d	1539m	.983mg	21.2mg	0/12	2.08mg	5/12						
N-NITROSOPIPERIDINE*** (PIP) 100-75-4												
391	1541	56.9mg	240.mg	0/50	8.18mg	4/30	34.1mg	6/30	68.2mg	10/30		Ketkar;clet,21,219-224;1983
a	1541	70.6mg	624.mg	0/50	8.18mg	4/30	34.1mg	5/30	68.2mg	7/30		
b	1541	133.mg	3.08gm	0/50	8.18mg	1/30	34.1mg	2/30	68.2mg	4/30		
c	1541	4.97mg	27.9mg	3/50	8.18mg	14/30	(34.1mg	12/30	68.2mg	16/30)		
392	1541	32.6mg	90.0mg	0/50	7.20mg	5/30	30.0mg	10/30	60.0mg	15/30		
a	1541	55.5mg	198.mg	0/50	7.20mg	0/30	30.0mg	4/30	60.0mg	13/30		
b	1541	71.2mg	312.mg	0/50	7.20mg	1/30	30.0mg	2/30	60.0mg	10/30		
c	1541	29.6mg	142.mg	8/50	7.20mg	9/30	30.0mg	12/30	60.0mg	19/30		
393	1634	.590mg	1.96mg	0/40	17.1ug	3/78	85.7ug	5/75	.429mg	16/34	(2.14mg 11/34)	Eisenbrand;iarc,657-663;1980
a	1634	1.51mg	3.80mg	0/40	17.1ug	0/78	85.7ug	2/75	.429mg	8/34	2.14mg 24/34	
b	1634	.998mg	2.69mg	4/40	17.1ug	7/78	85.7ug	7/75	.429mg	14/34	2.14mg 28/34	
PENTACHLOROETHANE (pentalin) 76-01-7												
394	c53894	24.0mg	68.0mg	3/50	177.mg	36/50	357.mg	32/50				liv:hpa,hpc.
a	c53894	38.3mg	118.mg	1/50	177.mg	28/50	357.mg	13/50				
b	c53894	69.1mg	367.mg	2/50	177.mg	8/50	357.mg	19/50				
c	c53894	24.1mg	69.1mg	22/50	177.mg	38/50	357.mg	33/50				
d	c53894	24.0mg	68.0mg	3/50	177.mg	36/50	357.mg	32/50				liv:hpa,hpc,nnd.
e	c53894	193.mg	n.s.s.	4/50	177.mg	0/50	357.mg	3/50				lun:a/a,a/c.
395	c53894	59.1mg	234.mg	4/50	177.mg	26/50	357.mg	7/50				liv:hpa,hpc. S
a	c53894	58.4mg	304.mg	14/50	177.mg	30/50	357.mg	14/50				
b	c53894	46.5mg	278.mg	20/50	177.mg	38/50	357.mg	14/50				liv:hpa,hpc,nnd.
c	c53894	58.4mg	304.mg	14/50	177.mg	30/50	357.mg	14/50				lun:a/a,a/c.
d	c53894	389.mg	n.s.s.	6/50	177.mg	5/50	357.mg	0/50				
396	c53894	79.4mg	n.s.s.	37/50	53.1mg	36/50	106.mg	26/50				liv:hpa,hpc,nnd.
a	c53894	409.mg	n.s.s.	1/50	53.1mg	3/50	106.mg	0/50				
397	c53894	240.mg	14.6gm	0/50	53.1mg	1/50	106.mg	4/50				kid:tia,uac.
a	c53894	229.mg	n.s.s.	1/50	53.1mg	2/50	106.mg	4/50				
b	c53894	107.mg	n.s.s.	36/50	53.1mg	26/50	106.mg	22/50				liv:hpa,hpc,nnd.
c	c53894	500.mg	n.s.s.	2/50	53.1mg	1/50	106.mg	1/50				
2,3,4,5,6-PENTACHLOROPHENOL*** (Dowicide-7, PCP) 87-86-5												
398	1581	73.0mg	n.s.s.	0/32	48.8mg	1/31						Boberg;canr,43,5163-5173;1983
a	1581	137.mg	n.s.s.	0/32	48.8mg	0/31						
PHENACETIN*** 62-44-2												
399	1740	1.86gm	n.s.s.	0/30	500.mg	0/41						Kunze;zkko,105,38-47;1983
PHENOBARBITAL*** (phenobarbitone) 50-06-6												
400	1582	137.mg	n.s.s.	0/30	100.mg	2/30						Miller;canr,43,1124-1134;1983
a	1582	210.mg	n.s.s.	1/30	100.mg	1/30						
401	1653	6.96mg	n.s.s.	0/12	10.0mg	0/6						Carr;carc,5,1583-1590;1984
a	1653	6.96mg	n.s.s.	0/12	10.0mg	0/6						
p-PHENYLENEDIAMINE 106-50-3												
402	1542	146.mg	n.s.s.	1/21	25.0mg	1/37	50.0mg	2/42				Imaida;txlt,16,259-269;1983
a	1542	78.3mg	n.s.s.	0/21	25.0mg	0/37	50.0mg	0/42				
403	1542	42.8mg	n.s.s.	6/19	20.0mg	8/35	40.0mg	10/36				
a	1542	57.4mg	n.s.s.	0/19	20.0mg	0/35	40.0mg	0/36				
PHENYLGLYCIDYL ETHER 122-60-1												
404	1737	31.2mg	812.mg	0/90	.460mg	0/90	5.52mg	4/90				Lee;ajpa,111,140-148;1983
405	1737	13.2mg	108.mg	1/90	.322mg	0/90	3.86mg	9/90				
beta-PHENYLISOPROPYLHYDRAZINE.HCl 66-05-7												
406	1675	23.0mg	n.s.s.	1/15	31.2mg	0/4	62.4mg	0/3				Toth;faat,2,173-176;1982/1980
a	1675	145.mg	n.s.s.	25/99	31.2mg	10/49	(62.4mg	2/45)				
407	1675	65.2mg	n.s.s.	0/99	26.0mg	0/42	52.0mg	0/7				
a	1675	143.mg	n.s.s.	26/100	26.0mg	5/42	(52.0mg	0/7)				
o-PHENYLPHENATE, SODIUM*** 132-27-4												
408	1647	3.28gm	n.s.s.	4/49	600.mg	5/50	1.20gm	7/50	(2.40gm	0/50)		Hagiwara;fctx,22,809-814;1984
a	1647	23.2gm	n.s.s.	0/49	600.mg	0/49	1.20gm	0/50	2.40gm	1/50		
b	1647	9.85gm	n.s.s.	5/49	600.mg	6/50	1.20gm	9/50	2.40gm	3/50		
409	1647	2.68gm	188.gm	4/49	554.mg	9/50	1.11gm	13/50	2.22gm	14/50		
a	1647	5.84gm	n.s.s.	0/49	554.mg	3/50	1.11gm	5/50	2.22gm	3/50		
b	1647	21.6gm	n.s.s.	0/49	554.mg	0/50	1.11gm	1/50	2.22gm	0/50		
c	1647	13.3gm	n.s.s.	1/49	554.mg	3/50	1.11gm	2/50	2.22gm	1/50		
d	1647	5.00gm	n.s.s.	16/49	554.mg	19/50	1.11gm	16/50	2.22gm	15/50		
e	1647	14.4gm	n.s.s.	3/49	554.mg	3/50	1.11gm	2/50	2.22gm	2/50		
f	1647	10.3gm	n.s.s.	4/49	554.mg	4/50	1.11gm	5/50	2.22gm	3/50		

	Spe Strain Site Xpo+Xpt Sex Route Hist Notes	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10	TD50 DR	2Tailpvl AuOp
o-PHENYLPHENOL***				
410	R m f3d eat ubl mix 91w91 ers	. + .	232.mg Z	P<.0005+
a	R m f3d eat ubl tcc 91w91 ers		296.mg Z	P<.0005+
b	R m f3d eat ubl nvt 91w91 ers		451.mg Z	P<.0005+
c	R m f3d eat ubl ivt 91w91 ers		1.65gm Z	P<.008 +
PILDRALAZINE				
411	M f b6c wat liv mix 19m29 e	.>	503.mg *	P<.2 -
a	M f b6c wat lun mix 19m29 e		no dre	P=1. -
412	M m b6c wat liv mix 19m29 e	.>	922.mg Z	P<.6 -
a	M m b6c wat lun mix 19m29 e		no dre	P=1. -
413	M f bld wat --- lym 19m29 e	.>	408.mg *	P<.6 -
a	M f bld wat liv hpa 19m29 e		no dre	P=1. -
b	M f bld wat lun mix 19m29 e		no dre	P=1. -
POLYBROMINATED BIPHENYL MIXTURE				
414	M f b6c gav liv hpc 6m30	: + :	.534mg *	P<.0005c
a	M f b6c gav TBA MXB 6m30		.338mg *	P<.003
b	M f b6c gav liv MXB 6m30		.402mg *	P<.0005
c	M f b6c gav lun MXB 6m30		.915mg *	P<.02
415	M m b6c gav liv hpc 6m30	: + :	.381mg *	P<.0005c
a	M m b6c gav TBA MXB 6m30		.418mg *	P<.0005
b	M m b6c gav liv MXB 6m30		.285mg *	P<.0005
c	M m b6c gav lun MXB 6m30		no dre	P=1.
416	R f f34 gav liv MXA 6m29 y	:(+):	.596mg *	P<.0005c
a	R f f34 gav liv nnd 6m29 y		1.10mg *	P<.0005c
b	R f f34 gav liv hpc 6m29 y		1.65mg *	P<.0005c
c	R f f34 gav liv clc 6m29 y		2.10mg *	P<.0005c
d	R f f34 gav TBA MXB 6m29 y		.365mg *	P<.009
417	R m f34 gav liv MXA 6m27 y	: (+) :	.148mg *	P<.0005c
a	R m f34 gav liv nnd 6m27 y		.168mg *	P<.0005c
b	R m f34 gav liv hpc 6m27 y		1.30mg *	P<.0005c
c	R m f34 gav liv clc 6m27 y		14.4mg *	P<.006 c
d	R m f34 gav TBA MXB 6m27 y		64.5ug *	P<.0005
PRIMIDOLOL.HCl				
418	M f cd1 eat lun ade 78w78 e	.>	449.mg *	P<.4
a	M f cd1 eat lun adc 78w78 e		1.67gm *	P<.4
b	M f cd1 eat liv hpc 78w78 e		1.67gm *	P<.2
c	M f cd1 eat tba mix 78w78 e		52.3mg *	P<.005
419	M m cd1 eat liv hpc 78w78 e	.>	935.mg	P<.5
a	M m cd1 eat liv cho 78w78 e		no dre	P=1.
b	M m cd1 eat liv ade 78w78 e		no dre	P=1.
c	M m cd1 eat lun adc 78w78 e		no dre	P=1.
d	M m cd1 eat lun ade 78w78 e		no dre	P=1.
e	M m cd1 eat tba mix 78w78 e		no dre	P=1.
PROPRANOLOL.HCl				
420	M f cd1 eat lun ade 78w92 e	.>	2.12gm	P<.7 -
a	M f cd1 eat liv tum 78w92 e		no dre	P=1. -
b	M f cd1 eat tba ben 78w92 e		1.99gm	P<.7 -
c	M f cd1 eat tba mal 78w92 e		no dre	P=1. -
d	M f cd1 eat tba mix 78w92 e		no dre	P=1. -
421	M m cd1 eat liv car 78w92 e	.>	2.91gm	P<.6 -
a	M m cd1 eat liv ade 78w92 e		no dre	P=1. -
b	M m cd1 eat lun ade 78w92 e		no dre	P=1. -
c	M m cd1 eat lun car 78w92 e		no dre	P=1. -
d	M m cd1 eat tba mal 78w92 e		670.mg	P<.4 -
e	M m cd1 eat tba ben 78w92 e		no dre	P=1. -
f	M m cd1 eat tba mix 78w92 e		no dre	P=1. -
422	R f lev eat liv tum 18m24 e	.>	no dre	P=1. -
a	R f lev eat tba mix 18m24 e		144.mg	P<.7 -
b	R f lev eat tba ben 18m24 e		no dre	P=1. -
c	R f lev eat tba mal 18m24 e		342.mg	P<.4 -
423	R m lev eat liv hpa 18m24 e	.>	no dre	P=1. -
a	R m lev eat tba mix 18m24 e		no dre	P=1. -
b	R m lev eat tba ben 18m24 e		no dre	P=1. -
c	R m lev eat tba mal 18m24 e		no dre	P=1. -
PROPYLENE				
424	M f b6c inh TBA MXB 24m24	:>	no dre	P=1. -
a	M f b6c inh liv MXB 24m24		no dre	P=1.
b	M f b6c inh lun MXB 24m24		no dre	P=1.
425	M m b6c inh TBA MXB 24m24		no dre	P=1. -
a	M m b6c inh liv MXB 24m24		no dre	P=1.
b	M m b6c inh lun MXB 24m24		no dre	P=1.
426	R f f34 inh TBA MXB 24m24	:>	no dre	P=1. -
a	R f f34 inh liv MXB 24m24		20.5gm *	P<.2
427	R m f34 inh TBA MXB 24m24	:>	15.5gm *	P<1. -
a	R m f34 inh liv MXB 24m24		4.61gm *	P<.06

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology / Brkly Code
o-PHENYLPHENOL* (orthoxenol, Dowicide-1) 90-43-7**								
410	1646	137.mg	430.mg	0/24	250.mg	0/20	500.mg	23/24 (1.00gm 4/23) Hiraga;fctx,22,865-870;1984
a	1646	171.mg	568.mg	0/24	250.mg	0/20	500.mg	20/24 (1.00gm 2/23)
b	1646	245.mg	960.mg	0/24	250.mg	0/20	500.mg	15/24 (1.00gm 2/23)
c	1646	625.mg	26.3gm	0/24	250.mg	0/20	500.mg	5/24 (1.00gm 0/23)
PILDRALAZINE 56393-22-7								
411	1567	160.mg	n.s.s.	6/49	13.0mg	5/48	25.9mg	5/49 51.8mg 10/46 Della Porta;zkko,106,97-101;1983
a	1567	475.mg	n.s.s.	4/49	13.0mg	4/48	25.9mg	2/49 51.8mg 2/46
412	1567	171.mg	n.s.s.	11/50	10.8mg	0/48	21.6mg	8/50 43.2mg 10/49
a	1567	232.mg	n.s.s.	5/50	10.8mg	10/48	21.6mg	5/50 43.2mg 5/49
413	1567	72.9mg	n.s.s.	16/46	13.0mg	31/49	25.9mg	23/50 51.8mg 23/47
a	1567	765.mg	n.s.s.	0/46	13.0mg	1/49	25.9mg	0/50 51.8mg 0/47
b	1567	149.mg	n.s.s.	14/46	13.0mg	12/49	25.9mg	16/50 51.8mg 13/47
POLYBROMINATED BIPHENYL MIXTURE (Firemaster FF-1) 67774-32-1								
414	c53635	.250mg	1.66mg	0/13	14.2ug	0/19	42.5ug	2/15 .142mg 2/11 .425mg 3/17 1.45mg 7/8
a	c53635	.141mg	2.97mg	12/13	14.2ug	13/19	42.5ug	12/15 .142mg 9/11 .425mg 16/17 1.45mg 8/8
b	c53635	.180mg	1.22mg	0/13	14.2ug	2/19	42.5ug	2/15 .142mg 3/11 .425mg 4/17 1.45mg 8/8 liv:hpa,hpc,nnd.
c	c53635	.285mg	n.s.s.	0/13	14.2ug	1/19	42.5ug	1/15 .142mg 1/11 .425mg 3/17 1.45mg 1/8 lun:a/a,a/c.
415	c53635	.200mg	.899mg	12/25	14.2ug	8/27	42.5ug	8/24 .142mg 12/25 .425mg 15/23 1.47mg 21/22
a	c53635	.190mg	1.87mg	20/25	14.2ug	23/27	42.5ug	22/24 .142mg 23/25 .425mg 21/23 1.47mg 22/22
b	c53635	.147mg	.685mg	14/25	14.2ug	9/27	42.5ug	12/24 .142mg 14/25 .425mg 17/23 1.47mg 22/22 liv:hpa,hpc,nnd.
c	c53635	.471mg	n.s.s.	1/25	14.2ug	1/27	42.5ug	3/24 .142mg 4/25 .425mg 3/23 1.47mg 0/22 lun:a/a,a/c.
416	c53635	.323mg	1.22mg	0/20	14.4ug	2/21	43.2ug	0/21 .144mg 2/11 .432mg 7/19 1.51mg 16/20 liv:clc,hpc,nnd.
a	c53635	.505mg	3.47mg	0/20	14.4ug	2/21	43.2ug	0/21 .144mg 2/11 .432mg 5/19 1.51mg 8/20
b	c53635	.619mg	4.21mg	0/20	14.4ug	0/21	43.2ug	0/21 .144mg 0/11 .432mg 3/19 1.51mg 7/20
c	c53635	.800mg	6.40mg	0/20	14.4ug	0/21	43.2ug	0/21 .144mg 0/11 .432mg 0/19 1.51mg 7/20
d	c53635	.136mg	13.7mg	18/20	14.4ug	18/21	43.2ug	17/21 .144mg 11/11 .432mg 19/19 1.51mg 17/20
417	c53635	45.7ug	.491mg	0/33	15.1ug	2/39	46.2ug	1/40 .151mg 5/31 .478mg 10/33 1.73mg 10/32 liv:clc,hpc,nnd.
a	c53635	47.2ug	.608mg	0/33	15.1ug	0/39	46.2ug	1/40 .151mg 4/31 .478mg 4/33 1.73mg 1/32
b	c53635	.484mg	3.70mg	0/33	15.1ug	2/39	46.2ug	0/40 .151mg 1/31 .478mg 7/33 1.73mg 7/32
c	c53635	3.45mg	286.mg	0/33	15.1ug	0/39	46.2ug	0/40 .151mg 0/31 .478mg 0/33 1.73mg 2/32
d	c53635	29.8ug	.163mg	30/33	15.1ug	34/39	46.2ug	34/40 .151mg 24/31 .478mg 25/33 1.73mg 18/32
PRIMIDOLOL.HCl 40778-40-3								
418	1669	95.9mg	n.s.s.	8/100	12.5mg	5/50	25.0mg	2/49 50.0mg 7/50 Faccini;txcy,21,279-290;1981
a	1669	272.mg	n.s.s.	0/100	12.5mg	0/50	25.0mg	1/49 50.0mg 0/50
b	1669	271.mg	n.s.s.	0/100	12.5mg	0/50	25.0mg	0/49 50.0mg 1/50
c	1669	25.5mg	595.mg	24/100	12.5mg	19/50	25.0mg	17/49 50.0mg 24/50
419	1669	130.mg	n.s.s.	2/100	50.0mg	2/50		
a	1669	290.mg	n.s.s.	1/100	50.0mg	0/50		
b	1669	290.mg	n.s.s.	8/100	50.0mg	0/50		
c	1669	290.mg	n.s.s.	1/100	50.0mg	0/50		
d	1669	121.mg	n.s.s.	22/100	50.0mg	7/50		
e	1669	101.mg	n.s.s.	48/100	50.0mg	15/50		
PROPRANOLOL.HCl 525-66-6								
420	1635	267.mg	n.s.s.	3/60	84.8mg	4/57		Weikel;jcph,19,591-604;1979
a	1635	779.mg	n.s.s.	0/60	84.8mg	0/57		
b	1635	243.mg	n.s.s.	4/60	84.8mg	5/57		
c	1635	323.mg	n.s.s.	13/60	84.8mg	7/57		
d	1635	211.mg	n.s.s.	16/60	84.8mg	12/57		
421	1635	371.mg	n.s.s.	1/57	84.8mg	2/61		
a	1635	672.mg	n.s.s.	6/57	84.8mg	1/61		
b	1635	228.mg	n.s.s.	11/57	84.8mg	10/61		
c	1635	512.mg	n.s.s.	1/57	84.8mg	1/61		
d	1635	171.mg	n.s.s.	5/57	84.8mg	9/61		
e	1635	314.mg	n.s.s.	19/57	84.8mg	11/61		
f	1635	203.mg	n.s.s.	23/57	84.8mg	18/61		
422	1635	347.mg	n.s.s.	0/60	28.0mg	0/60		
a	1635	19.4mg	n.s.s.	44/60	28.0mg	46/60		
b	1635	33.5mg	n.s.s.	43/60	28.0mg	40/60		
c	1635	78.0mg	n.s.s.	5/60	28.0mg	8/60		
423	1635	347.mg	n.s.s.	1/60	28.0mg	0/60		
a	1635	39.0mg	n.s.s.	44/60	28.0mg	39/60		
b	1635	59.6mg	n.s.s.	41/60	28.0mg	32/60		
c	1635	76.7mg	n.s.s.	12/60	28.0mg	12/60		
PROPYLENE 115-07-1								
424	c50077	7.47gm	n.s.s.	31/50	2.65gm	35/50	5.31gm	39/50
a	c50077	15.3gm	n.s.s.	2/50	2.65gm	3/50	5.31gm	5/50 liv:hpa,hpc,nnd.
b	c50077	17.1gm	n.s.s.	6/50	2.65gm	4/50	5.31gm	7/50 lun:a/a,a/c.
425	c50077	12.7gm	n.s.s.	37/50	2.21gm	25/50	4.42gm	28/50
a	c50077	13.2gm	n.s.s.	14/50	2.21gm	11/50	4.42gm	14/50 liv:hpa,hpc,nnd.
b	c50077	25.7gm	n.s.s.	16/50	2.21gm	4/50	4.42gm	7/50 lun:a/a,a/c.
426	c50077	915.mg	n.s.s.	37/50	638.mg	42/50	1.28gm	40/50
a	c50077	5.05gm	n.s.s.	0/50	638.mg	0/50	1.28gm	2/50 liv:hpa,hpc,nnd.
427	c50077	704.mg	n.s.s.	36/50	447.mg	38/50	893.mg	41/50
a	c50077	1.99gm	n.s.s.	0/50	447.mg	4/50	893.mg	3/50 liv:hpa,hpc,nnd.

	Spe Strain Site Xpo+Xpt Sex Route Hist Notes	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10	TD50 2Tailpvl DR AuOp
1,2-PROPYLENE OXIDE***			
428	M f b6c inh --- MXA 24m24	: + :	863.mg / P<.003
a	M f b6c inh nas MXA 24m24		1.21gm / P<.002 c
b	M f b6c inh mgl MXA 24m24		1.26gm * P<.01
c	M f b6c inh lun a/a 24m24		588.mg * P<.02
d	M f b6c inh --- hes 24m24		1.61gm * P<.02
e	M f b6c inh --- hem 24m24		1.81gm / P<.05
f	M f b6c inh nas hem 24m24		2.02gm * P<.02
g	M f b6c inh mgl adq 24m24		2.77gm * P<.03
h	M f b6c inh TBA MXB 24m24		226.mg * P<.01
i	M f b6c inh liv MXB 24m24		979.mg * P<.2
j	M f b6c inh lun MXB 24m24		588.mg * P<.02
429	M m b6c inh nas MXA 24m24	: + :	732.mg / P<.0005c
a	M m b6c inh --- MXA 24m24		753.mg * P<.006
b	M m b6c inh nas hem 24m24		1.47gm * P<.005
c	M m b6c inh nas hes 24m24		1.61gm * P<.006
d	M m b6c inh TBA MXB 24m24		722.mg * P<.4
e	M m b6c inh liv MXB 24m24		no dre P=1.
f	M m b6c inh lun MXB 24m24		no dre P=1.
430	R f f34 inh MXA MXA 24m24	: ±	156.mg * P<.04
a	R f f34 inh nas ppa 24m24		732.mg * P<.04 a
b	R f f34 inh TBA MXB 24m24		124.mg * P<.4
c	R f f34 inh liv MXB 24m24		no dre P=1.
431	R m f34 inh nas ppa 24m24	: ±	826.mg * P<.1 a
a	R m f34 inh TBA MXB 24m24		220.mg * P<.8
b	R m f34 inh liv MXB 24m24		528.mg * P<.4
432	R m f3h inh adr phe 23m24 eis pool	. (+) .	35.1mg \ P<.002 +
a	R m f3h inh liv hpc 23m24 eis		2.96gm * P<.3
b	R m f3h inh liv nnd 23m24 eis		no dre P=1.
PROQUAZONE		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10	
433	M f cd1 eat liv hem 86w86	.>	48.7gm * P<.9 -
a	M f cd1 eat liv hms 86w86		no dre P=1. -
b	M f cd1 eat liv hpc 86w86		no dre P=1. -
c	M f cd1 eat lun a/a 86w86		no dre P=1. -
d	M f cd1 eat lun a/c 86w86		no dre P=1. -
434	M m cd1 eat liv hpc 86w86	.>	4.35gm * P<.6 -
a	M m cd1 eat lun a/a 86w86		5.45gm * P<.7 -
b	M m cd1 eat liv hem 86w86		14.0gm * P<.2 -
c	M m cd1 eat lun a/c 86w86		no dre P=1. -
PYRILAMINE MALEATE		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10	
435	R f f34 eat liv mix 26m31	. ±	175.mg P<.02 +
a	R f f34 eat liv nnd 26m31		266.mg P<.08
b	R f f34 eat liv hpc 26m31		880.mg P<.1 +
436	R f f34 wat liv nnd 26m31	.>	1.25gm P<.7
437	R m f34 eat liv hpc 26m31	. ±	704.mg P<.1 +
a	R m f34 eat liv mix 26m31		518.mg P<.5
b	R m f34 eat liv nnd 26m31		no dre P=1.
438	R m f34 wat liv nnd 26m31	.>	no dre P=1.
QUERCETIN***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10	
439	R f f34 eat tba mix 64w64 fg	.>	no dre P=1. -
440	R m f34 eat tba mix 64w64	.>	no dre P=1. -
QUERCETIN DIHYDRATE***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10	
441	R f f34 eat adr coa 77w77 e	.>	118.mg P<.3 -
442	R m f34 eat tba mix 77w77 e		noTD50 P<.6 -
D & C RED NO. 5***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10	
443	R f wal eat liv mix 52w91 er	. + .	233.mg P<.0005+
a	R f wal eat liv hpc 52w91 er		2.62gm P<.3 +
444	R f wal eat liv mix 91w91 er	<+	noTD50 P<.0005+
a	R f wal eat liv hpc 91w91 er		3.27gm P<.2 +
HC RED NO. 3*		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10	
445	M f b6c gav for sqp 24m24 s	: ±	#721.mg * P<.04
a	M f b6c gav TBA MXB 24m24 s		292.mg * P<.5
b	M f b6c gav liv MXB 24m24 s		no dre P=1.
c	M f b6c gav lun MXB 24m24 s		4.67gm * P<.9
446	M m b6c gav liv MXA 24m24	:>	427.mg / P<.2 e
a	M m b6c gav TBA MXB 24m24		no dre P=1.
b	M m b6c gav liv MXB 24m24		427.mg / P<.2
c	M m b6c gav lun MXB 24m24		1.75gm * P<.7
447	R f f34 gav TBA MXB 24m25	:>	4.87gm * P<.9 -
a	R f f34 gav liv MXB 24m25		no dre P=1.
448	R m f34 gav TBA MXB 24m25	:>	500.mg * P<.3 -
a	R m f34 gav liv MXB 24m25		1510.gm P<1.

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
1,2-PROPYLENE OXIDE*** (1,2-epoxypropane) 75-56-9									
428	c50099	360.mg	5.43gm	1/50	148.mg	1/50	296.mg	7/50	---:hem,hes.	S
a	c50099	451.mg	4.63gm	0/50	148.mg	0/50	296.mg	5/50	nas:hem,hes.	
b	c50099	475.mg	80.3gm	0/50	148.mg	3/50	296.mg	3/50	mgl:adc,adq.	S
c	c50099	243.mg	n.s.s.	4/50	148.mg	7/50	296.mg	6/50		S
d	c50099	522.mg	n.s.s.	0/50	148.mg	1/50	296.mg	3/50		S
e	c50099	554.mg	n.s.s.	1/50	148.mg	0/50	296.mg	4/50		S
f	c50099	606.mg	n.s.s.	0/50	148.mg	0/50	296.mg	3/50		S
g	c50099	732.mg	n.s.s.	0/50	148.mg	0/50	296.mg	3/50		S
h	c50099	107.mg	15.0gm	28/50	148.mg	35/50	296.mg	23/50		
i	c50099	320.mg	n.s.s.	3/50	148.mg	7/50	296.mg	3/50	liv:hpa,hpc,nnd.	
j	c50099	243.mg	n.s.s.	4/50	148.mg	7/50	296.mg	6/50	lun:a/a,a/c.	
429	c50099	355.mg	1.95gm	0/50	123.mg	0/50	247.mg	10/50	nas:hem,hes.	
a	c50099	342.mg	8.20gm	2/50	123.mg	2/50	247.mg	10/50	---:hem,hes.	S
b	c50099	558.mg	12.1gm	0/50	123.mg	0/50	247.mg	5/50		S
c	c50099	604.mg	15.1gm	0/50	123.mg	0/50	247.mg	5/50		S
d	c50099	173.mg	n.s.s.	29/50	123.mg	31/50	247.mg	27/50		
e	c50099	425.mg	n.s.s.	14/50	123.mg	16/50	247.mg	9/50	liv:hpa,hpc,nnd.	
f	c50099	469.mg	n.s.s.	15/50	123.mg	14/50	247.mg	8/50	lun:a/a,a/c.	
430	c50099	71.3mg	n.s.s.	3/50	35.2mg	12/50	70.4mg	10/50	cvu:esp; ute:esp,ess.	S
a	c50099	221.mg	n.s.s.	0/50	35.2mg	0/50	70.4mg	3/50		
b	c50099	32.8mg	n.s.s.	38/50	35.2mg	46/50	70.4mg	44/50		
c	c50099	1.01gm	n.s.s.	1/50	35.2mg	0/50	70.4mg	0/50	liv:hpa,hpc,nnd.	
431	c50099	202.mg	n.s.s.	0/50	24.7mg	0/50	49.3mg	2/50		
a	c50099	27.8mg	n.s.s.	40/50	24.7mg	41/50	49.3mg	45/50		
b	c50099	133.mg	n.s.s.	1/50	24.7mg	2/50	49.3mg	3/50	liv:hpa,hpc,nnd.	
432	1624	18.4mg	144.mg	8/78p	14.2mg	25/78	(42.4mg | 22/80)	Lynch;txap,76,69-84;1984	
a	1624	482.mg	n.s.s.	0/78p	14.2mg	0/78	42.4mg	1/76		
b	1624	509.mg	n.s.s.	2/78p	14.2mg	1/78	42.4mg	1/76		
PROQUAZONE (1-isopropyl-7-methyl-4-phenyl-2(1H)-quinazolinone) 22760-18-5										
433	1667	2.50gm	n.s.s.	1/50	60.0mg	0/50	180.mg	0/50	360.mg	1/50	Van Ryzin;dact,3,361-379;1980	
a	1667	2.88gm	n.s.s.	1/50	60.0mg	0/50	180.mg	1/50	360.mg	0/50		
b	1667	1.65gm	n.s.s.	0/50	60.0mg	3/50	180.mg	0/50	360.mg	1/50		
c	1667	866.mg	n.s.s.	4/50	60.0mg	6/50	180.mg	10/50	360.mg	3/50		
d	1667	284.mg	n.s.s.	12/50	60.0mg	3/50	(180.mg | 2/50 | 360.mg | 1/50)		
434	1667	762.mg	n.s.s.	4/50	60.0mg	2/50	180.mg	8/50	360.mg	4/50		
a	1667	666.mg	n.s.s.	5/50	60.0mg	6/50	180.mg	9/50	360.mg	6/50		
b	1667	2.28gm	n.s.s.	0/50	60.0mg	0/50	180.mg	0/50	360.mg	1/50		
c	1667	861.mg	n.s.s.	12/50	60.0mg	11/50	180.mg	7/50	360.mg	10/50		
PYRILAMINE MALEATE 59-33-6										
435	1644	70.5mg	n.s.s.	3/20	82.7mg	10/20			Lijinsky;fctx,22,27-30;1984	
a	1644	91.9mg	n.s.s.	3/20	82.7mg	8/20				
b	1644	216.mg	n.s.s.	0/20	82.7mg	2/20				
436	1644m	145.mg	n.s.s.	3/20	67.5mg	4/20				
437	1644	173.mg	n.s.s.	0/20	66.2mg	2/20				
a	1644	95.7mg	n.s.s.	5/20	66.2mg	7/20				
b	1644	138.mg	n.s.s.	5/20	66.2mg	5/20				
438	1644m	98.7mg	n.s.s.	5/20	47.3mg	5/20				
QUERCETIN*** 117-39-5										
439	1648	69.1mg	n.s.s.	0/10	50.0mg	1/11	100.mg	0/11	Stoewsand;jtxe,14,105-114;1984	
440	1648	59.8mg	n.s.s.	1/10	40.0mg	0/10	80.0mg	1/11		
QUERCETIN DIHYDRATE*** 6151-25-3										
441	1662	27.2mg	n.s.s.	1/16	50.0mg	3/15			Takanashi;jfds,5,55-60;1983	
442	1662	n.s.s.	n.s.s.	15/16	40.0mg	15/15				
D & C RED NO. 5*** (ponceau MX) 3761-53-3										
443	1730m	107.mg	641.mg	0/6	714.mg	12/15			Grasso;txcy,7,327-347;1977/pers.comm.	
a	1730m	643.mg	n.s.s.	0/6	714.mg	2/15				
444	1730n	n.s.s.	488.mg	0/6	1.25gm	11/11				
a	1730n	800.mg	n.s.s.	0/6	1.25gm	2/11				
HC RED NO. 3* 2871-01-4										
445	c54922	208.mg	n.s.s.	0/50	88.4mg	0/50	177.mg	3/50		S
a	c54922	67.0mg	n.s.s.	16/50	88.4mg	15/50	177.mg	18/50		
b	c54922	273.mg	n.s.s.	4/50	88.4mg	1/50	177.mg	2/50	liv:hpa,hpc,nnd.	
c	c54922	241.mg	n.s.s.	1/50	88.4mg	2/50	177.mg	1/50	lun:a/a,a/c.	
446	c54922	141.mg	n.s.s.	25/50	88.4mg	15/50	177.mg	35/50	liv:hpa,hpc.	
a	c54922	142.mg	n.s.s.	44/50	88.4mg	36/50	177.mg	42/50		
b	c54922	141.mg	n.s.s.	25/50	88.4mg	15/50	177.mg	35/50	liv:hpa,hpc,nnd.	
c	c54922	251.mg	n.s.s.	11/50	88.4mg	13/50	177.mg	13/50	lun:a/a,a/c.	
447	c54922	238.mg	n.s.s.	45/50	177.mg	44/50	354.mg	41/50		
a	c54922	n.s.s.	n.s.s.	0/50	177.mg	0/50	354.mg	0/50	liv:hpa,hpc,nnd.	
448	c54922	154.mg	n.s.s.	44/50	177.mg	38/50	356.mg	38/50		
a	c54922	1.18gm	n.s.s.	4/50	177.mg	1/50	356.mg	3/50	liv:hpa,hpc,nnd.	

	Spe Strain Site Xpo+Xpt Sex Route Hist Notes	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10	TD50 DR	2Tailpvl AuOp
RIPAZEPAM				
449	M f cd1 eat liv hpa 78w78 e	. ±	352.mg *	P<.02 +
a	M f cd1 eat lun car 78w78 e		1.03gm *	P<.2
b	M f cd1 eat lun ade 78w78 e		no dre	P=1.
c	M f cd1 eat tba ben 78w78 e		287.mg *	P<.04
d	M f cd1 eat tba mal 78w78 e		1.19gm *	P<.5
e	M f cd1 eat tba mix 78w78 e		219.gm \	P=1.
450	M m cd1 eat liv hpa 78w78 e	. + .	67.8mg *	P<.0005+
a	M m cd1 eat liv hpc 78w78 e		3.15gm *	P<.2
b	M m cd1 eat lun car 78w78 e		no dre	P=1.
c	M m cd1 eat tba mix 78w78 e		72.2mg *	P<.004
d	M m cd1 eat tba ben 78w78 e		79.4mg *	P<.002
e	M m cd1 eat tba mal 78w78 e		35.0mg \	P<.05
451	R f cdr eat liv hpc 24m24 e	. ±	2.77gm *	P<.05 -
a	R f cdr eat liv hpa 24m24 e		3.67gm *	P<.7 -
b	R f cdr eat tba mal 24m24 e		1.44gm *	P<.5 -
c	R f cdr eat tba ben 24m24 e		no dre	P=1. -
d	R f cdr eat tba mix 24m24 e		no dre	P=1. -
452	R m cdr eat pit ade 24m24 e	. + .	147.mg *	P<.004 -
a	R m cdr eat liv hpa 24m24 e		988.mg *	P<.2 -
b	R m cdr eat tba mix 24m24 e		89.7mg *	P<.04 -
c	R m cdr eat tba ben 24m24 e		106.mg *	P<.03 -
d	R m cdr eat tba mal 24m24 e		2.25gm *	P<.7 -
p-ROSANILINE.HCl***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
453	M f b6c eat liv MXA 24m24	: + :	20.3mg *	P<.0005
a	M f b6c eat MXB MXB 24m24		28.8mg *	P<.0005
b	M f b6c eat liv hpc 24m24		32.3mg *	P<.0005c
c	M f b6c eat liv hpa 24m24		35.9mg \	P<.0005
d	M f b6c eat --- MXA 24m24		62.2mg *	P<.0005e
e	M f b6c eat adr MXA 24m24		90.6mg *	P<.0005c
f	M f b6c eat --- mlp 24m24		151.mg \	P<.002 e
g	M f b6c eat lun MXA 24m24		302.mg *	P<.002
h	M f b6c eat hag MXA 24m24		316.mg /	P<.002
i	M f b6c eat lun a/a 24m24		326.mg *	P<.003
j	M f b6c eat --- mlh 24m24		380.mg *	P<.004 e
k	M f b6c eat hag ade 24m24		548.mg *	P<.01
l	M f b6c eat hag MXA 24m24		388.mg /	P<.02
m	M f b6c eat TBA MXB 24m24		23.4mg *	P<.0005
n	M f b6c eat liv MXB 24m24		20.3mg *	P<.0005
o	M f b6c eat lun MXB 24m24		302.mg *	P<.002
454	M m b6c eat liv hpc 24m24	: + :	127.mg *	P<.002 c
a	M m b6c eat liv MXA 24m24		116.mg *	P<.04
b	M m b6c eat --- mlm 24m24		610.mg *	P<.02
c	M m b6c eat TBA MXB 24m24		222.mg *	P<.4
d	M m b6c eat liv MXB 24m24		116.mg *	P<.04
e	M m b6c eat lun MXB 24m24		no dre	P=1.
455	R f f34 eat mgl MXA 24m24	: + :	25.4mg *	P<.0005e
a	R f f34 eat mgl fba 24m24		27.9mg *	P<.0005e
b	R f f34 eat MXB MXB 24m24		32.2mg *	P<.0005
c	R f f34 eat sub MXA 24m24		40.9mg *	P<.0005
d	R f f34 eat sub MXA 24m24		42.8mg *	P<.0005
e	R f f34 eat sub fib 24m24		44.5mg *	P<.0005c
f	R f f34 eat ute ess 24m24		133.mg *	P<.006
g	R f f34 eat thy MXA 24m24		154.mg *	P<.0005c
h	R f f34 eat zym can 24m24		190.mg *	P<.002 c
i	R f f34 eat thy fca 24m24		318.mg /	P<.007
j	R f f34 eat mgl MXA 24m24		156.mg *	P<.03 e
k	R f f34 eat liv MXA 24m24		189.mg *	P<.04
l	R f f34 eat mgl acn 24m24		232.mg *	P<.06 e
m	R f f34 eat TBA MXB 24m24		17.8mg *	P<.0005
n	R f f34 eat liv MXB 24m24		189.mg *	P<.04
456	R m f34 eat tes ict 24m24	: + :	15.6mg /	P<.0005
a	R m f34 eat MXB MXB 24m24		21.2mg /	P<.0005
b	R m f34 eat sub MXA 24m24		33.0mg /	P<.0005
c	R m f34 eat sub MXA 24m24		33.4mg /	P<.0005
d	R m f34 eat sub fib 24m24		35.3mg /	P<.0005c
e	R m f34 eat liv MXA 24m24		41.5mg /	P<.0005
f	R m f34 eat thy MXA 24m24		57.0mg /	P<.0005c
g	R m f34 eat liv nnd 24m24		62.2mg *	P<.0005
h	R m f34 eat thy fcc 24m24		73.9mg /	P<.0005c
i	R m f34 eat ski MXA 24m24		93.8mg /	P<.0005
j	R m f34 eat zym can 24m24		124.mg /	P<.0005c
k	R m f34 eat ski sqc 24m24		130.mg /	P<.0005c
l	R m f34 eat liv hpc 24m24		140.mg /	P<.0005c
m	R m f34 eat pni MXA 24m24		152.mg *	P<.006
n	R m f34 eat thy fca 24m24		176.mg /	P<.0005c

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
RIPAZEPAM (pyrazapon) 26308-28-1									
449	1602	142.mg n.s.s.	5/50	15.0mg	2/50	150.mg	11/50	Fitzgerald;faat,4,178-190;1984	
a	1602	252.mg n.s.s.	0/50	15.0mg	2/50	150.mg	3/50		
b	1602	633.mg n.s.s.	3/50	15.0mg	1/50	150.mg	1/50		
c	1602	111.mg n.s.s.	10/50	15.0mg	6/50	150.mg	16/50		
d	1602	214.mg n.s.s.	2/50	15.0mg	7/50	150.mg	6/50		
e	1602	17.8mg n.s.s.	13/50	15.0mg	13/50	(150.mg	2/50)		
450	1602	38.9mg 157.mg	10/50	15.0mg	15/50	150.mg	33/50		
a	1602	513.mg n.s.s.	0/50	15.0mg	0/50	150.mg	1/50		
b	1602	496.mg n.s.s.	3/50	15.0mg	6/50	150.mg	2/50		
c	1602	33.7mg 618.mg	24/50	15.0mg	31/50	150.mg	39/50		
d	1602	39.2mg 394.mg	21/50	15.0mg	23/50	150.mg	36/50		
e	1602	13.5mg n.s.s.	4/50	15.0mg	11/50	(150.mg	5/50)		
451	1602	683.mg n.s.s.	0/50	15.0mg	0/50	150.mg	2/50		
a	1602	429.mg n.s.s.	4/50	15.0mg	6/50	150.mg	6/50		
b	1602	301.mg n.s.s.	9/50	15.0mg	7/50	150.mg	11/50		
c	1602	74.0mg n.s.s.	45/50	15.0mg	43/50	150.mg	44/50		
d	1602	68.2mg n.s.s.	48/50	15.0mg	47/50	150.mg	46/50		
452	1602	69.5mg 1.14gm	20/50	15.0mg	28/50	150.mg	36/50		
a	1602	304.mg n.s.s.	5/50	15.0mg	4/50	150.mg	9/50		
b	1602	31.6mg n.s.s.	40/50	15.0mg	43/50	150.mg	47/50		
c	1602	41.3mg n.s.s.	36/50	15.0mg	40/50	150.mg	45/50		
d	1602	324.mg n.s.s.	7/50	15.0mg	10/50	150.mg	10/50		
p-ROSANILINE.HCl*** (p-magenta, C.I. Basic Red 9.HCl) 569-61-9									
453	c54739	13.5mg 32.3mg	5/50	63.8mg	35/50	128.mg	41/50	liv:hpa,hpc.	S
a	c54739	18.9mg 46.5mg	4/50	63.8mg	25/50	128.mg	37/50	adr:phe,phm; liv:hpc.	C
b	c54739	20.9mg 52.5mg	3/50	63.8mg	19/50	128.mg	37/50		
c	c54739	18.6mg 85.9mg	2/50	63.8mg	18/50	(128.mg	4/50)		S
d	c54739	33.7mg 179.mg	17/50	63.8mg	24/50	128.mg	25/50	---:mlh,mlm,mlp,mlu,mno.	
e	c54739	45.0mg 245.mg	1/50	63.8mg	8/50	128.mg	8/50	adr:phe,phm.	
f	c54739	51.6mg 810.mg	0/50	63.8mg	5/50	(128.mg	1/50)		
g	c54739	108.mg 1.35gm	0/50	63.8mg	2/50	128.mg	5/50	lun:a/a,a/c.	S
h	c54739	106.mg 1.58gm	0/50	63.8mg	0/50	128.mg	5/50	hag:adn,cyn.	S
i	c54739	111.mg 1.95gm	0/50	63.8mg	2/50	128.mg	4/50		S
j	c54739	163.mg 2.64gm	1/50	63.8mg	3/50	128.mg	8/50		
k	c54739	147.mg 45.2gm	0/50	63.8mg	0/50	128.mg	3/50		S
l	c54739	121.mg n.s.s.	1/50	63.8mg	0/50	128.mg	5/50	hag:adn,can,cyn.	S
m	c54739	14.7mg 44.0mg	31/50	63.8mg	50/50	128.mg	49/50		
n	c54739	13.5mg 32.3mg	5/50	63.8mg	35/50	128.mg	41/50	liv:hpa,hpc,nnd.	
o	c54739	108.mg 1.35gm	0/50	63.8mg	2/50	128.mg	5/50	lun:a/a,a/c.	
454	c54739	69.0mg 582.mg	10/50	58.9mg	20/50	118.mg	27/50		
a	c54739	50.1mg n.s.s.	29/50	58.9mg	37/50	118.mg	41/50	liv:hpa,hpc.	S
b	c54739	263.mg n.s.s.	0/50	58.9mg	3/50	118.mg	4/50		S
c	c54739	56.8mg n.s.s.	44/50	58.9mg	43/50	118.mg	46/50		
d	c54739	50.1mg n.s.s.	29/50	58.9mg	37/50	118.mg	41/50	liv:hpa,hpc,nnd.	
e	c54739	284.mg n.s.s.	11/50	58.9mg	7/50	118.mg	8/50	lun:a/a,a/c.	
455	c54739	14.1mg 83.6mg	23/50	24.6mg	32/50	49.3mg	32/50	mgl:acn,adn,fba.	
a	c54739	15.0mg 108.mg	22/50	24.6mg	31/50	49.3mg	29/50		
b	c54739	21.2mg 51.7mg	0/50	24.6mg	16/50	49.3mg	21/50	sub:fib; thy:fca,fcc; zym:can.	C
c	c54739	25.1mg 82.0mg	1/50	24.6mg	17/50	49.3mg	12/50	sub:fbs,fib,srn.	S
d	c54739	26.5mg 76.6mg	0/50	24.6mg	16/50	49.3mg	10/50	sub:fbs,fib.	S
e	c54739	27.2mg 80.7mg	0/50	24.6mg	15/50	49.3mg	10/50		
f	c54739	60.0mg 1.50gm	1/50	24.6mg	5/50	49.3mg	6/50		S
g	c54739	68.8mg 534.mg	0/50	24.6mg	2/50	49.3mg	6/50	thy:fca,fcc.	
h	c54739	86.5mg 651.mg	0/50	24.6mg	2/50	49.3mg	7/50		
i	c54739	108.mg 5.07gm	0/50	24.6mg	0/50	49.3mg	4/50		S
j	c54739	63.2mg n.s.s.	2/50	24.6mg	4/50	49.3mg	6/50	mgl:acn,adn.	
k	c54739	73.0mg n.s.s.	1/50	24.6mg	4/50	49.3mg	4/50	liv:hpc,nnd.	S
l	c54739	79.3mg n.s.s.	2/50	24.6mg	2/50	49.3mg	5/50		
m	c54739	10.1mg 57.5mg	41/50	24.6mg	50/50	49.3mg	48/50		
n	c54739	73.0mg n.s.s.	1/50	24.6mg	4/50	49.3mg	4/50	liv:hpa,hpc,nnd.	
456	c54739	9.57mg 33.0mg	43/50	39.2mg	46/50	79.2mg	37/50		S
a	c54739	14.8mg 32.0mg	3/50	39.2mg	26/50	79.2mg	40/50	liv:hpc; ski:sea,sqc,tri; sub:fib; thy:fca,fcc; zym:can.	C
b	c54739	20.6mg 59.7mg	3/50	39.2mg	22/50	79.2mg	16/50	sub:fbs,fib.	S
c	c54739	20.8mg 62.6mg	6/50	39.2mg	24/50	79.2mg	19/50	sub:fbs,fib,srn.	S
d	c54739	22.2mg 62.9mg	2/50	39.2mg	20/50	79.2mg	16/50		
e	c54739	24.0mg 89.4mg	5/50	39.2mg	15/50	79.2mg	14/50	liv:hpc,nnd.	S
f	c54739	34.9mg 97.5mg	0/50	39.2mg	5/50	79.2mg	25/50	thy:fca,fcc.	
g	c54739	31.0mg 246.mg	5/50	39.2mg	14/50	79.2mg	6/50		S
h	c54739	42.1mg 137.mg	0/50	39.2mg	5/50	79.2mg	18/50		
i	c54739	47.9mg 235.mg	2/50	39.2mg	2/50	79.2mg	14/50	ski:sqc,sqp.	S
j	c54739	61.6mg 314.mg	1/50	39.2mg	1/50	79.2mg	13/50		
k	c54739	61.7mg 317.mg	0/50	39.2mg	1/50	79.2mg	10/50		
l	c54739	65.7mg 357.mg	0/50	39.2mg	2/50	79.2mg	8/50		
m	c54739	62.5mg 2.26gm	2/50	39.2mg	5/50	79.2mg	4/50	pni:isa,isc.	S
n	c54739	78.3mg 477.mg	0/50	39.2mg	0/50	79.2mg	9/50		

	Spe Strain Site Xpo+Xpt Sex Route Hist Notes	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10	TD50 DR	2Tailpvl AuOp
o	R m f34 eat ski tri 24m24		221.mg /	P<.0005c
p	R m f34 eat lun s/a 24m24		281.mg *	P<.006
q	R m f34 eat ski sea 24m24		424.mg /	P<.003 c
r	R m f34 eat MXA MXA 24m24		184.mg *	P<.02
s	R m f34 eat pni isc 24m24		252.mg *	P<.02
t	R m f34 eat lun MXA 24m24		254.mg *	P<.02
u	R m f34 eat ski bcc 24m24		385.mg /	P<.03
v	R m f34 eat liv MXA 24m24		557.mg /	P<.02
w	R m f34 eat TBA MXB 24m24		15.7mg /	P<.0005
x	R m f34 eat liv MXB 24m24		41.5mg /	P<.0005
RUTIN SULFATE		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
457	R f sde gav liv hpc 24m32 e	.>	44.8gm *	P<1. -
458	R m sde gav liv hpc 24m31 e	.>	no dre	P=1. -
SACCHARIN, SODIUM***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
459	*R m aci eat ubl pam 52w52 r*	. + .	1.11gm	*P<.0005+*
a	R m aci eat ubl tcc 52w52 r		3.71gm	P<.05 +
460	R m f34 eat ubl tum 52w52 r	.>	no dre	P=1. -
461	*R m fis eat liv tum 24m24*		*no dre*	P=1.
a	R m fis eat ubl tum 24m24		no dre	P=1.
462	R m fis eat tes ict 77w98	. + .	613.mg	P<.003
a	R m fis eat liv tum 77w98		no dre	P=1.
b	R m fis eat ubl tum 77w98		no dre	P=1.
463	R m sda eat ubl tum 52w52 r	.>	no dre	P=1. -
464	R m wis eat ubl tum 52w52 r	.>	no dre	P=1. -
SAFROLE***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
465	M f cd1 eat liv hpt 52w69 ev	. + .	59.7mg *	P<.0005+
a	M f cd1 eat lun tum 52w69 ev		3.50gm *	P<1.
466	M f cd1 eat liv hpt 50w78 v	. + .	56.4mg	P<.0005+
a	M f cd1 eat lun ade 50w78 v		no dre	P=1.
467	M f cd1 eat liv hpt 51w86 v	. +.	41.5mg *	P<.0005+
a	M f cd1 eat --- ang 51w86 v		213.mg *	P<.0005
b	M f cd1 eat lun ade 51w86 v		no dre	P=1.
SALBUTAMOL		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
468	R f cdr eat meo ley 24m24 er	. + .	44.6mg *	P<.0005+
SOTALOL.HCl		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
469	M f cd1 eat lun ade 78w92 e	.>	3.50gm *	P<.2 -
a	M f cd1 eat lun car 78w92 e		24.5gm *	P=1. -
b	M f cd1 eat liv tum 78w92 e		no dre	P=1. -
c	M f cd1 eat tba ben 78w92 e		1.74gm *	P<.05 -
d	M f cd1 eat tba mix 78w92 e		1.91gm *	P<.3 -
e	M f cd1 eat tba mal 78w92 e		no dre	P=1. -
470	M m cd1 eat lun ade 78w92 e	.>	31.4gm *	P<1. -
a	*M m cd1 eat liv car 78w92 e*		*no dre*	P=1. -
b	M m cd1 eat liv ade 78w92 e		no dre	P=1. -
c	M m cd1 eat lun car 78w92 e		no dre	P=1. -
d	M m cd1 eat tba ben 78w92 e		no dre	P=1. -
e	M m cd1 eat tba mal 78w92 e		no dre	P=1. -
f	M m cd1 eat tba mix 78w92 e		no dre	P=1. -
471	R f lev eat liv cho 18m24 e	.>	12.6gm *	P<.3 -
a	R f lev eat tba mix 18m24 e		477.mg *	P<.4 -
b	R f lev eat tba mal 18m24 e		1.60gm *	P<.2 -
c	R f lev eat tba ben 18m24 e		no dre	P=1. -
472	R m lev eat liv hpc 18m24 e	.>	12.4gm *	P<.3 -
a	R m lev eat liv hpa 18m24 e		309.gm *	P<1. -
b	R m lev eat tba mix 18m24 e		796.mg *	P<.6 -
c	R m lev eat tba mal 18m24 e		2.27gm *	P<.5 -
d	R m lev eat tba ben 18m24 e		no dre	P=1. -
STYRENE OXIDE		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
473	R f sda gav for mix 12m36 er	. + .	96.5mg *	P<.0005+
a	R f sda gav for sqc 12m36 er		102.mg *	P<.0005+
b	R f sda gav for sqn 12m36 er		129.mg *	P<.0005+
c	R f sda gav for sqi 12m36 er		301.mg *	P<.0005+
d	R f sda gav for ben 12m36 er		503.mg *	P<.009 +
474	R m sda gav for sqc 12m36 er	. + .	63.0mg \	P<.0005+
a	R m sda gav for mix 12m36 er		99.6mg *	P<.0005+
b	R m sda gav for sqn 12m36 er		140.mg *	P<.0005+
c	*R m sda gav for sqi 12m36 er*		*267.mg* *	*P<.004* +
d	R m sda gav for ben 12m36 er		354.mg *	P<.003 +

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc					Citation or Pathology	Brkly Code
o	c54739	90.5mg	711.mg	0/50	39.2mg	0/50	79.2mg	7/50						
p	c54739	98.7mg	2.79gm	0/50	39.2mg	3/50	79.2mg	3/50						S
q	c54739	157.mg	2.29gm	0/50	39.2mg	0/50	79.2mg	5/50						
r	c54739	70.1mg	42.6gm	1/50	39.2mg	5/50	79.2mg	3/50					bod:men; mls:men; mul:men; tnv:men,msm.	S
s	c54739	85.2mg	n.s.s.	0/50	39.2mg	3/50	79.2mg	1/50						S
t	c54739	90.9mg	n.s.s.	1/50	39.2mg	3/50	79.2mg	4/50					lun:a/a,a/c.	S
u	c54739	116.mg	n.s.s.	1/50	39.2mg	0/50	79.2mg	4/50						S
v	c54739	162.mg	n.s.s.	0/50	39.2mg	0/50	79.2mg	3/50					liv:bda,bdc.	S
w	c54739	9.99mg	29.7mg	41/50	39.2mg	47/50	79.2mg	45/50						
x	c54739	24.0mg	89.4mg	5/50	39.2mg	15/50	79.2mg	14/50					liv:hpa,hpc,nnd.	
RUTIN SULFATE 12768-44-4														
457	1604	480.mg	n.s.s.	0/12	3.48mg	0/12	8.75mg	0/12	23.0mg	1/12	65.4mg	1/12	162.mg 0/12 Nabs;clet,23,103-108;1984	
458	1604	8.95mg	n.s.s.	1/12	3.48mg	0/12	9.14mg	0/12	24.7mg	0/12	65.4mg	0/12	167.mg 0/12	
SACCHARIN, SODIUM*** 128-44-9														
459	1537	523.mg	3.41gm	0/30	2.00gm	9/34							Fukushima;gann,74,8-20;1983	
a	1537	1.12gm	n.s.s.	0/30	2.00gm	3/34								
460	1537	2.58gm	n.s.s.	0/25	2.00gm	0/25								
461	1574	8.24gm	n.s.s.	0/30	2.00gm	0/20							Murasaki;carc,4,97-99;1983	
a	1574	8.24gm	n.s.s.	0/30	2.00gm	0/20								
462	1657	232.mg	4.71gm	22/42	1.57gm	18/20							Cohen;canr,39,1207-1217;1979	
a	1657	5.75gm	n.s.s.	0/42	1.57gm	0/20								
b	1657	5.75gm	n.s.s.	0/42	1.57gm	0/20								
463	1537	2.58gm	n.s.s.	0/25	2.00gm	0/25							Fukushima;gann,74,8-20;1983	
464	1537	2.58gm	n.s.s.	0/25	2.00gm	0/25								
SAFROLE*** 94-59-7														
465	1581	39.3mg	95.8mg	0/32	125.mg	13/28	241.mg	24/34					Boberg;canr,43,5163-5173;1983	
a	1581	571.mg	n.s.s.	0/32	125.mg	1/28	241.mg	0/34						
466	1582m	32.3mg	108.mg	0/30	176.mg	21/30							Miller;canr,43,1124-1134;1983	
a	1582m	370.mg	n.s.s.	1/30	176.mg	1/30								
467	1582n	30.2mg	58.5mg	0/50	80.7mg	34/50	161.mg	39/50						
a	1582n	130.mg	389.mg	0/50	80.7mg	7/50	161.mg	16/50						
b	1582n	1.09gm	n.s.s.	2/50	80.7mg	2/50	161.mg	0/50						
SALBUTAMOL 18559-94-9														
468	1734	24.8mg	92.0mg	0/105	2.00mg	0/55	20.0mg	16/55					Jack;txcy,27,315-320;1983	
SOTALOL.HCl 959-24-0														
469	1635	1.16gm	n.s.s.	3/60	254.mg	6/60	509.mg	7/60					Weikel;jcph,19,591-604;1979	
a	1635	3.99gm	n.s.s.	0/60	254.mg	1/60	509.mg	0/60						
b	1635	1.64gm	n.s.s.	0/60	254.mg	0/60	509.mg	0/60						
c	1635	752.mg	n.s.s.	4/60	254.mg	11/60	509.mg	11/60						
d	1635	589.mg	n.s.s.	16/60	254.mg	18/60	509.mg	22/60						
e	1635	1.33gm	n.s.s.	13/60	254.mg	9/60	509.mg	12/60						
470	1635	1.07gm	n.s.s.	11/57	254.mg	12/57	509.mg	12/60						
a	1635	4.45gm	n.s.s.	1/57	254.mg	0/57	509.mg	1/60						
b	1635	4.33gm	n.s.s.	6/57	254.mg	1/57	509.mg	2/60						
c	1635	1.59gm	n.s.s.	1/57	254.mg	0/57	509.mg	0/60						
d	1635	1.60gm	n.s.s.	19/57	254.mg	14/57	509.mg	13/60						
e	1635	1.94gm	n.s.s.	5/57	254.mg	4/57	509.mg	5/60						
f	1635	1.47gm	n.s.s.	23/57	254.mg	17/57	509.mg	16/60						
471	1635	2.05gm	n.s.s.	0/60	102.mg	0/60	206.mg	1/60						
a	1635	118.mg	n.s.s.	44/60	102.mg	47/60	206.mg	48/60						
b	1635	535.mg	n.s.s.	5/60	102.mg	6/60	206.mg	10/60						
c	1635	186.mg	n.s.s.	43/60	102.mg	43/60	206.mg	43/60						
472	1635	2.03gm	n.s.s.	0/60	102.mg	0/60	206.mg	1/59						
a	1635	1.53gm	n.s.s.	1/60	102.mg	2/60	206.mg	1/59						
b	1635	142.mg	n.s.s.	44/60	102.mg	43/60	206.mg	46/59						
c	1635	468.mg	n.s.s.	12/60	102.mg	10/60	206.mg	15/59						
d	1635	224.mg	n.s.s.	41/60	102.mg	36/60	206.mg	40/59						
STYRENE OXIDE 96-09-3														
473	1702	60.6mg	167.mg	0/40	10.7mg	7/37	53.6mg	21/38					Maltoni;amet,2,97-110;1981	
a	1702	63.7mg	180.mg	0/40	10.7mg	7/37	53.6mg	20/38						
b	1702	78.0mg	264.mg	0/40	10.7mg	7/37	53.6mg	16/38						
c	1702	151.mg	755.mg	0/40	10.7mg	1/37	53.6mg	10/38						
d	1702	217.mg	19.7gm	0/40	10.7mg	2/37	53.6mg	5/38						
474	1702	29.6mg	184.mg	0/39	10.7mg	9/39	(53.6mg	16/39)						
a	1702	63.2mg	194.mg	0/39	10.7mg	10/39	53.6mg	19/39						
b	1702	84.3mg	284.mg	0/39	10.7mg	6/39	53.6mg	16/39						
c	1702	141.mg	2.30gm	0/39	10.7mg	5/39	53.6mg	8/39						
d	1702	172.mg	2.23gm	0/39	10.7mg	3/39	53.6mg	7/39						

	Spe Strain Site Xpo+Xpt Sex Route Hist Notes	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10	TD50 DR	2Tailpvl AuDp
TELONE II*				
475	M f b6c gav MXB MXB 24m25	: + :	36.3mg *	P<.0005
a	M f b6c gav ubl tcc 24m25		49.6mg *	P<.0005c
b	M f b6c gav lun a/a 24m25		149.mg *	P<.0005c
c	M f b6c gav liv MXA 24m25		89.3mg \	P<.02
d	M f b6c gav lun MXA 24m25		182.mg *	P<.03
e	M f b6c gav liv hpa 24m25		215.mg *	P<.03
f	M f b6c gav sto MXA 24m25		344.mg *	P<.02 c
g	M f b6c gav TBA MXB 24m25		34.9mg *	P<.002
h	M f b6c gav liv MXB 24m25		89.3mg \	P<.02
i	M f b6c gav lun MXB 24m25		182.mg *	P<.03
476	M m b6c gav TBA MXB 24m24 s	:>	309.mg *	P<.9
a	M m b6c gav liv MXB 24m24 s		1.93gm *	P<1.
b	M m b6c gav lun MXB 24m24 s		127.mg *	P<.4
477	R f f34 gav thy MXA 24m25	: ±	137.mg *	P<.03
a	R f f34 gav sto sqp 24m25		176.mg *	P<.05 a
b	R f f34 gav TBA MXB 24m25		no dre	P=1.
c	R f f34 gav liv MXB 24m25		168.mg *	P<.5
478	R m f34 gav MXB MXB 24m25	: + :	33.2mg *	P<.0005
a	*R m f34 gav MXA MXA 24m25*		*64.1mg /*	*P<.0005c*
b	R m f34 gav liv MXA 24m25		68.0mg *	P<.01
c	R m f34 gav MXA MXA 24m25		97.0mg *	P<.006 c
d	R m f34 gav liv nnd 24m25		76.0mg *	P<.02 c
e	R m f34 gav sto sqc 24m25		213.mg *	P<.02 c
f	R m f34 gav TBA MXB 24m25		no dre	P=1.
g	R m f34 gav liv MXB 24m25		68.0mg *	P<.01
TERBUTALINE		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
479	R f cdr eat meo ley 24m24 erv	. + .	410.mg *	P<.0005+
1,1,1,2-TETRACHLOROETHANE		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
480	M f b6c gav liv MXA 24m24 as	: + :	175.mg /	P<.0005c
a	M f b6c gav liv hpa 24m24 as		254.mg /	P<.0005c
b	M f b6c gav liv hpc 24m24 as		640.mg *	P<.0005c
c	M f b6c gav TBA MXB 24m24 as		110.mg /	P<.0005
d	M f b6c gav liv MXB 24m24 as		175.mg /	P<.0005
e	M f b6c gav lun MXB 24m24 as		1.82gm *	P<.07
481	M m b6c gav liv MXA 24m24 as	: + :	124.mg /	P<.0005
a	M m b6c gav liv hpa 24m24 as		190.mg /	P<.0005c
b	M m b6c gav TBA MXB 24m24 as		97.9mg /	P<.0005
c	M m b6c gav liv MXB 24m24 as		124.mg /	P<.0005
d	M m b6c gav lun MXB 24m24 as		1.33gm /	P<.3
482	R f f34 gav mgl fbs 24m24 s	: ±	#170.mg \	P<.04 -
a	R f f34 gav TBA MXB 24m24 s		no dre	P=1.
b	R f f34 gav liv MXB 24m24 s		3.98gm *	P<.5
483	R m f34 gav MXA MXA 24m24 s	: ±	#842.mg *	P<.03 -
a	R m f34 gav liv MXA 24m24 s		1.13gm *	P<.04
b	R m f34 gav TBA MXB 24m24 s		464.mg *	P<.4
c	*R m f34 gav liv MXB 24m24 s*		*1.13gm* *	*P<.04*
TETRACHLOROETHYLENE***		100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
484	M f b6c inh liv MXA 24m24	:+ :	188.mg /	P<.0005
a	M f b6c inh liv hpc 24m24		200.mg /	P<.0005c
b	M f b6c inh TBA MXB 24m24		211.mg *	P<.0005
c	M f b6c inh liv MXB 24m24		188.mg /	P<.0005
d	M f b6c inh lun MXB 24m24		no dre	P=1.
485	M m b6c inh liv hpc 24m24	: + :	162.mg \	P<.0005
a	M m b6c inh liv MXA 24m24		190.mg *	P<.0005c
b	M m b6c inh liv hpa 24m24		668.mg *	P<.04
c	M m b6c inh MXA MXA 24m24		681.mg \	P<.05
d	M m b6c inh TBA MXB 24m24		225.mg *	P<.003
e	M m b6c inh liv MXB 24m24		190.mg *	P<.0005
f	M m b6c inh lun MXB 24m24		6.05gm *	P<.8
486	R f f34 inh MXA MXA 24m24	:>	287.mg *	P<.2 a
a	R f f34 inh TBA MXB 24m24		869.mg *	P<.8
b	R f f34 inh liv MXB 24m24		no dre	P=1.
487	R m f34 inh MXB MXB 24m24	: + :	90.8mg *	P<.007
a	R m f34 inh tes ict 24m24		68.6mg *	P<.02
b	R m f34 inh MXA MXA 24m24		101.mg *	P<.02 c
c	R m f34 inh kid MXA 24m24		504.mg *	P<.07 c
d	R m f34 inh TBA MXB 24m24		77.7mg *	P<.04
e	R m f34 inh liv MXB 24m24		368.mg *	P<.2
*TETRAMETHYLTHIURAM DISULFIDE****		*100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10*		
488	R f f34 eat liv nnd 24m30 ev	.>	97.3mg	P<.2
489	R m f34 eat liv nnd 24m30 ev	.>	374.mg	P<.7
a	R m f34 eat liv mix 24m30 ev		no dre	P=1.
b	*R m f34 eat liv car 24m30 ev*		*no dre*	*P=1.*

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
TELONE II* (1,3-dichloropropene) 542-75-6										
475	c03985	24.5mg	57.1mg	0/50	20.8mg	12/50	41.7mg	26/50	lun:a/a; sto:sqc,sqp; ubl:tcc.	C
a	c03985	31.8mg	83.7mg	0/50	20.8mg	8/50	41.7mg	21/50		
b	c03985	74.7mg	446.mg	0/50	20.8mg	3/50	41.7mg	8/50		
c	c03985	37.3mg	n.s.s.	1/50	20.8mg	8/50	(41.7mg	3/50)	liv:hpa,hpc.	S
d	c03985	77.8mg	n.s.s.	2/50	20.8mg	4/50	41.7mg	8/50	lun:a/a,a/c.	S
e	c03985	97.3mg	n.s.s.	0/50	20.8mg	5/50	41.7mg	3/50		S
f	c03985	130.mg	n.s.s.	0/50	20.8mg	1/50	41.7mg	4/50	sto:sqc,sqp.	
g	c03985	19.3mg	140.mg	16/50	20.8mg	33/50	41.7mg	34/50		
h	c03985	37.3mg	n.s.s.	1/50	20.8mg	8/50	(41.7mg	3/50)	liv:hpa,hpc,nnd.	
i	c03985	77.8mg	n.s.s.	2/50	20.8mg	4/50	41.7mg	8/50	lun:a/a,a/c.	
476	c03985	26.7mg	n.s.s.	8/50	21.2mg	28/50	42.2mg	30/50		
a	c03985	63.6mg	n.s.s.	5/50	21.2mg	7/50	42.2mg	13/50	liv:hpa,hpc,nnd.	
b	c03985	37.2mg	n.s.s.	1/50	21.2mg	13/50	42.2mg	12/50	lun:a/a,a/c.	
477	c03985	55.8mg	n.s.s.	0/52	10.4mg	2/52	21.0mg	4/52	thy:fca,fcc.	S
a	c03985	66.3mg	n.s.s.	0/52	10.4mg	2/52	21.0mg	3/52		
b	c03985	17.6mg	n.s.s.	45/52	10.4mg	44/52	21.0mg	44/52		
c	c03985	39.0mg	n.s.s.	6/52	10.4mg	6/52	21.0mg	10/52	liv:hpa,hpc,nnd.	
478	c03985	19.3mg	85.7mg	2/52	10.5mg	7/52	21.0mg	19/52	for:sqp; liv:nnd; sto:sqc,sqp.	C
a	c03985	32.9mg	217.mg	1/52	10.5mg	1/52	21.0mg	13/52	for:sqp; sto:sqc,sqp.	
b	c03985	32.9mg	4.91gm	1/52	10.5mg	6/52	21.0mg	8/52	liv:hpc,nnd.	S
c	c03985	43.9mg	1.16gm	1/52	10.5mg	1/52	21.0mg	9/52	for:sqp; sto:sqp.	
d	c03985	35.1mg	n.s.s.	1/52	10.5mg	6/52	21.0mg	7/52		
e	c03985	73.6mg	n.s.s.	0/52	10.5mg	0/52	21.0mg	4/52		
f	c03985	17.1mg	n.s.s.	44/52	10.5mg	39/52	21.0mg	41/52		
g	c03985	32.9mg	4.91gm	1/52	10.5mg	6/52	21.0mg	8/52	liv:hpa,hpc,nnd.	
TERBUTALINE 23031-25-6										
479	1734	186.mg	1.33gm	0/105	8.42mg	1/55	84.2mg	7/55	Jack;txcy,27,315-320;1983	
1,1,1,2-TETRACHLOROETHANE 630-20-6										
480	c52459	108.mg	316.mg	5/50	177.mg	13/50	357.mg	30/50	liv:hpa,hpc.	
a	c52459	145.mg	517.mg	4/50	177.mg	8/50	357.mg	24/50		
b	c52459	275.mg	2.68gm	1/50	177.mg	5/50	357.mg	6/50		
c	c52459	66.5mg	225.mg	25/50	177.mg	31/50	357.mg	30/50		
d	c52459	108.mg	316.mg	5/50	177.mg	13/50	357.mg	30/50	liv:hpa,hpc,nnd.	
e	c52459	447.mg	n.s.s.	0/50	177.mg	2/50	357.mg	0/50	lun:a/a,a/c.	
481	c52459	75.3mg	255.mg	18/50	177.mg	27/50	357.mg	27/50	liv:hpa,hpc.	S
a	c52459	112.mg	391.mg	6/50	177.mg	14/50	357.mg	21/50		
b	c52459	58.4mg	215.mg	28/50	177.mg	36/50	357.mg	27/50		
c	c52459	75.3mg	255.mg	18/50	177.mg	27/50	357.mg	27/50	liv:hpa,hpc,nnd.	
d	c52459	334.mg	n.s.s.	6/50	177.mg	5/50	357.mg	3/50	lun:a/a,a/c.	
482	c52459	68.8mg	n.s.s.	6/50	88.4mg	15/50	(177.mg	7/50)		S
a	c52459	194.mg	n.s.s.	33/50	88.4mg	31/50	177.mg	21/50		
b	c52459	601.mg	n.s.s.	1/50	88.4mg	0/50	177.mg	2/50	liv:hpa,hpc,nnd.	
483	c52459	337.mg	n.s.s.	0/50	88.4mg	3/50	177.mg	3/50	mul:msm; per:men; tnv:men.	S
a	c52459	385.mg	n.s.s.	0/50	88.4mg	1/50	177.mg	3/50	liv:hpa,hpc,nnd.	S
b	c52459	115.mg	n.s.s.	25/50	88.4mg	19/50	177.mg	26/50		
c	c52459	385.mg	n.s.s.	0/50	88.4mg	1/50	177.mg	3/50	liv:hpa,hpc,nnd.	
TETRACHLOROETHYLENE*** (perchloroethylene) 127-18-4										
484	c04580	127.mg	314.mg	4/50	211.mg	17/50	422.mg	38/50	liv:hpa,hpc.	S
a	c04580	137.mg	313.mg	1/50	211.mg	13/50	422.mg	36/50		
b	c04580	119.mg	712.mg	27/50	211.mg	35/50	422.mg	43/50		
c	c04580	127.mg	314.mg	4/50	211.mg	17/50	422.mg	38/50	liv:hpa,hpc,nnd.	
d	c04580	1.20gm	n.s.s.	6/50	211.mg	3/50	422.mg	3/50	lun:a/a,a/c.	
485	c04580	90.4mg	407.mg	7/50	176.mg	25/50	(352.mg	26/50)		S
a	c04580	115.mg	459.mg	17/50	176.mg	31/50	352.mg	41/50	liv:hpa,hpc.	
b	c04580	283.mg	n.s.s.	12/50	176.mg	8/50	352.mg	19/50		S
c	c04580	234.mg	n.s.s.	3/50	176.mg	7/50	(352.mg	3/50)	mln:mno; mul:mno; spl:mno; sub:mno.	S
d	c04580	119.mg	1.30gm	29/50	176.mg	38/50	352.mg	43/50		
e	c04580	115.mg	459.mg	17/50	176.mg	31/50	352.mg	41/50	liv:hpa,hpc,nnd.	
f	c04580	706.mg	n.s.s.	6/50	176.mg	6/50	352.mg	5/50	lun:a/a,a/c.	
486	c04580	110.mg	n.s.s.	18/50	101.mg	30/50	201.mg	29/50	mul:mnl; spl:mnl.	
a	c04580	101.mg	n.s.s.	42/50	101.mg	45/50	201.mg	45/50		
b	c04580	706.mg	n.s.s.	2/50	101.mg	0/50	201.mg	2/50	liv:hpa,hpc,nnd.	
487	c04580	44.4mg	1.34gm	28/50	70.4mg	37/50	141.mg	39/50	kid:tla,uac; liv:mnl; mul:mnl; spl:mnl.	C
a	c04580	31.7mg	n.s.s.	35/50	70.4mg	39/50	141.mg	41/50		S
b	c04580	47.4mg	n.s.s.	28/50	70.4mg	37/50	141.mg	37/50	liv:mnl; mul:mnl; spl:mnl.	
c	c04580	173.mg	n.s.s.	1/50	70.4mg	3/50	141.mg	4/50	kid:tla,uac.	
d	c04580	33.7mg	n.s.s.	46/50	70.4mg	48/50	141.mg	50/50		
e	c04580	112.mg	n.s.s.	4/50	70.4mg	7/50	141.mg	5/50	liv:hpa,hpc,nnd.	
TETRAMETHYLTHIURAM DISULFIDE*** (TMTD, thiram) 137-26-8										
488	1645	28.8mg	n.s.s.	4/24	20.3mg	8/24			Lijinsky;jtxe,13,609-614;1984	
489	1645	46.3mg	n.s.s.	2/24	16.2mg	3/24				
a	1645	51.1mg	n.s.s.	3/24	16.2mg	3/24				
b	1645	125.mg	n.s.s.	1/24	16.2mg	0/24				

	Spe Strain Sex	Site Route	Xpo+Xpt Hist	Notes	100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10	TD50 DR	2Tailpvl AuOp
THIOSEMICARBAZIDE***							
490	M f swa	wat liv	hpt 29m29	aes	.>	no dre	P=1. -
a	M f swa	wat lun	tum 29m29	aes		no dre	P=1. -
491	M m swa	wat liv	hpt 27m28	aes	.>	no dre	P=1. -
a	M m swa	wat lun	tum 27m28	aes		no dre	P=1. -
DL-alpha-TOCOPHERYL ACETATE					100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
492	R f cdr	eat liv	tum 52w52	ek	.>	no dre	P=1. -
493	R f cdr	eat liv	tum 24m24	e		no dre	P=1. -
a	R f cdr	eat tba	mix 24m24	e		no dre	P=1. -
b	R f cdr	eat tba	mal 24m24	e		no dre	P=1. -
494	R m cdr	eat liv	tum 52w52	ek	.>	no dre	P=1. -
495	R m cdr	eat liv	tum 24m24	e		no dre	P=1. -
a	R m cdr	eat tba	mix 24m24	e		67.8gm	P<1. -
b	R m cdr	eat tba	mal 24m24	e		67.8gm	P<.9 -
TOLUENE					100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
496	R f f34	inh liv	mix 25m25	e	.>	1.76gm	P<.2 -
497	R m f34	inh liv	mix 25m25	e	.>	1.21gm	P<.4 -
*TRICHLOROETHYLENE****					*100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10*		
498	M f icm	inh lun	mix 24m25	e	. ±	3.37gm *	P<.07
a	M f icm	inh lun	adc 24m25	e		3.38gm *	P<.02 +
b	M f icm	inh liv	ade 24m25	e		42.3gm *	P<.2
c	M f icm	inh tba	mix 24m25	e		1.90gm *	P<.08
499	R f cdr	inh mgl	fba 24m25	e	.>	982.mg *	P<.2
a	R f cdr	inh liv	mix 24m25	e		12.3gm *	P<.6
b	R f cdr	inh tba	mix 24m25	e		no dre	P=1.
TRIS(2,3-DIBROMOPROPYL)PHOSPHATE***					..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
500	R m f34	gav col	pla 52w52	ekr	. + .	13.4mg	P<.006 +
a	R m f34	gav kid	adc 52w52	ekr		54.8mg	P<.2 +
b	R m f34	gav liv	tum 52w52	ekr		no dre	P=1.
TRIS(2-ETHYLHEXYL)PHOSPHATE					100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
501	M f b6c	gav liv	hpc 24m24		: +	2.56gm *	P<.005 a
a	M f b6c	gav liv	MXA 24m24			2.22gm *	P<.05
b	M f b6c	gav TBA	MXB 24m24			no dre	P=1.
c	M f b6c	gav liv	MXB 24m24			2.22gm *	P<.05
d	M f b6c	gav lun	MXB 24m24			13.7gm *	P<.6
502	M m b6c	gav TBA	MXB 24m24		:>	no dre	P=1. -
a	M m b6c	gav liv	MXB 24m24			9.00gm *	P<.9
b	M m b6c	gav lun	MXB 24m24			no dre	P=1.
503	R f f34	gav TBA	MXB 24m24		:>	230.gm *	P<1. -
a	R f f34	gav liv	MXB 24m24			no dre	P=1.
504	R m f34	gav adr	phe 24m24		: +	5.29gm *	P<.002 e
a	*R m f34*	*gav adr*	*MXA 24m24*			*5.29gm* *	*P<.002 e*
b	R m f34	gav MXA	MXA 24m24			16.7gm *	P<.05
c	R m f34	gav MXA	MXA 24m24			28.0gm *	P<.05
d	R m f34	gav TBA	MXB 24m24			14.2gm *	P<.7
e	R m f34	gav liv	MXB 24m24			no dre	P=1.
DL-TRYPTOPHAN					100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
505	R m fis	eat liv	tum 98w98		.>	no dre	P=1. -
a	R m fis	eat ubl	tum 98w98			no dre	P=1. -
L-TRYPTOPHAN***					100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
506	R m fis	eat liv	tum 24m24		.>	no dre	P=1.
a	R m fis	eat ubl	tum 24m24			no dre	P=1.
VINYL ACETATE					100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
507	*R f f34*	*wat thy*	*cca 23m30*		. + .	*420.mg* *	*P<.006* +
a	R f f34	wat liv	nnd 23m30			488.mg *	P<.003 +
b	R f f34	wat ute	adc 23m30			494.mg *	P<.006 +
c	R f f34	wat thy	ccr 23m30			25.5gm *	P<1. +
d	R f f34	wat tba	mix 23m30			no dre	P=1.
508	R m f34	wat liv	nnd 23m30		. ±	132.mg \	P<.02 +
a	R m f34	wat thy	ccr 23m30			no dre	P=1. +
b	R m f34	wat tba	mix 23m30			57.7mg *	P<.3
VINYL CHLORIDE***					100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10		
509	H f syg	inh mgl	car 6m24	es	. + .	32.3mg	P<.0005+
a	H f syg	inh sto	ade 6m24	es		47.2mg	P<.0005+
b	H f syg	inh ---	hes 6m24	es		78.6mg	P<.0005+
510	H f syg	inh mgl	car 12m24	es	. + .	27.7mg	P<.0005+
a	H f syg	inh ski	car 12m24	es		121.mg	P<.0005+
b	H f syg	inh ---	hes 12m24	es		314.mg	P<.002 +
c	H f syg	inh sto	ade 12m24	es		1.01gm	P<.5 +

RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc			Citation or Pathology / Brkly Code
THIOSEMICARBAZIDE* (thiocarbamylhydrazine) 79-19-6**										
490	1675	38.4mg	n.s.s.	1/15	31.2mg	0/14	62.4mg	0/3		Toth;faat,2,173-176;1982/1980
a	1675	469.mg	n.s.s.	24/98	31.2mg	9/49	62.4mg	4/39		
491	1675	204.mg	n.s.s.	0/100	26.0mg	0/49	52.0mg	0/33		
a	1675	207.mg	n.s.s.	26/100	26.0mg	5/49	(52.0mg	3/33)		
DL-alpha-TOCOPHERYL ACETATE (vitamin E) 59-02-9										
492	1558m	147.mg	n.s.s.	0/10	500.mg	0/10	1.00gm	0/10	2.00gm 0/10	Wheldon;ijvn,53,287-296;1983
493	1558n	24.4gm	n.s.s.	2/50	500.mg	1/49	1.00gm	1/50	2.00gm 0/50	
a	1558n	911.mg	n.s.s.	46/50	2.00gm	45/50				
b	1558n	8.01gm	n.s.s.	9/50	2.00gm	6/50				
494	1558m	147.mg	n.s.s.	0/10	500.mg	0/10	1.00gm	0/10	2.00gm 0/10	
495	1558n	21.4gm	n.s.s.	2/49	500.mg	1/50	1.00gm	0/50	2.00gm 1/50	
a	1558n	2.12gm	n.s.s.	28/49	2.00gm	29/50				
b	1558n	5.23gm	n.s.s.	7/49	2.00gm	8/50				
TOLUENE 108-88-3										
496	1578	490.mg	n.s.s.	1/90	84.6mg	4/90				Gralla;ctfr;1983/Gibson 1983
497	1578	297.mg	n.s.s.	3/89	59.2mg	6/90				
TRICHLOROETHYLENE* (TCE) 79-01-6**										
498	1626	1.26gm	n.s.s.	6/49	95.8mg	5/50	287.mg	13/50	862.mg 11/46	Fukuda;indh,21,243-254;1983
a	1626	1.46gm	n.s.s.	1/49	95.8mg	3/50	287.mg	8/50	862.mg 7/46	
b	1626	6.90gm	n.s.s.	0/49	95.8mg	0/50	287.mg	0/50	862.mg 1/46	
c	1626	704.mg	n.s.s.	18/49	95.8mg	18/50	287.mg	27/50	862.mg 24/46	
499	1626	320.mg	n.s.s.	6/50	22.8mg	12/50	68.4mg	10/47	205.mg 14/51	
a	1626	1.40gm	n.s.s.	0/50	22.8mg	1/50	68.4mg	0/47	205.mg 1/51	
b	1626	288.mg	n.s.s.	32/50	22.8mg	39/50	68.4mg	31/47	205.mg 32/51	
TRIS(2,3-DIBROMOPROPYL)PHOSPHATE* (TRIS) 126-72-7**										
500	1729	3.72mg	189.mg	0/9	71.4mg	3/5				Reznik;livt,44,74-83;1981
a	1729	8.84mg	n.s.s.	0/9	71.4mg	1/5				
b	1729	18.4mg	n.s.s.	0/9	71.4mg	0/5				
TRIS(2-ETHYLHEXYL)PHOSPHATE 78-42-2										
501	c54751	1.28gm	17.6gm	0/50	352.mg	4/50	704.mg	7/50		
a	c54751	995.mg	n.s.s.	2/50	352.mg	8/50	704.mg	10/50		liv:hpa,hpc. S
b	c54751	1.01gm	n.s.s.	24/50	352.mg	25/50	704.mg	25/50		
c	c54751	995.mg	n.s.s.	2/50	352.mg	8/50	704.mg	10/50		liv:hpa,hpc,nnd.
d	c54751	2.44gm	n.s.s.	2/50	352.mg	2/50	704.mg	4/50		lun:a/a,a/c.
502	c54751	1.09gm	n.s.s.	33/50	352.mg	30/50	704.mg	25/50		
a	c54751	785.mg	n.s.s.	15/50	352.mg	21/50	704.mg	18/50		liv:hpa,hpc,nnd.
b	c54751	1.99gm	n.s.s.	7/50	352.mg	3/50	704.mg	7/50		lun:a/a,a/c.
503	c54751	1.04gm	n.s.s.	37/50	704.mg	38/50	1.41gm	31/50		
a	c54751	13.9gm	n.s.s.	1/50	704.mg	0/50	1.41gm	0/50		liv:hpa,hpc,nnd.
504	c54751	2.86gm	24.9gm	2/50	1.41gm	9/50	2.82gm	14/50		
a	c54751	2.86gm	24.9gm	2/50	1.41gm	9/50	2.82gm	14/50		adr:pha,phm.
b	c54751	6.54gm	n.s.s.	1/50	1.41gm	2/50	2.82gm	6/50		thy:fca,fcc; tyf:cyn. S
c	c54751	9.66gm	n.s.s.	0/50	1.41gm	1/50	2.82gm	3/50		thy:fca; tyf:cyn. S
d	c54751	2.04gm	n.s.s.	32/50	1.41gm	34/50	2.82gm	35/50		
e	c54751	n.s.s.	n.s.s.	0/50	1.41gm	1/50	2.82gm	0/50		liv:hpa,hpc,nnd.
DL-TRYPTOPHAN 54-12-6										
505	1657	2.93gm	n.s.s.	0/42	800.mg	0/20				Cohen;canr,39,1207-1217;1979
a	1657	2.93gm	n.s.s.	0/42	800.mg	0/20				
L-TRYPTOPHAN* 73-22-3**										
506	1574	3.30gm	n.s.s.	0/30	800.mg	0/20				Murasaki;carc,4,97-99;1983
a	1574	3.30gm	n.s.s.	0/30	800.mg	0/20				
VINYL ACETATE 108-05-4										
507	1546	181.mg	4.68gm	0/20	44.0mg	2/20	110.mg	5/20		Lijinsky;txap,68,43-53;1983/pers.comm.
a	1546	198.mg	2.31gm	0/20	44.0mg	0/20	110.mg	6/20		
b	1546	201.mg	4.70gm	0/20	44.0mg	1/20	110.mg	5/20		
c	1546	590.mg	n.s.s.	1/20	44.0mg	0/20	110.mg	1/20		
d	1546	37.7mg	n.s.s.	20/20	44.0mg	18/20	110.mg	19/20		
508	1546	45.4mg	n.s.s.	0/20	27.5mg	4/20	(68.1mg	2/20)		
a	1546	254.mg	n.s.s.	1/20	27.5mg	2/20	68.1mg	1/20		
b	1546	14.8mg	n.s.s.	18/20	27.5mg	16/20	68.1mg	20/20		
VINYL CHLORIDE* 75-01-4**										
509	1536m	20.5mg	55.1mg	0/143	18.3mg	28/87				Drew;txap,68,120-130;1983/Maseman pers.comm.
a	1536m	27.1mg	105.mg	5/138	18.3mg	23/88				
b	1536m	41.4mg	177.mg	0/143	18.3mg	13/88				
510	1536n	17.7mg	46.4mg	0/143	36.7mg	31/52				
a	1636n	56.9mg	330.mg	0/133	36.7mg	9/48				
b	1536n	108.mg	1.73gm	0/143	36.7mg	4/52				
c	1536n	146.mg	n.s.s.	5/138	36.7mg	3/50				

```
     Spe Strain  Site    Xpo+Xpt                                                                                    TD50      2Tailpvl
       Sex    Route   Hist      Notes                                                                                   DR       AuOp

511  H f syg inh mgl car 18m24 es                                                                   .+ .           61.0mg    P<.0005+
 a   H f syg inh sto ade 18m24 es                                                                                  205.mg    P<.0005+
 b   H f syg inh --- hes 18m24 es                                                                                  1.92gm    P<.07  +
512  M f swi inh mgl car  6m24 es                                                            . + .                 10.6mg    P<.0005+
 a   M f swi inh --- hes  6m24 es                                                                                  12.5mg    P<.0005+
 b   M f swi inh lun car  6m24 es                                                                                  36.6mg    P<.03  +
513  M f swi inh --- hes 12m24 es                                                             . + .                13.8mg    P<.0005+
 a   M f swi inh mgl car 12m24 es                                                                                  22.9mg    P<.0005+
 b   M f swi inh lun car 12m24 es                                                                                  55.5mg    P<.02  +
514  M f swi inh mgl car 18m24 es                                                                 .  +  .          32.2mg    P<.0005+
 a   M f swi inh --- hes 18m24 es                                                                                  36.1mg    P<.0005+
 b   M f swi inh lun car 18m24 es                                                                                  143.mg    P<.2   +
515  R f f34 inh liv nnd  6m24 e                                                              .  +     .           17.6mg    P<.0005
 a   R f f34 inh mgl fba  6m24 e                                                                                   15.1mg    P<.03  +
 b   R f f34 inh --- hes  6m24 e                                                                                   91.2mg    P<.2   +
 c   R f f34 inh liv hpc  6m24 e                                                                                   103.mg    P<.2
516  R f f34 inh mgl fba 12m24 e                                                             .  +     .            14.6mg    P<.0005+
 a   R f f34 inh liv nnd 12m24 e                                                                                   16.2mg    P<.0005
 b   R f f34 inh --- hes 12m24 e                                                                                   29.5mg    P<.0005+
 c   R f f34 inh mgl adc 12m24 e                                                                                   38.0mg    P<.003 +
 d   R f f34 inh liv hpc 12m24 e                                                                                   101.mg    P<.03  +
517  R f f34 inh mgl fba 18m24 e                                                                .  +          .    29.7mg    P<.004 +
 a   R f f34 inh --- hes 18m24 e                                                                                   32.8mg    P<.0005+
 b   R f f34 inh liv hpc 18m24 e                                                                                   65.2mg    P<.0005+
 c   R f f34 inh mgl adc 18m24 e                                                                                   74.2mg    P<.02  +
 d   R f f34 inh liv nnd 18m24 e                                                                                   96.3mg    P<.03
518  R f f34 inh --- hes 24m24 e                                                                . + .              23.6mg    P<.0005+
 a   R f f34 inh mgl fba 24m24 e                                                                                   32.9mg    P<.002 +
 b   R f f34 inh liv hpc 24m24 e                                                                                   77.2mg    P<.0005+
 c   R f f34 inh liv nnd 24m24 e                                                                                   166.mg    P<.08
 d   R f f34 inh mgl adc 24m24 e                                                                                   264.mg    P<.3   +

VINYLIDENE CHLORIDE***          100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
519  R f sss wat liv nnd 24m24 e                                                                     .>           414.mg * P<.4   -
 a   R f sss wat liv hpc 24m24 e                                                                                   654.mg * P<.2   -
 b   R f sss wat mgl aff 24m24 e                                                                                   679.mg * P<1.   -
 c   R f sss wat pit ade 24m24 e                                                                                   no dre   P=1.   -
520  R m sss wat liv hpc 24m24 e                                                                      .>          22.9gm * P<1.   -
 a   R m sss wat liv nnd 24m24 e                                                                                   no dre   P=1.   -

FD & C VIOLET NO. 1***          100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
521  R f sda eat mgl car 51w52 erv                                                                         . + .   573.mg    P<.0005+
 a   R f sda eat ski sqc 51w52 erv                                                                                 1.10gm    P<.0005+
 b   R f sda eat tba mix 51w52 erv                                                                                 418.mg    P<.0005+

ZINC DIMETHYLDITHIOCARBAMATE*** 100ng..:..1ug....:..10.....:..100....:..1mg....:..10.....:..100....:..1g.....:..10
522  M f b6c eat lun a/a 24m24                                                                           :   ±     561.mg * P<.04  e
 a   M f b6c eat --- mlp 24m24                                                                                     947.mg * P<.05
 b   M f b6c eat TBA MXB 24m24                                                                                     no dre   P=1.
 c   M f b6c eat liv MXB 24m24                                                                                     no dre   P=1.
 d   M f b6c eat lun MXB 24m24                                                                                     710.mg * P<.2
523  M m b6c eat TBA MXB 24m24                                                                          :>         no dre   P=1.   -
 a   M m b6c eat liv MXB 24m24                                                                                     no dre   P=1.
 b   M m b6c eat lun MXB 24m24                                                                                     765.mg * P<.3
524  R f f34 eat TBA MXB 24m24                                                                   :>                no dre   P=1.   -
 a   R f f34 eat liv MXB 24m24                                                                                     no dre   P=1.
525  R m f34 eat thy ccr 24m24                                                                   :  +        :     95.8mg * P<.004 c
 a   R m f34 eat TBA MXB 24m24                                                                                     no dre   P=1.
 b   R m f34 eat liv MXB 24m24                                                                                     no dre   P=1.
```

	RefNum	LoConf	UpConf	Cntrl	1Dose	1Inc	2Dose	2Inc	Citation or Pathology	Brkly Code
511	1536o	42.5mg	91.6mg	0/143	55.0mg	47/102				
a	1536o	110.mg	579.mg	5/138	55.0mg	20/101				
b	1536o	473.mg	n.s.s.	0/143	55.0mg	2/103				
512	1536m	6.81mg	18.3mg	2/71	10.1mg	33/67				
a	1536m	7.87mg	21.9mg	1/71	10.1mg	29/67				
b	1536m	15.4mg	n.s.s.	9/71	10.1mg	18/65				
513	1536n	8.64mg	23.7mg	1/71	20.2mg	30/47				
a	1536n	13.4mg	45.2mg	2/71	20.2mg	22/47				
b	1536n	23.7mg	n.s.s.	9/71	20.2mg	15/47				
514	1536o	18.9mg	63.3mg	2/71	30.2mg	22/45				
a	1536o	20.9mg	71.4mg	1/71	30.2mg	20/45				
b	1536o	47.0mg	n.s.s.	9/71	30.2mg	11/45				
515	1536m	8.77mg	63.2mg	4/112	4.80mg	15/75				
a	1536m	6.50mg	n.s.s.	24/112	4.80mg	28/76				
b	1536m	23.2mg	n.s.s.	2/112	4.80mg	4/76				
c	1536m	25.8mg	n.s.s.	1/112	4.80mg	3/75				
516	1536n	7.52mg	52.0mg	24/112	9.60mg	28/56				
a	1536n	9.16mg	35.0mg	4/112	9.60mg	20/56				
b	1536n	14.5mg	85.5mg	2/112	9.60mg	12/56				
c	1536n	16.6mg	272.mg	5/112	9.60mg	11/56				
d	1536n	31.8mg	n.s.s.	1/112	9.60mg	4/56				
517	1536o	13.8mg	269.mg	24/112	14.4mg	24/55				
a	1536o	17.4mg	78.1mg	2/112	14.4mg	15/55				
b	1536o	28.5mg	255.mg	1/112	14.4mg	8/54				
c	1536o	29.1mg	n.s.s.	5/112	14.4mg	9/55				
d	1536o	34.1mg	n.s.s.	4/112	14.4mg	7/54				
518	1536r	14.2mg	43.9mg	2/112	19.1mg	24/55				
a	1536r	16.3mg	153.mg	24/112	19.1mg	26/55				
b	1536r	35.3mg	260.mg	1/112	19.1mg	9/55				
c	1536r	52.2mg	n.s.s.	4/112	19.1mg	6/55				
d	1536r	62.1mg	n.s.s.	5/112	19.1mg	5/55				
VINYLIDENE CHLORIDE*** 75-35-4										
519	1655	74.1mg	n.s.s.	1/80	2.86mg	1/48	5.71mg	0/48	11.4mg 2/48	Quast;feat,3,55-62;1983
a	1655	106.mg	n.s.s.	0/80	2.86mg	0/48	5.71mg	0/48	11.4mg 1/48	
b	1655	8.69mg	n.s.s.	53/75	2.86mg	40/47	5.71mg	36/47	11.4mg 35/48	
c	1655	19.3mg	n.s.s.	25/76	2.86mg	22/44	5.71mg	18/46	11.4mg 14/42	
520	1655	86.2mg	n.s.s.	2/80	2.50mg	0/48	5.00mg	1/48	10.0mg 1/47	
a	1655	14.1mg	n.s.s.	1/80	2.50mg	0/48	5.00mg	0/48	10.0mg 0/47	
FD & C VIOLET NO. 1*** (benzyl violet 4B) 1694-09-3										
521	1643	325.mg	1.14gm	0/35	2.41gm	18/35				Ikeda;txcy,2,275-284;1974
a	1643	547.mg	2.72gm	0/35	2.41gm	11/35				
b	1643	246.mg	779.mg	0/35	2.41gm	22/35				
ZINC DIMETHYLDITHIOCARBAMATE*** (methyl zimate, milbam, ziram) 137-30-4										
522	c50442	245.mg	n.s.s.	2/50	76.5mg	5/50	154.mg	10/50		
a	c50442	373.mg	n.s.s.	1/50	76.5mg	1/50	154.mg	7/50		S
b	c50442	338.mg	n.s.s.	28/50	76.5mg	19/50	154.mg	23/50		
c	c50442	341.mg	n.s.s.	9/50	76.5mg	4/50	(154.mg	1/50)		liv:hpa,hpc,nnd.
d	c50442	254.mg	n.s.s.	4/50	76.5mg	6/50	154.mg	11/50		lun:a/a,a/c.
523	c50442	192.mg	n.s.s.	31/50	70.6mg	24/50	143.mg	25/49		
a	c50442	209.mg	n.s.s.	19/50	70.6mg	9/50	(143.mg	9/49)		liv:hpa,hpc,nnd.
b	c50442	215.mg	n.s.s.	8/50	70.6mg	8/50	143.mg	12/49		lun:a/a,a/c.
524	c50442	39.5mg	n.s.s.	43/50	14.6mg	42/50	29.6mg	39/50		
a	c50442	n.s.s.	n.s.s.	0/50	14.6mg	0/50	29.6mg	0/50		liv:hpa,hpc,nnd.
525	c50442	45.1mg	602.mg	0/50	11.8mg	2/50	23.8mg	7/50		
a	c50442	21.8mg	n.s.s.	37/50	11.8mg	42/50	23.8mg	39/50		
b	c50442	140.mg	n.s.s.	2/50	11.8mg	2/50	23.8mg	1/50		liv:hpa,hpc,nnd.

APPENDIX 1: CHEMICAL NAMES AND SYNONYMS IN THIS PLOT

CAS NUMBER	CHEMICAL NAME
26148-68-5	A-alpha-C (see 2-AMINO-9H-PYRIDO(2,3-b)INDOLE)
103-90-2	ACETAMINOPHEN
53-96-3	2-ACETYLAMINOFLUORENE
1162-65-8	AFLATOXIN B1
97-59-6	ALLANTOIN
2835-39-4	ALLYL ISOVALERATE
97-53-0	1-ALLYL-3-METHOXY-4-HYDROXYBENZENE (see EUGENOL)
68006-83-7	2-AMINO-3-METHYL-9H-PYRIDO-[2,3-b]-INDOLE
67730-11-4	2-AMINO-6-METHYLDIPYRIDO[1,2-a:3',2'-d]IMIDAZOLE
76180-96-6	2-AMINO-3-METHYLIMIDAZO[4,5-f]QUINOLINE
28754-68-9	trans-5-AMINO-3[2-(5-NITRO-2-FURYL)VINYL-1,2,4-OXADIAZOLE
26148-68-5	2-AMINO-9H-PYRIDO(2,3-b)INDOLE
67730-10-3	2-AMINODIPYRIDO[1,2-a:3',2'-d]IMIDAZOLE
61-82-5	3-AMINOTRIAZOLE
61-82-5	AMITROL (see 3-AMINOTRIAZOLE)
104-46-1	ANETHOLE
518-75-2	ANTIMYCIN (see CITRININ)
61-94-9	ARECOLINE.HCl
11096-82-5	AROCLOR 1260
50-81-7	L-ASCORBIC ACID
50-78-2	ASPIRIN
115-02-6	AZASERINE
446-86-6	AZATHIOPRINE
25843-45-2	AZOXYMETHANE
71-43-2	BENZENE
531-85-1	BENZIDINE.2HCl
50-32-8	BENZO(a)PYRENE
50-32-8	BENZPYRENE (see BENZO(a)PYRENE)
50-32-8	3,4-BENZPYRENE (see BENZO(a)PYRENE)
1694-09-3	BENZYL VIOLET 4B (see FD & C VIOLET NO. 1)
25013-16-5	BHA (see BUTYLATED HYDROXYANISOLE)
53609-64-6	N-BIS(2-HYDROXYPROPYL)NITROSAMINE (see N-NITROSOBIS(2-HYDROXYPROPYL)AMINE)
54143-56-5	2,5-BIS(2,2,2-TRIFLUORETHOXYL)-N-(2-PIPERIDYLMETHYL) BENZAMIDE ACETATE (see FLECAINIDE ACETATE)
2475-45-8	C.I. DISPERSE BLUE 1
2784-94-3	HC BLUE NO. 1
33229-34-4	HC BLUE NO. 2
7758-01-2	BROMATE, POTASSIUM
106-99-0	1,3-BUTADIENE
3817-11-6	BUTYL-BUTANOL-NITROSAMINE (see N-BUTYL-N-(4-HYDROXYBUTYL) NITROSAMINE)
109-69-3	N-BUTYL CHLORIDE
25013-16-5	2(3)-tert-BUTYL-4-HYDROXYANISOLE (see BUTYLATED HYDROXYANISOLE)
3817-11-6	N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE
869-01-2	N-N-BUTYL-N-NITROSOUREA
25013-16-5	BUTYLATED HYDROXYANISOLE
58-08-2	CAFFEINE
2425-06-1	CAPTAFOL
56-23-5	CARBON TETRACHLORIDE
60391-92-6	CARBOXYMETHYLNITROSOUREA
63449-39-8	CHLORINATED PARAFFINS (C23, 43% CHLORINE)
63449-39-8	CHLORINATED PARAFFINS (C12, 60% CHLORINE)
75-88-7	2-CHLORO-1,1,1-TRIFLUOROETHANE (see FLUOROCARBON 133a)
50892-23-4	[4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYLTHIO]ACETIC ACID
108-90-7	CHLOROBENZENE
124-48-1	CHLORODIBROMOMETHANE
593-70-4	CHLOROFLUOROMETHANE (see FLUOROCARBON 31)
63449-39-8	CHLOROWAX 40 (see CHLORINATED PARAFFINS (C23, 43% CHLORINE))
63449-39-8	CHLOROWAX 500c (see CHLORINATED PARAFFINS (C12, 60% CHLORINE))
113-92-8	CHLORPHENIRAMINE MALEATE
52214-84-3	CIPROFIBRATE
518-75-2	CITRININ
55600-34-5	CLOPHEN A 30
11096-82-5	CLOPHEN A 60 (see AROCLOR 1260)
60391-92-6	CMNU (see CARBOXYMETHYLNITROSOUREA)
65765-07-3	COMPOUND 50-892
51630-58-1	CYANO-(3-PHENOXYPHENYL)METHYL-4-CHLORO-alpha-(1-METHYLETHYL) BENZENE ACETATE (see FENVALERATE)
50-18-0	CYCLOPHOSPHAMIDE
72-55-9	p,p'-DDE
50-29-3	DDT
1163-19-5	DECABROMODIPHENYL OXIDE
55-18-5	DEN (see N-NITROSODIETHYLAMINE)
9004-54-0	DEXTRAN
9011-18-1	DEXTRAN SULFATE SODIUM (DS-M-1)
9011-18-1	DEXTRAN SULFATE SODIUM (DST-H)
9011-18-1	DEXTRAN SULFATE SODIUM (KMDS-H)
3148-73-0	DIACETYL HYDRAZINE
131-17-9	DIALLYL PHTHALATE
5164-11-4	1,1-DIALLYLHYDRAZINE
124-48-1	DIBROMOCHLOROMETHANE (see CHLORODIBROMOMETHANE)
3296-90-0	DIBROMONEOPENTYL GLYCOL
924-16-3	DIBUTYLNITROSAMINE (see NITROSODIBUTYLAMINE)
7572-29-4	DICHLOROACETYLENE
95-50-1	1,2-DICHLOROBENZENE
95-50-1	o-DICHLOROBENZENE (see 1,2-DICHLOROBENZENE)
75-09-2	DICHLOROMETHANE (see METHYLENE CHLORIDE)
542-75-6	1,3-DICHLOROPROPENE (see TELONE II)
21498-08-8	2-[1-(2,6-DICHLORPHENOXY)-ETHYL]-2-IMIDAZOLINE.HCl (see LOFEXIDINE.HCl)
55-18-5	DIETHYLNITROSAMINE (see N-NITROSODIETHYLAMINE)
55-18-5	N,N-DIETHYLNITROSAMINE (see N-NITROSODIETHYLAMINE)
21626-89-1	DIFTALONE
68-89-3	(2,3-DIHYDRO-1,5-DIMETHYL-3-OXO-2-PHENYL-1H-PYRAZOL-4-YL) METHYLAMINO METHANESULFONATE MONOHYDRATE (see DIPYRONE)
868-85-9	DIMETHYL HYDROGEN PHOSPHITE
597-25-1	DIMETHYL MORPHOLINOPHOSPHORAMIDATE
1643-20-5	N,N-DIMETHYLDODECYLAMINE-N-OXIDE
62-75-9	DIMETHYLNITROSAMINE (see N-NITROSODIMETHYLAMINE)
62-75-9	N,N-DIMETHYLNITROSAMINE (see N-NITROSODIMETHYLAMINE)
1011-73-0	2,4-DINITROPHENOL, SODIUM
55380-34-2	1,4-DINITROSO-2,6-DIMETHYLPIPERAZINE
147-24-0	DIPHENHYDRAMINE.HCl
621-64-7	DIPROPYLNITROSAMINE (see N-NITROSODIPROPYLAMINE)
68-89-3	DIPYRONE
868-85-9	DMHP (see DIMETHYL HYDROGEN PHOSPHITE)
62-75-9	DMN (see N-NITROSODIMETHYLAMINE)
90-43-7	DOWICIDE-1 (see o-PHENYLPHENOL)
87-86-5	DOWICIDE-7 (see 2,3,4,5,6-PENTACHLOROPHENOL)
9011-18-1	DS-M-1 (see DEXTRAN SULFATE SODIUM (DS-M-1))
9011-18-1	DST-H (see DEXTRAN SULFATE SODIUM (DST-H))
50-18-0	ENDOXAN (see CYCLOPHOSPHAMIDE)
13838-16-9	ENFLURANE
759-73-9	ENU (see 1-ETHYL-1-NITROSOUREA)
134-72-5	EPHEDRINE SULPHATE
6381-77-7	ERYTHORBATE, SODIUM
75-56-9	1,2-EPOXYPROPANE (see 1,2-PROPYLENE OXIDE)
140-67-0	ESTRAGOLE
91-53-2	ETHOXYQUIN
64-17-5	ETHYL ALCOHOL
759-73-9	1-ETHYL-1-NITROSOUREA
759-73-9	N-ETHYL-N-NITROSOUREA (see 1-ETHYL-1-NITROSOUREA)
75-21-8	ETHYLENE OXIDE
759-73-9	ETHYLNITROSOUREA (see 1-ETHYL-1-NITROSOUREA)
97-53-0	EUGENOL
24554-26-5	FANFT (see N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]FORMAMIDE)
51630-58-1	FENVALERATE
67774-32-1	FIREMASTER FF-1 (see POLYBROMINATED BIPHENYL MIXTURE)
54143-56-5	FLECAINIDE ACETATE
53-96-3	FLUORENYLACETAMIDE (see 2-ACETYLAMINOFLUORENE)
53-96-3	N-2-FLUORENYLACETAMIDE (see 2-ACETYLAMINOFLUORENE)
7681-49-4	FLUORIDE, SODIUM
593-70-4	FLUOROCARBON 31
75-88-7	FLUOROCARBON 133a
50-00-0	FORMALDEHYDE
75-09-2	FREON 30 (see METHYLENE CHLORIDE)
23255-69-8	FUSARENON-X
67730-11-4	GLU-P-1 (see 2-AMINO-6-METHYLDIPYRIDO[1,2-a:3',2'-d]IMIDAZOLE)
67730-10-3	GLU-P-2 (see 2-AMINODIPYRIDO[1,2-a:3',2'-d]IMIDAZOLE)
56-86-0	L-GLUTAMIC ACID
608-73-1	HEXACHLOROCYCLOHEXANE
10034-93-2	HYDRAZINE SULFATE
53-95-2	N-HYDROXY-N-ACETYL-2-AMINOFLUORENE (see N-HYDROXY-2-ACETYLAMINOFLUORENE)
53-95-2	N-HYDROXY-2-ACETYLAMINOFLUORENE
53-95-2	HYDROXY-N-2-FLUORENYLACETAMIDE (see N-HYDROXY-2-ACETYLAMINOFLUORENE)

CAS NUMBER	CHEMICAL NAME
103-90-2	p-HYDROXYACETANILIDE (see ACETAMINOPHEN)
51410-44-7	1'-HYDROXYESTRAGOLE
148-24-3	8-HYDROXYQUINOLINE
5208-87-7	1'-HYDROXYSAFROLE
54-85-3	INH (see ISONIAZID)
76180-96-6	IQ (see 2-AMINO-3-METHYLIMIDAZO[4,5-f]QUINOLINE)
6381-77-7	ISOASCORBATE (see ERYTHORBATE, SODIUM)
760-60-1	N-ISOBUTYL-N-NITROSOUREA (see N-NITROSO-N-ISOBUTYLUREA)
54-85-3	ISONIAZID
1453-82-3	ISONICOTINAMIDE
54-85-3	ISONICOTINIC ACID HYDRAZIDE (see ISONIAZID)
78-59-1	ISOPHORONE
65765-07-3	1-ISOPROPYL-4-(m-METHOXYPHENYL)-7-METHYL-2(1H)-QUINAZOLINONE (see COMPOUND 50-892)
22760-18-5	1-ISOPROPYL-7-METHYL-4-PHENYL-2(1H)-QUINAZOLINONE (see PROQUAZONE)
520-18-3	KAEMPFEROL
9011-18-1	KMDS-H (see DEXTRAN SULFATE SODIUM (KMDS-H))
21498-08-8	LOFEXIDINE.HCl
67-20-9	MACRODANTIN (see 1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN)
569-61-9	p-MAGENTA (see p-ROSANILINE.HCl)
68006-83-7	MeA-alpha-C (see 2-AMINO-3-METHYL-9H-PYRIDO-[2,3-b]-INDOLE)
108-78-1	MELAMINE
19767-45-4	2-MERCAPTOETHANESULFONATE, SODIUM
135-23-9	METHAPYRILENE.HCl
25843-45-2	Z-METHYL-O,N,N-AZOXYMETHANE (see AZOXYMETHANE)
70-25-7	N-METHYL-N'-NITRO-N-NITROSOGUANIDINE
21308-79-2	METHYL 12-OXO-trans-10-OCTADECENOATE
614-00-6	METHYL-PHENYL-NITROSAMINE (see NITROSOMETHYLANILINE)
137-30-4	METHYL ZIMATE (see ZINC DIMETHYLDITHIOCARBAMATE)
75-09-2	METHYLENE CHLORIDE
13552-44-8	4,4'-METHYLENEDIANILINE.2HCl
33868-17-6	METHYLNITROSOCYANAMIDE
56-04-2	METHYLTHIOURACIL
137-30-4	MILBAM (see ZINC DIMETHYLDITHIOCARBAMATE)
70-25-7	MNNG (see N-METHYL-N'-NITRO-N-NITROSOGUANIDINE)
1068-57-1	MONOACETYL HYDRAZINE
108-90-7	MONOCHLOROBENZENE (see CHLOROBENZENE)
315-22-0	MONOCROTALINE
32221-81-1	DL-MONOSODIUM GLUTAMATE
142-47-2	L-MONOSODIUM GLUTAMATE
98-92-0	NICOTINAMIDE
7632-00-0	NITRITE, SODIUM
24554-26-5	N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]FORMAMIDE
67-20-9	NITROFURANTOIN (see 1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN)
67-20-9	1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN
108-03-2	1-NITROPROPANE
62641-67-2	1-NITROSO-5,6-DIHYDROTHYMINE
89911-79-5	N-NITROSO-2,3-DIHYDROXYPROPYL-2-HYDROXYPROPYLAMINE
92177-50-9	NITROSO-2,3-DIHYDROXYPROPYL-2-OXOPROPYLAMINE
89911-78-4	N-NITROSO-2,3-DIHYDROXYPROPYLETHANOLAMINE
75896-33-2	N-NITROSO-(2-HYDROXYPROPYL)-(2-HYDROXYETHYL)AMINE
56222-35-6	N-NITROSO-3-HYDROXYPYRROLIDINE
760-60-1	N-NITROSO-N-ISOBUTYLUREA
55090-44-3	N-NITROSO-N-METHYL-N-DODECYLAMINE
937-25-7	N-NITROSO-N-METHYL-4-FLUOROANILINE
943-41-9	N-NITROSO-N-METHYL-4-NITROANILINE
39884-52-1	N-NITROSO-1,3-OXAZOLIDINE
92177-49-6	NITROSO-2-OXOPROPYLETHANOLAMINE
15973-99-6	DI(N-NITROSO)-PERHYDROPYRIMIDINE
82018-90-4	N-NITROSO(2,2,2-TRIFLUOROETHYL)ETHYLAMINE
75881-18-4	1-NITROSO-3,4,5-TRIMETHYLPIPERAZINE
88208-16-6	N-NITROSOALLYL-2,3-DIHYDROXYPROPYLAMINE
91308-70-2	N-NITROSOALLYL-2-HYDROXYPROPYLAMINE
91308-71-3	N-NITROSOALLYL-2-OXOPROPYLAMINE
91308-69-9	N-NITROSOALLYLETHANOLAMINE
15216-10-1	N-NITROSOAZETIDINE
53609-64-6	N-NITROSOBIS(2-HYDROXYPROPYL)AMINE
60599-38-4	N-NITROSOBIS(2-OXOPROPYL)AMINE
73785-40-7	N-NITROSOCIMETIDINE
924-16-3	NITROSODIBUTYLAMINE
1116-54-7	N-NITROSODIETHANOLAMINE
55-18-5	N-NITROSODIETHYLAMINE
62-75-9	N-NITROSODIMETHYLAMINE
621-64-7	N-NITROSODIPROPYLAMINE
40580-89-0	NITROSODODECAMETHYLENEIMINE
10595-95-6	NITROSOETHYLMETHYLAMINE
932-83-2	N-NITROSOHEXAMETHYLENEIMINE
55090-44-3	NITROSOMETHYL-N-DODECYLAMINE (see N-NITROSO-N-METHYL-N-DODECYLAMINE)
86451-37-8	N-NITROSOMETHYL-2,3-DIHYDROXYPROPYLAMINE
75411-83-5	N-NITROSOMETHYL-2-HYDROXYPROPYLAMINE
614-00-6	NITROSOMETHYLANILINE
59-89-2	NITROSOMORPHOLINE (see N-NITROSOMORPHOLINE)
59-89-2	N-NITROSOMORPHOLINE
16543-55-8	N'-NITROSONORNICOTINE
78246-24-9	N'-NITROSONORNICOTINE-1-N-OXIDE
100-75-4	N-NITROSOPIPERIDINE
90-43-7	ORTHOXENOL (see o-PHENYLPHENOL)
103-90-2	PARACETAMOL (see ACETAMINOPHEN)
11096-82-5	PCB (see AROCLOR 1260)
87-86-5	PCP (see 2,3,4,5,6-PENTACHLOROPHENOL)
76-01-7	PENTACHLOROETHANE
87-86-5	2,3,4,5,6-PENTACHLOROPHENOL
76-01-7	PENTALIN (see PENTACHLOROETHANE)
127-18-4	PERCHLOROETHYLENE (see TETRACHLOROETHYLENE)
62-44-2	PHENACETIN
50-06-6	PHENOBARBITAL
50-06-6	PHENOBARBITONE (see PHENOBARBITAL)
106-50-3	p-PHENYLENEDIAMINE
50-06-6	PHENYLETHYLBARBITURIC ACID (see PHENOBARBITAL)
122-60-1	PHENYLGLYCIDYL ETHER
66-05-7	beta-PHENYLISOPROPYLHYDRAZINE.HCl
132-27-4	o-PHENYLPHENATE, SODIUM
90-43-7	o-PHENYLPHENOL
56393-22-7	PILDRALAZINE
100-75-4	PIP (see N-NITROSOPIPERIDINE)
67774-32-1	POLYBROMINATED BIPHENYL MIXTURE
3761-53-3	PONCEAU MX (see D & C RED NO. 5)
7758-01-2	POTASSIUM BROMATE (see BROMATE, POTASSIUM)
40778-40-3	PRIMIDOLOL.HCl
104-46-1	p-PROPENYLANISOLE (see ANETHOLE)
525-66-6	PROPRANOLOL.HCl
115-07-1	PROPYLENE
75-56-9	1,2-PROPYLENE OXIDE
621-64-7	DI-N-PROPYLNITROSAMINE (see N-NITROSODIPROPYLAMINE)
22760-18-5	PROQUAZONE
26308-28-1	PYRAZAPON (see RIPAZEPAM)
59-33-6	PYRILAMINE MALEATE
117-39-5	QUERCETIN
6151-25-3	QUERCETIN DIHYDRATE
148-24-3	8-QUINOLINOL (see 8-HYDROXYQUINOLINE)
569-61-9	C.I. BASIC RED 9.HCl (see p-ROSANILINE.HCl)
3761-53-3	D & C RED NO. 5
2871-01-4	HC RED NO. 3
26308-28-1	RIPAZEPAM
569-61-9	p-ROSANILINE.HCl
12768-44-4	RUTIN SULFATE
128-44-9	SACCHARIN, SODIUM
94-59-7	SAFROLE
18559-94-9	SALBUTAMOL
7681-49-4	SODIUM FLUORIDE (see FLUORIDE, SODIUM)
959-24-0	SOTALOL.HCl
28754-68-9	SQ 18506 (see trans-5-AMINO-3[2-(5-NITRO-2-FURYL)VINYL-1,2,4-OXADIAZOLE)
96-09-3	STYRENE OXIDE
68-89-3	SULPYRIN (see DIPYRONE)
79-01-6	TCE (see TRICHLOROETHYLENE)
542-75-6	TELONE II
23031-25-6	TERBUTALINE
630-20-6	1,1,1,2-TETRACHLOROETHANE
127-18-4	TETRACHLOROETHYLENE
137-26-8	TETRAMETHYLTHIURAM DISULFIDE
79-19-6	THIOCARBAMYLHYDRAZINE (see THIOSEMICARBAZIDE)
79-19-6	THIOSEMICARBAZIDE
137-26-8	THIRAM (see TETRAMETHYLTHIURAM DISULFIDE)
137-26-8	TMTD (see TETRAMETHYLTHIURAM DISULFIDE)
59-02-9	DL-alpha-TOCOPHERYL ACETATE
108-88-3	TOLUENE
79-01-6	TRICHLOROETHYLENE
126-72-7	TRIS (see TRIS(2,3-DIBROMOPROPYL)PHOSPHATE)
126-72-7	TRIS(2,3-DIBROMOPROPYL)PHOSPHATE
78-42-2	TRIS(2-ETHYLHEXYL)PHOSPHATE
54-12-6	DL-TRYPTOPHAN

CAS NUMBER	CHEMICAL NAME
73-22-3	L-TRYPTOPHAN
103-90-2	TYLENOL (see ACETAMINOPHEN)
108-05-4	VINYL ACETATE
75-01-4	VINYL CHLORIDE
75-35-4	VINYLIDENE CHLORIDE
1694-09-3	FD & C VIOLET NO. 1
50-81-7	VITAMIN C (see L-ASCORBIC ACID)
59-02-9	VITAMIN E (see DL-alpha-TOCOPHERYL ACETATE)
137-30-4	ZINC DIMETHYLDITHIOCARBAMATE
137-30-4	ZIRAM (see ZINC DIMETHYLDITHIOCARBAMATE)

CAS NUMBER = Chemical Abstracts Service registry number

APPENDIX 2: CHEMICAL NAMES IN THIS PLOT LISTED BY CAS NUMBER

CAS NUMBER	CHEMICAL NAME
50-00-0	FORMALDEHYDE
50-06-6	PHENOBARBITAL (phenobarbitone)
50-18-0	CYCLOPHOSPHAMIDE (Endoxan)
50-29-3	DDT
50-32-8	BENZO(a)PYRENE
50-78-2	ASPIRIN
50-81-7	L-ASCORBIC ACID (vitamin C)
53-95-2	N-HYDROXY-2-ACETYLAMINOFLUORENE (hydroxy-N-2-fluorenylacetamide)
53-96-3	2-ACETYLAMINOFLUORENE (N-2-fluorenylacetamide)
54-12-6	DL-TRYPTOPHAN
54-85-3	ISONIAZID (INH)
55-18-5	*N-NITROSODIETHYLAMINE (DEN)*
56-04-2	METHYLTHIOURACIL
56-23-5	CARBON TETRACHLORIDE
56-86-0	*L-GLUTAMIC ACID*
58-08-2	CAFFEINE
59-02-9	DL-alpha-TOCOPHERYL ACETATE (vitamin E)
59-33-6	*PYRILAMINE MALEATE*
59-89-2	N-NITROSOMORPHOLINE
61-82-5	3-AMINOTRIAZOLE (amitrol)
61-94-9	*ARECOLINE.HCl*
62-44-2	PHENACETIN
62-75-9	N-NITROSODIMETHYLAMINE (DMN)
64-17-5	ETHYL ALCOHOL
66-05-7	beta-PHENYLISOPROPYLHYDRAZINE.HCl
67-20-9	1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN (macrodantin, nitrofurantoin)
68-89-3	DIPYRONE (sulpyrin)
70-25-7	N-METHYL-N′-NITRO-N-NITROSOGUANIDINE (MNNG)
71-43-2	BENZENE
72-55-9	p,p′-DDE
73-22-3	L-TRYPTOPHAN
75-01-4	VINYL CHLORIDE
75-09-2	METHYLENE CHLORIDE (dichloromethane, Freon 30)
75-21-8	ETHYLENE OXIDE
75-35-4	VINYLIDENE CHLORIDE
75-56-9	1,2-PROPYLENE OXIDE (1,2-epoxypropane)
75-88-7	FLUOROCARBON 133a (2-chloro-1,1,1-trifluoroethane)
76-01-7	PENTACHLOROETHANE (pentalin)
78-42-2	TRIS(2-ETHYLHEXYL)PHOSPHATE
78-59-1	ISOPHORONE
79-01-6	TRICHLOROETHYLENE (TCE)
79-19-6	THIOSEMICARBAZIDE (thiocarbamylhydrazine)
87-86-5	2,3,4,5,6-PENTACHLOROPHENOL (Dowicide-7, PCP)
90-43-7	o-PHENYLPHENOL (orthoxenol, Dowicide-1)
91-53-2	ETHOXYQUIN
94-59-7	SAFROLE
95-50-1	1,2-DICHLOROBENZENE (o-dichlorobenzene)
96-09-3	*STYRENE OXIDE*
97-53-0	EUGENOL (1-allyl-3-methoxy-4-hydroxybenzene)
97-59-6	ALLANTOIN
98-92-0	*NICOTINAMIDE*
100-75-4	N-NITROSOPIPERIDINE (PIP)
103-90-2	ACETAMINOPHEN (Tylenol, paracetamol)

CAS NUMBER	CHEMICAL NAME
104-46-1	ANETHOLE (p-propenylanisole)
106-50-3	p-PHENYLENEDIAMINE
106-99-0	*1,3-BUTADIENE*
108-03-2	1-NITROPROPANE
108-05-4	VINYL ACETATE
108-78-1	MELAMINE
108-88-3	TOLUENE
108-90-7	CHLOROBENZENE (monochlorobenzene)
109-69-3	N-BUTYL CHLORIDE
113-92-8	CHLORPHENIRAMINE MALEATE
115-02-6	AZASERINE
115-07-1	PROPYLENE
117-39-5	QUERCETIN
122-60-1	PHENYLGLYCIDYL ETHER
124-48-1	CHLORODIBROMOMETHANE (dibromochloromethane)
126-72-7	TRIS(2,3-DIBROMOPROPYL)PHOSPHATE (TRIS)
127-18-4	TETRACHLOROETHYLENE (perchloroethylene)
128-44-9	SACCHARIN, SODIUM
131-17-9	DIALLYL PHTHALATE
132-27-4	o-PHENYLPHENATE, SODIUM
134-72-5	EPHEDRINE SULPHATE
135-23-9	METHAPYRILENE.HCl
137-26-8	TETRAMETHYLTHIURAM DISULFIDE (TMTD, thiram)
137-30-4	ZINC DIMETHYLDITHIOCARBAMATE (methyl zimate, milbam, ziram)
140-67-0	ESTRAGOLE
142-47-2	L-MONOSODIUM GLUTAMATE
147-24-0	DIPHENHYDRAMINE.HCl
148-24-3	8-HYDROXYQUINOLINE (8-quinolinol)
315-22-0	MONOCROTALINE
446-86-6	AZATHIOPRINE
518-75-2	CITRININ (antimycin)
520-18-3	KAEMPFEROL
525-66-6	PROPRANOLOL.HCl
531-85-1	BENZIDINE.2HCl
542-75-6	TELONE II (1,3-dichloropropene)
569-61-9	p-ROSANILINE.HCl (p-magenta, C.I. Basic Red 9.HCl)
593-70-4	*FLUOROCARBON 31* (chlorofluoromethane)
597-25-1	DIMETHYL MORPHOLINOPHOSPHORAMIDATE
608-73-1	HEXACHLOROCYCLOHEXANE
614-00-6	*NITROSOMETHYLANILINE*
621-64-7	N-NITROSODIPROPYLAMINE
630-20-6	1,1,1,2-TETRACHLOROETHANE
759-73-9	*1-ETHYL-1-NITROSOUREA (ENU, N-ethyl-N-nitrosourea)*
760-60-1	N-NITROSO-N-ISOBUTYLUREA (N-isobutyl-N-nitrosourea)
868-85-9	DIMETHYL HYDROGEN PHOSPHITE (DMHP)
869-01-2	*N-N-BUTYL-N-NITROSOUREA*
924-16-3	NITROSODIBUTYLAMINE
932-83-2	N-NITROSOHEXAMETHYLENEIMINE
937-25-7	N-NITROSO-N-METHYL-4-FLUOROANILINE
943-41-9	N-NITROSO-N-METHYL-4-NITROANILINE
959-24-0	SOTALOL.HCl
1011-73-0	2,4-DINITROPHENOL, SODIUM
1068-57-1	MONOACETYL HYDRAZINE
1116-54-7	N-NITROSODIETHANOLAMINE
1162-65-8	AFLATOXIN B1
1163-19-5	DECABROMODIPHENYL OXIDE
1453-82-3	ISONICOTINAMIDE
1643-20-5	N,N-DIMETHYLDODECYLAMINE-N-OXIDE
1694-09-3	FD & C VIOLET NO. 1 (benzyl violet 4B)
2425-06-1	CAPTAFOL
2475-45-8	C.I. DISPERSE BLUE 1
2784-94-3	HC BLUE NO. 1
2835-39-4	ALLYL ISOVALERATE
2871-01-4	HC RED NO. 3
3148-73-0	DIACETYL HYDRAZINE
3296-90-0	DIBROMONEOPENTYL GLYCOL
3761-53-3	D & C RED NO. 5 (ponceau MX)
3817-11-6	N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE (butyl-butanol-nitrosamine)
5164-11-4	1,1-DIALLYLHYDRAZINE
5208-87-7	*1′-HYDROXYSAFROLE*
6151-25-3	QUERCETIN DIHYDRATE
6381-77-7	ERYTHORBATE, SODIUM (isoascorbate)
7572-29-4	*DICHLOROACETYLENE*
7632-00-0	NITRITE, SODIUM
7681-49-4	FLUORIDE, SODIUM
7758-01-2	*BROMATE, POTASSIUM*
9004-54-0	DEXTRAN
9011-18-1	DEXTRAN SULFATE SODIUM (DS-M-1) (Mol. Wt. = 54,000)

CAS NUMBER	CHEMICAL NAME
9011-18-1	DEXTRAN SULFATE SODIUM (DST-H) (Mol. Wt. = 9500)
9011-18-1	DEXTRAN SULFATE SODIUM (KMDS-H) (Mol. Wt. = 520,000)
10034-93-2	HYDRAZINE SULFATE
10595-95-6	NITROSOETHYLMETHYLAMINE
11096-82-5	AROCLOR 1260 (PCB, clophen A 60)
12768-44-4	RUTIN SULFATE
13552-44-8	4,4'-METHYLENEDIANILINE.2HCl
13838-16-9	ENFLURANE
15216-10-1	N-NITROSOAZETIDINE
15973-99-6	DI(N-NITROSO)-PERHYDROPYRIMIDINE
16543-55-8	N'-NITROSONORNICOTINE
18559-94-9	SALBUTAMOL
19767-45-4	2-MERCAPTOETHANESULFONATE, SODIUM
21308-79-2	METHYL 12-OXO-trans-10-OCTADECENOATE
21498-08-8	LOFEXIDINE.HCl (2-[1-(2,6-dichlorphenoxy)-ethyl]-2-imidazoline.HCl)
21626-89-1	DIFTALONE
22760-18-5	PROQUAZONE (1-isopropyl-7-methyl-4-phenyl-2(IH)-quinazolinone)
23031-25-6	TERBUTALINE
23255-69-8	FUSARENON-X
24554-26-5	N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]FORMAMIDE (FANFT)
25013-16-5	BUTYLATED HYDROXYANISOLE (BHA, 2(3)-tert-butyl-4-hydroxyanisole)
25843-45-2	AZOXYMETHANE
26148-68-5	2-AMINO-9H-PYRIDO(2,3-b)INDOLE (A-alpha-C)
26308-28-1	RIPAZEPAM (pyrazapon)
28754-68-9	trans-5-AMINO-3[2-(5-NITRO-2-FURYL)VINYL-1,2,4-OXADIAZOLE (SQ 18506)
32221-81-1	DL-MONOSODIUM GLUTAMATE
33229-34-4	HC BLUE NO. 2
33868-17-6	METHYLNITROSOCYANAMIDE
39884-52-1	N-NITROSO-1,3-OXAZOLIDINE
40580-89-0	NITROSODODECAMETHYLENEIMINE
40778-40-3	PRIMIDOLOL.HCl
50892-23-4	[4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYLTHIO]ACETIC ACID
51410-44-7	1'-HYDROXYESTRAGOLE
51630-58-1	FENVALERATE (cyano-(3-phenoxyphenyl)methyl-4-chloro-alpha-(1-methylethyl)benzene acetate)
52214-84-3	CIPROFIBRATE
53609-64-6	N-NITROSOBIS(2-HYDROXYPROPYL)AMINE (N-bis(2-hydroxypropyl) nitrosamine)
54143-56-5	FLECAINIDE ACETATE (2,5-bis(2,2,2-trifluorethoxyl)-N-(2-piperidylmethyl)benzamide acetate)
55090-44-3	N-NITROSO-N-METHYL-N-DODECYLAMINE
55380-34-2	1,4-DINITROSO-2,6-DIMETHYLPIPERAZINE
55600-34-5	CLOPHEN A 30
56222-35-6	N-NITROSO-3-HYDROXYPYRROLIDINE
56393-22-7	PILDRALAZINE
60391-92-6	CARBOXYMETHYLNITROSOUREA (CMNU)
60599-38-4	N-NITROSOBIS(2-OXOPROPYL)AMINE
62641-67-2	1-NITROSO-5,6-DIHYDROTHYMINE
63449-39-8	CHLORINATED PARAFFINS (C12, 60% CHLORINE) (Chlorowax 500c, Avg. Mol. Wt. = 411)
63449-39-8	CHLORINATED PARAFFINS (C23, 43% CHLORINE) (Chlorowax 40, Avg. Mol. Wt. = 560)
65765-07-3	COMPOUND 50-892 (1-isopropyl-4-(m-methoxyphenyl)-7-methyl-2(1H)-quinazolinone)
67730-10-3	2-AMINODIPYRIDO[1,2-a:3',2'-d]IMIDAZOLE (Glu-P-2)
67730-11-4	2-AMINO-6-METHYLDIPYRIDO[1,2-a:3',2'-d]IMIDAZOLE (Glu-P-1)
67774-32-1	POLYBROMINATED BIPHENYL MIXTURE (Firemaster FF-1)
68006-83-7	2-AMINO-3-METHYL-9H-PYRIDO-[2,3-b]-INDOLE (MeA-alpha-C)
73785-40-7	N-NITROSOCIMETIDINE
75411-83-5	N-NITROSOMETHYL-2-HYDROXYPROPYLAMINE
75881-18-4	1-NITROSO-3,4,5-TRIMETHYLPIPERAZINE
75896-33-2	N-NITROSO-(2-HYDROXYPROPYL)-(2-HYDROXYETHYL)AMINE
76180-96-6	2-AMINO-3-METHYLIMIDAZO[4,5-f]QUINOLINE (IQ)
78246-24-9	N'-NITROSONORNICOTINE-1-N-OXIDE
82018-90-4	N-NITROSO(2,2,2-TRIFLUOROETHYL)ETHYLAMINE
86451-37-8	N-NITROSOMETHYL-2,3-DIHYDROXYPROPYLAMINE
88208-16-6	N-NITROSOALLYL-2,3-DIHYDROXYPROPYLAMINE
89911-78-4	N-NITROSO-2,3-DIHYDROXYPROPYLETHANOLAMINE
89911-79-5	N-NITROSO-2,3-DIHYDROXYPROPYL-2-HYDROXYPROPYLAMINE
91308-69-9	N-NITROSOALLYLETHANOLAMINE
91308-70-2	N-NITROSOALLYL-2-HYDROXYPROPYLAMINE
91308-71-3	N-NITROSOALLYL-2-OXOPROPYLAMINE
92177-49-6	NITROSO-2-OXOPROPYLETHANOLAMINE
92177-50-9	NITROSO-2,3-DIHYDROXYPROPYL-2-OXOPROPYLAMINE

APPENDIX 3: STRAIN CODES AND DEFINITIONS

Code	Strain
aap	Alpk/Ap
aci	ACI
alb	albino
b6b	(B6C3F1 X B6C3 background, brachymorphic) inter se = B6C3F2 brachymorphic
b6c	B6C3F1
b6n	(B6C3F1 X B6C3 background, brachymorphic) inter se = B6C3F2 phenotypically normal
bal	BALB/c
bd1	BDF1
bld	BALB/cLacDp
buf	Buffalo
c3s	C3H/St
c5v	C57BL/BVI
cbl	C57BL
cbn	C57BL/6JfC3Hf/Nctr X BALB/cStCrlfC3Hf/Nctr inter se
cd1	Charles River CD1
cdf	CDF1
cdr	Charles River CD
cff	C57BL/6JfC3Hf/Nctr X BALB/cStCrlfC3Hf/Nctr
cfi	C3H/FIB
crw	Charles River Crl:COBS(WI)BR
csb	CSb
dbx	DBA
ddd	DDD
don	Donryu
f34	Fischer 344
f3d	F344/DuCrj
f3h	Fischer 344/HAPBR
fis	Fischer
fmf	Fischer 344/Mai fBR
icm	ICR
ifm	IF
leb	Long-Evans BLU: (LE)
lev	Long-Evans
mrw	MRC-Wistar
nmr	NMRI
nzb	NZO/BlGd
nzd	NZR/Gd
osm	Osborne-Mendel
sda	Sprague-Dawley
sdz	Sandoz
sic	Swiss/ICR
sss	Sprague-Dawley Spartan
stm	ST/a
swa	Swiss albino
swi	Swiss
syg	Syrian Golden
wal	Wistar albino
wis	Wistar

APPENDIX 4: ROUTE OF ADMINISTRATION CODES AND DEFINITIONS

Code	Route of Administration
eat	diet
gav	gavage
inh	inhalation
ipj	intraperitoneal injection
ivj	intravenous injection
wat	water

APPENDIX 5: SITE CODES AND DEFINITIONS

Code	Site
---	all target sites
adr	adrenal gland
amd	*adrenal medulla*
blv	blood vessels
bod	body cavities
bom	bone marrow
bra	brain
cec	cecum
cli	clitoral gland
clr	colorectum
col	colon
cst	cardiac stomach
cvu	cervix uteri
dgt	digestive tract
duo	duodenum
edu	ear duct
eso	esophagus
for	forestomach
gam	gastric mucosa
git	gastrointestinal tract
hag	Harderian gland
hea	heart
itn	intestine
k/p	kidney/pelvis
kid	kidney
liv	liver
lmr	lymphoreticular system
lpp	lip
lun	lung
mam	mammary tissue (other than or including more than mammary gland)
meo	mesovarium
mey	mesentery
mgl	mammary gland
mix	more than one site; sites specified in published paper
mln	mesenteric lymph node
mls	multiple sites
mul	multiple organs
MXA	more than one site, combined by NCI/NTP
MXB	more than one site, combined by Berkeley
nac	nasal mucosa
nas	nasal cavity
ner	nervous system
ntu	nasal turbinate
omt	omentum
opx	oropharynx
ova	ovary
pal	palate
pan	pancreas
pdu	pancreatic duct
pec	peritoneal cavity
per	peritoneum
phr	pharynx
pit	pituitary gland
pls	palate, soft
pni	pancreatic islets
pnl	paranasal sinus
pns	peripheral nervous system
pre	preputial gland
pro	prostate
pty	parathyroid
rel	reticuloendothelium
res	respiratory system
ski	skin
slg	salivary gland
smi	small intestine
spl	spleen
ssq	stomach, squamous
stg	stomach, glandular
sto	*stomach*
sub	subcutaneous tissue
TBA	all tumor bearing animals, NCI/NTP
tba	all tumor bearing animals
tes	testis
thm	thymus gland
thx	thorax
thy	thyroid gland
tnv	*tunica vaginalis*
ton	tongue
trh	trachea
tyf	thyroid follicle
ubl	urinary bladder
unt	urinary tract
ute	uterus
utm	uterus/endometrium
vag	vagina
vse	vascular epithelium
zym	Zymbal's gland

APPENDIX 6: HISTOPATHOLOGY CODES AND DEFINITIONS

Code	Histopathology
a/2	adenoma/adenocarcinoma
a/a	alveolar/bronchiolar adenoma
a/c	alveolar/bronchiolar carcinoma
acc	acinar-cell carcinoma
acn	adenocarcinoma, NOS
adc	adenocarcinoma
ade	adenoma
adn	adenoma, NOS
adq	adenosquamous carcinoma
aff	adenofibroma/fibroadenoma
agm	angioma
ana	acinar-cell adenoma
ang	angiosarcoma
ast	astrocytoma
bcc	basal-cell carcinoma
bda	bile duct adenoma
bdc	bile duct carcinoma
ben	benign tumor
bsa	basophil adenoma
c/a	adenoma/carcinoma

Code	Histopathology
caa	cholangioadenoma/carcinoma
cad	cholangioadenoma
can	carcinoma, NOS
car	carcinoma
cas	carcinosarcoma
cca	c-cell adenoma
ccr	c-cell carcinoma
cho	cholangioma
cla	clear-cell adenoma
clc	cholangiocarcinoma
coa	cortical adenoma
cvh	cavernous hemangioma
cyc	cystadenocarcinoma
cye	cystadenoma
cyn	cystadenoma, NOS
epc	epidermoid carcinoma
ept	epidermoid tumor
esa	eosinophilic adenoma
esp	endometrial stromal polyp
ess	endometrial stromal sarcoma
fba	fibroadenoma
fbs	fibrosarcoma
fca	follicular-cell adenoma
fcc	follicular-cell carcinoma
fib	fibroma
gcc	granulosa-cell carcinoma
gct	granulosa-cell tumor
gli	glioma
h/2	hemangioma/hemangiosarcoma
hae	hemangioendothelioma
hca	hepatocellular carcinoma/adenoma
hct	hepatocellular tumor
hem	hemangioma
hes	hemangiosarcoma
hms	hemangioendothelial sarcoma
hnd	hyperplastic nodules
hpa	hepatocellular adenoma
hpc	hepatocellular carcinoma
hph	hepatocellular hyperplastic nodule
hps	hepatocellular carcinoma, solid
hpt	hepatoma
ica	interstitial-cell adenoma
ict	interstitial-cell tumor
isa	islet-cell adenoma
isc	islet-cell carcinoma
ivc	carcinoma, invasive
ivt	transitional-cell carcinoma, invasive
lei	leiomyosarcoma
ley	leiomyoma
lkn	leukemia, NOS
lut	luteoma
lym	lymphoma
mal	malignant tumor
mcc	mucinous carcinoma
mdt	medullary tumor
men	mesothelioma, NOS
mhb	hibernoma, malignant
mix	more than one tumor type; tumor types specified in published paper
mle	monocytic leukemia
mlh	malignant lymphoma, histiocytic type
mlm	malignant lymphoma, mixed type
mlp	malignant lymphoma, lymphocytic type
mlu	malignant lymphoma, undifferentiated type
mly	malignant lymphoma
mnl	mononuclear-cell leukemia
mno	malignant lymphoma, NOS
msm	mesothelioma, malignant
mso	mesothelioma
mtb	mixed tumor, benign
mtm	mixed tumor, malignant
MXA	more than one tumor type, combined by NCI/NTP
MXB	more than one tumor type, combined by Berkeley
nfs	neurofibrosarcoma
ngs	neurogenic sarcoma
nnd	neoplastic nodule
nvc	carcinoma, noninvasive
nvt	transitional-cell carcinoma, noninvasive
olc	olfactory carcinoma
pac	papillary adenocarcinoma
pam	papilloma
pcy	papillary cystadenoma, NOS
phe	pheochromocytoma
phm	pheochromocytoma, malignant
pla	polypoid adenoma
pmc	papillary carcinoma
pol	polyp
ppa	papillary adenoma
ppn	papilloma, NOS
rcs	round-cell sarcoma
sar	sarcoma
scs	spindle-cell sarcoma
sea	sebaceous adenoma
spt	spindle-cell tumor
sqc	squamous-cell carcinoma
sqi	squamous-cell carcinoma, invasive
sqn	squamous-cell carcinoma, in situ
sqp	squamous-cell papilloma
squ	squamous-cell carcinoma, unclassified
srn	sarcoma, NOS
ssc	squamous-cell carcinoma, sebaceous
tcc	transitional-cell carcinoma
thc	hepatocellular carcinoma, trabecular
tla	tubular-cell adenoma
tpp	transitional-cell papilloma
tri	trichoepithelioma
tua	tubular adenoma
tum	tumor or more than one tumor type; tumor types not specified in published paper
uac	tubular-cell adenocarcinoma
ulc	undifferentiated carcinoma
ule	undifferentiated leukemia

NOS = not otherwise specified.

APPENDIX 7: NOTECODES AND DEFINITIONS

Code	Definition
a	The exposure time reported on the plot is an average of the different exposure times of the individual dose groups in the experiment. For NCI/NTP bioassays, both exposure and experiment times have been averaged because of differential survival among the dose groups. (In the TD50 calculation for the NCI/NTP bioassays, full lifetable data have been used.)
b	Diet was specially prepared to be deficient in one or more vitamins.
c	Diet was specially prepared to be low in lipotropes.
e	For the general literature we have used an effective

Code	Definition
	number of animals in a group whenever possible. This effective number is either: (1) the number of animals examined, or (2) the number of animals alive at the time of appearance of the first tumor.
f	Diet was specially prepared to have a lower than average protein level.
g	Some or all of the animals were used as breeders during the course of the experiment.
i	Dosing in this test was intermittent; it was stopped for more than one week at some point in the experiment.
j	The data for this test have been previously published in the database. The experimental results have been revised and re-published by the authors. In the database, we give the same reference number to the test in both publications.
k	For interim and serial sacrifice experiments, we have reported, as a separate experiment, each sacrifice time that otherwise met the inclusion rules of the database. The k notecode identifies these sacrificed groups. Wherever possible, we have included unscheduled deaths with the terminal sacrifice data, and when this has been done, there is no k notecode for that experiment.
r	Restricted site analysis; the authors either examined or chose to report data for only a few selected tissues.
s	Authors noted that survival was decreased due to toxicity or disease.
v	Variable or irregular dosing schedules have been used, e.g., dose level changed during the experiment.
y	Animals were dosed for only 25 weeks; one week short of the standard criterion. Due to rounding, 6 months is reported as the exposure time on the plot.

APPENDIX 8: DOSE-RESPONSE CURVE SYMBOLS AND DEFINITIONS

Code	Dose-Response Curve
*	consistent with linearity
/	significant departure from linearity, upward curvature
\	significant departure from linearity, downward curvature
Z	significant departure from linearity, more than three dose groups including controls
blank	either no dose-related effect, or only two dose groups including controls, so not enough information to determine a curve shape

APPENDIX 9: REFERENCE CODES AND DEFINITIONS

Code	Reference
acnr	Anticancer Research
ajpa	American Journal of Pathology
ajsu	American Journal of Surgery
amet	Advances in Modern Environmental Toxicology
anes	Anesthesiology
apms	Acta Pathologica et Microbiologica Scandinavica Section A. Pathology
arzn	Arzneimittel-Forschung
canc	Cancer
canr	Cancer Research
carc	Carcinogenesis
ciit	A Chronic Inhalation Toxicology Study in Rats and Mice Exposed to Formaldehyde. (K.L. Pavkov, W.D. Kerns, R.I. Mitchell, M.M. Connell, D.J. Donofrio, H.H. Harroff, A.D. Barker, G.L. Fisher, R.L. Joiner, D.C. Thake) Final Report, CIIT Docket #10922. Chemical Industry Institute of Toxicology, Research Triangle Park, NC, 1981.
clet	Cancer Letters
ctfr	A Twenty-Four Month Inhalation Toxicology Study in Fischer-344 Rats Exposed to Atmospheric Toluene. (E.J. Gralla) Final Report, CIIT Docket #22000. Chemical Industry Institute of Toxicology, Research Triangle Park, NC, 1980.
dact	Drug and Chemical Toxicology
eaes	Ecotoxicology and Environmental Safety
eamp	Experimental and Molecular Pathology
enhp	Environmental Health Perspectives
faat	Fundamental and Applied Toxicology
fctx	Food and Chemical Toxicology (formerly Food and Cosmetics Toxicology, until 1982)
gann	Gann
hepg	Hepato-gastroenterology
hijm	Hiroshima Journal of Medical Sciences
iarc	IARC Scientific Publication #31. (E.A. Walker, L. Griciute, M. Castegnaro, and M. Borzsonyi, Eds.), World Health Organization, International Agency for Research on Cancer, Lyon, France, 1980.
ijcn	International Journal of Cancer (formerly International Union Against Cancer. Acta. Vol 1–20, 1936–64)
ijmr	Indian Journal of Medical Research
ijvn	International Journal for Vitamin and Nutrition Research
indh	Industrial Health
jcph	Journal of Clinical Pharmacology
jctx	Journal of Combustion Toxicology
jfds	Journal of Food Safety
jjem	Japanese Journal of Experimental Medicine
jnci	Journal of the National Cancer Institute (U.S. National Cancer Institute. Journal)
jsac	Journal of Studies on Alcohol
jtxe	Journal of Toxicology and Environmental Health
livt	Laboratory Investigation
onco	Oncology
pffm	Plant Foods for Man
pjpa	Proceedings of the Japan Academy
pseb	Proceedings of the Society for Experimental Biology and Medicine (New York)
sjge	Scandinavian Journal of Gastroenterology
txap	Toxicology and Applied Pharmacology
txcy	Toxicology
txlt	Toxicology Letters
zkko	Journal of Cancer Research and Clinical Oncology (formerly Zeitschrift fur Krebsforschung und Klinische Onkologie through Vol 9, 1979)

APPENDIX 10: NCI/NTP BIOASSAYS EVALUATED AS INADEQUATE IN TECHNICAL REPORTS

Chemical Name	Experiments Evaluated as Inadequate
CHLORODIBROMOMETHANE	male mice (low dose)
HC RED NO. 3	female mice
TELONE II	male mice

APPENDIX 11: AUTHOR'S OPINION CODES AND DEFINITIONS

Code	Author's Opinion for Each Site
a	NTP evaluation is "some evidence of carcinogenicity".
c	NTP evaluation is "clear evidence of carcinogenicity".
e	NTP evaluation is "equivocal evidence of carcinogenicity".
+	Author in general literature evaluated site as positive.
–	NTP evaluation of experiment is "no evidence of carcinogenicity" ("–" is given for most potent site in the experiment); or author in general literature evaluated site as negative.
blank	For NTP and general literature: all other sites.

APPENDIX 12
Bibliography: General Literature

1. Abe, I., Saito, S., Hori, K., Suzuki, M., and Sato, H. Sodium erythorbate is not carcinogenic in F344 rats. Exp. Mol. Pathol. 41: 35–43(1984).
2. Angsubhakorn, S., Bhamarapravati, N., Romruen, K., and Sahaphong, S. Enhancing effects of dimethylnitrosamine on aflatoxin B1 hepatocarcinogenesis in rats. Int. J. Cancer 28: 621–626(1981).
3. Arai, M., and Hibino, T. Tumorigenicity of citrinin in male F344 rats. Cancer Lett. 17: 281–287(1983).
4. Arai, M., St. John, M., Fukushima, S., Friedell, G. H., and Cohen, S. M. Long-term dose response study of N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide-induced urinary bladder carcinogenesis. Cancer Lett. 18: 261–269(1983).
5. Baden, J. M., Egbert, B., and Mazze, R. I. Carcinogen bioassay of enflurane in mice. Anesthesiology 56: 9–13(1982).
6. Bhide, S. V., Bhalerao, E. B., Sarode, A. V., and Maru, G. B. Mutagenicity and carcinogenicity of mono- and diacetyl hydrazine. Cancer Lett. 23: 235–240(1984).
7. Bhide, S. V., Gothoskar, S. V., and Shivapurkar, N. M. Arecoline tumorigenicity in Swiss strain mice on normal and vitamin B deficient diet. Cancer Res. Clin. Oncol. 107: 169–171(1984).
8. Boberg, E. W., Miller, E. C., Miller, J. A., Poland, A., and Liem, A. Strong evidence from studies with brachymorphic mice and pentachlorophenol that 1′-sulfooxysafrole is the major ultimate electrophilic and carcinogenic metabolite of 1′-hydroxysafrole in mouse liver. Cancer Res. 43: 5163–5173(1983).
9. Burek, J. D., Nitschke, K. D., Bell, T. J., Wackerle, D. L., Childs, R. C., Beyer, J. E., Dittenber, D. A., Rampy, L. W., and McKenna, M. J. Methylene chloride: a two-year inhalation toxicity and oncogenicity study in rats and hamsters. Fundam. Appl. Toxicol. 4: 30–47(1984).
10. Carr, B. I., Reilly, J. G., Smith, S. S., Winberg, C., and Riggs, A. The tumorigenicity of 5-azacytidine in the male Fischer rat. Carcinogenesis 5: 1583–1590(1984).
11. Case, M. T., Sibinski, L. J., and Steffen, G. R. Chronic oral toxicity and oncogenicity studies of flecainide, an antiarrhythmic, in rats and mice. Toxicol. Appl. Pharmacol. 73: 232–242(1984).
12. Cohen, S. M., Arai, M., Jacobs, J. B., and Friedell, G. H. Promoting effect of saccharin and DL-tryptophan in urinary bladder carcinogenesis. Cancer Res. 39: 1207–1217(1979).
13. Della Porta, G., and Dragani, T. A. Carcinogenicity study in mice on pildralazine, a hydralazinelike antihypertensive compound. Cancer Res. Clin. Oncol. 106: 97–101(1983).
14. Della Porta, G., Dragani, T. A., Barale, R., and Zucconi, D. Carcinogenic activity in mice of diftalone, an anti-inflammatory agent. Cancer Res. Clin. Oncol. 108: 308–311(1984).
15. Domellof, L., Eriksson, S., Mori, H., Weisburger, J. H., and Williams, G. M. Effect of bile acid gavage or vagotomy and pyloroplasty on gastrointestinal carcinogenesis. Am. J. Surg. 142: 551–554(1981).
16. Drew, R. T., Boorman, G. A., Haseman, J. K., McConnell, E. E., Busey, W. M., and Moore, J. A. The effect of age and exposure duration on cancer induction by a known carcinogen in rats, mice, and hamsters. Toxicol. Appl. Pharmacol. 68: 120–130(1983).
17. Dunsford, H. A., Keysser, C. H., Dolan, P. M., Seed, J. L., and Bueding, E. Carcinogenicity of the antischistosomal nitrofuran trans-5-amino-3-[2-(5-nitro-2-furyl)vinyl]-1,2,4-oxadiazole. J. Nat. Cancer Inst. 73: 151–160(1984).
18. Ebert, A. G. The dietary administration of monosodium glutamate or glutamic acid to C-57 black mice for two years. Toxicol. Lett. 3: 65–70(1979).
19. Eisenbrand, G., Habs, M., Schmahl, D., and Preussman, R. Carcinogenicity of N-nitroso-3-hydroxypyrrolidine and dose-response study with N-nitrosopiperidine in rats. In: IARC Scientific Publication #31. (E. A. Walker, L. Griciute, M. Castegnaro, and M. Borzsonyi, Eds.), World Health Organization, International Agency for Research on Cancer, Lyon, France, 1980, pp. 657–663.
20. Endo, H., Takahashi, K., Kinoshita, N., and Baba, T. Production of gastric and esophageal tumors in rats by

methylnitrosocyanamide, a possible candidate of etiologic factors for human gastric cancer. Proc. Japan Acad. 50: 497–502(1974).
21. Enomoto, M., Naoe, S., Harada, M., Miyata, K., Saito, M., and Noguchi, Y. Carcinogenesis in extrahepatic bile duct and gallbladder — carcinogenic effect of N-hydroxy-2-acetamidofluorene in mice fed a "gallstone-inducing" diet. Jpn. J. Exp. Med. 44: 37–54(1974).
22. Faccini, J. M., Irisarri, E., and Monro, A. M. A carcinogenicity study in mice of a beta-adrenergic antagonist, primidolol; increased total tumour incidence without tissue specificity. Toxicology 21: 279–290(1981).
23. Fitzgerald, J. E., de la Iglesia, F. A., and McGuire, E. J. Carcinogenicity studies in rodents with ripazepam, a minor tranquilizing agent. Fundam. Appl. Toxicol. 4: 178–190(1984).
24. Flaks, A., and Flaks, B. Induction of liver cell tumours in IF mice by paracetamol. Carcinogenesis 4: 363–368(1983).
25. Frankel, H. H., Yamamoto, R. S., Weisburger, E. K., and Weisburger, J. H. Chronic toxicity of azathioprine and the effect of this immunosuppressant on liver tumor induction by the carcinogen N-hydroxy-N-2-fluorenylacetamide. Toxicol. Appl. Pharmacol. 17: 462–480(1970).
26. Fukuda, K., Takemoto, K., and Tsuruta, H. Inhalation carcinogenicity of trichloroethylene in mice and rats. Ind. Health 21: 243–254(1983).
27. Fukushima, S., Arai, M., Nakanowatari, J., Hibino, T., Okuda, M., and Ito, N. Differences in susceptibility to sodium saccharin among various strains of rats and other animal species. Gann 74: 8–20(1983).
28. Garman, R. H., Snellings, W. M., and Maronpot, R. R. Brain tumors in F344 rats associated with chronic inhalation exposure to ethylene oxide. Neurotoxicology 6: 117–138(1985).
29. Gibson, J. E., and Hardisty, J. F. Chronic toxicity and oncogenicity bioassay of inhaled toluene in Fischer-344 rats. Fundam. Appl. Toxicol. 3: 315–319(1983).
30. Goodall, C. M., and Lijinsky, W. Carcinogenesis by N-nitrosohexamethyleneimine in NZO inbred mice. Toxicology 33: 251–259(1984).
31. Goodall, C. M., and Lijinsky, W. Carcinogenicity of nitrosododecamethyleneimine in NZR/Gd inbred rats. Carcinogenesis 5: 537–540(1984).
32. Gralla, E. J. A twenty-four month inhalation toxicology study in Fischer-344 rats exposed to atmospheric toluene. Final Report, CIIT Docket #22000. Chemical Industry Institute of Toxicology, Research Triangle Park, NC, 1980.
33. Grasso, P., and Gray, T. J. B. Long-term studies on chemically induced liver enlargement in the rat. III. Structure and behaviour of the hepatic nodular lesions induced by Ponceau MX. Toxicology 7: 327–347(1977).
34. Griciute, L. Investigation on the combined action of N-nitrosodiethylamine with other carcinogens. In: IARC Scientific Publication #31. (E. A. Walker, L. Griciute, M. Castegnaro, and M. Borzsonyi, Eds.), World Health Organization, International Agency for Research on Cancer, Lyon, France, 1980, pp. 813–822.
35. Griffin, T. B., Stein, A. A., and Coulston, F. Inhalation exposure of rats to vapors of 1-nitropropane at 100 ppm. Ecotoxicol. Environ. Saf. 6: 268–282(1982).
36. Habs, M., Eisenbrand, G., Habs, H., and Schmahl, D. No evidence of carcinogencity of N-nitrosocimetidine in rats. Hepato-Gastroenterol. 29: 265–266(1982).
37. Habs, M., Habs, H., Berger, M. R., and Schmahl, D. Negative dose-response study for carcinogenicity of orally administered rutin sulfate in Sprague-Dawley rats. Cancer Lett. 23: 103–108(1984).
38. Habs, M., Habs, H., and Bertram, B. Carcinogenicity of di(N-nitroso) perhydropyrimidine (DNPP) after repeated low-dose intraperitoneal administration to rats. Cancer Res. Clin. Oncol. 105: 191–193(1983).
39. Hagiwara, A., Shibata, M., Hirose, M., Fukushima, S., and Ito, N. Long-term toxicity and carcinogenicity study of sodium o-phenylphenate in B6C3F1 mice. Food Chem. Toxicol. 22: 809–814(1984).
40. Haley, T. J., Farmer, J., Jaques, W. E., Frith, C., Sprowls, R. W., and Schieferstein, G. Dose-response hyperplasia and neoplasia from feeding N-2-fluorenylacetamide (2-FAA) to BALB/c mice for varying time intervals (39350). Proc. Soc. Exp. Biol. Med. 152: 156–159(1976).
41. Hecht, S. S., Young, R., and Maeura, Y. Comparative carcinogenicity in F344 rats and Syrian golden hamsters of N′-nitrosonornicotine and N′-nitrosonornicotine-1-N-oxide. Cancer Lett. 20: 333–340(1983).
42. Hiraga, K., and Fujii, T. Induction of tumours of the urinary bladder in F344 rats by dietary administration of o-phenylphenol. Food Chem. Toxicol. 22: 865–870(1984).
43. Hirono, I., Kuhara, K., Yamaji, T., Hosaka, S., and Golberg, L. Carcinogenicity of dextran sulfate sodium in relation to its molecular weight. Cancer Lett. 18: 29–34(1983).
44. Ikeda, Y., Horiuchi, S., Imoto, A., Kodama, Y., Aida, Y., and Kobayashi, K. Induction of mammary gland and skin tumours in female rats by the feeding of benzyl violet 4B. Toxicology 2: 275–284(1974).
45. Imaida, K., Ishihara, Y., Nishio, O., Nakanishi, K., and Ito, N. Carcinogenicity and toxicity tests on p-phenylenediamine in F344 rats. Toxicol. Lett. 16: 259–269(1983).
46. Ito, A., Naito, M., Naito, Y., and Watanabe, H. Tumorigenicity test of N-(5-nitro-2-furfurylidene)-1-aminohydantoin by dietary administration in BDF1 mice. Hiroshima J. Med. Sci. 32: 99–102(1983).
47. Ito, N., Fukushima, S., Hagiwara, A., Shibata, M., and Ogiso, T. Carcinogenicity of butylated hydroxyanisole in F344 rats. J. Nat. Cancer Inst. 70: 343–352(1983).
48. Ito, N., Ogiso, T., Fukushima, S., Shibata, M., and Hagiwara, A. Carcinogenicity of captafol in B6C3F1 mice. Gann 75: 853–865(1984).
49. Ito, N., Shirai, T., Fukushima, S., and Hirose, M. Dose-response study of urinary bladder carcinogenesis

in rats by N-butyl-N-(4-hydroxybutyl) nitrosamine. Cancer Res. Clin. Oncol. 108: 169–173(1984).
50. Jack, D., Poynter, D., and Spurling, N. W. Beta-adrenoceptor stimulants and mesovarian leiomyomas in the rat. Toxicology 27: 315–320(1983).
51. Jemec, B. Studies of the tumorigenic effect of two goitrogens. Cancer 40: 2188–2202(1977).
52. Kandarkar, Y., Munir, K. M., Bhide, S. V., and Sirsat, S. M. Ultrastructural study of hepatocellular carcinoma induced by hexachlorocyclohexane. Indian J. Med. Res. 78: 155–161(1983).
53. Kerns, W. D., Pavkov, K. L., Donofrio, D. J., Gralla, E. J., and Swenberg, J. A. Carcinogenicity of formaldehyde in rats and mice after long-term inhalation exposure. Cancer Res. 43: 4382–4392(1983).
54. Ketkar, M. B., Fuhst, R., Preussmann, R., and Mohr, U. The carcinogenic effect of nitrosopiperidine administered in the drinking water of Syrian golden hamsters. Cancer Lett. 21: 219–224(1983).
55. Ketkar, M. B., Holste, J., Preussmann, R., and Althoff, J. Carcinogenic effect of nitrosomorpholine administered in the drinking water to Syrian golden hamsters. Cancer Lett. 17: 333–338(1983).
56. Keyes, D. G., Kociba, R. J., Schwetz, R. W., Wade, C. E., Dittenber, D. A., Quinn, T., Gorzinski, S. J., Hermann, E. A., Momany, J. J., and Schwetz, B. A. Results of a two-year toxicity and oncogenic study of rats ingesting diets containing dibromoneopentyl glycol (FR-1138). J. Combust. Toxicol. 7: 77–98(1980).
57. Kiaer, H. W., Glavind, J., and Arffmann, E. Carcinogenicity in mice of some fatty acid methyl esters. Acta Pathol. Microbiol. Scand. Sect. A. Suppl. 83: 550–558(1975).
58. Kroeger-Koepke, M. B., Reuber, M. D., Iype, P. T., Lijinsky, W., and Michejda, C. J. The effect of substituents in the aromatic ring on carcinogenicity of N-nitrosomethylaniline in F344 rats. Carcinogenesis 4: 157–160(1983).
59. Kumagai, H., Kawaura, A., Shibata, M., and Otsuka, H. Carcinogenicity of dipyrone in (C57Bl/6 x C3H)f1 mice. J. Nat. Cancer Inst. 71: 1295–1297(1983).
60. Kunze, E., Woltjen, H. H., Hartmann, B., and Engelhardt, W. Animal experiments regarding a possible carcinogenic effect of phenacetin on the resting and proliferating urothelium stimulated by cyclophosphamide. Cancer Res. Clin. Oncol. 105: 38–47(1983).
61. Kurokawa, Y., Hayashi, Y., Maekawa, A., Takahashi, M., Kokubo, T., and Odashima, S. Carcinogenicity of potassium bromate administered orally to F344 rats. J. Nat. Cancer Inst. 71: 965–972(1983).
62. Lawson, T. A., Mirvish, S. S., Pour, P., and Williams, G. Persistence of DNA single-strand breaks and other tests as indicators of the liver carcinogenicity of 1-nitroso-5,6-dihydrouracil and the noncarcinogenicity of 1-nitroso-5,6-dihydrothymine. J. Nat. Cancer Inst. 73: 515–519(1984).
63. Lee, K. P., Schneider, P. W., and Trochimowicz, H. J. Morphologic expression of glandular differentiation in the epidermoid nasal carcinomas induced by phenylglycidyl ether inhalation. Am. J. Pathol. 111: 140–148(1983).
64. Lijinsky, W. Chronic toxicity tests of pyrilamine maleate and methapyrilene hydrochloride in F344 rats. Food Chem. Toxicol. 22: 27–30(1984).
65. Lijinsky, W. Induction of tumors of the nasal cavity in rats by concurrent feeding of thiram and sodium nitrite. J. Toxicol. Environ. Health 13: 609–614(1984).
66. Lijinsky, W. Induction of tumours in rats by feeding nitrosatable amines together with sodium nitrite. Food Chem. Toxicol. 22: 715–720(1984).
67. Lijinsky, W., Knutsen, G. L., and Kovatch, R. M. Comparative carcinogenesis by hydroxylated nitrosopropylamines in Syrian hamsters. J. Nat. Cancer Inst. 74: 923–926(1985).
68. Lijinsky, W., Knutsen, G. L., and Reuber, M. D. Carcinogenicity of methylated nitrosopiperazines in rats and hamsters. Carcinogenesis 4: 1165–1167(1983).
69. Lijinsky, W., Knutsen, G., and Reuber, M. D. Failure of methapyrilene to induce tumors in hamsters or guinea pigs. J. Toxicol. Environ. Health 12: 653–657(1983).
70. Lijinsky, W., and Kovatch, R. M. Induction of liver tumors in rats by nitrosodiethanolamine at low doses. Carcinogenesis 6: 1697–1681(1985).
71. Lijinsky, W., Kovatch, R. M., and Knutsen, G. L. Carcinogenesis by nitrosomorpholines, nitrosooxazolidines and nitrosoazetidine given by gavage to Syrian golden hamsters. Carcinogenesis 5: 875–878(1984).
72. Lijinsky, W., Kovatch, R. M., and Knutsen, G. L. Carcinogenesis by oxygenated nitrosomethylpropylamines in Syrian hamsters. Cancer Res. Clin. Oncol. 109: 1–4(1985).
73. Lijinsky, W., Kovatch, R., and Riggs, C. W. Altered incidences of hepatic and hemopoietic neoplasms in F344 rats fed sodium nitrite. Carcinogenesis 4: 1189–1191(1983a).
74. Lijinsky, W., and Reuber, M. D. Carcinogenesis in Fischer rats by nitrosodipropylamine, nitrosodibutylamine and nitrosobis(2-oxopropyl)amine given by gavage. Cancer Lett. 19: 207–213(1983).
75. Lijinsky, W., and Reuber, M. D. Carcinogenesis in rats by nitrosodimethylamine and other nitrosomethylalkylamines at low doses. Cancer Lett. 22: 83–88(1984).
76. Lijinsky, W., and Reuber, M. D. Chronic toxicity studies of vinyl acetate in Fischer rats. Toxicol. Appl. Pharmacol. 68: 43–53(1983).
77. Lijinsky, W., and Reuber, M. D. Comparison of nitrosocimetidine with nitrosomethylnitroguanidine in chronic feeding tests in rats. Cancer Res. 44: 447–449(1984).
78. Lijinsky, W., and Reuber, M. D. Dose-response study with N-nitrosodiethanolamine in F344 rats. Food Chem. Toxicol. 22: 23–26(1984).
79. Lijinsky, W., Reuber, M. D., and Riggs, C. W. Carcinogenesis by combinations of N-nitroso compounds in rats. Food Chem. Toxicol. 21: 601–605(1983).
80. Lijinsky, W., Reuber, M. D., and Saavedra, J. E. The effect of deuterium substitution on carcinogenesis by azoxymethane. Cancer Lett. 24: 273–280(1984).
81. Lijinsky, W., Saavedra, J. E., and Reuber, M. D. Carcinogenesis in F-344 rats by nitrosobis(2-

oxopropyl)amine and related compounds administered in drinking water. Cancer Res. Clin. Oncol. 107: 178–182(1984).
82. Lijinsky, W., Saavedra, J. E., and Reuber, M. D. Carcinogenesis in rats by some hydroxylated acyclic nitrosamines. Carcinogenesis 5: 167–170(1984).
83. Lijinsky, W., Saavedra, J. E., and Reuber, M. D. Organ-specific carcinogenesis in rats by methyl- and ethylazoxyalkanes. Cancer Res. 45: 76–79(1985a).
84. Lijinsky, W., Singer, G. M., Saavedra, J. E., and Reuber, M. D. Carcinogenesis in rats by asymmetric nitrosamines containing an allyl group. Cancer Lett. 22: 281–288(1984).
85. Littlefield, N. A., Nelson, C. J., and Frith, C. H. Benzidine dihydrochloride: toxicological assessment in mice during chronic exposures. J. Toxicol. Environ. Health 12: 671–685(1983).
86. Littlefield, N. A., Nelson, C. J., and Gaylor, D. W. Benzidine dihydrochloride: risk assessment. Fundam. Appl. Toxicol. 4: 69–80(1984).
87. Longstaff, E., Robinson, M., Bradbrook, C., Styles, J. A., and Purchase, I. F. H. Genotoxicity and carcinogenicity of fluorocarbons: assessment by short-term in vitro tests and chronic exposure in rats. Toxicol. Appl. Pharmacol. 72: 15–31(1984).
88. Lynch, D. W., Lewis, T. R., Moorman, W. J., Burg, J. R., Groth, D. H., Khan, A., Ackerman, L. J., and Cockrell, B. Y. Carcinogenic and toxicologic effects of inhaled ethylene oxide and propylene oxide in F344 rats. Toxicol. Appl. Pharmacol. 76: 69–84(1984).
89. Maekawa, A., Ogiu, T., Matsuoka, C., Onodera, H., Furuta, K., Kurokawa, Y., Takahashi, M., Kokubo, T., Tanigawa, H., Hayashi, Y., Nakadate, M., and Tanimura, A. Carcinogenicity of low doses of N-ethyl-N-nitrosourea in F344 rats; a dose-response study. Gann 75: 117–125(1984).
90. Maekawa, A., Ogiu, T., Matsuoka, C., Onodera, H., Furuta, K., Tanigawa, H., and Odashima, S. Induction of tumors in the small intestine and mammary gland of female Donryu rats by continuous oral administration of N-carboxymethyl-N-nitrosourea. Cancer Res. Clin. Oncol. 106: 12–16(1983).
91. Maltoni, C. Early results of the experimental assessments of the carcinogenic effects of one epoxy solvent: styrene oxide. Adv. Mod. Environ. Toxicol. 2: 97–110(1981).
92. Masuda, M., and Takayama, S. Intestinal tumours in rats induced by mutagens from glutamic acid pyrolysate. Exp. Pathol. 26: 123–129(1984).
93. McGuinness, E. E., Hopwood, D., and Wormsley, K. G. Potentiation of pancreatic carcinogenesis in the rat by DL-ethionine-induced pancreatitis. Scand. J. Gastroenterol. 18: 189–192(1983).
94. Menon, M. M., and Bhide, S. V. Perinatal carcinogenicity of isoniazid (INH) in Swiss mice. Cancer Res. Clin. Oncol. 105: 258–261(1983).
95. Miller, E. C., Swanson, A. B., Phillips, D. H., Fletcher, T. L., Liem, A., and Miller, J. A. Structure-activity studies of the carcinogenicities in the mouse and rat of some naturally occurring and synthetic alkenylbenzene derivatives related to safrole and estragole. Cancer Res. 43: 1124–1134(1983).
96. Mohr, U., Althoff, J., Ketkar, M. B., Conradt, P., and Morgareidge, K. The influence of caffeine on tumour incidence in Sprague-Dawley rats. Food Chem. Toxicol. 22: 377–382(1984).
97. Morishita, Y., and Shimizu, T. Promoting effect of intestinal Pseudomonas aeruginosa on gastric tumorigenesis in rats with N-methyl-N′-nitro-N-nitrosoguanidine. Cancer Lett. 17: 347–352(1983).
98. Murasaki, G., and Cohen, S. M. Co-carcinogenicity of sodium saccharin and N-[4-(5-nitro-2-furyl)-2-thiazoyl]formamide for the urinary bladder. Carcinogenesis 4: 97–99(1983).
99. National Cancer Institute. Report on carcinogenesis bioassay of chloroform. N.C.I. Brief Communication. 1976.
100. Newberne, P. M., and Rogers, A. E. Nutrition, monocrotaline, and aflatoxin B1 in liver carcinogenesis. Plant Foods Man 1: 23–31(1973).
101. Ogiu, T., Matsuoka, C., Furuta, K., Takeuchi, M., Maekawa, A., Nakadate, M., and Odashima, S. Induction of angiogenic tumors in the duodenum of female Donryu rats by continuous oral administration of N-isobutyl-N-nitrosourea. Gann 74: 342–350(1983).
102. Ohgaki, H., Kusama, K., Matsukura, N., Morino, K., Hasegawa, H., Sato, S., Takayama, S., and Sugimura, T. Carcinogenicity in mice of a mutagenic compound, 2-amino-3-metylimidazo[4,5-f]quinoline, from broiled sardine, cooked beef and beef extract. Carcinogenesis 5: 921–924(1984).
103. Ohgaki, H., Matsukura, N., Morino, K., Kawachi, T., Sugimura, T., and Takayama, S. Carcinogenicity in mice of mutagenic compounds from glutamic acid and soybean globulin pyrolysates. Carcinogenesis 5: 815–819(1984).
104. Ohshima, M., Ward, J. M., Brennan, L. M., and Creasia, D. A. A sequential study of methapyrilene hydrochloride-induced liver carcinogenesis in male F344 rats. J. Nat. Cancer Inst. 72: 759–768(1984).
105. Parker, C. M., Patterson, D. R., Van Gelder, G. A., Gordon, E. B., Valerio, M. G., and Hall, W. C. Chronic toxicity and carcinogenicity evaluation of fenvalerate in rats. J. Toxicol. Environ. Health 13: 83–97(1984).
106. Pavkov, K. L., Kerns, W. D., Mitchell, R. I., Connell, M. M., Donofrio, D. J., Harroff, H. H., Barker, A. D., Fisher, G. L., Joiner, R. L., and Thake, D. C. A chronic inhalation toxicology study in rats and mice exposed to formaldehyde. Final Report, CIIT Docket #10922. Chemical Industry Institute of Toxicology, Research Triangle Park, NC, 1981.
107. Pour, P. M. Prostatic cancer induced in MRC rats by N-nitrosobis(2-oxopropyl)-amine and N-nitrosobis(2-hydroxypropyl)amine. Carcinogenesis 4: 49–55(1983).
108. Preussmann, R., Habs, M., Habs, H., and Stummeyer, D. Fluoro-substituted N-nitrosamines. 6. Carcinogenicity of N-nitroso-(2,2,2-trifluoroethyl)-ethylamine in rats. Carcinogenesis 4: 755–757(1983).
109. Quast, J. F., Humiston, C. G., Wade, C. E., Ballard,

J., Beyer, J. E., Schwetz, R. W., and Norris, J. M. A chronic toxicity and oncogenicity study in rats and subchronic toxicity study in dogs on ingested vinylidene chloride. Fundam. Appl. Toxicol. 3: 55–62(1983).

110. Rao, M. S., Lalwani, N. D., Watanabe, T. K., and Reddy, J. K. Inhibitory effect of antioxidants ethoxyquin and 2(3)-tert-butyl-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisome proliferator. Cancer Res. 44: 1072–1076(1984).
111. Reddy, J. K., Rao, M. S., Azarnoff, D. L., and Sell, S. Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator,[4-chloro-6-(2, 3-xylidino)-2-pyrimidinylthio]acetic acid [Wy-14,643], in rat and mouse liver. Cancer Res. 29: 152–161(1979).
112. Reichert, D., Spengler, U., Romen, W., and Henschler, D. Carcinogenicity of dichloroacetylene: an inhalation study. Carcinogenesis 5: 1411–1420(1984).
113. Reznik, G., Reznik-Schuller, H. M., Rice, J. M., and Hague, B. F. Pathogenesis of toxic and neoplastic renal lesions induced by the flame retardant tris(2,3-dibromopropyl)phosphate in F344 rats, and development of colonic adenomas after prolonged oral administration. Lab. Invest. 44: 74–83(1981).
114. Rossi, L., Barbieri, O., Sanguineti, M., Cabral, J. R. P., Bruzzi, P., and Santi, L. Carcinogenicity study with technical-grade dichlorodiphenyltrichloroethane and 1,1-dichloro-2,2-bis(p-chlorophenyl) ethylene in hamsters. Cancer Res. 43: 776–781(1983).
115. Saito, M., Horiuchi, T., Ohtsubo, K., Hatanaka, Y., and Ueno, Y. Low tumor incidence in rats with long-term feeding of fusarenon-x, a cytotoxic trichothecene produced by Fusarium nivale. Jpn. J. Exp. Med. 50: 293–302(1980).
116. Schaeffer, E., Greim, H., and Goessner, W. Pathology of chronic polychlorinated biphenyl (PCB) feeding in rats. Toxicol. Appl. Pharmacol. 75: 278–288(1984).
117. Schmahl, D. Investigations on the influence of immunodepressive means on the chemical carcinogenesis in rats. Cancer Res. Clin. Oncol. 81: 211–215(1974).
118. Schmahl, D., and Habs, M. Carcinogenic action of low-dose cyclophosphamide given orally to Sprague-Dawley rats in a lifetime experiment. Int. J. Cancer 23: 706–712(1979).
119. Schrauzer, G. N., McGinness, J. E., Ishmael, D., and Bell, L. J. Alcoholism and cancer: I. Effects of long-term exposure to alcohol on spontaneous mammary adenocarcinoma and prolactin levels in C3H/St mice. J. Stud. Alcohol 40: 240–246(1979).
120. Snellings, W. M., Weil, C. S., and Maronpot, R. R. A two-year inhalation study of the carcinogenic potential of ethylene oxide in Fischer 344 rats. Toxicol. Appl. Pharmacol. 75: 105–117(1984).
121. Steinhoff, D., Weber, H., Mohr, U., and Boehme, K. Evaluation of amitrole (aminotriazole) for potential carcinogenicity in orally dosed rats, mice, and golden hamsters. Toxicol. Appl. Pharmacol. 69: 161–169(1983).
122. Stoewsand, G. S., Anderson, J. L., Boyd, J. N., Hrzadina, G., Babish, J. G., Walsh, K. M., and Losco, P. Quercetin: a mutagen, not a carcinogen, in Fischer rats. J. Toxicol. Environ. Health 14: 105–114(1984).
123. Tacchi, A. M., Schmahl, D., and Habs, M. Delay of bladder cancer induction in rats treated with N-nitroso-N-butyl-N-(4-hydroxybutyl)amine by administration of sodium-2-mercaptoethanesulfonate (Mesna). Cancer Lett. 22: 89–94(1984).
124. Takanashi, H., Aiso, S., Hirono, I., Matsushima, T., and Sugimura, T. Carcinogenicity test of quercetin and kaempferol in rats by oral administration. J. Food Saf. 5: 55–60(1983).
125. Takayama, S., Masuda, M., Mogami, M., Ohgaki, H., Sato, S., and Sugimura, T. Induction of cancers in the intestine, liver and various other organs of rats by feeding mutagens from glutamic acid pyrolysate. Gann 75: 207–213(1984).
126. Takeuchi, M., Ogiu, T., Matsuoka, C., Furuta, K., Maekawa, A., Nakadate, M., and Odashima, S. Induction of digestive-tract tumors in F344 rats by continuous oral administration of N-butyl-N-nitrosourea. Cancer Res. Clin. Oncol. 107: 32–37(1984).
127. Tannenbaum, A., and Silverstone, H. Effect of low environmental temperature, dinitrophenol, or sodium fluoride on the formation of tumors in mice. Cancer Res. 9: 403–410(1949).
128. Toth, B. Effects of lifelong administration of beta-phenylisopropylhydrazine hydrochloride and thiocarbamylhydrazine in mice. Fundam. Appl. Toxicol. 2: 173–176(1982).
129. Toth, B. Lack of carcinogenicity of nicotinamide and isonicotinamide following lifelong administration to mice. Oncology 40: 72–75(1983).
130. Toth, B., Nagel, D., and Patil, K. Tumorigenic action of N-N-butyl-N-formylhydrazine in mice. Carcinogenesis 1: 589–593(1980).
131. Toth, B., Nagel, D., and Raha, C. Tumorigenesis with 1,1-diallylhydrazine in mice. Anticancer Res. 1: 259–262(1981).
132. Toth, B., Patil, K., Erickson, J., and Kupper, R. False morel mushroom Gyromitra esculenta toxin: N-methyl-N-formylhydrazine carcinogenesis in mice. Mycopathologia 68: 121–128(1979).
133. Tsai, T. H., Beitman, R. E., Gibson, J. P., Larson, E. J., Friehe, H., and Fontaine, R. Acute, subacute and chronic toxicity/carcinogenicity of lofexidine. Arzneim. -Forsch. 31: 955–962(1982).
134. Tsung-Hsien, C., Yu-Chung, L., Kwang-Yung, L., Cheng-Hsien, S., and Yee-Ping, C. Cocarcinogenic action of aspirin on gastric tumors induced by nitroso-N-methylnitroguanidine in rats. J. Nat. Cancer Inst. 70: 1067–1069(1983).
135. Van Ryzin, R. J., and Trapold, J. H. The toxicology profile of the anti-inflammatory drug proquazone in animals. Drug Chem. Toxicol. 3: 361–379(1980).
136. Wang, C. Y., Croft, W. A., and Bryan, G. T. Tumor production in germ-free rats fed 5-nitrofurans. Cancer Lett. 21: 303–308(1984).
137. Weikel Jr., J. H., and Kelly, W. A. Tumorigenicity assays of sotalol hydrochloride in rats and mice. J. Clin. Pharmacol. 19: 591–604(1979).

138. Weisburger, E. K. Carcinogenicity studies on halogenated hydrocarbons. Environ. Health Perspect. 21: 7–16(1977).
139. Wheldon, G. H., Bhatt, A., Keller, P., and Hummler, H. D,l-alpha-tocopheryl acetate (vitamin E): a long term toxicity and carcinogenicity study in rats. Int. J. Vitam. Nutr. Res. 53: 287–296(1983).

APPENDIX 13:

Bibliography: National Cancer Institute/ National Toxicology Program Technical Reports

CHEMICAL NAME	TECHNICAL REPORT NUMBER	PUBLICATION DATE
ALLYL ISOVALERATE	253	1983
L-ASCORBIC ACID (VITAMIN C)	247	1983
BENZENE	289	1986
C.I. DISPERSE BLUE 1	299	1986
HC BLUE NO. 1	271	1985
HC BLUE NO. 2	293	1985
1,3-BUTADIENE	288	1984
N-BUTYL CHLORIDE	312	1986
CHLORINATED PARAFFINS (C23, 43% CHLORINE)	305	1986
CHLORINATED PARAFFINS (C12, 60% CHLORINE)	308	1986
CHLOROBENZENE	261	1985
CHLORODIBROMOMETHANE	282	1985
DECABROMODIPHENYL OXIDE	309	1986
DIALLYL PHTHALATE (mice)	242	1983
DIALLYL PHTHALATE (rats)	284	1985
1,2-DICHLOROBENZENE	255	1985
DICHLOROMETHANE (METHYLENE CHLORIDE)	306	1986
DIMETHYL HYDROGEN PHOSPHITE	287	1985
DIMETHYL MORPHOLINOPHOSPHORAMIDATE	298	1986
EPHEDRINE SULPHATE	307	1986
EUGENOL	223	1983
8-HYDROXYQUINOLINE	276	1985
ISOPHORONE	291	1986
MELAMINE	245	1983
4,4'-METHYLENEDIANILINE DIHYDROCHLORIDE	248	1983
PENTACHLOROETHANE	232	1983
POLYBROMINATED BIPHENYL MIXTURE	244	1983
PROPYLENE	272	1985
1,2-PROPYLENE OXIDE	267	1985
HC RED NO. 3	281	1986
C.I. BASIC RED 9 MONOHYDROCHLORIDE	285	1986
TELONE II	269	1985
1,1,1,2-TETRACHLOROETHANE	237	1983
TETRACHLOROETHYLENE (PERCHLOROETHYLENE)	311	1986
TRIS(2-ETHYLHEXYL)PHOSPHATE	274	1984
ZIRAM	238	1983

APPENDIX 14: INDEX TO CHEMICAL NAMES IN ALL PLOTS

PLOT	CAS NUMBER	CHEMICAL NAME
3	26148-68-5	A-alpha-C (see 2-AMINO-9H-PYRIDO(2,3-b)INDOLE)
2	16568-02-8	ACETALDEHYDE METHYLFORMYLHYDRAZONE
1	60-35-5	ACETAMIDE
1,3	103-90-2	ACETAMINOPHEN
1	968-81-0	ACETOHEXAMIDE
1	18523-69-8	ACETONE[4-(5-NITRO-2-FURYL)-2-THIAZOLYL] HYDRAZONE
2	127-06-0	ACETOXIME
1	34627-78-6	1'-ACETOXYSAFROLE
1	65734-38-5	N'-ACETYL-4-(HYDROXYMETHYL)PHENYLHYDRAZINE
1	1078-38-2	1-ACETYL-2-ISONICOTINOYLHYDRAZINE
1	520-45-6	3-ACETYL-6-METHYL-2,4-PYRANDIONE
1	114-83-0	1-ACETYL-2-PHENYLHYDRAZINE
1	4075-79-0	4-ACETYLAMINOBIPHENYL
1	28314-03-6	1-ACETYLAMINOFLUORENE
1,2,3	53-96-3	2-ACETYLAMINOFLUORENE
1	28322-02-3	4-ACETYLAMINOFLUORENE
1	---	ACETYLATED DIAMYLOPECTIN PHOSPHATE
1	---	ACETYLATED DISTARCH ADIPATE
1	---	ACETYLATED DISTARCH GLYCEROL
1	---	ACETYLATED DISTARCH PHOSPHATE
1,2	3567-69-9	C.I. ACID RED 14, DISODIUM SALT (see C.I. FOOD RED 3)
1	7008-42-6	ACRONYCINE
1	107-13-1	ACRYLONITRILE
1	50-76-0	ACTINOMYCIN D
1	8052-16-2	ACTINOMYCIN C
1	628-94-4	ADIPAMIDE
1	3688-53-7	AF-2
1	29611-03-8	AFLATOXICOL
1,3	1162-65-8	AFLATOXIN B1
1	---	AFLATOXIN, CRUDE
2	9002-18-0	AGAR
2	2757-90-6	AGARITINE (see beta-N-[gamma-L(+)-GLUTAMYL]-4-HYDROXYMETHYLPHENYLHYDRAZINE)
1	101-73-5	AGERITE 150 (see p-ISOPROPOXYDIPHENYLAMINE)
1	103-16-2	AGERITE ALBA (see HYDROQUINONE MONOBENZYL ETHER)
1	74-31-7	AGERITE DPPD (see DIPHENYL-p-PHENYLENEDIAMINE)
1,2	135-88-6	AGERITE POWDER (see PHENYL-beta-NAPHTHYLAMINE)
1	93-46-9	AGERITE WHITE (see sym.-dibeta-NAPHTHYL-p-PHENYLENEDIAMINE)
1	54-80-8	ALDERLIN (see PRONETHALOL)
1	51-02-5	ALDERLIN.HCl (see PRONETHALOL.HCl)
1	116-06-3	ALDICARB
1	309-00-2	ALDRIN
1	---	ALKYLBENZENESULFONATE, LINEAR
3	97-59-6	ALLANTOIN
1	107-05-1	ALLYL CHLORIDE
2	57-06-7	ALLYL ISOTHIOCYANATE
3	2835-39-4	ALLYL ISOVALERATE
3	97-53-0	1-ALLYL-3-METHOXY-4-HYDROXYBENZENE (see EUGENOL)
1	52207-83-7	ALLYLHYDRAZINE.HCl
1	120-78-5	ALTAX (see BENZOTHIAZYL DISULFIDE)
1	---	ALUMINUM POTASSIUM SULFATE
1	915-67-3	AMARANTH (see FD & C RED NO. 2)
1	102-77-2	AMAX (see N-OXYDIETHYLENEBENZOTHIAZOLE-2-SULFENAMIDE)
1	97-56-3	2-AMINO-5-AZOTOLUENE (see o-AMINOAZOTOLUENE)
1	75104-43-7	3-AMINO-1,4-DIMETHYL-5H-PYRIDO[4,3-b]INDOLE ACETATE
1	97-56-3	4-AMINO-2,3-DIMETHYLAZOBENZENE (see o-AMINOAZOTOLUENE)
1	17026-81-2	3-AMINO-4-ETHOXYACETANILIDE
1	6109-97-3	3-AMINO-9-ETHYLCARBAZOLE.HCl
1	mixture	3-AMINO-9-ETHYLCARBAZOLE MIXTURE
1	4363-03-5	4-AMINO-3-HYDROXYBIPHENYL (see 3-HYDROXY-4-AMINOBIPHENYL)
1	59-05-2	4-AMINO-N10-METHYL-PTEROYLGLUTAMIC ACID (see METHOTREXATE)
3	68006-83-7	2-AMINO-3-METHYL-9H-PYRIDO-[2,3-b]-INDOLE
1	72254-58-1	3-AMINO-1-METHYL-5H-PYRIDO[4,3-b]INDOLE ACETATE
1	82-28-0	1-AMINO-2-METHYLANTHRAQUINONE
3	67730-11-4	2-AMINO-6-METHYLDIPYRIDO[1,2-a:3',2'-d]IMIDAZOLE
3	76180-96-6	2-AMINO-3-METHYLIMIDAZO[4,5-f]QUINOLINE
1	3775-55-1	2-AMINO-5-(5-NITRO-2-FURYL)-1,3,4-OXADIAZOLE
1	712-68-5	2-AMINO-5-(5-NITRO-2-FURYL)-1,3,4-THIADIAZOLE
1,2	38514-71-5	2-AMINO-4-(5-NITRO-2-FURYL)THIAZOLE
3	28754-68-9	trans-5-AMINO-3[2-(5-NITRO-2-FURYL)VINYL-1,2,4-OXADIAZOLE
1	119-34-6	4-AMINO-2-NITROPHENOL
1	2104-09-8	2-AMINO-4-(p-NITROPHENYL)THIAZOLE
1	121-66-4	2-AMINO-5-NITROTHIAZOLE
1	18968-99-5	2-AMINO-5-PHENYL-2-OXAZOLIN-4-ONE + Mg(OH)2
3	26148-68-5	2-AMINO-9H-PYRIDO(2,3-b)INDOLE
1	117-79-3	2-AMINOANTHRAQUINONE
1	97-56-3	o-AMINOAZOTOLUENE
1	118-92-3	AMINOBENZOIC ACID (see ANTHRANILIC ACID)
1	92-67-1	p-AMINOBIPHENYL (see 4-AMINODIPHENYL)
1	92-67-1	4-AMINODIPHENYL
1	3693-22-9	2-AMINODIPHENYLENE OXIDE
3	67730-10-3	2-AMINODIPYRIDO[1,2-a:3',2'-d]IMIDAZOLE
1	119-34-6	p-AMINONITROPHENOL (see 4-AMINO-2-NITROPHENOL)
1,3	61-82-5	3-AMINOTRIAZOLE
2	2432-99-7	11-AMINOUNDECANOIC ACID
1,3	61-82-5	AMITROL (see 3-AMINOTRIAZOLE)
1	12125-02-9	AMMONIUM CHLORIDE
1	3012-65-5	AMMONIUM CITRATE
1	1336-21-6	AMMONIUM HYDROXIDE
1	10589-74-9	1-AMYL-1-NITROSOUREA
2	---	1-AMYL-1-NITROSOURETHAN (see NITROSOAMYLURETHAN)
1	1119-68-2	n-AMYLHYDRAZINE.HCl (see n-PENTYLHYDRAZINE.HCl)
3	104-46-1	ANETHOLE
1	15879-93-3	ANHYDROGLUCOCHLORAL
1	101-05-3	ANILAZINE
1	62-53-3	ANILINE
1	142-04-1	ANILINE.HCl
1	134-29-2	o-ANISIDINE.HCl
1	20265-97-8	p-ANISIDINE.HCl
1	118-92-3	ANTHRANILIC ACID
1	84-65-1	9,10-ANTHRAQUINONE
1	28300-74-5	ANTIMONY POTASSIUM TARTRATE
3	518-75-2	ANTIMYCIN (see CITRININ)
1	60-80-0	ANTIPYRINE (see PHENAZONE)
1	86-88-4	ANTU (see 1-(1-NAPHTHYL)-2-THIOUREA)
1	8003-03-0	APC (see ASPIRIN, PHENACETIN, AND CAFFEINE)
1	140-57-8	ARAMITE
3	61-94-9	ARECOLINE.HCl
1	27323-18-8	AROCLOR 1254
1,3	11096-82-5	AROCLOR 1260
1	7631-89-2	ARSENATE, SODIUM
1	1327-53-3	ARSENIC TRIOXIDE (see ARSENIOUS OXIDE)
1	1327-53-3	ARSENIOUS OXIDE
1	7784-46-5	ARSENITE, SODIUM
3	50-81-7	L-ASCORBIC ACID
1	22839-47-0	ASPARTAME
1,3	50-78-2	ASPIRIN
1	8003-03-0	ASPIRIN, PHENACETIN, AND CAFFEINE
1	1912-24-9	ATRAZINE
1	51-55-8	ATROPINE
1	2465-27-2	AURAMINE-O
1	2303-16-4	AVADEX (see DIALLATE)
1	320-67-2	5-AZACYTIDINE
1,3	115-02-6	AZASERINE
3	446-86-6	AZATHIOPRINE
1	26628-22-8	AZIDE, SODIUM
1	86-50-0	AZINPHOSMETHYL
1	103-33-3	AZOBENZENE
3	25843-45-2	AZOXYMETHANE
1	543-80-6	BARIUM ACETATE
1	542-88-1	BCME (see BIS-(CHLOROMETHYL) ETHER)
1,3	71-43-2	BENZENE

PLOT	CAS NUMBER	CHEMICAL NAME
1	319-84-6	alpha-BENZENE HEXACHLORIDE (see alpha-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE)
2	369-57-3	BENZENEDIAZONIUM TETRAFLUOROBORATE
1	5351-65-5	BENZENESULPHONOHYDRAZIDE
1	613-94-5	BENZHYDRAZIDE (see BENZOYL HYDRAZINE)
1	92-87-5	BENZIDINE
2,3	531-85-1	BENZIDINE.2HCl
1,2,3	50-32-8	BENZO(a)PYRENE
1	532-32-1	BENZOATE, SODIUM
1	91-76-9	BENZOGUANAMINE
2	119-53-9	BENZOIN
1	91-64-5	1,2-BENZOPYRONE
1	51542-33-7	1-(2'-BENZOTHIAZOLYL)-3-METHYL-3-NITROSOUREA (see N-NITROSOBENZTHIAZURON)
1	120-78-5	BENZOTHIAZYL DISULFIDE
1	95-14-7	1H-BENZOTRIAZOLE
1	613-94-5	BENZOYL HYDRAZINE
1,2,3	50-32-8	BENZPYRENE (see BENZO(a)PYRENE)
1,2,3	50-32-8	3,4-BENZPYRENE (see BENZO(a)PYRENE)
1,3	1694-09-3	BENZYL VIOLET 4B (see FD & C VIOLET NO. 1)
1	20570-96-1	BENZYLHYDRAZINE.2HCl
1	13510-49-1	BERYLLIUM SULFATE
2,3	25013-16-5	BHA (see BUTYLATED HYDROXYANISOLE)
1,2	128-37-0	BHT (see BUTYLATED HYDROXYTOLUENE)
1	92-52-4	BIPHENYL
2	2185-92-4	2-BIPHENYLAMINE.HCl
1,2	108-60-1	BIS(2-CHLORO-1-METHYLETHYL) ETHER
1	111-44-4	*BIS-2-CHLOROETHYLETHER*
1	---	BIS-1,4-(CHLOROMETHOXY)BUTANE
1	13483-18-6	BIS-1,2-(CHLOROMETHOXY)ETHANE
1	---	*BIS-1,6-(CHLOROMETHOXY)HEXANE*
1	56894-91-8	BIS-1,4-(CHLOROMETHOXY)-p-XYLENE
1	542-88-1	BIS-(CHLOROMETHYL) ETHER
1	---	*4-BIS(2-HYDROXYETHYL)AMINO-2-(5-NITRO-2-THIENYL)QUINAZOLINE*
1	58139-47-2	4-BIS(2-HYDROXYETHYL)AMINO-2-(2-THIENYL) *QUINAZOLINE*
1	23746-34-1	BIS-2-HYDROXYETHYLDITHIOCARBAMIC ACID, POTASSIUM
1,3	*53609-64-6*	*N-BIS(2-HYDROXYPROPYL)NITROSAMINE* (see N-NITROSOBIS(2-HYDROXYPROPYL)AMINE)
3	54143-56-5	2,5-BIS(2,2,2-TRIFLUORETHOXYL)-N-(2-PIPERIDYLMETHYL)BENZAMIDE ACETATE (see FLECAINIDE ACETATE)
1	21260-46-8	BISMATE (see BISMUTH DIMETHYLDITHIOCARBAMATE)
1	21260-46-8	BISMUTH DIMETHYLDITHIOCARBAMATE
1	7787-59-9	BISMUTH OXYCHLORIDE
2	80-05-7	BISPHENOL A
1	2519-30-4	BLACK PN
1	1937-37-7	C.I. DIRECT BLACK 38
1	3844-45-9	FD & C BLUE NO. 1
1	860-22-0	FD & C BLUE NO. 2
3	2784-94-3	HC BLUE NO. 1
3	33229-34-4	HC BLUE NO. 2
3	2475-45-8	C.I. DISPERSE BLUE 1
1	2602-46-2	C.I. DIRECT BLUE 6
1	109-84-2	BOH (see 2-HYDROXYETHYLHYDRAZINE)
1	99-30-9	BOTRAN (see 2,6-DICHLORO-4-NITROANILINE)
1	2519-30-4	BRILLIANT BLACK BN (see BLACK PN)
1	3844-45-9	BRILLIANT BLUE FCF (see FD & C BLUE NO. 1)
1,2	5160-02-1	BRILLIANT RED (see D & C RED NO. 9)
1,3	7758-01-2	BROMATE, POTASSIUM
1	77-65-6	BROMODIETHYLACETYLUREA (see CARBROMAL)
1	16071-86-6	C.I. DIRECT BROWN 95
1	5351-65-5	BSH (see BENZENESULPHONOHYDRAZIDE)
1	55-98-1	BUSULFAN (see MYLERAN)
1	---	*BUTACIDE* (see *PIPERONYL BUTOXIDE IN SOLVENT*)
3	106-99-0	1,3-BUTADIENE
2	85-68-7	BUTYL BENZYL PHTHALATE
1,3	*3817-11-6*	*BUTYL-BUTANOL-NITROSAMINE* (see *N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE*)
3	109-69-3	N-BUTYL CHLORIDE
1	88-85-7	*2-sec-BUTYL-4,6-DINITROPHENOL*
1	---	N-N-BUTYL-N-FORMYLHYDRAZINE
2,3	25013-16-5	2(3)-tert-BUTYL-4-HYDROXYANISOLE (see BUTYLATED HYDROXYANISOLE)
1,3	3817-11-6	N-BUTYL-N-(4-HYDROXYBUTYL)NITROSAMINE
1	---	DI-tert-BUTYL-4-HYDROXYMETHYL PHENOL
1	*13010-08-7*	*N-BUTYL-N'-NITRO-N-NITROSOGUANIDINE*
3	869-01-2	N-N-BUTYL-N-NITROSOUREA
1	136-23-2	BUTYL ZIMATE (see ZINC DIBUTYLDITHIOCARBAMATE)
2,3	25013-16-5	BUTYLATED HYDROXYANISOLE
1,2	128-37-0	BUTYLATED HYDROXYTOLUENE
1	---	1,1-DI-N-BUTYLHYDRAZINE
1	56795-65-4	N-BUTYLHYDRAZINE.HCl
1	7422-80-2	1,2-DI-N-BUTYLHYDRAZINE.2HCl
1	592-31-4	N-BUTYLUREA
1	3068-88-0	beta-BUTYROLACTONE
1	75-60-5	CACODYLIC ACID (see DIMETHYLARSINIC ACID)
1	543-90-8	CADMIUM ACETATE
1	35658-65-2	CADMIUM CHLORIDE MONOHYDRATE
1	14239-68-0	CADMIUM DIETHYLDITHIOCARBAMATE
1	7790-84-3	CADMIUM SULPHATE
1,2,3	58-08-2	CAFFEINE
1	8003-03-0	CAFFEINE, ASPIRIN, AND PHENACETIN (see ASPIRIN, PHENACETIN, AND CAFFEINE)
1	156-62-7	CALCIUM CYANAMIDE (see CYANAMIDE, CALCIUM)
2	105-60-2	CAPROLACTAM
3	2425-06-1	CAPTAFOL
1	133-06-2	CAPTAN
1	149-30-4	CAPTAX (see 2-MERCAPTOBENZOTHIAZOLE)
1	563-41-7	CARBAMYL HYDRAZINE.HCl
1	103-03-7	1-CARBAMYL-2-PHENYLHYDRAZINE
1	121-59-5	CARBARSONE
1	63-25-2	CARBARYL
2	86-74-8	CARBAZOLE
1,3	56-23-5	CARBON TETRACHLORIDE
1,3	60391-92-6	CARBOXYMETHYLNITROSOUREA
1	77-65-6	CARBROMAL
1,2	3567-69-9	CARMOISINE (see C.I. FOOD RED 3)
2	9000-40-2	CAROB SEED GUM (see LOCUST BEAN GUM)
1,2	---	*CARRAGEENAN, ACID-DEGRADED*
1	9000-07-1	CARRAGEENAN, NATIVE
1	999-81-5	CCC (see (2-CHLOROETHYL)TRIMETHYLAMMONIUM *CHLORIDE*)
1	122-34-9	CDT (see SIMAZINE)
1	9004-32-4	CELLULOSE CARBOXYMETHYL ETHER, SODIUM (see *EDIFAS B*)
1	474-25-9	CHENODEOXYCHOLIC ACID
1	15879-93-3	alpha-CHLORALOSE (see ANHYDROGLUCOCHLORAL)
1	133-90-4	*CHLORAMBEN*
1	305-03-3	CHLORAMBUCIL
1	56-75-7	CHLORAMPHENICOL
1	118-75-2	CHLORANIL
1	106-47-8	4-CHLORANILIC (see p-CHLOROANILINE)
1,2	57-74-9	CHLORDANE
1	143-50-0	CHLORDECONE (see KEPONE)
1	80-33-1	CHLORFENSON (see p-CHLOROPHENYL-p-CHLOROBENZENE SULFONATE)
3	63449-39-8	CHLORINATED PARAFFINS (C23, 43% CHLORINE)
3	63449-39-8	CHLORINATED PARAFFINS (C12, 60% CHLORINE)
1	7782-50-5	CHLORINE
1	302-22-7	CHLORMADINONE ACETATE
1	101-79-1	4-CHLORO-4'-AMINODIPHENYLETHER
1	24358-29-0	2-CHLORO-5-(3,5-DIMETHYLPIPERIDINOSULPHONYL) BENZOIC ACID
1	97-00-7	1-CHLORO-2,4-DINITROBENZENE
1	100-00-5	1-CHLORO-4-NITROBENZENE
1	88-73-3	1-CHLORO-2-NITROBENZENE
1	95-83-0	4-CHLORO-o-PHENYLENEDIAMINE
1	5131-60-2	4-CHLORO-m-PHENYLENEDIAMINE
1	61702-44-1	2-CHLORO-p-PHENYLENEDIAMINE SULFATE
1	95-74-9	3-CHLORO-p-TOLUIDINE
1	95-79-4	5-CHLORO-o-TOLUIDINE
1	3165-93-3	4-CHLORO-o-TOLUIDINE.HCl
3	75-88-7	*2-CHLORO-1,1,1-TRIFLUOROETHANE* (see FLUOROCARBON 133a)
1,3	50892-23-4	[4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYLTHIO] *ACETIC ACID*
1	---	4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYLTHIO (N-beta-HYDROXYETHYL)ACETAMIDE
1	107-20-0	*CHLOROACETALDEHYDE*

PLOT	CAS NUMBER	CHEMICAL NAME
1	140-49-8	4'-(CHLOROACETYL)-ACETANILIDE
1	106-47-8	p-CHLOROANILINE
3	108-90-7	CHLOROBENZENE
1	510-15-6	CHLOROBENZILATE
3	124-48-1	CHLORODIBROMOMETHANE
1	54749-90-5	2-[3-(2-CHLOROETHYL)-3-NITROSOUREIDO]-D-GLUCOPYRANOSE (see CHLOROZOTOCIN)
1	999-81-5	(2-CHLOROETHYL)TRIMETHYLAMMONIUM CHLORIDE
3	593-70-4	CHLOROFLUOROMETHANE (see FLUOROCARBON 31)
1	67-66-3	CHLOROFORM
1	107-30-2	CHLOROMETHYL METHYL ETHER
1	6959-47-3	2-(CHLOROMETHYL)PYRIDINE.HCl
1	6959-48-4	3-(CHLOROMETHYL)PYRIDINE.HCl
1	56-75-7	CHLOROMYCETIN (see CHLORAMPHENICOL)
1	100-00-5	p-CHLORONITROBENZENE (see 1-CHLORO-4-NITROBENZENE)
1	80-33-1	p-CHLOROPHENYL-p-CHLOROBENZENE SULFONATE
1	150-68-5	3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA
1	10473-70-8	1-(4-CHLOROPHENYL)-1-PHENYL-2-PROPYNYL CARBAMATE
1	2227-13-6	p-CHLOROPHENYL-2,4,5-TRICHLOROPHENYL SULFIDE
1	94-20-2	1-(p-CHLOROPHENYLSULFONYL)-3-PROPYLUREA (see CHLORPROPAMIDE)
1	76-06-2	CHLOROPICRIN
1	683-50-1	2-CHLOROPROPANAL
1	107-05-1	CHLOROPROPENE (see ALLYL CHLORIDE)
1	590-21-6	1-CHLOROPROPENE
1	1897-45-6	CHLOROTHALONIL
3	63449-39-8	CHLOROWAX 40 (see CHLORINATED PARAFFINS (C23, 43% CHLORINE))
3	63449-39-8	CHLOROWAX 500c (see CHLORINATED PARAFFINS (C12, 60% CHLORINE))
1	54749-90-5	CHLOROZOTOCIN
3	113-92-8	CHLORPHENIRAMINE MALEATE
1	94-20-2	CHLORPROPAMIDE
1	101-21-3	CHLORPROPHAM (see ISOPROPYL-N-(3-CHLOROPHENYL)CARBAMATE)
1	2921-88-2	CHLORPYRIFOS (see O,O-DIETHYL-O-(3,5,6-TRICHLORO-2-PYRIDYL)PHOSPHOROTHIOATE)
1	12236-46-3	CHOCOLATE BROWN FB
1	4553-89-3	CHOCOLATE BROWN HT
1	1308-38-9	CHROMIC OXIDE PIGMENT
1	1066-30-4	CHROMIUM (III) ACETATE
2	87-29-6	CINNAMYL ANTHRANILATE
1	101-21-3	CIPC (see ISOPROPYL-N-(3-CHLOROPHENYL) CARBAMATE)
3	52214-84-3	CIPROFIBRATE
3	518-75-2	CITRININ
1	33979-15-6	CLIVORINE
1	637-07-0	CLOFIBRATE
1	43054-45-1	CLOMIPHENE CITRATE
1	1420-04-8	CLONITRALID
1,3	11096-82-5	CLOPHEN A 60 (see AROCLOR 1260)
3	55600-34-5	CLOPHEN A 30
1	107-30-2	CMME (see CHLOROMETHYL METHYL ETHER)
1,3	60391-92-6	CMNU (see CARBOXYMETHYLNITROSOUREA)
1	477-30-5	COLCEMID
3	65765-07-3	COMPOUND 50-892
1	---	CONJUGATED EQUINE ESTROGENS (see PREMARIN)
1	137-29-1	COPPER DIMETHYLDITHIOCARBAMATE
1	10380-28-6	COPPER-8-HYDROXYQUINOLINE
1	56-72-4	COUMAPHOS
1	91-64-5	COUMARIN (see 1,2-BENZOPYRONE)
1	120-71-8	p-CRESIDINE
1	102-50-1	m-CRESIDINE
1	137-29-1	CUMATE (see COPPER DIMETHYLDITHIOCARBAMATE)
1	135-20-6	CUPFERRON
1	156-62-7	CYANAMIDE, CALCIUM
3	51630-58-1	CYANO-(3-PHENOXYPHENYL)METHYL-4-CHLORO-alpha-(1-METHYLETHYL)BENZENE ACETATE (see FENVALERATE)
1	139-05-9	CYCLAMATE, SODIUM
2	55268-74-1	2-CYCLO-HEXYL-CARBONYL-1,3,4,6,7,11-b-HEXAHYDRO-2-H-PYRAZINE(2,1-a)ISOQUINOLINE-4-ONE (see PRAZIQUANTEL)
1	12663-46-6	CYCLOCHLOROTINE
1	95-33-0	N-CYCLOHEXYL-2-BENZOTHIAZOLE SULFENAMIDE
1	4998-76-9	CYCLOHEXYLAMINE.HCl
1	19834-02-7	CYCLOHEXYLAMINE SULFATE
1,3	50-18-0	CYCLOPHOSPHAMIDE
2	16170-75-5	CYTEMBENA
2	538-41-0	DAAB (see 4,4'-DIAMINOAZOBENZENE)
1	60-11-7	DAB (see N,N-DIMETHYL-4-AMINOAZOBENZENE)
2	785-30-8	DABA (see 4,4'-DIAMINOBENZANILIDE)
1	4342-03-4	DACARBAZINE
1	1897-45-6	DACONIL (see CHLOROTHALONIL)
1	1596-84-5	DAMINOZIDE
1	80-08-0	DAPSONE
1	58-14-0	DARAPRIN (see PYRIMETHAMINE)
1	96-12-8	DBCP (see 1,2-DIBROMO-3-CHLOROPROPANE)
1	488-41-5	DBM (see DIBROMOMANNITOL)
1	91-94-1	DCB (see 3,3'-DICHLOROBENZIDINE)
1	33857-26-0	DCDD (see 2,7-DICHLORODIBENZO-p-DIOXIN)
1	53-19-0	o,p'-DDD
1	72-54-8	p,p'-DDD
1,3	72-55-9	p,p'-DDE
1,3	50-29-3	DDT
1	62-73-7	DDVP (see DICHLORVOS)
3	1163-19-5	DECABROMODIPHENYL OXIDE
1	576-68-1	DEGRANOL (see MANNITOL NITROGEN MUSTARD)
1	520-45-6	DEHYDROACETIC ACID (see 3-ACETYL-6-METHYL-2,4-PYRANDIONE)
1,3	55-18-5	DEN (see N-NITROSODIETHYLAMINE)
1	625-89-8	6-F-DEN (see N-NITROSOBIS(2,2,2-TRIFLUOROETHYL) AMINE)
1	64039-27-6	beta-2'-DEOXY-6-THIOGUANOSINE MONOHYDRATE (see beta-THIOGUANINE DEOXYRIBOSIDE)
1	56-53-1	DES (see DIETHYLSTILBESTROL)
1	131-01-1	DESERPIDINE
3	9004-54-0	DEXTRAN
2,3	9011-18-1	DEXTRAN SULFATE SODIUM (DS-M-1)
3	9011-18-1	DEXTRAN SULFATE SODIUM (DST-H)
3	9011-18-1	DEXTRAN SULFATE SODIUM (KMDS-H)
1	---	N-1-DIACETAMIDOFLUORENE
3	3148-73-0	DIACETYL HYDRAZINE
1	2303-16-4	DIALLATE
3	131-17-9	DIALLYL PHTHALATE
3	5164-11-4	1,1-DIALLYLHYDRAZINE
2	---	1,2-DIALLYLHYDRAZINE.2HCl
1	720-69-4	4,6-DIAMINO-2-(5-NITRO-2-FURYL)-s-TRIAZINE
1	39156-41-7	2,4-DIAMINOANISOLE SULFATE
2	538-41-0	4,4'-DIAMINOAZOBENZENE
2	785-30-8	4,4'-DIAMINOBENZANILIDE
1	7411-49-6	3,3'-DIAMINOBENZIDINE.4HCl (see 3,3',4,4'-TETRAAMINOBIPHENYL.4HCl)
1	2243-62-1	1,5-DIAMINONAPHTHALENE (see 1,5-NAPHTHALENEDIAMINE)
1	95-80-7	2,4-DIAMINOTOLUENE
1	636-23-7	2,4-DIAMINOTOLUENE.2HCl
2	15481-70-6	2,6-DIAMINOTOLUENE.2HCl
1	6369-59-1	2,5-DIAMINOTOLUENE SULFATE
1	6358-85-6	DIARYLANILIDE YELLOW (see C.I. PIGMENT YELLOW 12)
1	333-41-5	DIAZINON
1	53-70-3	DIBENZ(a,h)ANTHRACENE
1	262-12-4	DIBENZO-p-DIOXIN
1	4106-66-5	3-DIBENZOFURANAMINE
1	96-12-8	1,2-DIBROMO-3-CHLOROPROPANE
3	124-48-1	DIBROMOCHLOROMETHANE (see CHLORODIBROMOMETHANE)
1	10318-26-0	DIBROMODULCITOL
1	106-93-4	1,2-DIBROMOETHANE
1	488-41-5	DIBROMOMANNITOL
3	3296-90-0	DIBROMONEOPENTYL GLYCOL
2	34522-69-5	5,7-DIBROMOQUINOLINE
1	56654-52-5	1,3-DIBUTYL-1-NITROSOUREA
1,3	924-16-3	DIBUTYLNITROSAMINE (see NITROSODIBUTYLAMINE)
1	1067-33-0	DIBUTYLTIN DIACETATE
1	4342-03-4	DIC (see DACARBAZINE)
1	117-80-6	DICHLONE (see 2,3-DICHLORO-1,4-NAPHTHOQUINONE)
1	51-75-2	DICHLOREN (see NITROGEN MUSTARD)
1	8001-50-1	DICHLORICIDE MOTHPROOFER (see STROBANE)
1	101-14-4	3,3'-DICHLORO-4,4'-DIAMINODIPHENYLMETHANE (see 4,4'-METHYLENE-BIS(2-CHLOROANILINE))

PLOT	CAS NUMBER	CHEMICAL NAME
2	23950-58-5	3,5-DICHLORO(N-1,1-DIMETHYL-2-PROPYNYL) BENZAMIDE
1	3883-43-0	2,3-DICHLORO-p-DIOXANE
1	87-56-9	alpha,beta-DICHLORO-beta-FORMYLACRYLIC ACID
1	2164-09-2	3,4'-DICHLORO-2-METHYLACRYLANILIDE
1	51-75-2	2,2'-DICHLORO-N-METHYLDIETHYLAMINE (see NITROGEN MUSTARD)
1	117-80-6	2,3-DICHLORO-1,4-NAPHTHOQUINONE
1	99-30-9	2,6-DICHLORO-4-NITROANILINE
2	609-20-1	2,6-DICHLORO-p-PHENYLENEDIAMINE
3	7572-29-4	DICHLOROACETYLENE
3	95-50-1	o-DICHLOROBENZENE (see 1,2-DICHLOROBENZENE)
3	95-50-1	1,2-DICHLOROBENZENE
1	91-94-1	3,3'-DICHLOROBENZIDINE
1	110-57-6	trans-1,4-DICHLOROBUTENE-2
1	33857-26-0	2,7-DICHLORODIBENZO-p-DIOXIN
1	107-06-2	1,2-DICHLOROETHANE
1	75-34-3	1,1-DICHLOROETHANE
3	75-09-2	DICHLOROMETHANE (see METHYLENE CHLORIDE)
1	120-36-5	alpha-(2,4-DICHLOROPHENOXY)PROPIONIC ACID
1	6965-71-5	alpha-(2,5-DICHLOROPHENOXY)PROPIONIC ACID
1	120-36-5	2-(2,4-DICHLOROPHENOXY)PROPIONIC ACID (see alpha-(2,4-DICHLOROPHENOXY)PROPIONIC ACID)
1	94-75-7	2,4-DICHLOROPHENOXYACETIC ACID
1	94-80-4	2,4-DICHLOROPHENOXYACETIC ACID, N-BUTYL ESTER
1	25168-26-7	2,4-DICHLOROPHENOXYACETIC ACID, ISOOCTYL ESTER
1	94-11-1	2,4-DICHLOROPHENOXYACETIC ACID, ISOPROPYL ESTER
1	330-54-1	3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA
1	97-16-5	2,4-DICHLOROPHENYLBENZENE SULFONATE
3	542-75-6	1,3-DICHLOROPROPENE (see TELONE II)
3	21498-08-8	2-[1-(2,6-DICHLORPHENOXY)-ETHYL]-2-IMIDAZOLINE.HCl (see LOFEXIDINE.HCl)
1	62-73-7	DICHLORVOS
1	115-32-2	DICOFOL
1	2164-09-2	DICRYL (see 3,4'-DICHLORO-2-METHYLACRYLANILIDE)
1	1212-29-9	N,N'-DICYCLOHEXYLTHIOUREA
1	81-21-0	DICYCLOPENTADIENE DIOXIDE
1	60-57-1	DIELDRIN
1	13366-73-9	DIELDRIN, PHOTO-
1	298-18-0	D,L-DIEPOXYBUTANE
1	7316-37-2	DIETHYL-beta,gamma-EPOXYPROPYLPHOSPHONATE
1	7347-49-1	N,N-DIETHYL-4-(4'-[PYRIDYL-1'-OXIDE]AZO)ANILINE
1	2921-88-2	O,O-DIETHYL-O-(3,5,6-TRICHLORO-2-PYRIDYL) PHOSPHOROTHIOATE
1	685-91-6	DIETHYLACETAMIDE
1	148-18-5	DIETHYLDITHIOCARBAMATE TRIHYDRATE, SODIUM (see SODIUM DIETHYLDITHIOCARBAMATE TRIHYDRATE)
1	111-46-6	DIETHYLENE GLYCOL
1	617-84-5	DIETHYLFORMAMIDE
1,3	55-18-5	DIETHYLNITROSAMINE (see N-NITROSODIETHYLAMINE)
1,3	55-18-5	N,N-DIETHYLNITROSAMINE (see N-NITROSODIETHYLAMINE)
1	56-53-1	DIETHYLSTILBESTROL
1	105-55-5	N,N'-DIETHYLTHIOUREA
1	628-36-4	1,2-DIFORMYLHYDRAZINE
3	21626-89-1	DIFTALONE
3	68-89-3	(2,3-DIHYDRO-1,5-DIMETHYL-3-OXO-2-PHENYL-1H-PYRAZOL-4-YL) METHYLAMINO METHANESULFONATE MONOHYDRATE (see DIPYRONE)
1	33389-33-2	1,2-DIHYDRO-2-(5-NITRO-2-THIENYL)QUINAZOLIN-4(3H)-ONE
1	3276-41-3	3,6-DIHYDRO-2-NITROSO-2H-1,2-OXAZINE
1,2	123-33-1	1,2-DIHYDRO-3,6-PYRIDAZINEDIONE (see MALEIC HYDRAZIDE)
1	94-58-6	DIHYDROSAFROLE
1	60-51-5	DIMETHOATE
1	828-00-2	DIMETHOXANE
1	5803-51-0	2,5-DIMETHOXY-4'-AMINOSTILBENE
1	54150-69-5	2,4-DIMETHOXYANILINE.HCl
1	91-93-0	3,3'-DIMETHOXYBENZIDINE-4,4'-DIISOCYANATE
1	1146-71-0	5,7-DIMETHOXYCYCLOPENTENE[c]COUMARIN
1	1150-42-1	5,7-DIMETHOXYCYCLOPENTENONE[2,3-c]COUMARIN
1	1150-42-1	5,7-DIMETHOXYCYCLOPENTENONE[3,2-c]COUMARIN
1	60-11-7	N,N-DIMETHYL-4-AMINOAZOBENZENE
1	57-97-6	9,10-DIMETHYL-1,2-BENZANTHRACENE (see 7,12-DIMETHYLBENZ(a) ANTHRACENE)
1	3851-16-9	N,N'-DIMETHYL-N,N'-DINITROSOPHTHALAMIDE
3	868-85-9	DIMETHYL HYDROGEN PHOSPHITE
3	597-25-1	DIMETHYL MORPHOLINOPHOSPHORAMIDATE
1	59-35-8	4,6-DIMETHYL-2-(5-NITRO-2-FURYL)PYRIMIDINE
1	551-92-8	1,2-DIMETHYL-5-NITROIMIDAZOLE
1	120-61-6	DIMETHYL TEREPHTHALATE
2	25812-30-0	2,2-DIMETHYL-5-(2,5-XYLYLOXY)VALERIC ACID (see GEMFIBROZIL)
1	55738-54-0	trans-2-[(DIMETHYLAMINO)METHYLIMINO]-5-[2-(5-NITRO-2-FURYL)VINYL]-1,3,4-OXADIAZOLE
1	6120-10-1	4-DIMETHYLAMINO-3,5-XYLENOL
1	75-60-5	DIMETHYLARSINIC ACID
1	57-97-6	7,12-DIMETHYLBENZ(a)ANTHRACENE
1	79-44-7	DIMETHYLCARBAMOYL CHLORIDE (see DIMETHYLCARBAMYL CHLORIDE)
1	79-44-7	DIMETHYLCARBAMYL CHLORIDE
1	598-64-1	DIMETHYLDITHIOCARBAMIC ACID, DIMETHYLAMINE
3	1643-20-5	N,N-DIMETHYLDODECYLAMINE-N-OXIDE
1	57-14-7	1,1-DIMETHYLHYDRAZINE
1	306-37-6	1,2-DIMETHYLHYDRAZINE.2HCl
1	26049-69-4	2-(2,2-DIMETHYLHYDRAZINO)-4-(5-NITRO-2-FURYL) THIAZOLE
1	4164-28-7	DIMETHYLNITRAMINE
1,2,3	62-75-9	DIMETHYLNITROSAMINE (see N-NITROSODIMETHYLAMINE)
1,2,3	62-75-9	N,N-DIMETHYLNITROSAMINE (see N-NITROSODIMETHYLAMINE)
1	6119-92-2	DINITRO(1-METHYLHEPTYL)PHENYL CROTONATE
1	51-28-5	2,4-DINITROPHENOL
3	1011-73-0	2,4-DINITROPHENOL, SODIUM
3	55380-34-2	1,4-DINITROSO-2,6-DIMETHYLPIPERAZINE
1	55557-00-1	DINITROSOHOMOPIPERAZINE
1	101-25-7	N,N-DINITROSOPENTAMETHYLENETETRAMINE
1	140-79-4	DINITROSOPIPERAZINE
1	121-14-2	2,4-DINITROTOLUENE
1	123-91-1	p-DIOXANE (see 1,4-DIOXANE)
1	123-91-1	1,4-DIOXANE
1	78-34-2	DIOXATHION
1	1746-01-6	DIOXIN (see 2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN)
1	971-15-3	DIPENTAMETHYLENETHIURAM HEXASULFIDE
3	147-24-0	DIPHENHYDRAMINE.HCl
1	74-31-7	DIPHENYL-p-PHENYLENEDIAMINE
1	86-29-3	DIPHENYLACETONITRILE
1	102-09-0	DIPHENYLCARBONATE
1	57-41-0	5,5-DIPHENYLHYDANTOIN
1	86-30-6	DIPHENYLNITROSAMINE (see N-NITROSODIPHENYLAMINE)
1	---	N,N-DIPROPYL-4-(4'-[PYRIDYL-1'-OXIDE]AZO)ANILINE
3	621-64-7	DIPROPYLNITROSAMINE (see N-NITROSODIPROPYLAMINE)
3	68-89-3	DIPYRONE
1	142-59-6	DISODIUM ETHYLENEBISDITHIOCARBAMATE (see ETHYLENEBISDITHIOCARBAMATE, DISODIUM)
1	7757-82-6	DISODIUM SULFATE (see SULFATE, SODIUM)
1	97-77-8	DISULFIRAM (see TETRAETHYLTHIURAM DISULFIDE)
1	142-59-6	DITHANE (see ETHYLENEBISDITHIOCARBAMATE, DISODIUM)
1	142-46-1	2,5-DITHIOBIUREA
1	79-40-3	DITHIOOXAMIDE
1	330-54-1	DIURON (see 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA)
1	1596-84-5	DMASA (see DAMINOZIDE)
1	57-97-6	DMBA (see 7,12-DIMETHYLBENZ(a)ANTHRACENE)
3	868-85-9	DMHP (see DIMETHYL HYDROGEN PHOSPHITE)
1,2,3	62-75-9	DMN (see N-NITROSODIMETHYLAMINE)
1	120-61-6	DMT (see DIMETHYL TEREPHTHALATE)
1	2439-10-3	N-DODECYLGUANIDINE ACETATE
1	2439-10-3	DODINE (see n-DODECYLGUANIDINE ACETATE)
1	88-06-2	DOWICIDE-2S (see 2,4,6-TRICHLOROPHENOL)
1,3	87-86-5	DOWICIDE-7 (see 2,3,4,5,6-PENTACHLOROPHENOL)
1,3	90-43-7	DOWICIDE-1 (see o-PHENYLPHENOL)
2,3	9011-18-1	DS-M-1 (see DEXTRAN SULFATE SODIUM (DS-M-1))
3	9011-18-1	DST-H (see DEXTRAN SULFATE SODIUM (DST-H))

PLOT	CAS NUMBER	CHEMICAL NAME
1	95-33-0	DURAX (see N-CYCLOHEXYL-2-BENZOTHIAZOLE SULFENAMIDE)
1	106-93-4	EDB (see 1,2-DIBROMOETHANE)
1	107-06-2	EDC (see 1,2-DICHLOROETHANE)
1	9004-32-4	EDIFAS B
1	9004-59-5	EDIFAS A
1	150-38-9	EDTA (see EDTA, TRISODIUM SALT TRIHYDRATE)
1	150-38-9	EDTA, TRISODIUM SALT TRIHYDRATE
1	316-42-7	EMETINE.2HCl
1	55965-13-4	EMULSIFIER YN
1	115-29-7	ENDOSULFAN
1,3	50-18-0	ENDOXAN (see CYCLOPHOSPHAMIDE)
1	72-20-8	ENDRIN
3	13838-16-9	ENFLURANE
1	---	ENOVID-E
1	8015-30-3	ENOVID
3	759-73-9	ENU (see 1-ETHYL-1-NITROSOUREA)
3	134-72-5	EPHEDRINE SULPHATE
1	106-89-8	EPICHLOROHYDRIN
2,3	75-56-9	1,2-EPOXYPROPANE (see 1,2-PROPYLENE OXIDE)
3	6381-77-7	ERYTHORBATE, SODIUM
1	16423-68-0	ERYTHROSINE (see FD & C RED NO. 3)
1	50-28-2	ESTRADIOL-17beta (see ESTRADIOL)
1	50-28-2	ESTRADIOL
1	22966-79-6	ESTRADIOL MUSTARD
3	140-67-0	ESTRAGOLE
1	536-33-4	ETHIONAMIDE
1	13073-35-3	ETHIONINE
2	67-21-0	DL-ETHIONINE
3	91-53-2	ETHOXYQUIN
1,2,3	64-17-5	ETHYL ALCOHOL
1	105-36-2	ETHYL BROMOACETATE
1	14239-68-0	ETHYL CADMATE (see CADMIUM DIETHYLDITHIOCARBAMATE)
1	637-07-0	ETHYL-alpha-p-CHLOROPHENOXYISOBUTYRATE (see CLOFIBRATE)
1	2629-59-6	S-ETHYL-L-CYSTEINE
1	72-56-0	p,p'-ETHYL-DDD
1	74920-78-8	N-ETHYL-N-FORMYLHYDRAZINE
2	77-83-8	ETHYL METHYLPHENYLGLYCIDATE
1	63885-23-4	N-ETHYL-N'-NITRO-N-NITROSOGUANIDINE
3	759-73-9	N-ETHYL-N-NITROSOUREA (see 1-ETHYL-1-NITROSOUREA)
3	759-73-9	1-ETHYL-1-NITROSOUREA
2	614-95-9	1-ETHYL-1-NITROSOURETHAN (see NITROSOETHYLURETHAN)
1	5456-28-0	ETHYL SELENAC (see SELENIUM DIETHYLDITHIOCARBAMATE)
1	20941-65-5	ETHYL TELLURAC
1	97-77-8	ETHYL TUADS (see TETRAETHYLTHIURAM DISULFIDE)
1	14324-55-1	ETHYL ZIMATE (see ZINC DIETHYLDITHIOCARBAMATE)
1	106-93-4	ETHYLENE DIBROMIDE (see 1,2-DIBROMOETHANE)
1	107-06-2	ETHYLENE DICHLORIDE (see 1,2-DICHLOROETHANE)
1	1072-53-3	ETHYLENE GLYCOL
1	151-56-4	ETHYLENE IMINE
2,3	75-21-8	ETHYLENE OXIDE
1	96-45-7	ETHYLENE THIOUREA
1	120-93-4	ETHYLENE UREA
1	142-59-6	ETHYLENEBISDITHIOCARBAMATE, DISODIUM
1	106-87-6	1-ETHYLENEOXY-3,4-EPOXYCYCLOHEXANE
2	103-23-1	DI(2-ETHYLHEXYL)ADIPATE
2	117-81-7	DI(2-ETHYLHEXYL)PHTHALATE
1	18413-14-4	ETHYLHYDRAZINE.HCl
1	38434-77-4	ETHYLNITROSOCYANAMIDE
3	759-73-9	ETHYLNITROSOUREA (see 1-ETHYL-1-NITROSOUREA)
1	842-00-2	4-ETHYLSULPHONYLNAPHTHALENE-1-SULFONAMIDE
1	297-76-7	ETHYNODIOL DIACETATE
1	8056-92-6	ETHYNODIOL DIACETATE/ETHINYL ESTRADIOL [10:1] (see OVULEN)
1	96-45-7	ETU (see ETHYLENE THIOUREA)
1	470-82-6	EUCALYPTOL
3	97-53-0	EUGENOL
1,2,3	24554-26-5	FANFT (see N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL] FORMAMIDE)
1	2353-45-9	FAST GREEN FCF (see FD & C GREEN NO. 3)
1	140-56-7	FENAMINOSULF, FORMULATED
1	55-38-9	FENTHION
3	51630-58-1	FENVALERATE
1	14484-64-1	FERBAM (see FERRIC DIMETHYLDITHIOCARBAMATE)
1	14484-64-1	FERRIC DIMETHYLDITHIOCARBAMATE
1	mixture	FERRIC NITROSODIMETHYLDITHIOCARBAMATE AND TETRAMETHYLTHIURAM DISULFIDE (see VANGUARD GF)
3	67774-32-7	FIREMASTER FF-1 (see POLYBROMINATED BIPHENYL MIXTURE)
3	54143-56-5	FLECAINIDE ACETATE
2	2164-17-2	FLUOMETURON
1	363-17-7	N-(2-FLUORENYL)-2,2,2-TRIFLUOROACETAMIDE
1	28314-03-6	N-1-FLUORENYLACETAMIDE (see 1-ACETYLAMINOFLUORENE)
1	28322-02-3	N-4-FLUORENYLACETAMIDE (see 4-ACETYLAMINOFLUORENE)
1,2,3	53-96-3	FLUORENYLACETAMIDE (see 2-ACETYLAMINOFLUORENE)
1,2,3	53-96-3	N-2-FLUORENYLACETAMIDE (see 2-ACETYLAMINOFLUORENE)
1	---	N-1-FLUORENYLDIACETAMIDE (see N-1-DIACETAMIDOFLUORENE)
1,3	7681-49-4	FLUORIDE, SODIUM
1	324-93-6	4'-FLUORO-4-AMINODIPHENYL
1	398-32-3	N-(4'-FLUORO-4-BIPHENYLYL)ACETAMIDE (see N-4-(4'-FLUOROBIPHENYL) ACETAMIDE)
1	398-32-3	N-4-(4'-FLUOROBIPHENYL)ACETAMIDE
3	593-70-4	FLUOROCARBON 31
3	75-88-7	FLUOROCARBON 133a
1	51-21-8	5-FLUOROURACIL
1	3570-75-0	FNT (see FORMIC ACID 2-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]HYDRAZIDE)
1	133-07-3	FOLPET (see N-(TRICHLOROMETHYLTHIO) PHTHALIMIDE)
2,3	50-00-0	FORMALDEHYDE
1	31873-81-1	FORMIC ACID 2-[4-(2-FURYL)-2-THIAZOLYL]HYDRAZIDE
1	32852-21-4	FORMIC ACID 2-(4-METHYL-2-THIAZOLYL)HYDRAZIDE
1	3570-75-0	FORMIC ACID 2-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL] HYDRAZIDE
1	140-56-7	FORMULATED FENAMINOSULF (see FENAMINOSULF, FORMULATED)
1	2302-84-3	1-FORMYL-3-THIOSEMICARBAZIDE
1	624-84-0	FORMYLHYDRAZINE
3	75-09-2	FREON 30 (see METHYLENE CHLORIDE)
1	2411-74-7	2-FURALDEHYDE SEMICARBAZONE
1	98-01-1	FURFURAL
1	3688-53-7	2-(2-FURYL)-3-(5-NITRO-2-FURYL)ACRYLAMIDE (see AF-2)
1	3688-53-7	FURYLFURAMIDE (see AF-2)
3	23255-69-8	FUSARENON-X
2	25812-30-0	GEMFIBROZIL
1	97-16-5	GENITE-R99 (see 2,4-DICHLOROPHENYLBENZENE SULFONATE)
1	---	GERMANATE, SODIUM
1	139-40-2	GESAMIL (see PROPAZINE)
1	77-06-5	GIBBERELLIC ACID
3	67730-10-3	GLU-P-2 (see 2-AMINODIPYRIDO[1,2-a:3',2'-d]IMIDAZOLE)
3	67730-11-4	GLU-P-1 (see 2-AMINO-6-METHYLDIPYRIDO[1,2-a:3',2'-d] IMIDAZOLE)
3	56-86-0	L-GLUTAMIC ACID
2	2757-90-6	beta-N-[gamma-L(+)-GLUTAMYL]-4-HYDROXYMETHYLPHENYLHYDRAZINE
1	96-24-2	GLYCEROL alpha-MONOCHLOROHYDRIN
1	765-34-4	GLYCIDALDEHYDE
1	1072-53-3	GLYCOL SULFATE (see ETHYLENE GLYCOL)
1	3741-38-6	GLYCOL SULFITE
1	2353-45-9	FD & C GREEN NO. 3
1	4680-78-8	FD & C GREEN NO. 1
1	5141-20-8	FD & C GREEN NO. 2
1	126-07-8	GRISEOFULVIN
2	9000-30-0	GUAR GUM
1	4680-78-8	GUINEA GREEN B (see FD & C GREEN NO. 1)
2	9000-01-5	GUM ACACIA (see GUM ARABIC)
2	9000-01-5	GUM ARABIC
1	86-50-0	GUSATHION (see AZINPHOSMETHYL)
1	118-74-1	HCB (see HEXACHLOROBENZENE)

PLOT	CAS NUMBER	CHEMICAL NAME
1	mixture	HCDD MIXTURE
1	517-28-2	HEMATOXYLIN
1	76-44-8	HEPTACHLOR
1	1121-92-2	HEPTAMETHYLENEIMINE
1	1241-27-6	HEPTYLAMINE
1	2163-79-3	HERCULES-7531 (see 3-(HEXAHYDRO-4,7-METHANOINDAN-5-YL)-1,1-DIMETHYLUREA)
1	87-51-4	HETEROAUXIN (see INDOLE-3-ACETIC ACID)
1	118-74-1	HEXACHLOROBENZENE
1	87-68-3	HEXACHLOROBUTADIENE
1	319-84-6	alpha-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE
1	319-85-7	beta-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE
1	58-89-9	gamma-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE
3	608-73-1	HEXACHLOROCYCLOHEXANE
1	67-72-1	HEXACHLOROETHANE
1	70-30-4	HEXACHLOROPHENE
1	2163-79-3	3-(HEXAHYDRO-4,7-METHANOINDAN-5-YL)-1,1-DIMETHYLUREA
1	100-97-0	HEXAMETHYLENETETRAMINE
1	531-18-0	HEXAMETHYLMELAMINE
1	628-02-4	HEXANAMIDE
1	26049-68-3	HNT (see 2-HYDRAZINO-4-(5-NITRO-2-FURYL) THIAZOLE)
1	302-01-2	HYDRAZINE
1,2,3	10034-93-2	HYDRAZINE SULFATE
1	26049-71-8	2-HYDRAZINO-4-(p-AMINOPHENYL)THIAZOLE
1	26049-68-3	2-HYDRAZINO-4-(5-NITRO-2-FURYL)THIAZOLE
1	26049-70-7	2-HYDRAZINO-4-(p-NITROPHENYL)THIAZOLE
1	34176-52-8	2-HYDRAZINO-4-PHENYLTHIAZOLE
1	619-67-0	p-HYDRAZINOBENZOIC ACID
1	122-66-7	HYDRAZOBENZENE
1	50-23-7	HYDROCORTISONE
1	7722-84-1	HYDROGEN PEROXIDE
1	103-16-2	HYDROQUINONE MONOBENZYL ETHER
1,3	53-95-2	*N-HYDROXY-N-ACETYL-2-AMINOFLUORENE* (see N-HYDROXY-2-ACETYLAMINOFLUORENE)
1	4463-22-3	3-HYDROXY-4-ACETYLAMINOBIPHENYL
1,3	53-95-2	N-HYDROXY-2-ACETYLAMINOFLUORENE
1	4363-03-5	3-HYDROXY-4-AMINOBIPHENYL
2	119-53-9	2-HYDROXY-1,2-DIPHENYLETHANONE (see BENZOIN)
1,3	53-95-2	HYDROXY-N-2-FLUORENYLACETAMIDE (see N-HYDROXY-2-ACETYLAMINOFLUORENE)
1,3	103-90-2	p-HYDROXYACETANILIDE (see ACETAMINOPHEN)
3	51410-44-7	1′-HYDROXYESTRAGOLE
1	5036-03-3	1-(2-HYDROXYETHYL)-3-[(5-NITROFURFURYLIDENE) AMINO]-2-IMIDAZOLIDINONE
1	13743-07-2	1-(2-HYDROXYETHYL)-1-NITROSOUREA
1	33389-36-5	4-(2-HYDROXYETHYLAMINO)-2-(5-NITRO-2-THIENYL) QUINAZOLINE
1	109-84-2	2-HYDROXYETHYLHYDRAZINE
1	---	HYDROXYPROPYL DISTARCH GLYCEROL
1,2,3	148-24-3	8-HYDROXYQUINOLINE
1,3	5208-87-7	1′-HYDROXYSAFROLE
1	21416-87-5	ICRF-159
1	120-93-4	2-IMIDAZOLIDINONE (see ETHYLENE UREA)
1	3458-22-8	3,3′-IMINOBIS-1-PROPANOL DIMETHANESULFONATE (ESTER).HCl (IPD)
1	32607-00-4	IMINODIACETIC ACID, MONOSODIUM
1	860-22-0	INDIGO CARMINE (see FD & C BLUE NO. 2)
1	87-51-4	INDOLE-3-ACETIC ACID
1,2,3	54-85-3	INH (see ISONIAZID)
1	75-47-8	IODOFORM
1	122-42-9	IPC (see ISOPROPYL-N-PHENYL CARBAMATE)
1	3458-22-8	IPD (see 3,3′-IMINOBIS-1-PROPANOL DIMETHANESULFONATE (ESTER).HCl (IPD))
3	76180-96-6	IQ (see 2-AMINO-3-METHYLIMIDAZO[4,5-f]QUINOLINE)
3	6381-77-7	ISOASCORBATE (see ERYTHORBATE, SODIUM)
1	297-78-9	ISOBENZAN (see TELODRIN)
1	5461-85-8	N-ISOBUTYL-N′-NITRO-N-NITROSOGUANIDINE
3	760-60-1	N-ISOBUTYL-N-NITROSOUREA (see N-NITROSO-N-ISOBUTYLUREA)
1	119-38-0	ISOLAN (see 1-ISOPROPYL-3-METHYL-s-PYRAZOLYLDIMETHYL CARBAMATE)
1,2,3	54-85-3	ISONIAZID
3	1453-82-3	ISONICOTINAMIDE
1	55-22-1	ISONICOTINIC ACID
1,2,3	54-85-3	ISONICOTINIC ACID HYDRAZIDE (see ISONIAZID)
1	149-17-7	ISONICOTINIC ACID VANILLYLIDENEHYDRAZIDE
3	78-59-1	ISOPHORONE
1	3778-73-2	ISOPHOSPHAMIDE
1	101-73-5	p-ISOPROPOXYDIPHENYLAMINE
1	101-21-3	ISOPROPYL-N-(3-CHLOROPHENYL)CARBAMATE
3	65765-07-3	1-ISOPROPYL-4-(m-METHOXYPHENYL)-7-METHYL-2(1H)-QUINAZOLINONE (see COMPOUND 50-892)
3	22760-18-5	1-ISOPROPYL-7-METHYL-4-PHENYL-2(IH)-QUINAZOLINONE (see PROQUAZONE)
1	119-38-0	*1-ISOPROPYL-3-METHYL-s-PYRAZOLYLDIMETHYL* CARBAMATE
1	122-42-9	ISOPROPYL-N-PHENYL CARBAMATE
2	80-05-7	4,4′-ISOPROPYLIDENEDIPHENOL (see BISPHENOL A)
1	120-58-1	ISOSAFROLE
3	520-18-3	KAEMPFEROL
1	6119-92-2	KARATHANE (see DINITRO(1-METHYLHEPTYL) PHENYL CROTONATE)
1	330-54-1	KARMEX (see 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA)
1	115-32-2	KELTHANE (see DICOFOL)
1	143-50-0	KEPONE
3	9011-18-1	KMDS-H (see DEXTRAN SULFATE SODIUM (KMDS-H))
1	303-34-4	LASIOCARPINE
1	301-04-2	LEAD ACETATE
1	1335-32-6	LEAD ACETATE, BASIC
1	19010-66-3	LEAD DIMETHYLDITHIOCARBAMATE
1	1335-32-6	LEAD SUBACETATE (see LEAD ACETATE, BASIC)
1	19010-66-3	LEDATE (see LEAD DIMETHYLDITHIOCARBAMATE)
1	24365-47-7	LEUPEPTIN
1	5141-20-8	LIGHT GREEN SF YELLOWISH (see FD & C GREEN NO. 2)
1	58-89-9	LINDANE (see gamma-1,2,3,4,5,6-HEXACHLOROCYCLOHEXANE)
1	434-13-9	LITHOCHOLIC ACID
2	9000-40-2	LOCUST BEAN GUM
3	21498-08-8	LOFEXIDINE.HCl
1	21884-44-6	LUTEOSKYRIN
1	8065-91-6	LUTESTRAL
1,3	67-20-9	MACRODANTIN (see 1-[(5-NITROFURFURYLIDENE) AMINO]HYDANTOIN)
1,2	632-99-5	MAGENTA I (see ROSANILINE.HCl)
1,2,3	569-61-9	p-MAGENTA (see p-ROSANILINE.HCl)
1	18968-99-5	MAGNESIUM PEMOLINE (see 2-AMINO-5-PHENYL-2-OXAZOLIN-4-ONE + Mg(OH)2)
1	1634-78-2	MALAOXON
1	121-75-5	MALATHION
1	1634-78-2	MALATHION-O-ANALOG (see MALAOXON)
1,2	123-33-1	MALEIC HYDRAZIDE
2	24382-04-5	MALONALDEHYDE, SODIUM
1	mixture	MAM ACETATE AND CYCASIN MIXTURE (see METHYLAZOXYMETHANOL ACETATE AND CYCASIN MIXTURE)
1	12427-38-2	MANEB (see MANGANESE ETHYLENEBISTHIOCARBAMATE)
1	12427-38-2	MANGANESE ETHYLENEBISTHIOCARBAMATE
2	69-65-8	D-MANNITOL
1	576-68-1	MANNITOL NITROGEN MUSTARD
3	68006-83-7	MeA-alpha-C (see 2-AMINO-3-METHYL-9H-PYRIDO-[2,3-b]-INDOLE)
3	108-78-1	MELAMINE
1	148-82-3	MELPHALAN
1	15356-70-4	DL-MENTHOL
1	67-98-1	MER-25
1	149-30-4	2-MERCAPTOBENZOTHIAZOLE
1	155-04-4	2-MERCAPTOBENZOTHIAZOLE, ZINC
3	19767-45-4	2-MERCAPTOETHANESULFONATE, SODIUM
1	50-44-2	6-MERCAPTOPURINE
1	7487-94-7	MERCURIC CHLORIDE
1	115-09-3	MERCURYMETHYLCHLORIDE
1	72-33-3	MESTRANOL
1	57-39-6	METEPA
3	135-23-9	METHAPYRILENE.HCl
1	60-56-0	METHIMAZOLE
1	59-05-2	METHOTREXATE
2	---	2-METHOXY-4-AMINOAZOBENZENE
2	3544-23-8	3-METHOXY-4-AMINOAZOBENZENE
1	5834-17-3	2-METHOXY-3-AMINODIBENZOFURAN

PLOT	CAS NUMBER	CHEMICAL NAME
1	5834-17-3	2-METHOXY-3-DIBENZOFURANAMINE (see 2-METHOXY-3-AMINODIBENZOFURAN)
1	72-43-5	METHOXYCHLOR
1	1701-77-5	METHOXYPHENYLACETIC ACID
3	25843-45-2	Z-METHYL-O,N,N-AZOXYMETHANE (see AZOXYMETHANE)
1	6294-89-9	METHYL CARBAZATE
2	21340-68-1	METHYL CLOFENAPATE
1	---	1-METHYL-1,4-DIHYDRO-7-[2-(5-NITROFURYL)VINYL]-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLATE, POTASSIUM
1	99-80-9	N-METHYL-N,4-DINITROSOANILINE
1	9004-59-5	METHYL ETHYL CELLULOSE (see EDIFAS A)
1,2	758-17-8	N-METHYL-N-FORMYLHYDRAZINE
2	27323-65-5	METHYL LINOLEATE HYDROPEROXIDE
2	---	METHYL LINOLEATE, NATIVE
1	66-27-3	METHYL METHANESULFONATE
1,2,3	70-25-7	N-METHYL-N'-NITRO-N-NITROSOGUANIDINE
1	129-15-7	2-METHYL-1-NITROANTHRAQUINONE
1	21638-36-8	4-METHYL-1-[(5-NITROFURFURYLIDENE)AMINO]-2-IMIDAZOLIDINONE
1	16699-10-8	4-(4-N-METHYL-N-NITROSAMINOSTYRYL)QUINOLINE
1	63412-06-6	N-METHYL-N-NITROSOBENZAMIDE
1	---	N-(N-METHYL-N-NITROSOCARBAMOYL)-L-ORNITHINE
1	14026-03-0	R(-)-2-METHYL-N-NITROSOPIPERIDINE
1	36702-44-0	S(+)-2-METHYL-N-NITROSOPIPERIDINE
1	684-93-5	N-METHYL-N-NITROSOUREA (see N-NITROSO-N-METHYLUREA)
1	140-56-7	METHYL ORANGE B (see FENAMINOSULF, FORMULATED)
3	21308-79-2	METHYL 12-OXO-trans-10-OCTADECENOATE
1	298-00-0	METHYL PARATHION
1,3	614-00-6	METHYL-PHENYL-NITROSAMINE (see NITROSOMETHYLANILINE)
1	144-34-3	METHYL SELENAC (see SELENIUM DIMETHYLDITHIOCARBAMATE)
1,3	137-30-4	METHYL ZIMATE (see ZINC DIMETHYLDITHIOCARBAMATE)
1	443-72-1	(N-6)-METHYLADENINE
1	1867-73-8	(N-6)-METHYLADENOSINE
1	mixture	METHYLAZOXYMETHANOL ACETATE AND CYCASIN MIXTURE
1,2	56-49-5	METHYLCHOLANTHRENE (see 3-METHYLCHOLANTHRENE)
1,2	56-49-5	3-METHYLCHOLANTHRENE
1	101-14-4	4,4'-METHYLENE-BIS(2-CHLOROANILINE)
1	64049-29-2	4,4'-METHYLENE-BIS(2-CHLOROANILINE).2HCl
1	838-88-0	4,4'-METHYLENE-BIS(2-METHYLANILINE)
3	75-09-2	METHYLENE CHLORIDE
1	101-61-1	4,4'-METHYLENEBIS(N,N-DIMETHYL)BENZENAMINE
3	13552-44-8	4,4'-METHYLENEDIANILINE.2HCl
1	471-29-4	METHYLGUANIDINE
1	578-76-7	7-METHYLGUANINE
1	60-34-4	METHYLHYDRAZINE
1	302-15-8	METHYLHYDRAZINE SULFATE
1	115-09-3	METHYLMERCURIC ACETATE (see MERCURYMETHYLCHLORIDE)
1	115-09-3	METHYLMERCURY CHLORIDE (see MERCURYMETHYLCHLORIDE)
1	---	(N-6)-(METHYLNITROSO)ADENINE
1	---	(N-6)-(METHYLNITROSO)ADENOSINE
3	33868-17-6	METHYLNITROSOCYANAMIDE
2	91-62-3	6-METHYLQUINOLINE
2	611-32-5	8-METHYLQUINOLINE
1,3	56-04-2	METHYLTHIOURACIL
1	5800-19-1	METIAPINE
1	443-48-1	METRONIDAZOLE
1	315-18-4	MEXACARBATE
1	90-94-8	MICHLER'S KETONE
1,3	137-30-4	MILBAM (see ZINC DIMETHYLDITHIOCARBAMATE)
1	2385-85-5	MIREX
1	39801-14-4	MIREX, PHOTO-
1	126-85-2	MITOMEN (see NITROGEN MUSTARD N-OXIDE)
1	50-07-7	MITOMYCIN-C
1	66-27-3	MMS (see METHYL METHANESULFONATE)
1,2,3	70-25-7	MNNG (see N-METHYL-N'-NITRO-N-NITROSOGUANIDINE)
1	684-93-5	MNU (see N-NITROSO-N-METHYLUREA)
1	101-14-4	MOCA (see 4,4'-METHYLENE-BIS(2-CHLOROANILINE))
3	1068-57-1	MONOACETYL HYDRAZINE
1	79-11-8	MONOCHLOROACETIC ACID
3	108-90-7	MONOCHLOROBENZENE (see CHLOROBENZENE)
3	315-22-0	MONOCROTALINE
3	142-47-2	L-MONOSODIUM GLUTAMATE
3	32221-81-1	DL-MONOSODIUM GLUTAMATE
1	32607-00-4	MONOSODIUM IMINODIACETIC ACID (see IMINODIACETIC ACID, MONOSODIUM)
1	150-68-5	MONURON (see 3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA)
1	58139-48-3	4-MORPHOLINO-2-(5-NITRO-2-THIENYL)QUINAZOLINE
1	3031-51-4	L-5-MORPHOLINOMETHYL-3-[(5-NITROFURFURYLIDENE)AMINO]-2-OXAZOLIDINONE.HCl
1	87-56-9	MUCOCHLORIC ACID (see alpha,beta-DICHLORO-beta-FORMYLACRYLIC ACID)
1	55-98-1	MYLERAN
1	142-59-6	NABAM (see ETHYLENEBISDITHIOCARBAMATE, DISODIUM)
1	86-86-2	1-NAPHTHALENE ACETAMIDE
1	86-87-3	1-NAPHTHALENE ACETIC ACID
1	2243-62-1	1,5-NAPHTHALENEDIAMINE
1	1465-25-4	N-(1-NAPHTHYL)ETHYLENEDIAMINE.2HCl
1	93-46-9	sym.-dibeta-NAPHTHYL-p-PHENYLENEDIAMINE
1	86-88-4	1-(1-NAPHTHYL)-2-THIOUREA
1,2	91-59-8	beta-NAPHTHYLAMINE (see 2-NAPHTHYLAMINE)
1,2	91-59-8	2-NAPHTHYLAMINE
2	81-16-3	2-NAPHTHYLAMINO,1-SULFONIC ACID
2	81-16-3	NAS (see 2-NAPHTHYLAMINO,1-SULFONIC ACID)
1	2611-82-7	NEW COCCINE (see SX PURPLE)
1	531-82-8	NFTA (see N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL] ACETAMIDE)
1	7440-02-0	NICKEL
1	373-02-4	NICKEL (II) ACETATE
1	13927-77-0	NICKEL DIBUTYLDITHIOCARBAMATE
1	1420-04-8	NICLOSAMIDE (see CLONITRALID)
3	98-92-0	NICOTINAMIDE
1	54-11-5	NICOTINE
2	636-79-3	NICOTINE.HCl
2	59-67-6	NICOTINIC ACID
1	553-53-7	NICOTINIC ACID HYDRAZIDE
1	---	NIGROSINE
1	12034-09-2	NIOBATE, SODIUM
1	139-94-6	NITHIAZIDE
1,2	7631-99-4	NITRATE, SODIUM
1	10102-43-9	NITRIC OXIDE
1	139-13-9	NITRILOTRIACETIC ACID
1	18662-53-8	NITRILOTRIACETIC ACID, TRISODIUM SALT, MONOHYDRATE
1,2,3	7632-00-0	NITRITE, SODIUM
1	1777-84-0	3-NITRO-p-ACETOPHENETIDE
1	99-59-2	5-NITRO-o-ANISIDINE
1	59-87-0	5-NITRO-2-FURALDEHYDE SEMICARBAZONE
1	772-43-0	5-NITRO-2-FURAMIDOXIME
1	92-55-7	5-NITRO-2-FURANMETHANEDIOL DIACETATE
1	75198-31-1	3-(5-NITRO-2-FURYL)-IMIDAZO(1,2-alpha)PYRIDINE
1	2122-86-3	5-(5-NITRO-2-FURYL)-1,3,4-OXADIAZOLE-2-OL
1	36133-88-7	N-[[3-(5-NITRO-2-FURYL)-1,2,4-OXADIAZOLE-5-YL]-METHYL]ACETAMIDE
1	2578-75-8	N-[5-(5-NITRO-2-FURYL)-1,3,4-THIADIAZOL-2-YL] ACETAMIDE
2	53757-28-1	4-(5-NITRO-2-FURYL)THIAZOLE
1	531-82-8	N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]ACETAMIDE
1,2,3	24554-26-5	N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]FORMAMIDE
1	51325-35-0	N,N'-[6-(5-NITRO-2-FURYL)-s-TRIAZINE-2,4-DIYL] BISACETAMIDE
1	4812-22-0	3-NITRO-3-HEXENE
1	121-19-7	NITRO-4-HYDROXYPHENYLARSONIC ACID
1	5307-14-2	2-NITRO-p-PHENYLENEDIAMINE
1	99-56-9	4-NITRO-o-PHENYLENEDIAMINE
1	99-55-8	5-NITRO-o-TOLUIDINE
1	602-87-9	5-NITROACENAPHTHENE
1	619-17-0	4-NITROANTHRANILIC ACID
1	94-52-0	6-NITROBENZIMIDAZOLE
1	1836-75-5	NITROFEN

PLOT	CAS NUMBER	CHEMICAL NAME
1,3	67-20-9	NITROFURANTOIN (see 1-[(5-NITROFURFURYLIDENE) AMINO]HYDANTOIN)
1,3	67-20-9	1-[(5-NITROFURFURYLIDENE)AMINO]HYDANTOIN
1	555-84-0	1-[(5-NITROFURFURYLIDENE)AMINO]-2-IMIDAZOLIDINONE
1	51-75-2	NITROGEN MUSTARD
1	126-85-2	NITROGEN MUSTARD N-OXIDE
1	86-57-7	1-NITRONAPHTHALENE
1	56-75-7	D-(-)-threo-1-(p-NITROPHENYL)-2-DICHLOROACETAMIDO-1,3-PROPANEDIOL (see CHLORAMPHENICOL)
3	108-03-2	1-NITROPROPANE
1	79-46-9	2-NITROPROPANE
1	504-88-1	3-NITROPROPIONIC ACID
2	613-50-3	6-NITROQUINOLINE
2	607-35-2	8-NITROQUINOLINE
1	38777-13-8	NITROSO-BAYGON
2	---	N-NITROSO-BIS-(4,4,4-TRIFLUORO-N-BUTYL)AMINE
1	3276-41-3	N-NITROSO-3,6-DIHYDROOXAZINE-1,2 (see 3,6-DIHYDRO-2-NITROSO-2H-1, 2-OXAZINE)
3	62641-67-2	1-NITROSO-5,6-DIHYDROTHYMINE
1	16813-36-8	1-NITROSO-5,6-DIHYDROURACIL
3	89911-79-5	N-NITROSO-2,3-DIHYDROXYPROPYL-2-HYDROXYPROPYLAMINE
3	92177-50-9	NITROSO-2,3-DIHYDROXYPROPYL-2-OXOPROPYLAMINE
3	89911-78-4	N-NITROSO-2,3-DIHYDROXYPROPYLETHANOLAMINE
2	61034-40-0	1-NITROSO-3,5-DIMETHYL-4-BENZOYLPIPERAZINE
1	1456-28-6	NITROSO-2,6-DIMETHYLMORPHOLINE
1	13743-07-2	N-NITROSO-2-HYDROXYETHYLUREA (see 1-(2-HYDROXYETHYL)-1-NITROSOUREA)
3	75896-33-2	N-NITROSO-(2-HYDROXYPROPYL)-(2-HYDROXYETHYL)AMINE
3	56222-35-6	N-NITROSO-3-HYDROXYPYRROLIDINE
3	760-60-1	N-NITROSO-N-ISOBUTYLUREA
2,3	55090-44-3	N-NITROSO-N-METHYL-N-DODECYLAMINE
3	937-25-7	N-NITROSO-N-METHYL-4-FLUOROANILINE
3	943-41-9	N-NITROSO-N-METHYL-4-NITROANILINE
1	13256-11-6	NITROSO-N-METHYL-N-(2-PHENYL)ETHYLAMINE
2	75881-20-8	N-NITROSO-N-METHYL-N-TETRADECYLAMINE
2	75881-22-0	N-NITROSO-N-METHYLDECYLAMINE
1	684-93-5	N-NITROSO-N-METHYLUREA
1	615-53-2	N-NITROSO-N-METHYLURETHAN
3	39884-52-1	N-NITROSO-1,3-OXAZOLIDINE
3	92177-49-6	NITROSO-2-OXOPROPYLETHANOLAMINE
3	15973-99-6	DI(N-NITROSO)-PERHYDROPYRIMIDINE
1	55556-92-8	NITROSO-1,2,3,6-TETRAHYDROPYRIDINE
3	82018-90-4	N-NITROSO(2,2,2-TRIFLUOROETHYL)ETHYLAMINE
1	29929-77-9	N-NITROSO-2,2,4-TRIMETHYL-1,2-DIHYDROQUINOLINE POLYMER
3	75881-18-4	1-NITROSO-3,4,5-TRIMETHYLPIPERAZINE
3	88208-16-6	N-NITROSOALLYL-2,3-DIHYDROXYPROPYLAMINE
3	91308-70-2	N-NITROSOALLYL-2-HYDROXYPROPYLAMINE
3	91308-71-3	N-NITROSOALLYL-2-OXOPROPYLAMINE
3	91308-69-9	N-NITROSOALLYLETHANOLAMINE
2	---	NITROSOAMYLURETHAN
1	1133-64-8	NITROSOANABASINE
3	15216-10-1	N-NITROSOAZETIDINE
1	51542-33-7	N-NITROSOBENZTHIAZURON
1,3	53609-64-6	N-NITROSOBIS(2-HYDROXYPROPYL)AMINE
2,3	60599-38-4	N-NITROSOBIS(2-OXOPROPYL)AMINE
1	625-89-8	N-NITROSOBIS(2,2,2-TRIFLUOROETHYL)AMINE
1	---	NITROSOCHLORDIAZEPOXIDE
3	73785-40-7	N-NITROSOCIMETIDINE
1,3	924-16-3	NITROSODIBUTYLAMINE
2,3	1116-54-7	N-NITROSODIETHANOLAMINE
1,3	55-18-5	N-NITROSODIETHYLAMINE
1,2,3	62-75-9	N-NITROSODIMETHYLAMINE
1	156-10-5	p-NITROSODIPHENYLAMINE
1	86-30-6	N-NITROSODIPHENYLAMINE
3	621-64-7	N-NITROSODIPROPYLAMINE
3	40580-89-0	NITROSODODECAMETHYLENEIMINE
1	17608-59-2	N-NITROSOEPHEDRINE
1	38434-77-4	NITROSOETHANECARBAMONITRILE (see ETHYLNITROSOCYANAMIDE)
3	10595-95-6	NITROSOETHYLMETHYLAMINE
2	614-95-9	NITROSOETHYLURETHAN
1	20917-49-1	NITROSOHEPTAMETHYLENEIMINE
3	932-83-2	N-NITROSOHEXAMETHYLENEIMINE
1	42579-28-2	1-NITROSOHYDANTOIN
1	30310-80-6	NITROSOHYDROXYPROLINE
1	25081-31-6	NITROSOIMINODIACETIC ACID
3	86451-37-8	N-NITROSOMETHYL-2,3-DIHYDROXYPROPYLAMINE
2,3	55090-44-3	NITROSOMETHYL-N-DODECYLAMINE (see N-NITROSO-N-METHYL-N-DODECYLAMINE)
3	75411-83-5	N-NITROSOMETHYL-2-HYDROXYPROPYLAMINE
1	16219-98-0	2-NITROSOMETHYLAMINOPYRIDINE
1	69658-91-9	3-NITROSOMETHYLAMINOPYRIDINE
1	16219-99-1	4-NITROSOMETHYLAMINOPYRIDINE
1,3	614-00-6	NITROSOMETHYLANILINE
1	55557-03-4	NITROSOMETHYLPHENIDATE
1	68107-26-6	NITROSOMETHYLUNDECYLAMINE
1	684-93-5	NITROSOMETHYLUREA (see N-NITROSO-N-METHYLUREA)
3	59-89-2	NITROSOMORPHOLINE (see N-NITROSOMORPHOLINE)
3	59-89-2	N-NITROSOMORPHOLINE
3	16543-55-8	N'-NITROSONORNICOTINE
3	78246-24-9	N'-NITROSONORNICOTINE-1-N-OXIDE
1	4515-18-8	NITROSOPIPECOLIC ACID
1	5632-47-3	NITROSOPIPERAZINE (see N-NITROSOPIPERAZINE)
1	5632-47-3	N-NITROSOPIPERAZINE
1	5632-47-3	1-NITROSOPIPERAZINE (see N-NITROSOPIPERAZINE)
1,3	100-75-4	N-NITROSOPIPERIDINE
1	7519-36-0	NITROSOPROLINE
1,2	930-55-2	NITROSOPYRROLIDINE (see N-NITROSOPYRROLIDINE)
1,2	930-55-2	N-NITROSOPYRROLIDINE
1	26541-51-5	N-NITROSOTHIOMORPHOLINE
2	611-23-4	o-NITROSOTOLUENE
1	mixture	beta-NITROSTYRENE AND STYRENE MIXTURE (see STYRENE AND beta-NITROSTYRENE MIXTURE)
1	68-23-5	NORETHYNODREL
1	---	NORETHYNODREL/MESTRANOL [25:1] (see ENOVID-E)
1	8015-30-3	NORETHYNODREL/MESTRANOL [66:1] (see ENOVID)
1	244-63-3	NORHARMAN
1,2	8015-12-1	NORLESTRIN
1	---	NOVADELOX
1	303-47-9	OCHRATOXIN A
1	50-28-2	17beta-OESTRADIOL (see ESTRADIOL)
1,3	90-43-7	ORTHOXENOL (see o-PHENYLPHENOL)
1	80-33-1	OVEX (see p-CHLOROPHENYL-p-CHLOROBENZENE SULFONATE)
1	8056-92-6	OVULEN
1	3096-50-2	N-(9-OXO-2-FLUORENYL)ACETAMIDE
1	30418-53-2	1'-OXOSAFROLE
1	6452-73-9	OXPRENOLOL.HCl
2	101-80-4	4,4'-OXYDIANILINE
1	102-77-2	N-OXYDIETHYLENEBENZOTHIAZOLE-2-SULFENAMIDE
1,3	103-90-2	PARACETAMOL (see ACETAMINOPHEN)
1	56-38-2	PARATHION
1	92-69-3	PARAXENOL (see p-PHENYLPHENOL)
1	149-29-1	PATULIN
1	27323-18-8	PCB (see AROCLOR 1254)
1,3	11096-82-5	PCB (see AROCLOR 1260)
1	82-68-8	PCNB (see PENTACHLORONITROBENZENE)
1,3	87-86-5	PCP (see 2,3,4,5,6-PENTACHLOROPHENOL)
3	76-01-7	PENTACHLOROETHANE
1	82-68-8	PENTACHLORONITROBENZENE
1,3	87-86-5	2,3,4,5,6-PENTACHLOROPHENOL
3	76-01-7	PENTALIN (see PENTACHLOROETHANE)
1	13010-10-1	N-PENTYL-N'-NITRO-N-NITROSOGUANIDINE
1	1119-68-2	n-PENTYLHYDRAZINE.HCl
1	8006-90-4	PEPPERMINT OIL
1,3	127-18-4	PERCHLOROETHYLENE (see TETRACHLOROETHYLENE)
1	72-56-0	PERTHANE (see p,p'-ETHYL-DDD)
1	60102-37-6	PETASITENINE
1,2,3	62-44-2	PHENACETIN
1	8003-03-0	PHENACETIN, ASPIRIN, AND CAFFEINE (see ASPIRIN, PHENACETIN, AND CAFFEINE)
1	60-80-0	PHENAZONE
1	136-40-3	PHENAZOPYRIDINE.HCl
1	3546-10-9	PHENESTERIN
1	834-28-6	PHENFORMIN.HCl
1,2,3	50-06-6	PHENOBARBITAL

PLOT	CAS NUMBER	CHEMICAL NAME
1	57-30-7	PHENOBARBITAL, SODIUM
1,2,3	50-06-6	PHENOBARBITONE (see PHENOBARBITAL)
2	108-95-2	PHENOL
1	92-84-2	PHENOTHIAZINE
1	63-92-3	PHENOXYBENZAMINE.HCl
1	7227-91-0	1-PHENYL-3,3-DIMETHYLTRIAZENE
1	103-72-0	PHENYL ISOTHIOCYANATE
1	89-25-8	1-PHENYL-3-METHYL-5-PYRAZOLONE
1,2	135-88-6	PHENYL-beta-NAPHTHYLAMINE
1	2198-59-6	N-PHENYL-p-PHENYLENEDIAMINE.HCl
1	103-85-5	1-PHENYL-2-THIOUREA
1	4075-79-0	4'-PHENYLACETANILIDE (see 4-ACETYLAMINOBIPHENYL)
1,2	842-07-9	1-PHENYLAZO-2-NAPHTHOL
3	106-50-3	p-PHENYLENEDIAMINE
1	541-69-5	m-PHENYLENEDIAMINE.2HCl
1	615-28-1	o-PHENYLENEDIAMINE.2HCl
1	624-18-0	p-PHENYLENEDIAMINE.2HCl
1,2,3	50-06-6	PHENYLETHYLBARBITURIC ACID (see PHENOBARBITAL)
1	156-51-4	PHENYLETHYLHYDRAZINE SULFATE
3	122-60-1	PHENYLGLYCIDYL ETHER
1	100-63-0	PHENYLHYDRAZINE
1	59-88-1	PHENYLHYDRAZINE.HCl
3	66-05-7	beta-PHENYLISOPROPYLHYDRAZINE.HCl
1	62-38-4	PHENYLMERCURIC ACETATE
1,3	132-27-4	o-PHENYLPHENATE, SODIUM
1	92-69-3	p-PHENYLPHENOL
1,3	90-43-7	o-PHENYLPHENOL
1	17673-25-5	PHORBOL
1	13171-21-6	PHOSPHAMIDON
1	---	PHOSPHATED DISTARCH PHOSPHATE
1	13366-73-9	PHOTODIELDRIN (see DIELDRIN, PHOTO-)
1	39801-14-4	PHOTOMIREX (see MIREX, PHOTO-)
1	88-96-0	PHTHALAMIDE
1	85-44-9	PHTHALIC ANHYDRIDE
1	149-17-7	PHTIVAZID (see ISONICOTINIC ACID VANILLYLIDENEHYDRAZIDE)
1	1918-02-1	PICLORAM
3	56393-22-7	PILDRALAZINE
1	92-13-7	PILOCARPINE
1	7681-93-8	PIMARICIN
1,3	100-75-4	PIP (see N-NITROSOPIPERIDINE)
1	110-85-0	PIPERAZINE
1	110-89-4	PIPERIDINE
1	51-03-6	PIPERONYL BUTOXIDE
1	---	PIPERONYL BUTOXIDE IN SOLVENT
1	120-62-7	PIPERONYL SULFOXIDE
1	1955-45-9	PIVALOLACTONE
1	86-87-3	PLANOFIX (see 1-NAPHTHALENE ACETIC ACID)
3	67774-32-7	POLYBROMINATED BIPHENYL MIXTURE
1	59536-65-1	POLYBROMINATED BIPHENYLS
1	---	POLYVINYLPYRIDINE-N-OXIDE
1	4548-53-2	PONCEAU SX (see FD & C RED NO. 4)
1,3	3761-53-3	PONCEAU MX (see D & C RED NO. 5)
1	3564-09-8	PONCEAU 3R (see FD & C RED NO. 1)
1	2611-82-7	PONCEAU 4R (see SX PURPLE)
1,3	7758-01-2	POTASSIUM BROMATE (see BROMATE, POTASSIUM)
1	---	POTASSIUM METABISULFITE (see SULFITE, POTASSIUM METABI-)
2	55268-74-1	PRAZIQUANTEL
1	---	PREMARIN
3	40778-40-3	PRIMIDOLOL.HCl
1	671-16-9	PROCARBAZINE
1	366-70-1	PROCARBAZINE.HCl
1	952-23-8	PROFLAVINE.HCl HEMIHYDRATE
1	54-80-8	PRONETHALOL
1	51-02-5	PRONETHALOL.HCl
1	1120-71-4	PROPANE SULTONE
1	139-40-2	PROPAZINE
3	104-46-1	p-PROPENYLANISOLE (see ANETHOLE)
1,2	57-57-8	beta-PROPIOLACTONE
3	525-66-6	PROPRANOLOL.HCl
1	1114-71-2	PROPYL N-ETHYL-N-BUTYLTHIOCARBAMATE
1	77337-54-3	N-N'-PROPYL-N-FORMYLHYDRAZINE
2	121-79-9	PROPYL GALLATE
1	83-59-0	N-PROPYL ISOME
1	13010-07-6	N-PROPYL-N'-NITRO-N-NITROSOGUANIDINE
3	115-07-1	PROPYLENE
1	57-55-6	PROPYLENE GLYCOL
2,3	75-56-9	1,2-PROPYLENE OXIDE
1	56795-66-5	PROPYLHYDRAZINE.HCl
3	621-64-7	DI-N-PROPYLNITROSAMINE (see N-NITROSODIPROPYLAMINE)
1	51-52-5	PROPYLTHIOURACIL
3	22760-18-5	PROQUAZONE
1	1508-45-8	PRORESID
1	2611-82-7	SX PURPLE
3	26308-28-1	PYRAZAPON (see RIPAZEPAM)
1	98-96-4	PYRAZINAMIDE
1	553-53-7	3-PYRIDOYL HYDRAZINE (see NICOTINIC ACID HYDRAZIDE)
3	59-33-6	PYRILAMINE MALEATE
1	58-14-0	PYRIMETHAMINE
1,3	117-39-5	QUERCETIN
1,2,3	6151-25-3	QUERCETIN DIHYDRATE
1,2	---	QUILLAIA EXTRACT
1,2,3	148-24-3	8-QUINOLINOL (see 8-HYDROXYQUINOLINE)
1	105-11-3	p-QUINONE DIOXIME
1	82-68-8	QUINTOZINE (see PENTACHLORONITROBENZENE)
1	---	D & C RED NO. 10
1	16423-68-0	FD & C RED NO. 3
1	3564-09-8	FD & C RED NO. 1
1	4548-53-2	FD & C RED NO. 4
1	915-67-3	FD & C RED NO. 2
1,2	5160-02-1	D & C RED NO. 9
1,3	3761-53-3	D & C RED NO. 5
3	2871-01-4	HC RED NO. 3
1,2	3567-69-9	C.I. FOOD RED 3
1,2,3	569-61-9	C.I. BASIC RED 9.HCl (see p-ROSANILINE.HCl)
1	86-30-6	REDAX (see N-NITROSODIPHENYLAMINE)
1	2318-18-5	RENARDINE (see SENKIRKINE)
1	50-55-5	RESERPINE
1	13292-46-1	RIFAMPICIN
3	26308-28-1	RIPAZEPAM
1,2	632-99-5	ROSANILINE.HCl
1,2,3	569-61-9	p-ROSANILINE.HCl
1	149-30-4	ROTAX (see 2-MERCAPTOBENZOTHIAZOLE)
1	83-79-4	ROTENONE
1,2	153-18-4	RUTIN (see RUTIN TRIHYDRATE)
3	12768-44-4	RUTIN SULFATE
1,2	153-18-4	RUTIN TRIHYDRATE
1	81-07-2	SACCHARIN
1,2,3	128-44-9	SACCHARIN, SODIUM
1,2,3	94-59-7	SAFROLE
3	18559-94-9	SALBUTAMOL
1	8052-16-2	SANAMYCIN (see ACTINOMYCIN C)
1	148-82-3	L-SARCOLYSIN (see MELPHALAN)
1	148-18-5	SDDC (see SODIUM DIETHYLDITHIOCARBAMATE TRIHYDRATE)
1	7782-49-2	SELENIUM
1	5456-28-0	SELENIUM DIETHYLDITHIOCARBAMATE
1	144-34-3	SELENIUM DIMETHYLDITHIOCARBAMATE
1	7446-34-6	SELENIUM SULFIDE
1	2318-18-5	SENKIRKINE
1	63-25-2	SEVIN (see CARBARYL)
1	122-34-9	SIMAZINE
1	7784-46-5	SODIUM ARSENITE (see ARSENITE, SODIUM)
1	26628-22-8	SODIUM AZIDE (see AZIDE, SODIUM)
1	532-32-1	SODIUM BENZOATE (see BENZOATE, SODIUM)
1	6385-58-6	SODIUM BITHIONOLATE
1	139-05-9	SODIUM CYCLAMATE (see CYCLAMATE, SODIUM)
1	148-18-5	SODIUM DIETHYLDITHIOCARBAMATE TRIHYDRATE
1,3	7681-49-4	SODIUM FLUORIDE (see FLUORIDE, SODIUM)
1	12034-09-2	SODIUM NIOBATE (see NIOBATE, SODIUM)
1,2	7631-99-4	SODIUM NITRATE (see NITRATE, SODIUM)
1	7757-82-6	SODIUM SULFATE (see SULFATE, SODIUM)
2	13755-29-8	SODIUM TETRAFLUOROBORATE (see TETRAFLUOROBORATE, SODIUM)
1	13472-45-2	SODIUM TUNGSTATE (see TUNGSTATE, SODIUM)
1	110-44-1	SORBIC ACID
3	959-24-0	SOTALOL.HCl
1	8002-43-5	SOYBEAN LECITHIN

PLOT	CAS NUMBER	CHEMICAL NAME
3	28754-68-9	SQ 18506 (see trans-5-AMINO-3[2-(5-NITRO-2-FURYL) VINYL-1,2,4-OXADIAZOLE)
1,2	7772-99-8	STANNOUS CHLORIDE (see TIN (II) CHLORIDE)
1	---	STARCH ACETATE
1,2	10048-13-2	STERIGMATOCYSTIN
2	77-83-8	STRAWBERRY ALDEHYDE (see ETHYL METHYLPHENYLGLYCIDATE)
1	18883-66-4	STREPTOZOTOCIN
1	8001-50-1	STROBANE
1	100-42-5	STYRENE
1	mixture	STYRENE AND beta-NITROSTYRENE MIXTURE
3	96-09-3	STYRENE OXIDE
1	1596-84-5	SUCCINIC ACID 2,2-DIMETHYLHYDRAZIDE (see DAMINOZIDE)
1	57-50-1	SUCROSE
1	971-15-3	SULFADS (see DIPENTAMETHYLENETHIURAM HEXASULFIDE)
1	95-06-7	SULFALLATE
1	7757-82-6	SULFATE, SODIUM
1	127-69-5	SULFISOXAZOLE
1	---	SULFITE, POTASSIUM METABI-
1	77-79-2	3-SULFOLENE
1	77-46-3	4,4'-SULFONYLBISACETANILIDE
3	68-89-3	SULPYRIN (see DIPYRONE)
1,2	2783-94-0	SUNSET YELLOW FCF (see FD & C YELLOW NO. 6)
1	22571-95-5	SYMPHYTINE
1	569-57-3	TACE
2	39300-88-4	TARA GUM
1	1934-21-0	TARTRAZINE (see FD & C YELLOW NO. 5)
1	97-18-7	TBP (see 2,2-THIOBIS(4,6-DICHLOROPHENOL))
1	1746-01-6	TCDD (see 2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN)
1,3	79-01-6	TCE (see TRICHLOROETHYLENE)
1	72-54-8	TDE (see p,p'-DDD)
1	297-78-9	TELODRIN
3	542-75-6	TELONE II
1	150-68-5	TELVAR (see 3-(p-CHLOROPHENYL)-1,1-DIMETHYLUREA)
1	116-06-3	TEMIK (see ALDICARB)
3	23031-25-6	TERBUTALINE
1	7411-49-6	3,3',4,4'-TETRAAMINOBIPHENYL.4HCl
1	118-75-2	TETRACHLORO-p-BENZOQUINONE (see CHLORANIL)
1	2438-88-2	2,3,5,6-TETRACHLORO-4-NITROANISOLE
1	15721-02-5	2,2',5,5'-TETRACHLOROBENZIDINE
1	1746-01-6	2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN
1	116-29-0	2,4,5,4'-TETRACHLORODIPHENYL SULFONE
1	79-34-5	1,1,2,2-TETRACHLOROETHANE
3	630-20-6	1,1,1,2-TETRACHLOROETHANE
1,3	127-18-4	TETRACHLOROETHYLENE
1	961-11-5	TETRACHLORVINPHOS
1	97-77-8	TETRAETHYLTHIURAM DISULFIDE
1	116-29-0	TETRAFIDON (see 2,4,5,4'-TETRACHLORODIPHENYL SULFONE)
1	63886-77-1	TETRAFLUORO-m-PHENYLENEDIAMINE.2HCl
2	13755-29-8	TETRAFLUOROBORATE, SODIUM
1	40548-68-3	TETRAHYDRO-2-NITROSO-2H-1,2-OXAZINE
1,3	137-26-8	TETRAMETHYLTHIURAM DISULFIDE
1	mixture	TETRAMETHYLTHIURAM DISULFIDE AND FERRIC NITROSODIMETHYLDITHIOCARBAMATE (see VANGUARD GF)
1	97-74-5	TETRAMETHYLTHIURAM MONOSULFIDE
1	2227-13-6	TETRASUL (see p-CHLOROPHENYL-2,4,5-TRICHLOROPHENYL SULFIDE)
1	64039-27-6	beta-TGdR (see beta-THIOGUANINE DEOXYRIBOSIDE)
1	52-24-4	THIO-TEPA
1	62-55-5	THIOACETAMIDE
1	97-18-7	2,2-THIOBIS(4,6-DICHLOROPHENOL)
1,3	79-19-6	THIOCARBAMYLHYDRAZINE (see THIOSEMICARBAZIDE)
1	115-29-7	THIODAN (see ENDOSULFAN)
1	139-65-1	4,4'-THIODIANILINE
1	64039-27-6	beta-THIOGUANINE DEOXYRIBOSIDE
1,3	79-19-6	THIOSEMICARBAZIDE
1	141-90-2	THIOURACIL
1	62-56-6	THIOUREA
1,3	137-26-8	THIRAM (see TETRAMETHYLTHIURAM DISULFIDE)
1	1114-71-2	TILLAM-6-E (see PROPYL N-ETHYL-N-BUTYLTHIOCARBAMATE)
1,2	7772-99-8	TIN (II) CHLORIDE
1	13463-67-7	TITANIUM DIOXIDE
1	---	TITANIUM OXALATE, POTASSIUM
1,3	137-26-8	TMTD (see TETRAMETHYLTHIURAM DISULFIDE)
3	59-02-9	DL-alpha-TOCOPHERYL ACETATE
1	1156-19-0	TOLAZAMIDE
1	64-77-7	TOLBUTAMIDE
3	108-88-3	TOLUENE
1	636-23-7	2,4-TOLUENEDIAMINE.2HCl (see 2,4-*DIAMINOTOLUENE.2HCl*)
2	15481-70-6	2,6-TOLUENEDIAMINE.2HCl (see 2,6-DIAMINOTOLUENE.2HCl)
1	6369-59-1	2,5-TOLUENEDIAMINE SULFATE (see 2,5-DIAMINOTOLUENE SULFATE)
1	88-19-7	o-TOLUENESULFONAMIDE
1	540-23-8	p-TOLUIDINE.HCl
1	638-03-9	m-TOLUIDINE.HCl
1,2	636-21-5	o-TOLUIDINE.HCl
1	622-51-5	p-TOLYLUREA
1	8001-35-2	TOXAPHENE
1	68-76-8	TRENIMON
1	6379-46-0	1,2,3-TRICHLORO-4,6-DINITROBENZENE
1	634-93-5	2,4,6-TRICHLOROANILINE
1	79-00-5	1,1,2-TRICHLOROETHANE
1	71-55-6	1,1,1-TRICHLOROETHANE
1,3	79-01-6	TRICHLOROETHYLENE
1	75-69-4	TRICHLOROFLUOROMETHANE
1	133-07-3	N-(TRICHLOROMETHYLTHIO)PHTHALIMIDE
1	88-06-2	2,4,6-TRICHLOROPHENOL
1	93-72-1	2-(2,4,5-TRICHLOROPHENOXY)PROPIONIC ACID
1	93-76-5	2,4,5-TRICHLOROPHENOXYACETIC ACID
1	102-71-6	TRIETHANOLAMINE
1	112-27-6	TRIETHYLENE GLYCOL
1	42011-48-3	2,2,2-TRIFLUORO-N-[4-(5-NITRO-2-FURYL)-2-THIAZOLYL]ACETAMIDE
1	1582-09-8	TRIFLURALIN
1	75-47-8	TRIIODOMETHANE (see IODOFORM)
1	137-17-7	2,4,5-TRIMETHYLANILINE
1	21436-97-5	2,4,5-TRIMETHYLANILINE.HCl
1	6334-11-8	2,4,6-TRIMETHYLANILINE.HCl
1	512-56-1	TRIMETHYLPHOSPHATE
1	2489-77-2	TRIMETHYLTHIOUREA
1	900-95-8	TRIPHENYLTIN ACETATE
1	76-87-9	TRIPHENYLTIN HYDROXIDE
1,3	126-72-7	TRIS (see TRIS(2,3-DIBROMOPROPYL)PHOSPHATE)
1	38571-73-2	TRIS-1,2,3-(CHLOROMETHOXY)PROPANE
1,3	126-72-7	TRIS(2,3-DIBROMOPROPYL)PHOSPHATE
3	78-42-2	TRIS(2-ETHYLHEXYL)PHOSPHATE
1	150-38-9	TRISODIUM ETHYLENEDIAMINETETRAACETATE TRIHYDRATE (see EDTA, TRISODIUM SALT TRIHYDRATE)
1	72254-58-1	TRP-P-2 ACETATE (see 3-AMINO-1-METHYL-5H-PYRIDO[4,3-b]INDOLE ACETATE)
1	75104-43-7	TRP-P-1 ACETATE (see 3-AMINO-1,4-DIMETHYL-5H-PYRIDO[4,3-b]INDOLE ACETATE)
1,2,3	73-22-3	L-TRYPTOPHAN
3	54-12-6	DL-TRYPTOPHAN
1	83-79-4	TUBATOXIN (see ROTENONE)
1	13472-45-2	TUNGSTATE, SODIUM
1,3	103-90-2	TYLENOL (see ACETAMINOPHEN)
1	97-74-5	UNADS (see TETRAMETHYLTHIURAM MONOSULFIDE)
1	57-13-6	UREA
1	51-79-6	URETHANE
1	27774-13-6	VANADYL SULFATE
1	6379-46-0	VANCIDE PB (see 1,2,3-TRICHLORO-4,6-DINITROBENZENE)
1	6385-58-6	VANCIDE BN (see SODIUM BITHIONOLATE)
1	97-18-7	VANCIDE BL (see 2,2-THIOBIS(4,6-DICHLOROPHENOL))
1	13927-77-0	VANGAURD N (see NICKEL DIBUTYLDITHIOCARBAMATE)
1	mixture	VANGUARD GF
1	62-73-7	VAPONA (see DICHLORVOS)
1	865-21-4	VINBLASTINE
3	108-05-4	VINYL ACETATE
1	593-60-2	VINYL BROMIDE
1,2,3	75-01-4	VINYL CHLORIDE
1,2,3	75-35-4	VINYLIDENE CHLORIDE

PLOT	CAS NUMBER	CHEMICAL NAME
1,3	1694-09-3	FD & C VIOLET NO. 1
1	50-14-6	VITAMIN D2
3	59-02-9	VITAMIN E (see DL-alpha-TOCOPHERYL ACETATE)
3	50-81-7	VITAMIN C (see L-ASCORBIC ACID)
1	302-79-4	VITAMIN A ACID
1	21436-96-4	2,4-XYLIDINE.HCl
1	51786-53-9	2,5-XYLIDINE.HCl
1	1934-21-0	FD & C YELLOW NO. 5
1	6358-85-6	DIARYLANILIDE YELLOW (see C.I. PIGMENT YELLOW 12)
1,2	2783-94-0	FD & C YELLOW NO. 6
2	2832-40-8	C.I. DISPERSE YELLOW 3
1	128-66-5	C.I. VAT YELLOW 4
1	6358-85-6	C.I. PIGMENT YELLOW 12
1,2	842-07-9	C.I. SOLVENT YELLOW 14 (see 1-PHENYLAZO-2-NAPHTHOL)
1	5979-28-2	C.I. PIGMENT YELLOW 16
1	5567-15-7	C.I. PIGMENT YELLOW 83
2	17924-92-4	ZEARALENONE
1	315-18-4	ZECTRAN (see MEXACARBATE)
1	155-04-4	ZETAX (see 2-MERCAPTOBENZOTHIAZOLE, ZINC)
1	136-23-2	ZINC DIBUTYLDITHIOCARBAMATE
1	14324-55-1	ZINC DIETHYLDITHIOCARBAMATE
1,3	137-30-4	ZINC DIMETHYLDITHIOCARBAMATE
1	12122-67-7	ZINC ETHYLENEBISTHIOCARBAMATE
1	12122-67-7	ZINEB (see ZINC ETHYLENEBISTHIOCARBAMATE)
1,3	137-30-4	ZIRAM (see ZINC DIMETHYLDITHIOCARBAMATE)
1	14644-61-2	ZIRCONIUM (IV) SULFATE

CAS NUMBER = Chemical Abstracts Service registry number

PLOT 1 = Gold, L.S., Sawyer, C.B., Magaw, R., Backman, G.M., de Veciana, M., Levinson, R., Hooper, N.K., Havender, W.R., Bernstein, L., Peto,, R., Pike, M., and Ames, B.N. A carcinogenic potency database of the standardized results of animal bioassays. Env. Hlth. Pers. 58: 9–319 (1984).

PLOT 2 = Gold, L., de Veciana, M., Backman, G., Magaw, R., Lopipero, P., Smith, M., Blumenthal, M., Levinson, R., Bernstein, L., and Ames, B.N. Chronological supplement to the carcinogenic potency database: standardized results of animal bioassays published through December 1982. Env. Hlth. Pers. 67: 161–200 (1986).

PLOT 3 = This publication